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Abstract
Background
Diabetic Foot ulceration has devastating complications. These include amputations resulting in
poor quality of life, and serious infections including osteomyelitis and life threatening sepsis.
Diabetic wounds can be protracted, take significant time to heal, and they can recur after they
have healed. They can be very costly and consume healthcare resources. These consequences
have serious public health and clinical implications. Debridement is often used as a standard of
care in efforts to help avert these consequences. It is used to remove nonviable or necrotic tissue
such as nonviable tissue in order to facilitate the wound healing process and help prevent these
disabling outcomes. What is/are the most effective method(s) of debridement remains unclear?
This systematic review of the literature on debridement of diabetic foot ulcers synthesizes all
experimental evidence in an effort to help answer this important question.
Foot ulceration affects 15% of diabetics at some point in their lives. The prevalence of diabetic
foot ulcers is 4.6% in the UK, 8.3% in the US, and includes 7% of the world’s population. The
non-healing wound increases the risk of amputations, complicating infections, healthcare costs,
and reduces quality of life. Debridement is regarded as an effective intervention to accelerate
ulcer healing and to decrease the risk of serious complications.
Current published literature is unclear on which specific method of debridement interventions
have the optimal effect on these important public health and clinical implications including:
amputation rates, complicating infection rates, quality of life, cost of care) and clinical
implications (wound healing rates, wound recurrence rates, and time to complete healing.
Analyzing moderators or prognostic risk factors can facilitate the development of populationspecific guidelines or recommendations on the effects of debridement. This can promote better
understanding of which groups may benefit from debridement based on prognostic factors. This
understanding could increase adherence to the common practices used in diabetic wound care
including debridement, provided the evidence supports its efficacy.
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Objectives
The current systematic review and meta-analysis was conducted in order to obtain overall effect
sizes of all debridement interventions on the following outcomes (Amputation frequency,
Complicating wound infection rates such as Methicillin Resistant Staphylococcus Aureus
(MRSA), Quality of life, Proportion of ulcers healing, Proportion of ulcer recurrence, Cost, and
Time to complete healing). The goal was to evaluate the variability and consistency of these
effects across the current literature on this topic. Any significant variability across the current
literature was investigated using moderator analysis based on study-specific and sample-specific
characteristics.
Does the use of any form of debridement in diabetic foot ulcers demonstrate benefit over any
other form of debridement including standard gauze dressings with respect to amputation
frequency, complicating infection rates, quality of life, cost, proportion of ulcers healed,
recurrence rates, and time to healing? Are any prognostic or other moderating factors predictive
of benefit in some populations or groups? This study summarizes and synthesizes the evidence in
a comprehensive qualitative systematic review and quantitative systematic review/meta-analysis
of all randomized control trials (RCT’s) on this research question.

Methods
A comprehensive literature search was conducted to retrieve articles that met the following
inclusion criteria.
Inclusion/Exclusion Criteria
The following inclusion/exclusion criteria were utilized:
a) Individual studies, Systematic reviews (SR’s) and/or meta-analyses (MA’s) that included
randomized controlled trials (RCT’s) on debridement of diabetic foot ulcers. Comparison
of any method of debridement (i.e. the removal of nonviable tissue from the wound, by
either mechanical or non-mechanical debridement) with control or an alternative method
of debridement were included The search included any form of debridement but did not
include studies on Negative Pressure Wound Therapy (NPWT). NPWT includes
mechanical debridement but has other functions.
b) Adult Type 1, or Type 2 diabetics with ischemic, neuropathic, or neuro-ischemic diabetic
foot ulcers. The wounds were not limited in severity or in grading system utilized
including Wagner Wound Grade, and the Texas Classification systems.
c) There were no other limitations based on age, gender, country, healthcare setting, or
language.
d) RCT’s, and Systematic reviews/Meta-analyses that included other wound types i.e.
venous stasis ulcers, arterial insufficiency ulcers in non-diabetics, pressure ulcers, and
atypical ulcers were excluded.
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e) Studies that were nonrandomized (observational studies) were excluded. Systematic
Reviews/Meta-analyses that were limited to nonrandomized studies were excluded. All
systematic reviews were retrieved along with RCT’s for purposes of comparison and
contrasting them with the results of this review.

Search methods
The search included: The Cochrane Wounds Group Specialized Register; The Cochrane Central
Register of Controlled Trials (CENTRAL) (The Cochrane Library); Ovid MEDLINE, PubMed,
EMBASE, EBSCO, CINAHL, and Web of Science.

Selection criteria
Randomized controlled trials (RCTs) evaluating any method of debridement used in diabetic foot
ulcers. There was no restriction on articles/trials based on language or publication status.

Data collection and analysis
Data extraction and assessment of study quality were undertaken by two independent reviewers
and referred to a methods expert and content expert when there was disagreement. When
necessary, if disagreements were not resolved they were referred to the Wounds Group to resolve
any remaining discordance between reviewers.
The primary outcomes of interest included: 1) Amputation rates, 2) Complicating wound
infection rates, and 3) Quality of life.
The secondary outcomes of interest included: 4) Proportion of participants with ulcers
completely healed, 5) Time to complete healing, 6) Proportion of ulcers recurring after healing,
and 7) Cost of treatment.
These outcomes have direct bearing on clinical and public health implications including
morbidity and mortality. These consequences cause significant hardships for individuals with
wounds. A major amputation (above or below knee) is considered by experts to be a predictor of
increased 5-year mortality.
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Results
Descriptive Statistics
Sample sizes
This review included an analysis of thirty studies with a total of 2654 participants. All 30 studies
reported total sample size for each of the included studies. The mean sample size for the included
studies was 152 (SD = 119) participants. The included studies ranged from sample sizes of 18 to
619 participants.
Range of follow-up and study period duration
The range of follow up was 10 days to 24 weeks for the included studies. The study period or
duration ranged from 1992 – 2012 for the included studies.
Participant characteristics (age, gender, ethnicity)
The mean ages for the samples in the included studies ranged from 52.1 years through 69.3
years. A total of 23 studies reported mean age, 1 study reported a median age of 59.5 years
(Roberts 2001), while 6 other studies did not report age. The mean age for the sample of studies
was 59.01 (SD = 4.31) years.
Gender was reported in 21/30 (70%) of studies. The number of male participants ranged from 12
to 240, while the number of female participants ranged from 1 to 88 for the reported studies.
Ethnicity was reported in 5/30 (16.7%) studies.
Socioeconomic status was reported in 1/30 (3.3%) study.
Geographic location and healthcare setting
A majority of the studies were conducted in the US or Europe 21/30 (70%) and published in
English 28/30 (93%). The study settings included outpatient or specialized clinics 17/30 (56.7%),
hospital settings 8/30 (26.7%), and both inpatient-hospital and outpatient settings 2/30 (6.7%),
and was unclear in 5/30 (16.7%) studies.
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Wound severity
Thirteen studies reported on wound severity, which included wounds up to Wagner grade 4, and
wounds up to Texas classification Grade 3. The size of the wound was reported in 20/30 (67%)
studies. Depth of wound was specified in 5/30 (16.7%) studies. A total of 14/30 (70%) studies
reported on wound duration which ranged from 0 – 60 weeks.
Clinical prognostic factors
8/30 (26.7%) studies reported on hemoglobin a1c which ranged from 7.25% – 9.25%. 14/30
(70%) studies reported on duration of diabetes which ranged from 13 to 21 years. The proportion
of baseline peripheral arterial insufficiency was reported in 9/30 (30%) studies. BMI was
reported in 5/30 (16.7%) studies.
Table 1 Descriptive summaries of the 30 included studies used in this systematic review and
meta-analysis.
Table 1 of Descriptive Statistics
Total number of studies
30
Total number of participants
2564
Sample size range
18 to 619
Average sample size per
152
study
Total Range of follow up
10 days to 24 weeks
Total Study period or
1992 - 2012
duration
Studies reporting age
24/30 (70%)
Mean age (range)
52.1 – 69.3 years
Total number of studies
21/30 (70%)
reporting gender
Range of number of males
12 to 240
Range of number of females
1 to 88
Number of studies reporting
5/30 (16.7%)
ethnicity
Number of studies reporting
1/30 (3.3%)
socioeconomic status
Geographic setting
Europe and US (70%)
Publication Language
English 93%
Hospital 8/30 (26.7%)
Healthcare setting
Outpatient 17/30 (56.7%)

Studies reporting wound size
(area)
Studies reporting wound
duration
Studies reporting
Hemoglobin a1c (Hgba1c)
Hgba1c (range)
Studies reporting on duration
of diabetes
Duration of diabetes (range)
Studies reporting baseline
peripheral arterial
insufficiency
Studies reporting BMI

Both 2/30 (6.7%)
20/30 (67%)
14/30 (70%)
8/30 (26.7%)
7.25% - 9.25%
14/30 (70%)
13 to 21 years
9/30 (30%)

5/30 (16.7%)
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Intervention comparisons
Nineteen combinations of debridements or debridement with the control condition were made.
This included 12 forms of debridement: 1) sharp, 2) larva, 3) low frequency ultrasound, 4)
jet/irrigation lavage, 5) wet to dry gauze, 6) hydrogel, 7) foam, 8) silver based foam dressing, 9)
fibrous-hydrocolloid, 10) alginates, 11) honey/jam, and 12) collagenase. The debridements were
either compared to each other, or to a gauze/control condition. The control condition included
moistened gauze that usually was moistened with saline but could have included an antiseptic
(e.g. iodine). The intervention arms were paired with a “standard therapy” (adjunctive wound
care measures).
These comparisons included debridement interventions against standard gauze therapy
(moistened/saline gauze which may be categorized as a form of autolytic debridement) which
was frequently used as a control condition in the included studies OR one form of debridement
compared to another form of debridement.
There were significant effects of debridement for some of the outcomes of interest reported in
single studies that utilized distinct debridement combination. These combinations could not be
pooled in the meta-analysis portion of this systematic review since each of the distinct
debridement combinations was only available in one study. These findings are summarized
below with respect to the outcomes of interest.
Comparison 1 (Piaggesi 1998) – Sharp surgical debridement demonstrated a statistically
significant reduction in quality of life score by 2.2 as compared with nonsurgical management 2.20 (95% CI -3.16 to -1.24), (Heterogeneity: Tau2 = 0.00, χ2 = 0.11, I2=0%). Sharp surgical
debridement demonstrated a statistically significant increase in time to complete healing by 82
days as compared with nonsurgical management 81.68 (95% CI 41.07 to 122.29).
Comparison 2 (Goretti 2008) – Superoxide solution demonstrated a significant beneficial effect
as compared with standard local treatment using povidone iodine dressing. There was a decrease
in time to complete healing by 6 days compared with standard local treatment with povidone
iodine -6.00 (95% CI -6.94 to -5.06).
Comparison 5 (Whalley 2001) – Hydrogel purilon as compared with hydrogel intrasite reported a
difference of 35% versus 19% in proportion of ulcers healing. It was unclear whether this was
significant beneficial effect as there was not enough information reported to make that
determination (e.g. no reported counts of events/nonevents).
Comparison 8 (Lalau 2002) – Calcium alginate demonstrated a significant increase in time to
complete healing by 2.8 days as compared with gauze 2.80 (95% CI 1.46 to 4.14).
Comparison 12 (Jeffcoate 2009) – Iodine impregnated fiber dressing demonstrated a 45%
increase in the number of infections as compared with gauze dressing 1.45 (95% CI 1.13 to
1.86).
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Comparison 15 (EhsanUrRehman 2013) – Honey soaked gauze as compared with iodine saline
dressing demonstrated a cost difference of 334 Jordanian Dinars in mean difference (MD 334.00, 95% CI -373.99 to -294.01).
Comparison 16 (Hammouri 2004) – Honey/saline dressing demonstrated a statistically
significant decrease in treatment cost as compared with iodine peroxide saline – 334.00 (95% CI
– 373.99 to – 294.01).
Eight other distinct comparisons that were described in single studies could not be pooled, as
there were no other similar intervention comparisons in at least one other study. These studies
included: Comparison 3 (Amini 2013) Low frequency ultrasound compared with sharp
debridement, Comparison 4 (Markevich 2000) Larvae compared with hydrogel, Comparison 7
(Clever 1995) Polyurethane gel as compared with polyurethane foam, Comparison 9 (Apelqvist
1990) Hydrocolloid as compared with adhesive Zinc, Comparison 11 (Roberts 2001) Foam
dressing as compared with saline nonadherent gauze dressing, Comparison 14 (Foster 1994)
Hydrocellular polyurethane as compared with Calcium alginate, Comparison 17 (Rhaiem 1998)
Sugar Jam with Hydrogen peroxide and topical antibiotic as compared with hydrogen peroxide
and topical antibiotic, and Comparison 18 (Belcaro 2010) Silver (standard cleaning and
compression management methods) dressing group as compared with (standard cleaning and
compression management methods without silver ointment). These comparisons either did not
report or did not demonstrate any significant difference in treatment effects for this systematic
review’s prespecified outcomes of interest.
Four of the 19 distinct comparisons did include 2 or more studies. These 4/19 comparisons were
pooled in meta-analyses for the pre-specified outcomes of interest if reported. This included
comparisons 6, 10, 13, and 19.
Pooled data in four separate comparisons including: Comparison 6 Hydrogel compared with
gauze (3 studies pooled including: (D'Hemecourt 1998; Jensen 1998; Vandeputte 1997),
Comparison 10 Foam dressing compared with Wet to Dry (2 studies pooled including:
(Blackman 1994; Mazzone 1993), Comparison 13 Hydrofiber compared with gauze (2 studies
pooled including: (Jeffcoate 2009; Piaggesi 2001), and Comparison 19 - Any debridement
compared with gauze (10 studies pooled including: (Jeffcoate 2009; Jensen 1998; Piaggesi 2001;
Piaggesi 1998; Vandeputte 1997; Lalau 2002; D'Hemecourt 1998; Donaghue 1998; Goretti 2008;
Roberts 2001) found no significant beneficial difference, except for the proportion of ulcers
completely healed in Comparison 19 - Any debridement as compared with gauze, and
Comparison 6 – Hydrogel as compared with gauze.
Comparison 6 - Hydrogel demonstrated a significant beneficial effect as compared with saline
gauze. There was a 71% increase in the number of ulcers healed as compared with good wound
care 1.71 (95% CI 1.16 to 2.52), (Heterogeneity: Tau2 = 0.00, χ2 = 0.95, I2=0%).
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Comparison 19 - Any debridement demonstrated a 17% increase in the number of ulcers healed
as compared with saline gauze 1.17 (95% CI 1.00 to 1.36), (Heterogeneity: χ2 = 13.89, I2 = 28%).
However, when the two studies available only as abstracts were removed in a subgroup analysis
a weaker and nonsignificant beneficial difference was found. 1.12 (95% CI 0.95 to 1.32),
(Heterogeneity: χ2 = 2.23, I2 = 55.1%).
There was no significant study heterogeneity that was explained with any of univariate models
that were analyzed, except gender. The effects demonstrated low to moderate heterogeneity for
the specified outcomes used in this systematic review. Moderators that were analyzed included
age, peripheral arterial disease, duration of diabetes, gender, data collection year, and study
follow-up duration. All moderators were scrutinized for the recommended number of studies per
covariate for each of the prespecified outcomes of interest. There were 6 moderators that
satisfied these requirements for the intervention comparison Any debridement as compared with
gauze. This analysis was only possible for two of the outcomes of interest this included
proportion of infections, and proportion of ulcers healed. There was no significant association or
effect using the moderators for either of these two outcomes of interest. A Meta-regression was
performed and none of the candidate moderators yielded results any different from the null
hypothesis with the exception of the moderator “gender”. This coincides with data that support a
gender differential favoring males in the development of wounds in diabetics and amputations
having a higher sex predilection among male diabetics. However, the effect was nonsignificant
prior to the use of gender as a moderating variable.
Publication bias was assessed and based on the combination of funnel plot and statistical tests
(Beggs, Eggers). No significant publication bias was observed despite the fact that 13/30 studies
were supported financially by industry.
The GRADE approach was utilized to construct summary of findings tables in order to
summarize our conclusions using a structured standardized evidence grading format. This
yielded very low to low evidence of efficacy.

Conclusion
Currently there exists weak research evidence to suggest that debridement in one form is more
effective in diabetic foot ulcers than other competing forms of debridement or standard gauze for
the outcomes of interest in this review. Many of the randomized studies included in this review
used small sample sizes that may have been underpowered with too few events/nonevents to
make meaningful conclusions. This is evidenced by studies of varying sizes yielding too few
events in the intervention arms making it challenging to detect true effects. The included studies
often demonstrated significant risk of bias that contributed to the low quality evidence. The
studies were variable in the inclusion/exclusion criteria reported.
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The findings of researchers could be better supported by following standardized reporting
guidelines such as the CONSORT statement. The existing body of literature complicates efforts
to synthesize the evidence in systematic reviews. Stakeholders, including patients, physicians,
public health professionals, and policy makers, may consider individualized decision making
such as indications/contraindications, allergies, tolerability, response, and cost as alternatives
pending more definitive standardized RCT’s on this research question. The range of insufficient
information in reporting and variation in methods used are summarized in this systematic review.
Investigators interested in this research question may benefit from the findings reported in this
systematic review as an aide in guiding the design of future randomized studies.
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Chapter 1
Background
Diabetic Foot ulceration has devastating complications. These include amputations resulting in
poor quality of life, and serious infections including osteomyelitis and life threatening sepsis.
Diabetic wounds can be protracted, take significant time to heal and they can recur after they
have healed. They can be very costly and consume healthcare resources. These consequences
have serious public health and clinical implications. Debridement is often used as a standard of
care in efforts to help avert these consequences. It is used to remove nonviable or necrotic tissue
in order to facilitate the wound healing process and help prevent these disabling outcomes. What
is/are the most effective method(s) of debridement remains unclear? This systematic review of
the literature on debridement of diabetic foot ulcers synthesizes all experimental evidence in an
effort to help answer this important question.

Global Data Reports

In 2009 the International Working Group on the Diabetic Foot (IWGDF) began its efforts to
produce consensus guidelines on the diabetic foot. In 2011 the IWGDF estimated that worldwide
approximately 366 million people have diabetes, which includes 7.0% of the world’s population.
80% of these people live in developing countries. The IWGDF 2012 estimated that by the year
2030 there will be 552 million individuals globally who are afflicted with Diabetes (Type 1 and
Type 2) or approximately 8% of the adult population. Younger people are developing DM at an
alarming rate. Annually approximately 1 million people undergo a limb amputation, or 1
amputation occurs every 30 seconds. The majority of amputations are preceded by a foot ulcer.
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The most important risk factors involved in the development of these ulcers include peripheral
neuropathy, foot deformities, relatively minor foot trauma, and peripheral arterial disease (PAD).
Once the ulcer appears, infection and peripheral arterial disease are considered major causes
leading to amputation. The burden of amputations in the developing world is greater than it is in
the developed world. The working group estimated that approximately one quarter of wounds
will not heal, and 28% may progress to the point where they require amputation (Bakker 2012;
IWGDF 2012; Ragnarson 2000).

There is a significant psychosocial impact in that people with foot ulcers and amputations often
have comorbid depression and a reduced quality of life (Cosgrove 2012; Kumari 2004). There is
an increase in “social isolation”. Stress can have immunocompromising effects (Nakata 2012).
Risk of amputation is increased in people living alone, and those who lack the social support of
family and friends. Timely healing was found to be important in improving quality of life. The
working group has stated that investing in diabetic foot care guidelines is one of the most costeffective forms of health-care expenditure (IWGDF 2012).

These global data by the IWGDF is contrasted below with country-specific data using US and
UK data. This is done in order to better compare global health data on this question with health
data from two industrialized countries in Europe and North America. This contrast is to help the
reader better appreciate the context of global heath data from the developing world against
country-specific health data from selected representative countries in the industrialized world.
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US Data Reports

In the United States the diabetes epidemic includes 25.8 million children and adults, or 8.3% of
the U.S. population, approximating 1 in 12 people. A total of 18.8 million people are diagnosed,
7.0 million people are undiagnosed. There are approximately 79 million people living with prediabetes. This includes over 104.8 million individuals with some stage of diabetes, or
approximately 1/3 of the U.S population. These data correspond with the rising rates of obesity,
hypertension, and the increasing age of the US population. There were 1.9 million incident cases
of diabetes diagnosed in people aged 20 years and older in 2010. The disease burden varies
among race and ethnicity including 7.1% of non-Hispanic whites, 8.4% of Asian Americans,
12.6% of non-Hispanic blacks, and 11.8% of Hispanics. The annual death toll includes 231,404
deaths exceeding HIV/AIDS, and Breast Cancer combined. The diabetes epidemic is the number
1 cause of blindness or 4.8% of 30 million people. It is the leading cause of kidney failure
accounting for 44% of new cases or 202,290 people per year, and as in the UK is the leading
cause of amputations in the United States (ADA 2011; USAHQR 2012; USCDC 2012; Ramsey
1999).

Surgical amputations in the United States have reached staggering levels among diabetics
including 65,700 (60% of nontraumatic amputations in 2006). The prevalence of diabetic foot
ulcers is estimated to be up to 8% of the diabetic population. Approximately 15% of diabetics are
expected to develop a wound in their lifetime.
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Based on pathophysiology irrespective of diabetes status 82% of amputations are due to vascular
disease (includes diabetics), 22% due to trauma, 4% due to congenital causes, and 4% due to
tumors. Approximately 1.6 million people are living with amputations in the U.S. and
approximately 113,000 lower limb amputations are performed each year from all causes in the
US (ADA 2011; USAHQR 2012; USCDC 2012).

Among diabetics approximately 75 percent of all amputations occur in people over the age of 65.
Amputation rates are higher in males than they are in females, 12% versus 10.8% respectively.
African-Americans with diabetes have a 1.5 to 2.5 time’s greater rate of amputation than their
Caucasian counterparts with diabetes (Ashry 1998). Poor circulation including microarterial
occlusive disease is the main cause of amputation and accounts for over half of all amputations
that occur among diabetics (ADA 2011; USAHQR 2012; USCDC 2012). Major amputations
(above knee, or below knee) are a marker for increased mortality. It is estimated that 5-year
mortality may be increased as high as 61% - 74% after a major amputation (Robbins 2008;
Tentolouris 2004).

UK Data Reports

Approximately 4.6 % of the UK population or 2.9 million people are estimated to have diabetes,
which is increased from 2% of the population almost a decade earlier. 10% of diabetics have
Type 1 diabetes and 90% have Type 2 diabetes. Foot ulceration is thought to affect 15% of
people with diabetes at some time in their lives. In the UK people with diabetes are 15 times
more likely to undergo lower limb amputations than people without diabetes. In the UK 70 % of
people die within 5 years of having an amputation due to diabetes. Diabetes accounts for onehalf of all limb amputations in the UK (DiabetesUKorg 2013).
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These data are not significantly changed from those previously reported in 1997 and 2009.
(SIGN 1997; SIGN 2009; Spencer 2000).

The World Health organization reports that 9.2% of males and 7.6% of females have raised
blood glucose in the UK based on 2008 data estimates. 67.7% of males and 60.8% of females are
overweight or obese. 65.6% of males and 65.7% of females have raised cholesterol while 46.4%
and 40.8% had raised blood pressure in 2008. These risk factors are collectively referred to as
“metabolic syndrome” and are driving the rising trend in diabetes, diabetic foot ulcers and the
associated complications including amputations (WHO 2011; Calman 1998).

Estimated Costs

Global Cost Estimates

The International working group on the Diabetic Foot (IWGDF) has issued a report on the cost
of Diabetic foot ulcers and amputations. Foot related problems may use 12-15% of healthcare
resources for diabetes in the developed world, whereas in developing countries this may be as
high as 40% (Bakker 2012; IWGDF 2012) see Table 2 below.
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Table 2 IWGDF 2012 (Reproduced here with permission from the IWGDF)
Table of Costs of Treating Foot Ulcers and Amputations
Reference
Country
Number
Costs
USD 2005 Comments
of
(year of
equivalent
Patients
costing)
Ulcers not requiring amputation
Apelqvist et al, Sweden
197
Sweden
8,654
All ulcer types; total
1994
197 SEK
51,000

Harrington, et
al, 2000

Holzer et al,
1998

Metha et al,
1999

USA

USA

USA

400,000

1846 c

5149

(1990)
USA
400,000
USD
3,999-6
(1996)
USD
1,929
(1992)
USA
5149
USD

4,9827,821

Inpatient and
outpatient costs

2,695

1,1503,322

Inpatient and
outpatient costs, those
>64 yr. excluded
Private insurance
charges; mean age 51
yr.

900-2,600

Ragnarson
Tennvall et al,
2000

Ramsey et al,
1999

Van Acker et al
2000

Sweden

USA

Belgium

88

514 d

120

(1995)
Sweden
88 SEK
136,600
(1997)
USD
27,987
(1995)
Belgium
120 USD
5,227
(1993)

Costs of lower extremity amputations

6

18,719

Deep foot infection;
total direct costs

35,758

Including 2 yr. after
diagnosis

7,039

Inpatient and
outpatient costs

Apelqvist et al
1994

Apelqvist et al
1994

Sweden

Sweden

27

50

Sweden
27 SEK
258,000
(1990)
Sweden
50 SEK
390,000

43,778

All ulcer types; minor
LEA; total direct
costs

66,176

All ulcer types; major
LEA; total direct
Costs

Ashry et al 1998 USA

Holzer et al,
1998

van Houtum et
al, 1995

USA

Netherlands

Panayiotopoulos UK
et al, 1997

5062

(1990)
USA
5062
USD
27,930

39,891

Hospital charges
Only

504 c

(1991)
USD
15,792

22,062

Gangrene/amputation,
those >64 yr.
excluded

1575 e

(1992)
NLG
28,433

19,052

Hospital costs only

33,587

Inpatient and
prostheses costs

20

(1992)
UK 20
GBP
15,500

(46% diabetics)
Ragnarson
Tennvall

Sweden

77

(1994-95)
Sweden
77 SEK
261,000

35,767

Deep infection;
minor LEA; total

et al, 2000
Ragnarson
Tennvall

Sweden

19

Belgium

7

(1997)
Sweden
19 SEK
234,500

32,136

direct costs
Deep infection; major
LEA; total direct
costs

et al, 2000
Van Acker et al,
2000

(1997)
Belgium
7 USD
18,515
(1993)

7

24,933

Inpatient and
outpatient costs;
minor LEA

Van Acker et al,

Belgium

9

2000

Belgium
9 USD
41,984

56,538

Inpatient and
outpatient costs;
major LEA

(1993)
Footnotes
For comparison of the results, costs were first adjusted for inflation to 2005 prices with the
consumer price index f and then converted to USD with the appropriate currency exchange
rate for 2005.
NA = not applicable.
LEA = Lower Extremity Amputation.
Minor = amputation below the ankle;
Major = amputation above the ankle.
a Based on data from observational studies
b Based on data from databases and other secondary sources
c Number of episodes
d Includes 80 amputations
e Number of hospitalizations

US Cost Estimates

The estimated total cost of diabetes in the United States in 2007 was $218 billion, exceeding 1/5
of a trillion dollars. This includes direct and indirect costs. The peak age-range for amputations is
between 41 and 70 years. This is a time period of prime working age and productivity for adults.
This poses a significant health challenge to our workforce since amputations can result in
permanent impairment often qualifying an individual for disability benefits resulting in lost
wages, and productivity (Holtzer 1998). This poses a significant stress on the family unit.
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It imposes an economic burden upon society at large in providing for impaired and disabled
individuals. The rate of amputations is rising and these factors are directly contributing to this
alarming trend (ADA 2011; USAHQR 2012; USCDC 2012).

US Government estimates for the 2007 GDP portion allocated for direct healthcare costs was
$2.2 trillion or 16% of the GDP (NCHS 2010). Chronic diseases, including heart disease, stroke,
cancer, and diabetes, cause 7 out of 10 deaths and are responsible for 75% of the $2 trillion spent
on health care (CDC 2009). In comparison the direct and indirect costs for Diabetes in 2007
approximate 10% of 2.2 trillion dollars. Up to 15% of costs for DM in the developed world is
estimated to be allocated for foot related problems, approximately 33 billion dollars in the US
(IWGDF 2012; Harrington 2000).

UK Cost Estimates

The UK National Health Service (NHS) spends an estimated £10 billion per year on diabetes or
10% of the National Health Service budget. Total direct and indirect costs for diabetes in the UK
is £23.7 billion per year (DiabetesUKorg 2013). In the previous protocol from 2001 it was
estimated that £12.4 million was spent on amputations per year. A report published in March of
2012 by the British National Health Service (NHS) - Diabetes estimates that £650 million ( £1 in
£150 in the NHS total expenditures) is spent on foot ulcers or amputations each year (NHS 2012;
King's Fund 1996).
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Description of the condition
Etiology of Diabetic Foot Ulcers
The diabetic foot ulcer is considered multifactorial in its etiology.

Wound progression
Wound repair and closure helps re-establish hemostasis, preserving the barrier function of the
skin in order to prevent infection, and maintaining the overall protective role of the skin. An
ulcer is the result of a break in the dermal barrier, with subsequent erosion of underlying
subcutaneous tissue. In severe cases, the breach may be extended to muscle and bone. The
progression to ulceration may be attributed to an impaired arterial supply, neuropathy, musculoskeletal deformities, or a combination of these factors (Bauer 2000). If the process of wound
healing is impaired and the wound progresses then the risks of infection, amputation, morbidity
and mortality increase (Sheffield 2004).

Wound development and progression are a major risk factor for amputation and follow what is
considered a predictable course among experts in the field. Wounds healing progresses through
the following phases: 1) Hemostasis/Coagulation phase, 2) Inflammatory phase 3) Proliferative
phase, 4) Maturation/Remodeling phase (Baronski 2008; Myers 2008; Sheffield 2004).
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Problems with wound healing may impede wound progression and are considered multifactorial
in diabetics. These prognostic problems may include some or all of the following: vascular
insufficiency/peripheral arterial disease, peripheral neuropathy (sensory, motor, and autonomic),
immunosuppression, critical colonization/infection. These prognostic problems may be more
common in the presence of nonviable tissue (contributing to an increased risk of infection and
delayed wound healing), smoking (contributory to the risk of vascular insufficiency, and
inflammatory burden), and poor nutritional status (inadequate protein and nutrients required for
wound healing). It is believed that these combined problems contribute to the wound stagnating
within the inflammatory phase of the healing process. Typically, the development of a wound
involves a relatively minor soft-tissue injury or insult possibly compounded by these other
factors. The trauma can be the result of friction, mechanical shearing forces, direct pressure, or
penetrating tissue injury including sharp or blunt trauma (Baronski 2008; Myers 2008; Sheffield
2004).

These factors are believed to have a major role in the pathogenesis of diabetic foot ulcerations
leading to wound progression and the associated complications including serious infection and
amputation (Davies 1989).

Vascular Insufficiency
Disease of blood vessels are a major cause of complications in diabetes and affects all types of
vessels (Faris 1991a). The Framingham study reported that more than 50% of men and women
with diabetes had absent foot pulses (Abbott 1990).
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Peripheral vascular disease (PVD) tends to occur at a younger age in people with diabetes and is
believed to involve smaller blood vessels and capillaries further away from the heart. Reports
from US, UK and Finland (Pecoraro 1990; Reiber 1999; Siitonen 1993) have concur that PVD is
a major contributory factor in the pathogenesis of foot ulceration and subsequent major
amputations (Boulton 2000).

Impaired blood flow can occur at both the microvascular and macrovascular arterial circulation
levels in diabetics and can compound the problem of delayed wound healing by leading to
inadequate tissue oxygenation. Microcirculation involvement includes the occlusion of small
blood vessels and capillaries, whereas macrovascular insufficiency is defined as the occlusion of
medium and large sized blood vessels. Hemodynamically significant macrovascular arterial
insufficiency is considered an advanced stage of peripheral arterial disease (PAD). This may
warrant surgical revascularization procedures (Panayiotopoulos 1997). These vascular occlusions
and the resulting wound hypoxia poses a major risk factor in the development of non-healing
problem wounds (IWGDF 2012; Neuman 2008; Sheffield 2004). A host of considerations are
believed to compound vascular insufficiency which restricts the delivery of oxygen and nutrients
required for adequate wound healing, immune function, and can increase susceptibility of coinfections. Considerations may include nutritional status, cardiovascular insufficiency, hydration
status, psychosocial factors, smoking and alcohol history, patient compliance, socioeconomic
status, availability of ancillary treatment modalities, proficiency and expertise of the healthcare
provider involved in the wound care, the type of wound and the presence of wound occurrence
from combined wound mechanisms, the age of the patient, and possibly the type of debridement
method provided to the patient for removal of nonviable tissue from the wound bed and
periwound (Bakker 2012; Edwards 2011; IWGDF 2012; Smith 2002; Sheffield 2004).
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Neuropathy (Sensory, Motor, Autonomic)
Impairment of nerve function is an important and frequent complication of diabetes. All types of
nerve fibers can be affected including motor, sensory and autonomic nerve fibers and their
associated functions. Impaired nerve function in the foot is common in people with diabetes
although the person themselves may be unaware of its presence. Neuropathy remains one of the
major factors leading to the development of foot lesions in people with diabetes (Le Quesne
1991).

This is a frequent occurrence among diabetics. Approximately 60-70% of diabetics have
neurologic disease, most often a peripheral neuropathy involving the lower extremities (ADA
2011; USAHQR 2012; USCDC 2012). This microvascular disease component is believed to
cause occlusion within the vasonervorum which provides the blood supply to the nerves. This is
may be due to the direct cytotoxic effect of the hyperglycemia. This form of microvascular
occlusive disease contributes to the development of peripheral neuropathy. Since diabetic
neuropathy involves motor, sensory and autonomic nerve fibers the pathologic deficits may
include the deformed, insensate, and dry cracking foot.

a) Sensory neuropathy

Damage to the nerves carrying signals from the foot renders the foot insensitive to temperature,
vibration, pressure, and pain. This is referred to as sensory neuropathy. The loss of sensation
means that small injuries often go undetected.
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b) Motor neuropathy

Denervation of muscles has direct effects on the function of the foot. The small muscles of the
foot, the extensor digitorum brevis, lumbrical and interosseous muscles are commonly affected.
Paralysis of these small muscles results in the metatarsophalangeal joints becoming hyperextended and the interphalangeal joints becoming flexed. The joints initially remain mobile, but
later degenerative changes occur and the joints become fixed (Le Quesne 1991). The
consequence of such muscle wastage is a foot shape that increases foot pressures over bony
prominences where wounds most commonly occur in diabetics.

c) Autonomic neuropathy

Autonomic neuropathy is thought to contribute to the pathogenesis of ulceration, neuropathic
edema, and Charcot arthropathy (Le Quesne 1991). Impairment of sweating is suggested to
contribute, through dehydration, to the formation of hyperkeratotic plaques and fissures in the
skin. If this callus (increased glycation of keratin) becomes too thick, it presses on the soft tissues
underneath contributing to ulceration (Edmonds 2000a). Callus is defined as a buildup of
keratinized skin, in reaction to persistent pressure (Cutting 1999), and can itself exert pressure on
the soft tissues of the foot.

The dry cracking foot is a function of the anhidrosis that can develop due to the autonomic
neuropathic changes. Impaired temperature regulation from the autonomic neuropathy may
contributes to these local effects (IWGDF 2012).
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Immunosuppression/Critical Colonization/Infection
Diabetes is considered an immune-compromising condition. It has been observed that white
blood cells may behave atypically in a hyperglycemic (high glucose) environment. They
demonstrate dysfunctional behavior and do not marginate, migrate, or secrete the cytokines
sufficiently that are required in order to combat infection. This can increase the risk of critical
colonization and infection. Critical colonization is defined as a concentration of bacteria at least
100,000 organisms per gram of tissue. The immunosuppressive state that may occur in Diabetes
in the presence of an open wound can lead to critical colonization and infection which are
complicating factors that can increase the risk of non-healing chronic wound (IWGDF 2012;
Sheffield 2004).

The chronicity of this condition may increase the risk of Methicillin Resistant Staphylococcus
Aureus (MRSA), which is among the cultured organisms found in chronic wounds and a major
public health concern. Infections that have reached the deeper bony level of tissue involvement
may become especially problematic making them refractory to treatment. The patient can be at
risk for life threatening sepsis from a wound as an infectious source (IWGDF 2012; Sheffield
2004). This may warrant urgent amputation to remove the source of life threatening sepsis.

Pathway to Ulceration
Despite the presence of the predisposing factors noted above, an uninjured foot may not develop
serious problems. Physical trauma is an inciting event e.g. a puncture wound, localized pressure,
repeated mechanical trauma, heat or chemical injury (Faris 1991b).
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When there is sensory impairment, a small lesion may progress because it may go unrecognized
and the source of injury not alleviated. Lack of sensation allows the damage to progress to
ulceration. Impairment of the blood supply may result in delayed healing. Complicating infection
may contribute as an additional risk factor by increasing the amount of damaged tissue (Faris
1991b).

Chronic wounds may continue to progress beyond full thickness (limited to the epidermis and
dermis). This progression can extend further involving deeper tissues including the hypodermis,
muscle, tendon, and bone. Progression of vascular compromise and infection may lead to tissue
ischemia, non-viable tissue, and gangrene. This pathway ultimately may lead to limb amputation.
Deep seated wound infections such as chronic osteomyelitis and significant bone destruction can
become considerations in the decision to amputate limbs (ADA 2011; Bakker 2012; Edwards
2011; Smith 2002; USAHQR 2012; USCDC 2012).

Common Grading systems used to classify the severity of diabetic wounds
The Wagner grading system and the Texas classifications are internationally utilized grading
systems. These grading systems were compared and the results concluded that increasing stage,
regardless of the grade, is associated with increased risk of amputation and a delay in ulcer
healing time. The University of Texas system's inclusion of stage suggested it was a superior
predictor of outcome (Oyibo 2001) See Table 3; Table 4 below.
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Table 3 Wagner Wound Grade Classification System
Grade
0
1
2
3

4

5

No ulcer in a
high risk foot

Localized
gangrene

Extensive
gangrene
involving
the whole
foot

Wound
involving full
skin thickness

Wound
extending to
ligament and
muscle

Wound with
cellulitis or
abscess

Table 4 University of Texas Wound Classification System
Grade
Stage
0
1
2

3

Pre or Post
ulcerative lesion
completely
epithelialized

Superficial wound
not involving
tendon, muscle, or
bone

Wound
penetrating to
tendon or capsule

Wound
penetrating to
bone or joint

A

0A

1A

2A

3A

No Infection, or
Ischemia
B

0B

1B

2B

3B

Infection but no
ischemia
C

0C

1C

2C

3C

Ischemia but no
infection
D

0D

1D

2D

3D

Infection and
ischemia are
present
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Description of the intervention
Debridement as the Wound Care Intervention of Interest

Currently debridement is considered a central component of conventional treatment in wound
care (the removal of non-viable or necrotic “dead” tissue from the wound). This component of
wound care is used to remove non-viable tissue which may pose a risk of colonization and
infection. Nonviable tissue may impede wound healing by obstructing cellular migration across
the wound. It is believed to impede the normal development of the wound bed and prevent
granulation tissue formation (Baronski 2008; Sheffield 2004; Strohal 2013).

Debridement is considered to be a means of enabling the clinician to better gauge the size of the
wound. Debridement may facilitate drainage from the wound. Removal of nonviable tissue may
reduce the risk of infection and facilitate cellular migration of cells in the wound healing process.
It is believed that an accurate wound culture should be obtained post-debridement and following
saline irrigation of the wound itself (Sheffield 2004; Strohal 2013).

Treatment is focused on closing the wounds within the first 4-6 weeks of their development.
Wounds that decrease their surface area by 20 – 40 % within the first 4 weeks are considered to
have a higher likelihood of closing by experts (Baronski 2008; Sheffield 2004). Desirable goals
include reducing the time to complete healing, accelerate healing rates, and reducing the rates of
recurrence of wounds. If the wound is closed in a timely manner the risks of complicating
infections, and amputation may be prevented thus improving the patient’s overall quality of life.

The following are considered alternate methods of wound debridement:
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Mechanical Debridement – This method uses mechanical energy such as surgical debridement,
high pressure saline irrigation, whirlpool, wet to dry saline dressings, ultrasound, or jet lavage.
The nonselective nature of these forms of debridement can remove granulation tissue that is
produced during the proliferative phase of wound healing Table 5.

i)

Sharp Surgical Debridement – This may be performed either in the inpatient or
outpatient settings. It may be done in the operating room suite if an extensive
debridement is required in lieu of an outpatient “office” surgical procedure when the
debridement is less extensive and superficial. Ultimately the decision on what setting
in which to perform the debridement is based both upon the patient’s comfort level
and how extensive a debridement procedure is required. Expert opinion in sharp
surgical debridement has generally dictated that all the nonviable and necrotic tissue
should be removed and debrided down to bleeding tissue, in effect creating a new
acute wound. This repeats the phases of wound healing from the beginning. This is
often not possible without injuring healthy tissue in the process of attempting to
remove nonviable (dead) tissue. This dissection process can be time-intensive and is
considered semi or non-selective. The injury of healthy tissue results from the
delicate task of separating viable from nonviable tissue using standard sharp
dissection instruments i.e. scalpels and curettes.
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Gross dissection using instruments classified as blunt are not capable of ultraselective microdissection even in the hands of the most skilled health professionals.
Microdissection may only be possible with the use of biosurgery or maggot
debridement therapy described later. This may be problematic in that every “new”
injury increases the risk for a complicating superinfection (Bakker 2012; Edwards
2011; Smith 2002; Strohal 2013).

ii)

Wet to Dry Mechanical Debridement removes non-viable tissue by allowing gauze
saturated with saline and applied to a wound to dry. The gauze then become adherent
to the wound during the drying phase. The gauze is then removed, which can nonselectively pull away both non-viable tissues along with viable granulation tissue
(Sheffield 2004; Strohal 2013).

iii)

Aqueous high pressure lavage/irrigation involves a jet-stream of saline that
mechanically removes nonviable tissue. This is considered a non-selective form of
debridement and is capable of removing granulation tissue. This theoretically may
pose a risk to the healthcare provider performing the debridement. The mist created
by the high pressure irrigation may expose the provider to contamination (Sheffield
2004; Strohal 2013). Whirlpool also involves a form of high pressure hydroirrigation except the entire limb or patient is immersed in a whirlpool bath during
irrigation. Cross contamination is possible using this method as other wounds and
body surfaces may be immersed in the same water. This is also considered a nonselective form of debridement (Sheffield 2004; Strohal 2013).
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iv)

Ultrasound Debridement utilizes sound energy to mechanically debride wounds. This
is usually carried out through contact or noncontact low frequency ultrasound energy.

v)

Biosurgery or Maggot Debridement Therapy (MDT) - This has been an area of
interest for over 400 years and provides a complex system of wound care. Maggots
are larva of flies such as Lucilia Sericata that consume nonviable tissue selectively.
This is typically done in the U.S. with another form of larva, the blow fly maggot
variety (Phoenicia Sericata larvae). Medicinal maggots are believed to carry out this
biosurgical debridement of nonviable tissue selectively as compared with blunt
dissection using sharp surgical instruments. This may reduce the risk of secondary or
superinfection. The species of flies used are cultured for this purpose and provide a
source of enzymatic debridement. The maggots are capable of consuming bacteria
and are believed to produce antimicrobial secretions. This has been demonstrated in
mechanistic in vitro studies (Margolin 2010). Maggot debridement therapy may have
antimicrobial properties including those from hospital acquired resistant organisms
such as MRSA. They may secrete substances that stimulate wound healing (Margolin
2010).
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Non-Mechanical Debridement

i)

Enzymatic Debridement – This involves the use of exogenous enzyme products that
digest the non-viable tissue as opposed to exclusively relying on endogenously
produced wound enzymes such as matrix metalloproteinases that provide autolytic
debridement.

ii)

Autolytic Debridement – This approach involves keeping the wound moist which
may facilitate the endogenous enzymes produced by the wound itself in order to autodigest or “self-digest” nonviable tissue. The use of agents such as hydrogel facilitates
moist wound healing and allows endogenous locally produced enzymes to digest the
non-viable tissues. Many topical agents that are applied directly to skin facilitate
autolytic debridement such as topical antimicrobials even though they are also used to
treat local wound infections. The ability of a variety of topical agents to maintain a
moist wound environment permits concurrent autolytic debridement irrespective of
the other functions of the topical agent used. Other dressings that facilitate autolytic
debridement include: Alginates, Hydrocolloids, Foam, Film, and Honey. Moist saline
gauze is commonly used and has served as a control or standard form of debridement
in studies (Sheffield 2004; Strohal 2013). See Table 5 for a comparison of methods of
debridement.

The evidence to support these various forms of debridement and their impact on such important
indicators as amputation frequency, complicating wound infection frequency, cost, quality of
life, and wound healing rates, recurrence, and time to complete healing will be scrutinized in this
review.

22

Standard Wound Care Prevention and Treatment

The treatment of diabetic foot ulcer generally involves a multidisciplinary team approach and
includes comprehensive advanced wound care. This team may be comprised of a primary care
physician, wound care physician, a wound care nurse, a nutritionist, orthotics consultant,
physical therapist, and a hyperbaracist. This comprehensive advanced wound care approach
provided by a multi-disciplinary team may include the following interventions: (Baronski 2008;
Sheffield 2004).

i) Off-loading: Weight bearing redistribution is the considered the most important consideration
for wound healing of the diabetic foot ulcer. This provides support by redistribution of weight
bearing away from the wound and relocates it to the adjacent surfaces of the affected foot or leg
through the use of orthotics. Alternatively, complete offloading can be achieved by using
wheelchairs, walkers, crutches, or other wheeled mobile devices to remove all weight bearing
entirely (non-weight bearing) from the affected wound (Sheffield 2004).

ii) Physical Therapy: The use of offloading equipment may require special instruction routinely
provided by a physical therapy department. This may require instruction in the proper use of
crutches, wheelchair, or other ancillary mobile non-weight bearing equipment.

The patient may require rehabilitation due to long periods of immobility in order to regain
function and strength in order to maintain function and support the use of offloading devices.

iii) Medical Optimization of Comorbidities including Diabetes: The patient may require
optimization of current treatment for diabetes and other conditions that if left untreated or poorly
controlled may impede wound healing.
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iv) Nutritional Consultation Services and Supplementation: These services have been utilized
to address nutritional deficiency states that may impede wound healing. Laboratory markers such
as Total Lymphocyte Count, pre-Albumin, Albumin, and Total Protein along with clinical
parameters have been used to help direct the proper nutritional interventions.

v) Infection Eradication: If the wound is critically colonized or infected then this may impair
wound healing and antimicrobial therapy is often prescribed. Treatment can be directed locally
or systemically depending on the extent of the infection.

vi) Medical and Surgical Vascular interventions: Hemodynamically significant macrovascular
insufficiency can compound microarterial insufficiency and may require vascular surgical
evaluation. Therapy may involve more extensive medical treatment or it may require surgical revascularization. Surgical revascularization could include angioplasty, stenting, atherectomy, or
surgical bypass grafting.

vii) Hyperbaric Oxygen Therapy: Periwound tissue hypoxia can be measured using
transcutaneous oximetry. If tissue hypoxia is found to be reversible with normobaric or
hyperbaric oxygen challenge; then adjuvant hyperbaric oxygen therapy has been considered
adjuvant therapy in healing problem wounds in diabetics. This testing may suggest
microvascular insufficiency. Hyperbaric oxygen therapy may increase tissue oxygen tensions up
to fifteen times normal. Angiogenesis and vasculogenesis are believed to be stimulated by the
use of hyperbaric oxygen therapy, which may enhance the blood supply around the wound. Proinflammatory intracellular adhesion molecules are down regulated providing an antiinflammatory effect (Thom 1989). Edema may be decreased by the use of hyperbaric oxygen
therapy through peripheral vasoconstriction without a negative effect on tissue oxygenation.
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Oxygen diffusion is increased up to a factor of 4 in the affected tissues (Fife 2007).
Antimicrobial tissue penetration and leukocyte function is believed to be enhanced by the use of
hyperbaric oxygen therapy. Susceptible organisms such as anaerobic or facultative anaerobic
organisms that do not tolerate high oxygen environments may be inhibited by the use of
hyperbaric oxygen therapy. An increase in stem cell production, differentiation, and presence in
the wound bed has been demonstrated (Thom 2005). Hyperbaric oxygen therapy may be
especially useful in those diabetics that have had wound care for greater than 4 weeks with poor
or no response to treatment (Sheffield 2004; UHMS 2008).

Mechanism of the Intervention
Debridement - Current practice
Debridement involves the removal of devitalized, contaminated or foreign material from within
or adjacent to a wound, until surrounding viable tissue is exposed. It is widely practiced in
diabetic foot care (Dorland's 1998). Debridement is regarded by many as an effective
intervention to speed up ulcer healing. Sharp debridement of an ulcer, including the removal of
callus (which may surround or “roof over” an ulceration) and all devitalized tissue may facilitate
wound healing, though direct evidence of this is lacking.

Once an ulcer has developed the aim is to heal it in as short a time period as possible and prevent
recurrence. Margolis conducted a meta-analysis of the control group healing of 10 treatment
trials in people with diabetic neuropathic foot ulcers and estimated that 24% heal within 12
weeks and 31% by 20 weeks with good wound care (Margolis 1999).
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High quality management of the diabetic foot often requires multidisciplinary input and good
communication between primary and tertiary care providers (Young 2000).

Edmonds (Edmonds 2000b) suggests six aspects of "control" to be addressed when caring for
people with diabetes, particularly in relation to foot health:


mechanical control;



wound control;



microbiological control;



vascular control;



metabolic control;



educational control.

Debridement (see Table 5 Methods of debridement) is recommended by the SIGN diabetic foot
guidelines (SIGN 1997) alongside antibiotic therapy for infection and pressure relief as a
treatment for patients who have developed ulceration or gangrene with risk of amputation. The
Royal College of General Practitioners' Guidelines (RCGP 2000) also recommend debridement
as a treatment of the ulcerated foot alongside local wound management and appropriate
dressings. Neither of the guidelines recommend a specific method of debridement.
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Edmonds gave the following rationale for debridement of neuropathic ulcers which included
(Edmonds 2000b):



enables the true dimensions of the ulcer to be perceived



allows drainage of exudate and removal of dead tissue, both render infection less likely



enables a deep swab to be taken for culture



encourages healing.
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Figure 1 Serial images depicting measurements of wound progress over the course of
sequential combined forms of debridement lasting 12 weeks including sharp, enzymatic,
and autolytic.

28

The diabetic foot ulcer has serious consequences to the individual patient, their families, the
healthcare system, and to society as a whole. The patients who undergo amputations, serious
infections along with the associated impairment and disability results in financial hardship and
lost productivity. The patient faces a reduced quality of life along and an increase in 5-year
mortality.

These outcomes may be averted if efforts are made to accelerate successful wound healing.
Wound care is considered by many to be a multidisciplinary team approach. The standard of care
in wound care includes debridement. There are numerous methods of debridement and it is
unclear which method(s) is/are effective.
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Chapter 2 Literature Search for Prior Systematic Reviews
with a Similar Research Question
Introduction/Background
Systematic Reviews and Meta-analyses are important tools in Evidence Based Medicine and
Healthcare. These tools provide researchers with an exhaustive, objective, and transparent
scientific approach using duplicate efforts in synthesizing the evidence around a specific research
question. They provide researchers with the means of determining what the best available
evidence concludes. The systematic review itself is a scientific investigation that is
comprehensive, transparent, promotes duplication of effort, and facilitates replication (Cooper
2009; Higgins 2008).

This may include a qualitative systematic review, and when possible a quantitative systematic
review. The qualitative systematic review exhaustively pools together and collectively
summarizes all the available evidence retrieved and extracted on a specific research question. It
does so by using objective search methods, a data extraction tool, and an objective risk of bias
evaluation tool to assess and judge the quality of the evidence (Cooper 2009; Higgins 2008).

The researchers can determine if a quantitative systematic review (meta-analysis) is warranted
based on the results of the qualitative systematic review. The meta-analysis is a quantitative
synthesis or combination of the evidence from the sample of studies that are included in the
review. The quantitative systematic review may pool together these raw data originally used in
the included studies. Alternatively, and more commonly the summary statistics from each of the
included separate studies are pooled together. This will include the various effect estimates
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which may have been measured on different scales. If the scales differ the researchers can
transform the different effect estimates into a common scale effect estimate. The effect estimates
could include mean differences, odds ratios, relative risk ratios, standardized mean differences,
or correlation coefficients (Cooper 2009; Higgins 2008).

Pre-requisite to any planned systematic review requires an exhaustive search of the literature
systematically for other systematic reviews (SR’s) that may have been conducted on a similar
research question.

The retrieval of prior systematic reviews that evaluated competing debridement interventions to
treat diabetic foot ulcers for comparative effectiveness is an essential component of this current
review. The goal is to help determine what is/are the most effective form(s) of debridement in
treating non-healing wounds in diabetics. The prior systematic reviews may have afforded
researcher’s new information on reducing the risk of amputations and associated mortality,
reducing complicating wound infections, improving quality of life, accelerating healing rates,
and reducing costs.

Contrasting our systematic review against other similar reviews is essential to determine if our
systematic review is to add additional knowledge to the body of literature on this important
research question.

Objectives
This review included the literature search and retrieval of all other systematic reviews on this
research question using similar inclusion and exclusion criteria. These other systematic reviews
could then be compared and contrasted with this review.
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Methods
Inclusion/Exclusion Criteria

The inclusion/exclusion criteria that were utilized to retrieve all prior systematic reviews on the
same research question included the following:
a) Systematic reviews (SR’s) and/or meta-analyses (MA’s) that included randomized
controlled trials (RCT’s) on debridement of diabetic foot ulcers. The search included any
form of debridement but did not include SR’s on Negative Pressure Wound Therapy
(NPWT). NPWT includes debridement as one of its numerous functions but this form of
therapy has been studied in a separate Cochrane review.
b) Adult Type 1, or Type 2 diabetics with ischemic, neuropathic, or neuroischemic diabetic
foot ulcers. The wounds were not limited in severity or in grading system utilized
including Wagner Wound Grade, and Texas Classification.
c) There were no other limitations based on age, gender, country, healthcare setting, or
language.
d) RCT’s that included other wound types i.e. venous stasis ulcers, arterial insufficiency
ulcers in non-diabetics, pressure ulcers, and atypical ulcers were excluded.
e) Systematic reviews that were limited to nonrandomized trials or that focused exclusively
on other wound types were excluded.

Database searched

Data sources were searched and collected accordingly per the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses: The PRISMA Statement Reporting guidelines.
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The searches utilized the following databases and dates: Ovid Medline (1996 – 2013 March
Week 4), PubMed (1940’s – Present), Ovid Embase (1996 – 2013 week 13), Embase via Scopus
(1960 – Present), EBSCO CINAHL (1981 to Present), Web of Science (1974 – Present), The
Cochrane Library, Cochrane Wounds Group Specialized Register (4/15/2015). The detailed
search methods utilized are included under Search Strategies (Appendix 1).

Data Extraction

Two independent reviewers reviewed the search results and independently extracted all
systematic reviews that met the pre-determined inclusion criteria. These data from the SR’s were
extracted from the SR’s along with the respective authors conclusions for comparison with this
review using the same data extraction tool (Appendix 2) used for our review of randomized
controlled trials (RCT’s) for our systematic review. However, the SR’s were not pooled and no
meta-analysis was conducted on the retrieved SR’s. The data extraction was used to facilitate a
qualitative review of the SR’s for contrast purposes with this systematic review. The retrieved
bibliographies were hand searched to locate additional RCT’s for this SR.

These data extracted from systematic reviews included:

a) Author/year which served as a study ID.
b) Number of studies included in the systematic review.
c) Study types including randomized, non-randomized and the number of studies for each
designation.
d) Total number of participants included.
e) Follow up period
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f) Study period
g) Wound severity or grade
h) Debridement intervention type(s).
i) Outcomes included in the systematic reviews.
j) Identification as a Cochrane review or not.
k) The SR’s authors concluding statements regarding the outcome effects and their findings
along with the strength of the evidence were extracted verbatim and are listed in
quotations.

These are summarized in Table 3a below in the results section.

Results
The search retrieved 10 related systematic reviews. Four of the studies retrieved combined both
randomized and nonrandomized studies. This practice is discouraged as randomized studies and
nonrandomized studies should generally be combined with similarly designed studies in separate
systematic reviews i.e. randomized studies alone and nonrandomized studies alone. The
reasoning behind this approach is that non-randomized studies are generally considered to be at
higher risk of demonstrating biased exaggerated effect estimates than randomized studies.
Despite this concern the findings in the four systematic reviews that included non-randomized
studies are came to comparable conclusions with other systematic reviews that were limited to
randomized studies. See table 3a below.
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The number of systematic reviews that used similar inclusion/exclusion criteria as this review
(i.e. Type 1 or 2 Diabetic participants with foot ulcers, randomized studies, and any debridement
method) are listed in the following table:
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These systematic reviews included a range of 4 to 10 studies. Six of the systematic reviews were
restricted to randomized studies, whereas 4 systematic reviews included randomized and nonrandomized studies. The publication years ranged from 1999 – 2013. The number of participants
ranged from 149 - 575 participants. The number of comparisons ranged from 1 - 4 methods of
debridement in the studies retrieved for the 10 systematic reviews SR’s listed in table 3a above.
The types of debridement included sharp, autolytic (hydrogel, foam, alginates, hydrocolloids,
semipermeable polymeric membranes, silver-containing), larva or maggot debridement, and
hydrotherapy. Four of these systematic reviews were Cochrane reviews.

Two out of 10 studies included venous ulcers in addition to diabetic foot ulcers, and one of these
two studies also included ischemic ulcers. The outcome measures of interest included the
following: amputation frequency, infections rates, complete healing rates, time to complete
healing, wound size reduction, health related quality of life (HRQoL), wound recurrence, and
adverse events. The majority of systematic reviews ranged in their findings on the quality of the
evidence from Low evidence to no evidence that forms of non-autolytic debridement studied
were beneficial. Two studies suggested moderate evidence to low evidence that forms of
autolytic debridement were beneficial.

Conclusion
The study’s findings were relatively consistent in that they reported weak or poor evidence to
conclude that one form of debridement was superior to either an alternate form of debridement;
or the control condition or standard treatment. The form of debridement used as control was
autolytic debridement specifically using moistened gauze with either saline or an antiseptic such
as iodine.
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Iodine is frequently used to clean wounds as part of adjunctive measures of wound preparation
prior to and post-debridement. Many of the conclusions reported in these reviews regarding the
direction of future trials included the need for larger sample sizes, and standardized reporting
among authors. The findings in these systematic reviews were relatively consistent in that they
found weak evidence that any debridement or debridement dressing type was more effective than
other dressings in healing diabetic foot ulcers.

Patients, healthcare providers, policy makers, and all other stakeholders are strongly cautioned in
altering clinical practice on the basis of findings derived from small trials of unclear or high risk
of bias including nonrandomized studies.

Stakeholders are cautioned on extrapolation of findings to other wound types, though diabetic
wounds are considered among the most recalcitrant of wounds. Therefore, findings related to
these resistant wound types may be applicable to researchers studying more resistant wound
types. The findings in reviewing the literature for systematic reviews that were conducted on a
similar research question support the need to design and conduct a comprehensive exhaustive
systematic review that strictly utilizes all of our best available evidence i.e. randomized
controlled trials. The systematic review of experimental evidence should retrieve the maximum
number of comparisons that were made between debridement types in order to help delineate
how these interventions compare to each another. This will assist all stakeholders in making
important clinical, public health and policy decisions regarding debridement interventions.
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Chapter 3 Systematic Review Objectives
Study Aims

Study Aim 1. Perform a comprehensive and worldwide systematic review of the literature on all
forms of debridement as a treatment for diabetic foot ulcers.

Study Aim 2. Assessment of the evidence of the effectiveness of all commonly used forms of
debridement as a treatment for diabetic foot ulcers, and the quantitative evidence assessment of
the possible variability or heterogeneity among the comparisons.

Study Aim 3. Meta-regression and subgroup analysis for possible characteristics that may be
moderating the variability of the effectiveness of debridement as a treatment across populations,
settings, and study characteristics.

Research Questions and Research Hypotheses

Study Aim 1. Perform a comprehensive and worldwide systematic review of the literature on all
forms of debridement as a treatment for diabetic foot ulcers.

Research Question 1. How many experimental studies have been published on the topic of
debridement of diabetic foot ulcers?

Research Hypothesis 1a (RH1a): There exists a sufficient number of experimental studies on the
topic of debridement of diabetic foot ulcers to enable the researcher to conduct a meta-analysis.
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Research Question 2. Has all the literature on this topic been published or is there a
substantial body of literature that remains unpublished?

RH2a: There exists a substantial body of literature on the topic of debridement of diabetic foot
ulcers that remains unpublished and is eligible for inclusion in the meta-analysis.

Research Question 3. For the studies that exist are they of sufficient quality with relatively low
risk of bias that makes them eligible for inclusion in our analysis?

RH3a: There exist both published and unpublished experimental studies that meet the eligibility
criteria for inclusion in a meta-analysis that are of sufficient quality and relatively low risk of
bias.

Study Aim 2. Assessment of the evidence of the effectiveness of all commonly used forms of
debridement as a treatment for diabetic foot ulcers, and the quantitative evidence assessment of
the possible variability or heterogeneity among the comparisons.

Research Question 4. Does any form of debridement and standard wound care as compared to
autolytic debridement and standard wound care:

i)

Reduce the time to complete healing of diabetic foot ulcers?

RH4a: There will be a difference in time to complete healing of diabetic foot ulcers using
debridement in any form as compared to standard wound care and autolytic debridement, with
significant variability in the distribution of the effects.
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ii) Improve healing rates of diabetic foot wounds?

RH4b: The healing rates of diabetic foot ulcers using debridement in any form will be different
as compared to standard wound care and autolytic debridement with significant variability in the
distribution of the effects.

iii) Decrease recurrence rates of diabetic foot wounds?

RH4c: There is a difference in the frequency of recurrent diabetic foot ulcers using debridement
in any form with standard wound care as compared to autolytic debridement and standard wound
care, with significant variability in the distribution of the effects.

iv) Decrease the frequency of amputations that may result from diabetic foot wounds?

RH4d: There is a difference in the frequency of amputations associated with diabetic foot ulcers
using debridement in any form as compared to autolytic debridement with standard wound care,
with significant variability in the distribution of the effects.

v) Decrease the frequency of Methicillin Resistant Staphylococcus Aureus (MRSA) or other
wound infections that may complicate diabetic foot wounds?

RH4e: There is a difference in the frequency of MRSA or other wound infections in diabetic foot
ulcers using debridement in any form against autolytic debridement with standard wound care.
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vi) Reduce healthcare costs for diabetic foot wounds?

RH4f: There is a difference in the healthcare costs associated in treating diabetic foot ulcers
using debridement in any form as compared to using autolytic debridement with standard wound
care.

vii) Improve the quality of life for those with diabetic foot wounds?

RH4g: There is a difference in quality of life indicators in treating diabetic foot ulcers using
debridement in any form as compared to autolytic debridement with standard wound care.

Research Question 5. Which specific method(s) of debridement is/are most effective at
achieving the desirable outcomes listed? Do the specific method(s) of debridement:

i)

Differ in the time to complete healing of diabetic foot ulcers?

RH5a: The time to complete healing of diabetic foot ulcers is dependent on the method of
debridement used.

ii) Improve healing rates of diabetic foot wounds?

RH5b: The healing rates of diabetic foot ulcers are dependent on the method of debridement
used.

iii) Decrease recurrence rates of diabetic foot wounds?

RH5c: The frequency of recurrent diabetic foot ulcers is dependent on the method of
debridement used.
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iv) Decrease the frequency of amputations that may result from diabetic foot wounds?

RH5d: The frequency of amputations associated with diabetic foot ulcers is dependent on the
method of debridement used.

v) Decrease the frequency of Methicillin Resistant Staphylococcus Aureus (MRSA) or other
wound infections that may complicate diabetic foot wounds?

RH5e: The frequency of MRSA or other wound infections is dependent on the method of
debridement used.

vi) Reduce healthcare costs for diabetic foot wounds?

RH5f: The healthcare costs associated with treating diabetic foot ulcers is dependent on the
method of debridement used.

vii) Improve the quality of life for those with diabetic foot wounds?

RH5g: The Quality of life indices among those with diabetic foot ulcers is dependent on the
method of debridement used.

Study Aim 3. Meta-regression and subgroup analysis for possible characteristics that may be
moderating the variability of the effectiveness of debridement as a treatment across populations,
settings, and study characteristics.
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Research Question 5. Do there exist any prognostic or other moderating factors that are
population specific, disease specific, or study specific characteristics that explain the
variability of the effect sizes for the various forms of debridement?

RH5a: There exist moderating factors responsible for the variability of the effect sizes among the
debridement interventions compared.
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Chapter 4
Methods
In accordance with our primary aim, Study Aim 1, this method sections describes in detail the
methods used to perform a comprehensive and worldwide systematic review of the literature on
all forms of debridement as a treatment for diabetic foot ulcers. The search was designed to
capture all randomized controlled trials and all systematic reviews pertaining to our research
question. Data sources were collected accordingly per the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses: The PRISMA Statement Reporting guidelines Moher
2009.

Inclusion/Exclusion Criteria
Types of studies
All Randomized controlled trials (RCTs), either published or unpublished were included, which
compare the effectiveness of two or more methods of debridement in the treatment of diabetic
foot ulcers. There will be no restriction in the search or in the studies included for analysis based
on language, or country of origin.

Non-randomized studies were excluded. This exclusion includes prospective cohort studies, case
controlled studies, cross sectional studies, data archival analysis, Case series/Case studies.
Mechanistic in vitro or animal studies were also rejected.
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Types of participants
Studies with samples of participants that have Type 1 or 2 diabetes, with an active foot ulcer or
wounds of neuropathic, neuro-ischemic, or ischemic etiology were included. The review was
limited to participants >/= 18 years of age. There were no other limitations based on age, gender,
country, healthcare setting, or language. The wounds are not limited in severity or in grading
system utilized including Wagner Wound Grade, and Texas Classification.

Studies that included non-diabetics were excluded. Studies that included venous stasis wounds,
nondiabetic arterial insufficiency wounds, pressure ulcers, or atypical wounds were excluded.

Types of interventions
Comparison of any method of debridement (i.e. the removal of necrotic tissue from the wound,
by either mechanical or non-mechanical debridement) with no debridement, control, or an
alternative method of debridement were included Table 5.

These debridement methods included: autolytic debridement (including moistened saline gauze,
or antiseptic treated gauze as a control condition), sharp surgical debridement, enzymatic
debridement, biosurgery (or Maggot Debridement Therapy, MDT), mechanical debridement
(including wet to dry, and ultrasound debridement). The search included any form of
debridement but did not include SR’s on Negative Pressure Wound Therapy (NPWT). NPWT
includes debridement a one of its functions but this form of therapy has other mechanisms and
has been studied in a separate Cochrane review Dumville 2013b.
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The ancillary and adjunctive services that are provided as part of routine standard of care
discussed were coded to control for them as possible modifying factors favoring the intervention
or control effect. It was anticipated that both the control group and debridement intervention
groups would have received these other adjunctive services. However, the researchers coded
accordingly to ensure there was no evidence of differential standards of care in favor of
treatment or control.
The term “autolytic debridement” is a process that occurs, naturally, in all wounds. Autolytic
debridement is however enhanced with the application of certain “autolytic debridement agents”,
hence using autolytic debridement as a control is based on the naturally occurring phenomenon
in all wounds such as proteolytic enzymes e.g. Matrix - Metalloproteinases that are released from
the wound for “self-digestion” or debridement of the wound. We have restricted the “control
condition” specifically to using autolytic debridement with saline moist gauze, and or antiseptic
agents such as betadine, or chlorhexidine. Autolytic debridement agents (e.g. hydrogel) that
facilitate moist wound healing other than “saline moistened gauze and antiseptic agents” (control
condition) were compared as experimental interventions against alternate forms of autolytic
debridement, or other forms of debridement (mechanical). These alternate forms of autolytic
debridement were often compared to the “control group” defined here as gauze, saline moistened
gauze, or antiseptic dressings in the included studies. Wet to dry saline moistened gauze was
designated as a form of mechanical debridement and not autolytic debridement. Using saline
moistened gauze and antiseptic cleaning solutions has been widely used for an extensive period
as a form of default wound dressing. This warranted the use of this type of autolytic debridement
with gauze, saline moistened gauze, and/or antiseptic solutions as a control condition in this
systematic review (Strohal 2013).
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Types of outcome measures
Included studies were searched for any of the following outcome measures reported.
1. Amputation frequency – The frequency of amputations, and type major (above or below knee)
or minor (digital, ray, transmetatarsal, forefoot)
2. MRSA or other complicating wound infection frequency – These may include the frequency
of MRSA or other wound complicating infections such as osteomyelitis, cellulitis, or Clostridia
infection and gas gangrene.
3. Quality of Life (QOL) – This may include subjective ordinal scales such as an SF-36
questionnaire or some other established alternative quality of life metric.

4. Healing rates -The rate of reduction in wound size expressed in either absolute or relative
terms.

5. Time to complete healing or the proportion of people whose ulcers heal completely at a fixed
point in time.

6. Recurrence rates - The proportion of ulcers recurring among participants in or near the same
location as the previously healed ulcer.
7. Cost of care – This could have been presented as cost per wound treated or based on a
reference cost of treatment and is conducted in cost effectiveness analysis (CEA). Cost was not
standardized across included studies that reported on this outcome. Currency and cost of
treatment was also anticipated to vary across countries.
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Primary outcomes

The primary outcomes of interest that were considered to be most relevant included 1-3: These
outcomes have direct bearing on clinical and public health implications.

Secondary outcomes

The secondary outcomes of interest were considered to have indirect but important bearing on
the primary outcomes and included 4 – 7.

Search methods for identification of studies
Three separate searches were conducted between March of 2103 and March of 2015, see
Appendix 1. They included two separate searches by the trials search coordinator at the
Cochrane Review Group - wounds in March of 2013 and in March of 2015. A separate
institutional search in collaboration with the University of Connecticut medical research librarian
was also conducted in April of 2014.

Six computer databases were searched, as were other relevant sources. The specialized trials
register of the Cochrane Review Group - Wounds was searched for Randomized Controlled
Trials (RCT) on debridement of diabetic foot ulcers without any country, language, or year
restriction that are available to date. The register is compiled by searching bibliographic
databases such as MEDLINE, CINAHL, EMBASE, Cochrane Controlled Trials Register, Web
of Science, CINAHL, World Health Organization, Conference Proceedings and Abstracts
relevant to wound care including International Working Group on the Diabetic Foot, the
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European Wound Management Association, the American Professional Wound Care
Association, and the European Tissue Repair Society (Booth 2006; Cooper 2009; DeLuca 2008;
Warren 2011). Searches were limited to humans and to experimental studies.

The search strategy incorporated the type of participants including adult (>/= 18 years of age)
type 1 and type 2 diabetics with Diabetic or lower extremity non-healing ulcerations/wounds.
The intervention is any treatment classified as a form of debridement.

This systematic review was restricted to include all randomized controlled trials and all existing
systematic reviews related to the research question (Lefebvre 2011).

Hand searching included conference proceedings and journals not indexed in electronic
databases. Citations within systematic reviews and the bibliographies of included studies were
scrutinized to identify additional studies.

Manufacturers and distributors of debridement products were contacted for details of
unpublished and ongoing trials. Experts in the field of diabetic foot management were also
contacted for details of unpublished and ongoing trials. The search was not limited by language
or publication status.

Upon completion of our search the studies that were accepted and met the two independent
reviewers’ shared inclusion/exclusion criteria were retrieved along with studies for which the
reviewers were not able to determine eligibility based solely on the title and abstracts alone.
These studies were retrieved and the full text article was scrutinized further if not excluded
earlier based on title and/or abstract.
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Electronic searches
A comprehensive literature search was conducted. The literature searches were conducted
separately with the assistance of the trials search coordinator at the Cochrane Review Group –
Wounds, and with the assistance of the University of Connecticut Medical Health Sciences
Librarian. The search terms included medical subject headings and other search terms that are
directly related to the aims of this study. Detailed search strategies and search terms used for this
review are illustrated in Appendix 1.

For this review we searched the following electronic databases to find reports of relevant RCTs:


The Cochrane Wounds Group Specialized Register (4/15/2015);



The Cochrane Central Register of Controlled Trials (CENTRAL) (1898 to present);



Ovid MEDLINE (1996 to March Week 4 2013);



Ovid MEDLINE (In-Process & Other Non-Indexed Citations, (1946 to Present, 2013 to
April 14 2015);



Ovid EMBASE (1974 to 2015, June 16 1996 to 2013 Week 13, 2013 to April 14 2015);



EBSCO CINAHL (1981 - present, 2013 to April 15 2015)



EMBASE via Scopus (1960 to present)



Web of Science (1974 to present)

Searching other resources
We searched the bibliographies of all included studies and all existing systematic reviews related
to the research question.
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Selection of studies
Studies were selected independently for inclusion based on the consensus of two independent
reviewers. An independent subject/content area expert, and an independent methods expert were
available for technical support and to resolve any discordance between the two primary
reviewers.

Any disagreements were initially resolved through discussion between the two primary
reviewers and then if unresolved referred to the respective independent experts. Any
disagreements that still remained were referred for arbitration to the Cochrane Review Groups –
Wounds. However, no disagreements were referred to the review group, as they were all
resolved internally. Any studies that required full article retrieval and were subsequently rejected
were included in the excluded studies section with the reason for rejection See Characteristics of
Excluded studies section. These steps are in accordance with efforts to maximize the
transparency and redundancy in the process (Cooper 2009; Higgins 2008).

Data collection and analysis
A coding system using a data extraction form was developed and pilot tested for use with all the
variables selected for coding. See Appendix 2 for the full version of the data extraction form
used in this analysis. The coding data extraction form created included study-specific
characteristics, quality-specific characteristics, participant-specific characteristics, and
intervention-specific characteristics. The breadth of the coding form comprises summary
statistical fields, prognostic predictor variables, outcome variables, study design and quality
indicators including risk of bias indicators, and demographic information.
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The program Microsoft Access was used to create an electronic data entry form/program based
on the data extraction form in Appendix 2. This was to facilitate data entry, and reduce data entry
errors that can occur by inputting data directly into a data grid by the two independent reviewers.

The variables were extracted and transferred onto an Excel spreadsheet independently by each
reviewer using the (reliability pre-tested) data extraction tool (Cooper 2009; Higgins 2008). The
extraction of these characteristics were dependent upon reporting status in the respective studies
selected. Many of the pre-specified variables were either not reported or were not uniformly
reported in the studies.

Variables that represented study-specific characteristics were grouped together including for
example publication year, and data collection year. The estimated year of data collection (earliest
date for data collection or manuscript submission/publication were used. If the study was
unpublished and/or the date unknown, then the length of follow-up and/or year of manuscript
was used as an estimate for data collection year. Other study-specific characteristics included
language, and the source, or type of publication (abstract, conference proceeding, journal article,
book, unpublished manuscript, thesis/dissertation) were extracted.

The variables included in the coding form represented sample characteristics, e.g. age (mean and
standard deviation), gender (percentage of males and females in the sample), region (country or
city where the study was conducted), hospital or outpatient settings (specialized center, or private
office settings), and racial/ethnic composition (the proportion of minorities in each of the
respective samples). Ethnicity was coded as a moderator for the higher risk of amputations that
has been observed in minority groups, and for lower socioeconomic status. Socioeconomic status
was included as a surrogate for healthcare literacy, and access to healthcare.
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Covariates or modifiers that are suspected of influencing wound healing and represent clinically
prognostic risk factors were extracted. Separate from the nonclinical sample characteristic
moderators described above, clinically relevant modifiers were included such as peripheral
vascular disease status (percentage of the sample), periwound tissue oxygen levels (mean and
standard deviation), diabetes disease severity indicators such as hgba1c (mean and standard
deviation), diabetes duration (percentage of the sample), Body Mass Index (BMI, mean and
standard deviation), hypertension status (percentage of the sample), and immunosuppression
status (percentage of the sample). Immunosuppression was coded and included percentage of the
sample that were HIV positive or receiving Immunosuppressive medication, if reported in the
study.

Study characteristics included quality-specific indicators (following the Cochrane Risk of Bias
table format) was collected from the individual studies selected for the review, and were coded
for analysis. Specific quality indicators included: random sequence generation, allocation
concealment, blinding (specific to participants, personnel delivering interventions, and outcome
assessors), incomplete outcome data, and selective reporting, and other bias (e.g. industry
support).

Data extraction and management
Data extraction
A comprehensive data extraction tool or coding form was created to acquire relevant data based
on the prevailing standards in wound care. The data extraction form had a total of 237 possible
variables. These variables represented outcome variables of interest and moderators.
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Efforts were made to help facilitate and minimize the risk of incorrect data entry between the two
independent authors and an electronic data entry form was created using the Microsoft Access
program.

After retrieval of the included studies data were extracted in duplicate by two separate
independent reviewers.

The data extraction tool that was created was reliability tested between the 2 reviewers and
utilized all of the included studies. The reliability testing of the data extraction coding form was
conducted after data extraction and prior to the data analysis phase of this systematic review. All
of the variable results were used except for the outcome variables. The data extraction was
evaluated and expected to demonstrate a kappa statistic that reflected at minimum a 0.74 or
greater agreement prior to its use on studies selected for inclusion (Higgins 2008). Any
discrepancies between the two reviewers were reconciled until all entries were finalized and
identical. The data extraction form served as the sole data extraction tool for each of the studies
selected. Any disagreements in extracted content were fully resolved by discussion and if
unresolved would be referred to the content and methods expert, and if still unresolved, to the
Cochrane Review Group Wounds for arbitration (Cooper 2009; Higgins 2008).

Collectively the 30 individual studies selected did contain every outcome effect of interest. The
Meta-analysis portion of the analysis was conducted on similar studies based on shared outcome
effects as all studies did not necessarily report on all of the outcomes of interest. The way that
missing data were handled in the studies (i.e. Bayesian methods, imputation methods, last
observation carried forward) was reported in the systematic review.
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Intention-to-treat analysis was evaluated further by the reviewers in order to determine if the
specific method used and classified by the authors as intention-to-treat was reported in the
methods section of each study (Harel 2012).

Reliability testing
Reliability testing was conducted on all of the modifying factors for the 30 included studies as
these represented the majority of the 235 variables in the data extraction coding form.

The dichotomous variables were compared between the two researchers using cross tabulations.
Percent agreement and kappa statistics were calculated. The kappa statistics representing each of
the categorical variables were averaged, and the mean kappa was 0.33, which is representative of
poor agreement between coders for the data extraction coding form.

The continuous variables were compared between the two researchers using correlation matrices.
Pearson's correlations were obtained for each of the respective continuous variables and then
they were subsequently averaged. The mean Pearson's correlation was 0.75 which is
representative of good agreement between the researchers. This contrasted significantly with the
kappa for the categorical data.

This difference likely reflected the inherent subjectivity in many of the dichotomous variables
that included quality assessment judgments, whereas the continuous variables represented more
objective variables e.g. hemoglobin a1c. Another possibility may have been a differences in
background knowledge between the two researchers.
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The third source of discordant data extraction may have been that the data extraction tool
included some questions with ambiguous meaning to the reviewers. The data extraction coding
form was then edited for future updates of the present systematic review with the intent of
reducing discordant responses between reviewers.

Regardless of the source of discordant data extraction all disagreements were reconciled in a
series of meetings. A general reliability calculator was used for the reliability process (HuedoMedina 2013). The general reliability calculator is a program that utilizes an excel spreadsheet
with predesigned formula to permit data entry in either a Pearson correlation matrix for
continuous variables or a cross tabulation for categorical variables. The program helps generate
the Pearson correlations and chi square values for all variables compared. It then can be used to
calculate reliability between two reviewers using a data extraction coding form.

Assessment of risk of bias in included studies
The assessment of the risk of bias for each of the studies included in the systematic review relied
on the Cochrane Collaboration’s Risk of Bias table format. The risk of bias tables included the
following indicators the this systematic review (Higgins 2008; Hulley 2007):

i)

Allocation sequence generation (randomization status and method of randomization

reported)

ii)

Allocation of concealment (concealment of the order of random allocation from the

investigators assigning individuals to treatment groups reported) (EBN 2001)
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iii)

Blinding (blinding status of participants, investigators, and outcome assessors

reported) (EBN 2001)

iv)

Incomplete outcome data addressed (reporting of missing data along with

procedures used to address missing data)

v)

Free of selective reporting (selective reporting of outcomes pre-specified in the

protocol or the methods)

vi)

Free of other bias (other potential threats to validity related to the specific study

design used, early stopping of study, baseline imbalance between the comparison

groups i.e. high suspicion of confounding/effect modification)

These risk of bias considerations were extracted accordingly into the data coding form (Higgins
2008).

Funnel plot assessment of reporting bias was conducted on the individual studies included in the
review. A minimum of 10 studies is recommended for assessment of publication bias. The funnel
plot graphs standard error against the effect size. The positive/negative study classification can
then be graphically compared for smaller and larger studies. If the studies fall in a symmetric
pattern around the null value than the likelihood of publication bias is lessened. If the funnel plot
is asymmetric favoring positive effect sizes this suggests publication bias.
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Beggs and Eggers statistical tests were also utilized to evaluate for reporting bias. These test are
explained further below (Cooper 2009; Higgins 2008).

Measures of treatment effect
The effect measures included dichotomous events/nonevents data which were used to generate
Relative risks (RR) for proportion of sample with amputation, proportion of sample with
infections, proportion of sample with wound recurrence, and proportion of sample with wound
completely healed. Difference in means (MD) or standardized mean difference (SMD) were used
for continuous data such as time to complete healing, cost, quality of life index. Mean difference
was favored for purposes of reporting in this systematic review provided the scale and
measurement were comparable. This was used because mean difference is inherently better
understood by the reader than is standardized mean difference.

Dichotomous events/nonevents data used to calculate the effect estimate risk ratio (RR):

1) Proportion with amputations

2) Proportion with complicating infections

3) Proportion with ulcers completely healed

4) Proportion with ulcer recurrence

Continuous data (MD), (SMD)

5) Quality of Life Index
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6) Time to complete healing

7) Treatment cost

Statistical Analysis
Effect size (ES) estimates for the association of each independent variable with each of the
outcomes were extracted accordingly using an effect size extraction program (Huedo-Medina
2013). The trials varied in the effect measures reported. The Effect size calculator utilizes an
excel spreadsheet with included formulas that converts effect sizes into different forms
interchangeably.

Proportion of participants with amputations, infections, complete ulcer healing, and ulcer
recurrence were reported for each of the included studies from events and nonevents for both the
intervention and control groups. The results were extracted from dichotomous events/nonevents
data into the respective proportions and these effects were transformed into Relative Risk ratios
(RR). Risk difference (RD). Numbers Needed to Treat for an additional Beneficial outcome
(NNTB), and Numbers Needed to Treat for an additional Harmful outcome (NNTH) were then
subsequently calculated (Morris 2002).

Time to complete healing, and cost of care were reported as continuous effect sizes measures
using mean differences (MD) along their respective standard deviations (SD) for both the
intervention and control groups.

Quality of life was reported using subjective questionnaire scales on a continuous or ordinal
scale. These scales were not necessarily standardized across studies using similar or identical
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debridement interventions. Therefore, the effect sizes were converted to mean differences if a
similar scale was used, or to a standardized mean differences (d) if the scales differed.

These procedures were used in order to make it possible to compare the effects of the
intervention regardless of the outcome metric used. These conversions or transformations were
contingent upon the same intervention being used in at least two studies.

The standardized mean difference is defined as the difference between the treatment and control
groups divided by the pooled standard deviation for two-groups design, or the difference
between two d for pre-post group design, one for the experimental and another for the control
group. The pre-post design d (Cohen’s d) is defined as the posttest and baseline difference of
sample means divided by the baseline standard deviation (Becker 1988; Hedges 1981; McGrath
2006).

In the absence of means and standard deviations, other statistical information (e.g., F-values, pvalues) could be used as surrogates for effect estimates, these statistics were also extracted.
Although using test statistics and p-values is less ideal than using the direct effect size estimates
(Huedo-Medina 2006; Huedo-Medina 2013; Sanchez 2003; Hedges 1985). Effect sizes for the
same outcomes may be reported differently in different studies. Therefore, transformation of the
outcome effect sizes into the same effect estimate in order to standardize them for comparison
purposes was required. This was utilized in the meta-analysis by transforming the statistical
information reported into a uniform effect size estimate for analysis, e.g. RR, OR, MD,
standardized mean difference, d, using HLSM-Meta software version 0.9 (Huedo-Medina 2006;
Huedo-Medina 2013).
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Unit of analysis issues
The unit of analysis reported was based on a single outcome response per individual. There were
studies that reported simultaneous treatment of wounds on multiple sites for each individual; the
authors of the studies generally based the outcome assessments on the most severe of these
wounds.

Few studies reported multiple time points or observations for the same outcome (e.g. repeated
measurements, recurring events). The studies all reported post design (final observations). The
limited studies that did report multiple time points, were reported in this study as post design
(e.g. final observations number with amputations by the end of the study) for both the
intervention and control groups. In the studies where initial measurements or observations were
reported these were summarized for the reader in tabular format along with wound severity based
on classification and/or wound duration at baseline.

The follow up periods and the length of the study are reported, and summarized between studies
for the reader. This review prioritized sustained or long term outcome or last reported outcome
responses for debridement interventions, as these were considered the optimal long-term
indicators of outcome success or failure.

Study treatment of missing data
The individual included studies were not expected to contain every outcome effect of interest for
this review. The pooled date for the meta-analyses utilized similar studies based on shared
outcome effects and interventions. The respective included studies sharing similar intervention
comparisons and outcomes were then grouped and analyzed together.
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When these data were extracted the method used to address missing data was scrutinized and
reported accordingly, e.g. Intention to treat analysis, last observation carried forward, Bayesian
methods, or imputation. The method of missing data treatment was scrutinized for each of the
respective included studies and if reported the method was subsequently reported in this
systematic review (Harel 2012).

If studies with continuous outcome measures reported effect sizes but did not report the
associated standard deviations; then the respective continuous study outcome was not analyzed
in the meta-analysis phase of this review. In studies reporting dichotomous outcomes, if the
actual number of events/nonevents were not reported or could not be extracted or calculated from
a respective study; then the outcome was not included in the meta-analysis phase of this review.

Assessment of reporting biases
Publication bias and other reporting biases were addressed using funnel plots, statistical tests and
through the use of Cochrane risk of bias tables. The authors acknowledge that asymmetric funnel
plots are not necessarily caused by publication bias (and that publication bias does not
necessarily cause asymmetry in a funnel plot). For example, the other reasons that may bias the
results toward exaggerated positive findings in smaller studies might include differences in
methodological quality, heterogeneity in the intervention effects in certain higher risk groups,
and random error.
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Cochrane risk of bias tables were used to assess each study for sequence generation, allocation
concealment, blinding (including 3 categories participant, personnel delivering interventions,
outcome assessor), reporting biases, and other biases including funding sources, unpublished
abstracts.

Funnel plot assessment of publication bias was conducted on the studies included in the review.
This was based on standard assessment that includes sample size and positive/negative effect
size magnitude and direction. Asymmetries of effect sizes suggest reporting biases as they may
be found associated with a propensity to report positive studies disproportionately as compared
to negative studies (Cooper 2009; Higgins 2008).

Alternatively, tests were used for publication bias including Beggs technique uses a
nonparametric rank correlation test to detect publication bias in meta-analyses (Begg 1994). The
test is an adjusted rank correlation test which is considered a statistical analogue of the funnel
plot. The test generates a Kendall’s tau between the standardized effect size and the variances (or
standard errors) of these effects. Tau is interpreted analogous to a correlation. A value of zero
indicating no relationship between effect size and precision (variance or standard error). Values
in either direction away from “0” indicates an association.

The test is considered powerful and useful for large meta-analyses that include at least 75 studies
or greater, but moderate power for meta-analyses with at least 25 - 75 included studies. The test
is not ideal for small studies. Bias cannot be ruled out if the test result is non-significant. The test
is considered complementary to the funnel plot (Begg 1994).
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An alternative graphical test is available called Egger’s technique which detects bias in metaanalyses (Egger 1997). Funnel plots can plot effect estimates against standard error in order to
detect bias in meta-analyses. Egger uses a “simple” test of asymmetry of funnel plots in order to
attempt to predict discordance of results among meta-analyses when they are compared to large
trials. The degree of funnel plot asymmetry is assessed. This is based on imprecision of the
intercept obtained through regression analysis for standard normal. Egger uses the effect sizes
and precision, which differs from Beggs which uses ranks.

The Egger test uses the standard normal deviate (effect size divided by its standard error) and
this is regressed upon precision (inverse of the standard error). The intercept in this regression
corresponds to the slope in a weighted regression of the effect size on the standard error. By
demonstrating that it is no different from 0 suggests that there is no asymmetry in the funnel plot
(Egger 1997).

The trim and fill method was another alternative method considered. This method removes the
most extreme small study studies from positive side of the funnel plot to evaluate what the effect
estimate would be without them. This approach can add symmetrically mirror image extreme
small studies to the negative side of the funnel plot to determine how that impacts the overall
effect estimate. (Duval 2000).
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Data synthesis
This systematic review included a meta-analysis using a random effects model. A random effects
model was considered appropriate in this analysis since it is difficult to assume that an
intervention has a singular fixed effect in complex biological organisms using healthcare
interventions (Cooper 2009; Higgins 2008; Schmidt 2009). Treatment effects are expected to
vary widely due to the wide variation in practices that constitute standards of care among the
healthcare community. This is in addition to individual patient’s biological variability.

A random effects model approach was considered because it provided a more conservative
estimate of outcome effects when considering the variation in healthcare interventions. The more
conservative larger confidence interval is likely more reflective of the broader range of treatment
effects in healthcare interventions. There exists significant variability between individual
subjects in their responses to interventions. There are variables that are not accounted for, since
some mechanisms responsible for the effects of treatment in an individual remain poorly
understood. These unknown prognostic factors are irrespective of efforts to use modeling to
account for known modifying characteristics that may interact with the intervention or confound
the intervention and effect. There may be hyper-responders that may be suggested by outliers.
There is large biological complexity, making it is reasonable to infer that there likely exist
numerous treatment effects among the population rather than a single fixed effect. Therefore, our
analysis accounted for both conditional, and random variability (Cooper 2009; Higgins 2008,
Borenstein 2009).
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Sensitivity analysis
Efforts were made to determine whether the decisions made during the review process were
robust, such as the inclusion/exclusion of particular studies from the meta-analyses with missing
or insufficient data such as abstracts.

Studies that were restricted to unpublished abstracts (Goretti 2008; Roberts 2001) were removed
and a meta-analysis was then conducted separately in order to determine if the summary effect
estimates were robust despite the exclusion of these two studies. This was considered appropriate
since abstracts did not include the degree of information available in full study articles. Risk of
bias assessments are difficult in light of the limited information provided by abstracts alone. Data
were extracted from these abstracts for use in the systematic review.

However, it was important to determine if pooled effect size estimate were disproportionately
influenced by the inclusion of these two abstracts.

The decision to use a random effects model for this systematic review was pre-specified. The
effect estimates using a random effects model were compared to the effect estimates using a
fixed effects model to determine if the findings were robust despite the model type used in the
analysis.
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Chapter 5
Results
Description of included studies
Upon retrieval of all full text studies a total of thirty studies met the Inclusion/Exclusion criteria
for this systematic review Figure 2; see Characteristics of included studies section. The studies
were qualitatively and comprehensively summarized, see the Characteristics of included studies
section of this systematic review. The accompanying risk of bias tables assessed the risk of bias
in each of the 30 studies Figure 3; Figure 4. Collectively the included studies comprised a total of
2539 participants Table 7; Figure 5.

Inclusion / exclusion criteria for the individual included studies
See Inclusion and exclusion criteria for the individual included studies in the Additional Tables
section of this review Table 8. The list of inclusion/exclusion criteria in Table 8 represent the
criteria the authors of the individual studies used, and do not represent the inclusion/exclusion
criteria used in this review. There was significant variability in the inclusion and exclusion
criteria between studies Table 8.
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Study Characteristics for the 30 included studies
Study duration and follow up period

The study period ranged from 1992 - 2012 for the 30 included studies Figure 6. The follow up
period for the included studies ranged from 10 days to 24 weeks see Characteristics of included
studies.

Study Settings for the individual included studies

The study settings were primarily outpatient or specialized clinic settings (17 studies). However,
8 of the studies were reported in hospital settings, 2 studies included both inpatient-hospital and
outpatient settings, and the setting was unclear in 5 studies.

The studies were conducted in the following countries (included in brackets () is the number of
studies conducted in that respective country): Belgium (2), Brazil (1), Canada (1), Denmark (),
France (1), Germany (2), Iran (1), Italy (5), Jordan (1 study), Malaysia (2), Pakistan (1), Saudi
Arabia (1 study), Slovenia (1), Sweden (1), Switzerland (1), Tunisia (1), Turkey (1), UK (5), and
US (7), Europe (2), Unclear (1) Table 7. Four of the studies were conducted in more than one
country and the adjacent study numbers are reflective of this.

Sample sizes for the individual included studies

The included studies ranged from sample sizes of 18 to 619 participants. Table 9; Figure 5. All
30 included studies reported total sample size. The mean sample size for the included studies was
85 (SD = 119) participants.
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Study Participants in the included studies
See “Study year, sample sizes and study setting for included studies table” in the Additional
Tables Section Table 7.

a) Age

The mean ages for the included studies ranged from 52.1 through 69.3 years Figure 7. A total of
23 studies reported on age. The mean age for the reported sample of studies was 59.01 (SD =
4.31) years.

b) Gender

In the majority of studies most participants were men with two studies reporting one or no
female participants Figure 8; Figure 9. A total of studies 21/30 studies reported gender
composition, 9 studies did not report gender Table 9. The number of males ranged from 12 to
240. The total mean number of males was 49 (SD = 53) for the reported studies. The number of
females ranged from 1 to 88 for the reported studies. The total mean number of females was 26
(SD = 22) for the reported studies.

c) Ethnicity

Ethnicity was reported in 4/30 studies. Four studies out of thirty reported on ethnicity including
(Shukrimi 2008, Tallis 2013, Singh 2006, and Dhemecourt 1998).
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Study participants

d) Other participant data

BMI was reported in 5/30 studies. Socioeconomic status was reported in 1 study.

Wound specific characteristics for the included studies grading, surface area, and depth

Grading of the ulcer (severity) was used in 13 studies and included the use of the Wagner wound
grading system and the University of Texas classification systems. The wounds were classified
up to Wagner grade 4 or Texas classification grade 3. A total of 17 studies did not specify the
wound classification and referred to the wounds as diabetic foot ulcers with partial or full
thickness wounds. The initial size of the wound was specified in 20 out of the 30 studies using
wound surface area. This was reported for both the intervention and control groups for each of
these studies reporting. Depth of the wound was specified in 5 out of 30 studies. Table 10;
Figure10: Figure 11.

Wound duration at baseline for the included studies

Fourteen out of 30 studies reported on wound duration. Wound duration ranged from 1 week to
15.8 (SD = 10.7) years Figure 12; Figure 13.
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Prognostic risk factors for the included studies

a) Mean Hemoglobin a1c, and duration of diabetes status at baseline for the included
studies

The studies that reported on comorbidities that may impact wound healing included the
following information: 8/30 studies reported on mean hemoglobin a1c, mean hgba1c ranged
from 7.25% to 9.25% Figure 14. 14/30 studies reported on mean duration of diabetes which
ranged from 13 (SD= 10.6) years to 20.5 (SD = 13.5) years Table 11 Figure 15.

b) Peripheral arterial disease (PAD) status at baseline for the included studies

The proportion of the sample with baseline arterial insufficiency was reported in 9 studies Table
11, Figure 16.

c) Infection status at baseline for the included studies

The infection status at study onset was reported in 11 studies Table 11, Figure 17

d) Offloading status at baseline for the included studies

Offloading status was reported in 9 studies Table 11, Figure 18.

e) Immunosuppression status at baseline for the included studies

Immunosuppression status was reported in 1 study Table 11, Figure 19.
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f) Nutritional status at baseline for the included studies

Two of the studies included nutritional status indicator at baseline using albumin Table 11,
Figure 20.

g) Smoking status at baseline for the included studies

The proportion of smokers at baseline was reported in 5 studies Table 11, Figure 21.

h) Venous insufficiency status at baseline for the included studies

The proportion of the sample with baseline venous insufficiency was not reported Table 11.

i) Industry support was reported in 13/30 of the included studies Figure 22.

Results of the search
The three separate searches collectively retrieved a total of 3553 citations.

To these were added 160 citations retrieved through a hand search of the bibliographies of
systematic reviews related to the research question that were among the full text studies
retrieved. A hand search of the bibliographies of all 30 included studies along with 10 systematic
reviews retrieved on a similar research question was conducted.

After duplicates were removed a total of 2625 citations remained. A total of 2513 citations were
excluded based on title and abstract using the pre-specified eligibility criteria. 112 full text
studies were retrieved for further review.
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Upon scrutinizing 112 full-text articles, 82 of these studies did not meet the inclusion/exclusion
criteria and were rejected, reasons for rejection are included in this systematic review, see
Characteristics of excluded studies section of this review. A total of 30 studies met the prespecified inclusion/exclusion criteria for this systematic review.

See Study selection Prisma flow diagram in Figure 2.

Excluded studies
A total of 82 studies were excluded from this review. The main reasons cited for exclusion
included: see Characteristics of excluded studies
1) The study was not randomized - 30 studies
2) The intervention was not classifiable as a recognized form of debridement - 30 studies
3) Other debridement intervention(s) besides the comparison interventions were applied to both
treatment arms - 12 studies
4) Other reasons were reported for the remaining - 10 studies

Risk of bias in included studies
The risk of bias in included studies was appraised in 6 separate areas including random sequence
generation, allocation concealment, blinding, incomplete outcome data, selective outcome
reporting, and other potential sources of bias.

All of the included studies reported random sequence generation. However in most studies the
method of randomization was unspecified with the exception of five studies (Amini 2013;
Bowling 2011; Jeffcoate 2009; Munter 2006; Tallis 2013).
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The method of sequence generation included simple randomization in (Amini 2013), and
computer random sequence generation in the other four studies. See Risk of Bias Figure 3 and
Figure 4.

Allocation concealment was assessed as a form of selection bias. Most of the included studies
did not report whether allocation concealment was utilized with the exception of 5 studies;
(Bowling 2011, Jeffcoate 2009, Jude 2007a, Munter 2006, and Tallis 2013). See Risk of Bias
Figure 3 and Figure 4.

Blinding was assessed as a form of performance bias and detection bias. The blinding of
outcome assessors was reported in 7 studies (Ali 2013, Goretti 2008, Jeffcoate 2009, Lalau 2002,
Piaggesi 2001, Shukrimi 2008, Singh 2006). Three studies (Apelqvist1990, D'Hemecourt 1998,
Piaggesi 1998) reported double blinding including outcome assessors and the delivery of the
intervention. However double blinding was not uniformly and clearly defined. Blinding was
either not conducted or unclear in the remaining studies. This may have been attributable to the
nature of the interventions (e.g. surgical debridement, mechanical jet irrigation). See Risk of Bias
Figure 3 and Figure 4.

Incomplete outcome data were assessed as a form of attrition bias. Most of the studies did not
report on the status of incomplete outcome data. One study (Belcaro 2010) reported that there
were no drop outs in the study. Another study (Whalley 2001) reported withdrawals but reasons
for withdrawals was unclear and method of addressing withdrawals was not specified.
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Eight studies (Markevich 2000, Mazzone 1993, Ogce 2007, Piaggesi 1998, Rhaiem 1998,
Roberts 2001, Shukrimi 2008, and Singh 2006), did not report whether there were any
participant withdrawals nor was the method of addressing missing data specified. Eight studies
(Blackman 1994, Clever 1995, Foster 1994, Hammouri 2004, Jensen 1998, Lalau 2002, Piaggesi
2001, and Vandeputte 1997), reported participant withdrawals or drop outs and cited reasons
however the methods of addressing missing data were not specified.

Two studies (D'Hemecourt 1998; Donaghue 1998) reported that an intention to treat analysis was
conducted but did not specify the method that was used. Three studies (Jeffcoate 2009, Munter
2006, Tallis 2013), reported using an intention to treat analysis and specified that the method
used was last observation carried forward.

Selective outcome reporting was assessed as a form of reporting bias. No pre-study protocols
were available for any of the studies. Therefore, an assessment of selective reporting was based
on discordance between pre-specified outcomes reported in the methods section not appearing in
the results sections of the studies. Approximately 14 out of 30 studies were at low risk for
selective reporting. Approximately 11 out of 30 studies were at high risk for selective reporting
based on discordance between outcomes reported in the methods and results sections of the
study.

17 out of the 30 studies were at high risk for other potential sources of bias. In the other 13
studies it was unclear whether other potential sources of bias were likely, since insufficient
information was available to make this determination. Important sources of confounding were
not addressed in the results section to determine if they were balanced in both treatment arms,
especially since many of the studies included small sample sizes.
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Randomization has a higher likelihood of balancing unknown or uncontrolled confounders in
both treatment arms the greater the sample size. Characteristics of included studies; Szklo 2007,

The studies had a broad range of follow up periods with some being as brief as 10 days and
others being as long as 24 weeks Characteristics of included studies.

13 of the 30 studies received private source of financial support, 2/30 reported not receiving any
financial support, and in 15 other studies the source of financial support could not be determined
or was not reported Table 12; Figure 22.

Effects of interventions
Twenty-two out of the 30 included studies collectively represent 19 separate comparisons that
reported on a minimum of 1 of the 7 pre-specified outcomes of interest for this review.
These 19 comparisons included one study each in comparisons 1 – 5, 7, 8, 9, 11, 12, 14, 15, 16,
17, and 18; three studies in comparison 6; two studies in comparisons 10 and 13; and 10 studies
in comparison 19 Table 13.

The comparisons include effect sizes for each of the interventions per outcome of interest that
were reported and include the results of the meta-analyses carried out on 4 comparisons
including: comparison 6 (3 studies), 10 (2 studies), 13 (2 studies), and 19 (10 studies). The
effects of the interventions are described under each of the primary outcomes of interest
(proportion of participants with amputations, proportion of participants with complicating
infections, and quality of life), and secondary outcomes of interest (proportion of ulcers healed,
time to complete healing, proportion of ulcers recurring after healing, and cost of treatment).
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8 out of the 30 studies, despite meeting our inclusion criteria for the review, did not report on any
of the pre-specified outcomes of interest. These included the following studies Ali 2013; Baker
1993; Bowling 2011; Munter 2006; Ogce 2007; Shukrimi 2008; Singh 2006; Tallis 2013.

The studies are reported in the Characteristics of Included Studies section of this systematic
review as they did meet our inclusion criteria but are not reported in this effects of interventions
section since they did not include the outcomes of interest. These 8 studies were not pooled in
any of the meta-analyses for this reason. The pre-specified outcomes of interest were not used as
eligibility criteria as this would have restricted the number of studies captured in the search
phase of this systematic review. They are summarized and included in the Characteristics of
Included Studies section to prevent the introduction of biased reporting into this systematic
review.

Comparison 1: Surgical debridement compared with conventional non-surgical
management (1 trial, 42 participants)
This comparison included 1 trial (Piaggesi 1998) with 42 participants. The follow up period was
24 weeks. The study period was 1995. There was significant risk of bias as many of the risk of
bias considerations were unclear or high risk Figure 3; Figure 4.

Types of interventions

The surgical debridement group underwent surgical excision, eventual debridement or removal
of bone segments underlying the lesion and surgical closure. The conventional management
group received saline moistened gauze after an initial surgical debridement. Pressure relief was
provided to both groups along with regular dressings. Table 5; Table 13.
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Initial wound stage
The mean baseline maximum wound size depth was 1.58 (SD = 2.2) cm2 in the sharp
debridement group and 1.98 (SD = 1.07) cm2 in the conventional non-surgical management
group Table 10.

Participant characteristics

The study comprised a total of 42 participants. The mean age for the study was 64.39 (SD =
11.67) years. The number of males and females was not reported Table 9. The study setting
included outpatients in Italy Table 7. Baseline data were collected for the type and duration of
diabetes, the age of patients, and their HBA1c Table 11.

Primary outcomes

Proportion of participants with amputations

The proportion of individuals with amputations was lower in the surgical debridement group
0/22 as compared with the conventional non-surgical management group 1/24. (RR 0.36, 95% CI
0.02 to 8.46; participants = 46; studies = 1) Analysis Table 1.1. No statistically significant
difference was found.
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Proportion of participants with complicating infections

The proportion of participants with complicating infections was lower (64% risk reduction) in
the surgical debridement group 1/24 (5%) than the convention non-surgical treatment group 3/24
(13%) (RR 0.36, 95% CI 0.04 to 3.24; participants = 46; studies = 1) Analysis Table 1.2 No
statistically significant difference.

Quality of life

No data were reported although Piaggesi 1998 reported that patients reported a higher degree of
satisfaction with surgical debridement as well as lower discomfort but did not report how this
outcome was measured and whether a valid scale had been used. (MD -2.20, 95% CI -3.16 to 1.24; participants = 46; studies = 1) Analysis Table 1.3

Secondary outcomes

Proportion of ulcers completely healed

Conservative care healed 19/24 (79%) ulcers, compared with 21/22 (95%) of ulcers treated by
surgical debridement. The number of ulcers healed was 15% greater in the surgical debridement
group than in the conservative non-surgical treatment group. (RR 1.15, 95% CI 0.90 to 1.47;
participants = 46; studies = 1) (No statistically significant difference was found) Analysis Table
1.4.
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Time to complete healing

The ulcers treated with conservative methods took longer to heal on average; 129 (+/- 87 days)
compared with the surgically treated group whose healing time was 47 (+/- 39 days). It was
unclear in the trial whether the figures in parentheses were ranges, standard errors or standard
deviations as this was unspecified.

The mean difference in healing was approximately 82 days shorter in the sharp surgical
treatment group as compared with the conventional non-surgical treatment group (MD 81.68,
95% CI 41.07 to 122.29; participants = 46; studies = 1) (statistically significant difference was
observed). Analysis Table 1.5.

Proportion of ulcers recurring after healing

In the non-surgical treatment group, 8/24 (33%) ulcers recurred within six months, compared
with 3/22 (14%) in the surgical debridement group; There was a 59% reduction in ulcer
recurrence favoring the sharp surgical debridement group. (RR 0.41, 95% CI 0.12 to 1.35;
participants = 46; studies = 1) (No statistically significant difference) Analysis Table 1.6.
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No data were reported for the pre-specified outcome cost of treatment.
Analysis Table 1.1 – 1.6 Sharp Surgical Debridement compared to nonsurgical
management

Outcome or
Subgroup
1.1 Number of
amputations
reported
1.2 Number of
Infections reported

Studies

Participants

1

46

1

46

1.3 Quality of life /
Limitations

1

46

1.4 Number of
ulcers completely
healed
1.5 Time to
complete healing
(days)

1

46

1

46

1.6 Recurrence rates

1

46

Statistical
Method
Risk Ratio (MH, Random,
95% CI)
Risk Ratio (MH, Random,
95% CI)
Mean
Difference (IV,
Random, 95%
CI)
Risk Ratio (MH, Random,
95% CI)
Mean
Difference (IV,
Random, 95%
CI)
Risk Ratio (MH, Random,
95% CI)

Effect
Estimate
0.36 [0.02,
8.46]
0.36 [0.04,
3.24]
-2.20 [-3.16, 1.24]

1.15 [0.90,
1.47]
81.68 [41.07,
122.29]

0.41 [0.12,
1.35]

Comparison 2: Superoxide solution compared with standard local treatment
with povidone iodine (1 trial, 40 participants)
This included 1 trial Goretti 2008 with 40 participants. The study was available in unpublished
abstract form only. The range of follow up was 24 weeks. The study comparison period was not
reported. There was significant risk of bias since the study information was limited to an
unpublished abstract and much of the risk of bias considerations were unclear Figure 3; Figure 4.
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Types of Interventions

The interventions in these studies included superoxide solution as compared with standard local
treatment with povidone iodine. Standard local treatment was not defined in the study Table 5;
Table 13.

Initial Wound Stage
The mean wound size in the study was reported as greater than 5 cm2. The mean wound depth,
wound staging, and mean duration of ulcers in the study was not reported Table 10.

Participant Characteristics

The studies comprised a total of 40 participants. The mean ages for the study was not reported.
The number of males and females included were not reported Table 9. The study setting included
hospitalized patients and was conducted in Italy Table 3.

Goretti 2008

Primary Outcomes

No data were reported for any of the primary outcomes of interest.
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Secondary Outcomes

Proportion of participants with ulcers completely healed

Proportion of participants with ulcers healed was higher 17/20 (85%) in the superoxide solution
group than the standard local treatment with iodine group 11/20 (55%). There was a 55%
increase in ulcer healing favoring the superoxide solution group as compared to the standard
local treatment with iodine group (RR 1.55, 95% CI 1.00 to 2.39; participants = 40; studies = 1)
Analysis 2.1. No statistically significant difference was observed.

Time to complete healing

Time to complete healing was reported to be 6 days shorter (MD -6.00, 95% CI -6.94 to -5.06;
participants = 40; studies = 1) Analysis 2.2 in the superoxide solution group 10.5 (SD = 1.3 days)
than the standard local treatment with iodine group 16.5 (SD = 1.7days). A statistically
significant difference.

No data were reported for the secondary outcomes proportion of ulcers recurring after healing,
and cost of treatment.
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Analysis Table 2.1 – 2.2 Superoxide solution dressing and
standard local treatment as compared with standard local
treatment with povidone iodine dressing
Outcome or
Subgroup
2.1 Number of
ulcers completely
healed
2.2 Time to
complete healing
(days)

Studies

Participants

Statistical
Method

Effect Estimate

1

40

Risk Ratio (M-H,
Random, 95% CI)

1.55 [1.00, 2.39]

1

40

Mean Difference
(IV, Random,
95% CI)

-6.00 [-6.94, 5.06]

Comparison 3: Low frequency ultrasound compared with sharp debridement (1
trial, 40 participants)
This comparison included 1 trial Amini 2013 with 40 participants. The range of follow up was 6
months or until complete wound healing. The study comparison period was March 2009 to May
2010. There was significant risk of bias since much of the risk of bias characteristics were not
reported. Figure 3; Figure 4.

Types of Interventions

The interventions in these studies included low frequency ultrasound debridement as compared
with standard local sharp debridement Table 5; Table 13.
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Initial Wound Stage

The mean wound size in the study was reported to be 6.8 (SD = 6) cm2 in the ultrasound group
and 9.9 (SD = 7.6) cm2 in the sharp debridement group. The mean wound depth was not
reported. The wound stage in the study was Wagner Grade 3. The mean duration of ulcers in the
study was 15.6 (SD=16.8) weeks in the low frequency ultrasound group and 17.6 (SD = 18.8)
weeks in the sharp debridement group Table 10.

Participant Characteristics

The studies comprised a total of 40 participants. The mean age for the study was not 55.2 (SD =
9.4) years. The study included 24 males and 16 females Table 9. The study setting was a diabetic
foot ulcer clinic in Iran Table 3.

Primary Outcomes

No data were reported for any of the primary outcomes.

Secondary Outcomes

Proportion of participants with ulcers completely healed

The proportion of participants with ulcers completely healed was 9% higher (RR 1.09, 95% CI
0.64 to 1.86; participants = 40; studies = 1) Analysis 3.1 in the low frequency ultrasound
debridement group 12/20 (60%) as compared with the sharp debridement group 11/20 (55%). No
statistically significant difference.
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Time to complete healing (days)

The mean time to complete healing was 19.6 days shorter (MD -19.60, 95% CI -69.96 to 30.76;
participants = 40; studies = 1) Analysis 3.2 in the low frequency ultrasound debridement group
61.6 (SD = 84 days) than in the sharp debridement group 81.2 (SD = 78.4). No statistically
significant difference.

No data were reported for the secondary outcomes proportion of participants with ulcers
recurring, or cost of treatment.

Analysis Table 3.1 – 3.2 Low frequency ultrasound
debridement compared with sharp debridement
Outcome or
Subgroup

Studies

Participants

3.1 Number of ulcers
completely healed

1

40

3.2 Time to complete
healing (days)

1

40

Statistical
Method

Effect
Estimate

Risk Ratio (M-H,
Random, 95%
CI)
Mean Difference
(IV, Random,
95% CI)

1.09 [0.64, 1.86]

-19.60 [-69.96,
30.76]

Comparison 4: Larvae compared with hydrogel (1 trial, 140 participants)
This comparison included 1 study Markevich 2000 and a total of 140 participants. The range of
follow up was 10 days. The study period was not reported. The study was available in abstract
form. The abstract reports follow up was 10 days whilst the trial was reported to be 30 months in
duration. Attempts to contact the authors have been unsuccessful.
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Types of Interventions

The interventions in these studies included maggot debridement therapy as compared with
hydrogel Table 5; Table 13.

Initial Wound Stage

The baseline wound characteristics were reported as comparable between both groups but were
not otherwise specified. The mean wound depth was not reported. The average ulcer duration at
baseline was 15.8 (SD = 10.7) years. The wound grade or stage was not reported. The mean
duration of ulcers in the study was not reported Table 10.

Participant Characteristics

The studies comprised a total of 140 participants. The mean age for the study was not 53.6 (SD =
15.4) years. The number of males and females were not reported Table 9. The study setting was
conducted in Europe Table 3.

Primary Outcomes

No data were reported for any of the primary outcomes.
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Secondary Outcomes

Proportion of ulcers completely healed

In the larvae group 5/70 (7%) patients achieved complete healing, compared with 2/70 (3%)
patients from the hydrogel group. There was a 150% greater healing rate in the larvae group as
compared with the hydrogel group (RR 2.50, 95% CI 0.50 to 12.46; participants = 140; studies =
1) (no statistically significant difference) Analysis 4.1.

No were reported for the secondary outcomes time to complete healing, proportion of
participants with ulcers recurring after healing, and cost of treatment.

Analysis Table 4.1 Larvae compared with Hydrogel
Outcome or
Subgroup
4.1 Number of
ulcers completely
healed

Studies
1

Participants
140

Statistical
Method

Effect Estimate

Risk Ratio (M-H,
Random, 95% CI)

2.50 [0.50, 12.46]

Comparison 5: Hydrogel purilon gel compared with hydrogel intrasite (1 trial, 74
patients)
This comparison included 1 trial Whalley 2001 and a total of 74 participants (Whalley 2001).
The range of follow up was until ulcer healing or a maximum of 10 weeks. The study period was
not reported and it was published in abstract form only. Attempts to contact the authors have
been unsuccessful.
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Types of Interventions

The interventions in these studies included hydrogel purilon gel as compared with hydrogel
intrasite Table 5; Table 13.

Initial Wound Stage
The baseline wound size in surface area was 2.5 (SD = 3.2) cm2 in the purilon hydrogel group
and 2.4 (SD = 2.9) cm2 in the intrasite hydrogel group. The mean wound depth was not reported.
Wounds with wound grade 1 - 2 were included. The average ulcer duration at baseline was not
reported. The mean duration of ulcers in the study was not reported Table 10.

Participant Characteristics

The studies comprised a total of 74 participants. The mean age for the study was not reported.
The number of males and females was not reported Table 9. The study specific setting
(outpatient or inpatient was unreported. The study was conducted in Europe. Table 3.

Primary Outcomes

No data were reported for any of the primary outcomes.
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Secondary outcomes

Proportion of ulcers completely healed

66 people were evaluated for this outcome and in the first hydrogel group (Purilon) 35%
achieved complete healing compared with 19% in the second hydrogel group (Intrasite) Analysis
5.1 . The numbers of people in each group were not reported in the abstract, therefore no further
analysis was possible.

No data were reported for the secondary outcomes time to complete healing (days), proportion of
participants with ulcers recurring after healing, and cost of treatment.

Analysis Table 5.1 Hydrogel purilon compared with
hydrogel intrasite
Outcome or
Subgroup
5.1 Number of
ulcers completely
healed

Studies
1

Participants

Statistical
Method
Other data
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Effect Estimate
No numeric data

Comparison 6: Hydrogel compared with gauze/good wound care (3 trials, 232
participants)
D'Hemecourt 1998; Jensen 1998; Vandeputte 1997

Trial 1: Hydrogel compared with wet to moist saline gauze (31 participants)

This comparison included 1 study (Jensen 1998) and a total of 31 participants. The range of
follow up was 20 weeks. The study period was not reported.
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Types of Interventions

The interventions in these studies included hydrogel as compared with wet to moist saline gauze
Table 5; Table 13.

Initial Wound Stage
The study included all ulcers of at least 1 cm2 mean wound surface area. The mean wound depth
was not reported. The study included Wagner grade 2 wounds. The ulcer duration at baseline
was not reported. The mean duration of ulcers was 32 weeks in the hydrogel group and 12 weeks
in the wet to moist saline gauze group Table 10. Good wound care and other ancillary care is
defined in the characteristics of included studies tables for each of the respective studies.

Participant Characteristics

The studies comprised a total of 31 participants. The mean age for the study was not reported.
The number of males and females in the study was not reported Table 9. The hospital/outpatient
study setting was unclear, and the study was conducted in Europe Table 3.

Primary outcomes

Proportion of participants with amputations

0/14 or 0% amputations were reported in the hydrogel group as compared with 1/17 or 5.9% in
the wet to moist saline group. There was a 60% reduction in amputations favoring the hydrogel
group as compared with the control group (RR 0.40, 95% CI 0.02 to 9.12; participants = 31;
studies = 1) No statistically significant difference was demonstrated.
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Proportion of participants with complicating infections

2/14 or 14.3% of complicating wound infections were reported in the hydrogel group as
compared with 1/17 or 5.9% in the wet to moist saline group. There was a 143% increase in
complicating infections in the hydrogel group as compared with control (RR 2.43, 95% CI 0.24
to 24.07; participants = 31; studies = 1); No statistically significant difference was observed.

No data were reported for the primary outcome quality of life.

Secondary outcomes

Proportion of ulcers completely healed

In the hydrogel group 11/14 (79%) of patients healed completely compared with 6/17 (46%) in
the control group. There was a 123% increase in ulcers healed in the hydrogel group as
compared with the control group (RR 2.23, 95% CI 1.11 to 4.48; participants = 98; studies = 3).
There was a statistically significant difference demonstrated.

Time to complete healing

Those ulcers treated with the hydrogel were reported as achieving healing in an average of 10
weeks, with the control group healing in an average of 12 weeks (no statistically significant
difference was observed).

No data were reported for the secondary outcome proportion of participants with ulcers recurring
after healing.
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Cost of treatment

Insufficient reporting prevented the determination of whether the difference in cost between
hydrogel ($7/day) as compared with the control condition ($12/day) was statistically significant.

Trial 2: Hydrogel (NaCMC aqueous based gel) compared with good wound care alone (172
participants)

This comparison included 1 study (D'Hemecourt 1998) and a total of 172 participants. The range
of follow up was 20 weeks. The study period was not reported. In this trial the intention-to-treat
population consisted of 172 patients.

Types of Interventions

The interventions in these studies included NaCMC aqueous based gel as compared with good
wound care alone Table 5; Table 13.

Initial Wound Stage

The study included ulcers with a mean baseline wound surface area and depth of 3.5 (SD = 3.53)
cm2, 0.4 (SD = 0.52) cm in the aqueous based gel group as compared with 3.2 (SD = 2.75) cm2,
0.4 (SD = 0.20) cm in the control group respectively. The study included Wagner grade 3 to 4
wounds. The mean duration of ulcers at baseline was 42 +/- 42 weeks and 52.8 (SD = 60.92)
weeks in the aqueous based gel and control group respectively Table 10.
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Participant Characteristics

The studies comprised a total of 172 participants. The mean age for the study was 58.3 (SD =
12.13) years. There were 127 males and 45 females in the study Table 9. The study setting was
unclear and was conducted in the USA Table 3.

Primary outcomes

Proportion of participants with complicating infections

21/70 or 30% of participants in the aqueous based gel group developed complicating wound
infections as compared with 19/68 or 28% in the control group. There was a 7% increase in the
proportion of participants with complicating wound infections in the aqueous based gel group as
compared with the control group (RR 1.07, 95% CI 0.64 to 1.81); no statistically significant
difference was observed.

No data were reported for the primary outcomes proportion of participants with amputations,
quality of life.

In the control group 10/68 (15%) of patients reported an increase in pain compared with 11/70
(16%) in the hydrogel group, RR 1.07 (95% CI 0.49 to 2.35) (no statistically significant
difference). It is not clear in the reporting of the trial how pain was measured or whether a valid
scale was used.
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Secondary outcomes

Proportion of ulcers completely healed

Within a 20-week study period 15/68 (22%) of patients healed with good wound care alone
(daily dressing changes; sharp debridement of ulcer; systemic control of any present infection;
off-loading of pressure) compared with 25/70 (36%) of patients healed with hydrogel. There was
a 62% increase in proportion of healed participants as compared with the good wound care alone
group, RR 1.62 (95% CI 0.94 to 2.80) (no statistically significant difference).

No data were reported for the secondary outcomes time to complete healing, proportion of
participants with ulcers recurring after healing, cost of treatment

Trial 3: "Immunomodulating" hydrogel compared with dry gauze (29 participants)

This comparison included 1 study (Vandeputte 1997) and a total of 29 participants. The range of
follow up was 12 weeks. The study period was not reported.

Types of Interventions

The interventions in these studies included hydrogel as compared with dry gauze; Table 5; Table
13.

Initial Wound Stage

The baseline wound size, depth, wound stage, and duration of ulcer was not reported for this
study Table 10.
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Participant Characteristics

The studies comprised a total of 29 participants. The mean age for the study was 63.95 +/- 14.5
years. There were 13 males and 16 females in the study Table 9. The study was conducted in the
outpatient setting in Belgium Table 3.

Primary outcomes

Proportion of participants with amputations

1/14 or 7.1% of amputations were reported in the hydrogel group as compared with 5/15 or
33.3% in the gauze group. There was a 79% reduction in amputations favoring the hydrogel
group as compared with the gauze group (RR 0.21, 95% CI 0.03 to 1.61; participants = 29;
studies = 1). No statistically significant difference was observed.

Proportion of participants with complicating infections

1/15 or 7% of complicating wound infections were reported in the hydrogel group as compared
with 7/14 or 50% in the gauze group. There was an 87% reduction in complicating wound
infections in the hydrogel group as compared with control (RR 0.13, 95% CI 0.02 to 0.95;
participants = 29; studies = 1); there was a statistically significant difference. It was not reported
that the study was stopped early.

No data were reported for the primary outcome quality of life.
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Secondary outcomes

Proportion of ulcers completely healed

7/15 (47%) of ulcers were completely healed in the hydrogel group as compared with 5/14 (36%)
in the gauze group. This was a 31% increase in proportion of participants with ulcers completely
healed; RR 1.31, 95% CI 0.54 to 3.17). No statistically significant difference.

No data were reported for the secondary outcomes time to complete healing, proportion of
participants with ulcers recurring after healing, and cost of treatment.

Summary: Hydrogel compared with gauze/good wound care alone

The three trials (D'Hemecourt 1998; Jensen 1998; Vandeputte 1997) comparing hydrogel with
either gauze dressing or good wound care (dressing not specified) were considered sufficiently
similar to pool, using a random effects model. They included a combined total of 232
participants. The follow up ranged from 12 - 20 weeks. The study period was not reported in the
3 studies. There was unclear to high risk of bias as many of the risk of bias considerations
utilized in this review were either unclear or high Figure 3; Figure 4.
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Proportion of participants with amputations

The two studies that reported number of amputations were pooled these included Jensen 1998
and Vandeputte 1997. Pooling these two studies yielded a relative risk for amputation of 0.26
(95% CI 0.05 to 1.40; participants = 60; studies = 2; in the presence of heterogeneity, p = 0.74, I2
= 0%) Analysis 6.1. No statistically significant difference. This translates to 74% reduction in
proportion of amputations for the hydrogel group as compared to gauze and a number needed to
treat of 8 (95% CI 3 [NNTB], 12 [NNTH]): that is to prevent one additional patient with diabetic
foot ulcer from having an amputation, eight patients must be treated with hydrogel instead of
gauze or standard care (treatment time varied from 12 to 20 weeks). No statistical significant
difference was observed Figure 23.

Proportion of participants with complicating infections

All 3 studies reported on proportion of infections, and on the proportion of ulcers completely
healed.

Pooling the three trials yielded a relative risk for infections with hydrogel of 0.74, (95% CI 0.18
to 2.99; participants = 198; studies = 3; in the presence of heterogeneity, p = 0.09, I2 = 59%)
Analysis 6.2. This translates to a 26% reduction in proportion of infections for the hydrogel
group as compared to gauze, and a number needed to treat of 12 (95% CI 3 [NNTB], 6 [NNTH]):
that is to prevent one additional patient with diabetic foot ulcer from having an infection, twelve
patients must be treated with hydrogel instead of gauze or standard care (treatment time varied
from 12 to 20 weeks). No statistically significant difference was observed Figure 24.
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Proportion of participants with ulcers healed

The proportion of ulcers healed yielded a relative risk of 1.71, 95% CI 1.16 to 2.52; participants
= 198; studies = 3; in the absence of significant heterogeneity, p = 0.62, I2 = 0%) Analysis 6.3.
This translates to a 71% increase in the proportion of ulcers healed in the hydrogel group as
compared to gauze group, and a number needed to treat of 12 (95% CI 50 [NNTB] to 3
[NNTB]): that is to heal one additional patient with diabetic foot ulcer, twelve patients must be
treated with hydrogel instead of gauze or standard care (treatment time varied from 12 to 20
weeks). No statistically significant difference was observed Figure 25.

Quality of life index, proportion of participants with recurrent ulcers, time to complete healing,
and cost of treatment were either not reported at all or not reported in at least two or more
studies.

Analysis Table 6.1 – 6.3 Hydrogel compared with gauze or
good wound care (gwc)
Outcome or
Subgroup
6.1 Number of
amputations
reported
6.2 Number of
Infections reported
6.3 Number of
ulcers completely
healed

Studies

Participants

Statistical
Method

Effect Estimate

2

60

Risk Ratio (M-H,
Random, 95% CI)

0.26 [0.05, 1.40]

3

198

0.74 [0.18, 2.99]

3

198

Risk Ratio (M-H,
Random, 95% CI)
Risk Ratio (M-H,
Random, 95% CI)
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1.71 [1.16, 2.52]

Comparison 7 Polyurethane gel dressing compared with polyurethane foam
dressing (1 trial, 40 participants)
This included 1 trial Clever 1995 with 40 participants. The study was available in unpublished
abstract form only. The range of follow included healing occurrence or a maximum of 16 weeks.
The study comparison period was not reported. There was significant risk of bias since many of
the risk of bias considerations were either unclear or high risk Figure 3; Figure 4.

Types of Interventions

The interventions in these studies included Hydroactive polyurethane gel dressing (Cutinova
Hydro) and standard therapy as compared with Hydrophilic polyurethane foam dressing
(Allevyn) and standard therapy. Standard therapy was defined as offloading, infection control
with antibiotics, wound cleansing with ringer’s solution, and "debridement" with removal of
callus if needed. The separate form of debridement was not defined Table 5; Table 13.

Initial Wound Stage
The initial mean wound surface area in the study was reported to be 2.05 (SD = 3.14) cm2 in the
polyurethane gel dressing group and 2.08 (SD = 2.72) cm2 in the polyurethane foam dressing
group. The initial mean depth of wound, or wound stage was not reported for either the
intervention or comparison groups. The initial mean duration of ulcers in the study was 162.37
(SD = 325.55) days in the polyurethane gel dressing group and 165 (SD = 318.68) days in the
polyurethane foam dressing group Table 10.
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Participant Characteristics

The studies comprised a total of 40 participants. The mean age for the study was 56 (SD = 13.13)
years. There were 32 males and 8 females. The study setting included outpatients, and the study
was conducted in Germany.

Primary Outcomes

No data were reported for any of the primary outcomes.

Secondary Outcomes

Proportion of participants with ulcers completely healed

The proportion of patients with ulcers completely healed was lower in the Polyurethane gel
dressing group 14/20 (70%) as compared with the polyurethane foam dressing group 16/20
(80%) (RR 0.88, 95% CI 0.61 to 1.26; participants = 40; studies = 1) Analysis 7.1 No
statistically significant difference was observed.

Time to complete healing (days)

The time to complete healing was on average 4.76 days shorter in the Polyurethane gel dressing
group as compared with the polyurethane foam dressing group (MD -4.76, 95% CI -16.93 to
7.41; participants = 40; studies = 1) Analysis 7.2. No statistically significant difference was
observed.

No data were reported for the secondary outcomes proportion of participants with ulcers
recurring after healing, cost of treatment.
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Analysis Table 7.1 -7.2 Polyurethane gel dressing
compared with polyurethane foam dressing
Outcome or
Subgroup

Studies

Participants

7.1 Number of ulcers
completely healed

1

40

7.2 Time to complete
healing (days)

1

40

Statistical
Method

Effect
Estimate

Risk Ratio (M-H,
Random, 95%
CI)
Mean Difference
(IV, Random,
95% CI)

0.88 [0.61, 1.26]

-4.76 [-16.93,
7.41]

Comparison 8 Alginate dressing compared with gauze (2 Trials, 152
participants)
Trial 1: Calcium alginate as compared with Vaseline gauze (1 trial, 77 participants)

This comparison included 1 trial Lalau 2002 with 77 participants. The range of follow up was 4
weeks this was reduced from the planned 6 week follow up period due to 13 withdrawals. The
study comparison period was not reported. There was significant risk of bias since many of the
risk of bias considerations were either unclear or high risk. See Figure 3; Figure4.

Types of Interventions

The interventions in these studies included the calcium alginate dressing group as compared with
Vaseline gauze. The study reported that no other treatments were permitted, except unrestricted
saline solution and mechanical debridement was authorized "as needed" Table 5; Table 13.

107

Initial Wound Stage
The initial mean wound surface area was reported as 8.0 (SD = 10.5) cm2 in the calcium alginate
dressing group and 8.8 (SD = 16.0) cm2 in the Vaseline gauze dressing group. The initial mean
wound depth and wound staging were not reported. The mean duration of ulcers was 19.6 (SD =
31.2) weeks in the Calcium alginate group, and 36.4 (SD = 52.4) weeks in the Vaseline gauze
group Table 10.

Participant Characteristics

The studies comprised a total of 77 participants. The mean age reported was 62.2 (SD = 11.75)
years. There were 45 males and 32 females in the study. Table 9 The study was conducted at 13
outpatient settings "throughout" France. Table 3

Primary Outcomes

Proportion of participants with complicating infections

1/39 (2.6%) complicating wound infections were reported in the calcium alginate group as
compared with 3/38 (7.9%) in the Vaseline gauze group. There was a 68% reduction in
complicating wound infections in the calcium alginate group as compared with the Vaseline
gauze group (RR 0.32, 95% CI 0.04 to 2.99; participants = 77; studies = 1) Analysis 8.1. No
statistically significant difference was observed.

No data were reported for the primary outcomes proportion of participants with amputations, and
quality of life.
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Secondary Outcomes

No data were reported for any of the secondary outcomes.

Trial 2: Collagen alginate as compared with moist gauze (1 trial, 75 participants)

This comparison included 1 trial Donaghue 1998 with 75 participants. The follow up period was
until the wound healed or a maximum of 8 weeks. The study comparison period was not
reported. There was significant risk of bias since many of the risk of bias considerations were
either unclear or high risk. See Figure 3; Figure 4.

Types of Interventions

The interventions in these studies included the collagen alginate dressing group as compared
with moist gauze Table 5; Table 13. The study reported that in all participant’s weight-bearing
limitations for offloading were employed using self-adhesive felted foam with a window at the
wound site, and "healing" sandals.

Initial Wound Stage
The initial mean wound surface area was reported as 2.6 (SD = 0.50) cm2 in the collagen alginate
dressing group and 2.99 (SD = 0.62) cm2 in the moist gauze group. The initial mean wound depth
was 0.4 (SD = 0.52) cm in the collagen alginate group, and 0.4 (SD = 0.20) cm in the moist
gauze group. The wound staging reported as Wagner grade 1 to 3. The mean duration of ulcers
was 20.86 (SD = 10.43) weeks in the collagen alginate group, and 32.14 (SD = 14.86) weeks in
the Vaseline gauze group Table 10.
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Participant Characteristics

The studies comprised a total of 75 participants. The mean age reported was 59.5 years (no SD
reported). There were 54 males and 21 females in the study. Table 9 The study was conducted at
outpatient settings in the US. Table 3

Primary Outcomes

No data were reported for any of the primary outcomes.

Secondary Outcomes

Proportion of participants with ulcers completely healed

The proportion of patients with ulcers completely healed were greater in the collagen alginate
dressing group 24/50 (48%) as compared with the Vaseline gauze dressing group 9/25 (36%).
There was a 33% increase in the proportion of ulcers healed in the collagen alginate group as
compared with Vaseline gauze group (RR 1.33, 95% CI 0.73 to 2.42; participants = 75; studies =
1) Analysis 8.2 No statistically significant difference was observed.

Time to complete healing (days)

The time to complete healing was on average 2.80 days shorter in the calcium alginate dressing
group as compared with the Vaseline gauze dressing group. (MD 2.80, 95% CI 1.46 to 4.14;
participants = 75; studies = 1) Analysis 8.3. There was a statistically significant difference
observed.
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No data were reported for the secondary outcomes proportion of participants with ulcers
recurring after healing, and cost of treatment.

Analysis Table 8.1 – 8.3 Calcium alginate compared with
moist gauze
Outcome or
Subgroup
8.1 Number of
Infections reported
8.2 Number of
ulcers completely
healed
8.3 Time to
complete healing
(days)

Studies

Participants

1

77

1

75

1

75

Statistical
Method

Effect Estimate

Risk Ratio (M-H,
Random, 95% CI)
Risk Ratio (M-H,
Random, 95% CI)

0.32 [0.04, 2.99]

Mean Difference
(IV, Random,
95% CI)

2.80 [1.46, 4.14]

1.33 [0.73, 2.42]

Comparison 9 Hydrocolloid dressing compared with adhesive Zinc tape dressing

(1 trial, 44 participants)
This included 1 trial Apelqvist 1990 with 44 participants. The follow up period was 5 weeks. The
study comparison period was not reported. There was significant risk of bias since many of the
risk of bias considerations were unclear. Figure 3: Figure 4.

Types of Interventions

The interventions in these studies included hydrocolloid dressing as compared with Zinc
adhesive tape dressing (Allevyn). All patient received pressure relief offloading. All ulcers were
cleaned with sterile saline Table 5; Table 13.
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Initial Wound Stage
The initial mean wound surface area in the study was reported to be 2.2 cm2 in the hydrocolloid
dressing group and 2.2 cm2 in the Zinc adhesive tape dressing group. The initial mean depth of
wound, initial wound stage, and mean duration of ulcers were not reported in the study for either
intervention arm Table 10.

Participant Characteristics

The studies comprised a total of 40 participants. The mean age for the study was 63 (SD = 36)
years. There were 26 males and 20 females. Table 9 The study setting included outpatients, and
the study was conducted in Sweden Table 3.

Primary Outcomes

Proportion of participants with complicating infections

There were a greater number of complicating infections 1/22 (4.5%) in the hydrocolloid dressing
group as compared with 0/22 (0%) of the Zinc adhesive tape dressing group. (RR 3.00, 95% CI
0.13 to 69.87; participants = 44; studies = 1) No statistically significant difference was observed.

No data were reported for the primary outcomes proportion of participants with amputations, and
quality of life.
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Secondary Outcomes

Proportion of participants with ulcers completely healed

The proportion of patients with ulcers completely healed was lower in the Hydrocolloid dressing
group 5/22 (22.3%) as compared with the Zinc adhesive tape dressing group 9/22 (40.9%). There
was a 44% reduction in ulcers healed in the hydrocolloid dressing group as compared with the
Zinc adhesive tape dressing group (RR 0.56, 95% CI 0.22 to 1.39; participants = 44; studies = 1)
Analysis 9.2 No statistically significant difference was observed.

Time to complete healing (days)

No data were reported for the secondary outcomes proportion of participants with ulcers
recurring after healing, and cost of treatment.

Analysis Table 9.1 – 9.2 Hydrocolloid dressing compared
with adhesive Zinc tape dressing
Outcome or
Subgroup

Studies

Participants

9.1 Number of
Infections reported

1

44

9.2 Number of ulcers
completely healed

1

44

Statistical
Method
Risk Ratio (M-H,
Random, 95%
CI)
Risk Ratio (M-H,
Random, 95%
CI)
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Effect
Estimate
3.00 [0.13,
69.87]
0.56 [0.22, 1.39]

Comparison 10 Foam dressing compared with Wet to dry gauze dressing (2
trials, 37 participants)
Trial 1: Polymeric membrane foam dressing as compared with Wet to dry saline gauze (18
participants)

This comparison included 1 trial Blackman 1994 with 18 participants. The follow up period was
6 months or until the ulcer healed. The study comparison period was not reported. There was
significant risk of bias since many of the risk of bias considerations were either unclear or high
risk Figure 3; Figure 4.

Types of Interventions

The interventions in these studies included a Polymeric membrane foam dressing group as
compared with a Wet to dry saline gauze group. All the participants were "encouraged" to obtain
orthotic foot wear Table 5; Table 13.

Initial Wound Stage
The initial mean wound surface area was reported as 2.67 (SD = 1.20) cm2 in the calcium
alginate dressing group and 1.81 (SD = 0.75) cm2 in the wet to dry gauze dressing group. The
initial mean wound depth was not reported. Wagner grade 1 and 2 wounds were included. The
mean duration of ulcers was 25 (SD = 7) weeks in the Polymeric membrane group, and 28 (SD =
6) weeks in the Wet to dry saline group Table 10.

114

Participant Characteristics

The studies comprised a total of 18 participants. The mean age reported was 55.9 (SD = 13.6)
years. There were 17 males and 1 female in the study Table 9. The inpatient/outpatient study
setting was unclear, and the study was conducted in the US Table 3.

Primary Outcomes

No data were reported for any of the primary outcomes.

Secondary Outcomes

Proportion of participants with ulcers completely healed

The proportion of participants with ulcers completely healed was higher in the Polymeric
membrane dressing group 8/11 (73%) as compared with the Wet to dry saline dressing group 0/7
(0%). There was an increased risk of healing in the Polymeric membrane dressing group as
compared with 0/7 (0%) in the Wet to dry saline dressing group (RR 11.33, 95% CI 0.76 to
170.03; participants = 37; studies = 1).

No data were reported for the secondary outcomes time to complete healing (days), proportion of
participants with ulcers recurring after healing, and cost of treatment.
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Trial 2: Polymeric foam membrane dressing as compared with Wet to dry saline gauze
mesh (19 participants)

This comparison included 1 trial Mazzone 1993 with 19 participants. The follow up period was 8
weeks. The study comparison period was not reported. There was significant risk of bias as many
of the risk of bias considerations were either unclear or high risk Figure 3; Figure 4. The study
was only available as a published abstract.

Types of Interventions

The interventions in these studies included Polymeric foam membrane as compared with Wet to
dry saline gauze mesh. No other treatments were reported Table 5; Table 13.

Initial Wound Stage

The initial mean wound surface area, initial mean wound depth, wound staging, and mean
duration of ulcers was not reported Table 10.

Participant Characteristics

The studies comprised a total of 19 participants. Age, and gender composition were not reported
Table 9. The study was conducted in an outpatient setting in the US Table 3.

Primary Outcomes

No data were reported for any of the primary outcomes.
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Secondary Outcomes

Proportion of participants with ulcers completely healed

The proportion of patients with ulcers completely healed was greater in the Polymeric foam
membrane group 7/11 (48%) as compared with the Wet to dry saline gauze mesh dressing group
2/8 (36%). There was a 155% increase in the proportion of ulcers healed in the Polymeric foam
membrane group as compared with Wet to dry saline gauze mesh dressing group (RR 2.55, 95%
CI 0.71 to 9.16; participants = 19; studies = 1) No statistically significant difference was
observed.

No data were reported for the secondary outcomes time to complete healing (days), proportion of
participants with ulcers recurring after healing, cost of treatment

Summary: Foam compared with gauze/good wound care alone

The two trials (Blackman 1994; Mazzone 1993) comparing Foam dressing with Wet to dry gauze
dressing were considered sufficiently similar to pool, using a random effects model. They
included a combined total of 37 participants. The follow up period ranged from 8 - 24 weeks.
The study comparison period was not reported in the 2 studies. There was unclear to high risk of
bias as many of the risk of bias considerations were either unclear or high Figure 3: Figure 4.

Types of Interventions

The interventions in these studies included Foam dressing as compared with Wet to dry gauze
Table 5; Table 13.
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Initial Wound Stage

The initial mean wound surface area was reported in Blackman 1994, but not in Mazzone 1993.
The mean wound depth was not reported in either study. The wound staging included in the
studies were classified as Wagner grade 1 - 2 in the Blackman 1994 but not reported in Mazzone
1993. The mean duration of ulcers was 25 (SD = 7) weeks in the Blackman 1994 study and not
reported in Mazzone 1993; Table 10.

Participant Characteristics

The studies comprised a total of 37 participants. The mean ages for the studies were 55.9 (SD =
13.6) years in Blackman 1994 and was not reported in Mazzone 1993. There were a total of 17
males and 1 female in Blackman 1994, while gender was not reported in Mazzone 1993; Table 4.
The study setting was unclear in Blackman 1994 and was conducted in an outpatient setting in
Mazzone 1993. Both studies were conducted in the US Table 3.

Proportion of participants with ulcers healed

The proportion of ulcers healed yielded a relative risk of (RR 3.56, 95% CI 0.93 to 13.66;
participants = 37; studies = 2); in the absence of significant heterogeneity, p = 0.28, I2 = 13%);
Analysis 10.1; No statistically significant difference was observed. This translates to a 256%
increase in the proportion of ulcers healed in the foam membrane group as compared with the
Wet to dry gauze group, and a number needed to treat of 2 (95% CI 2 [NNTB] to 5 [NNTB]):
that is to heal one additional patient with a diabetic foot ulcer, two patients must be treated with
foam dressing instead of Wet to dry gauze (treatment time varied from 8 to 24 weeks). No
statistically significant difference was observed.
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Proportion of participants with amputations, Proportion of participants with complicating
infections, Quality of life index, Proportion of participants with recurrent ulcers, Time to
complete healing, and Cost of treatment were either not reported at all or were not reported in
both studies and therefore could not be pooled for a meta-analysis Figure 26.

Analysis Table 10.1 Foam dressing compared with Wet to
Dry Saline
Outcome or
Subgroup
10.1 Number of
ulcers completely
healed

Studies
2

Participants
37

Statistical
Method

Effect Estimate

Risk Ratio (M-H,
Random, 95% CI)

3.56 [0.93, 13.66]

Comparison 11 Foam dressing compared with saline nonadherent gauze dressing
(1 trial, 30 participants)
Roberts 2001

This comparison included 1 trial with 30 participants. The follow up period was 13 weeks. The
study comparison period was not reported. There was significant risk of bias since many of the
risk of bias considerations were either unclear or high Figure 3; Figure 4.

Types of Interventions

The interventions in these studies included Foam dressing as compared with saline nonadherent
Gauze dressing. All patient received "standard podiatric care" which was not defined Table 5;
Table 13.
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Initial Wound Stage
The initial median wound surface area in the study was reported to be 1.1 cm2 in the Foam
dressing group and 1.45 cm2 in the saline nonadherent Gauze dressing group. The initial depth of
wound, wound stage were not reported in the study for either treatment arm. The mean duration
of ulcers for the sample was 15.2 weeks. Table 10

Participant Characteristics

The studies comprised a total of 30 participants. The median age for the study was 59.5 years.
There were 23 males and 7 females Table 9. The study setting included hospitalized patients, and
the study was conducted in UK Table 3.

Primary Outcomes

No data were reported for any of the primary outcomes.

Secondary Outcomes

Proportion of participants with ulcers completely healed

The proportion of participants with ulcers completely healed was higher in the foam dressing
group 6/14 (43%) as compared with the saline nonadherent gauze dressing group 4/16 (25%)
(RR 1.71, 95% CI 0.60 to 4.86; participants = 30; studies = 1). There was a 71% increase in the
proportion of participants with ulcers completely healed in the foam dressing group than in the
nonadherent gauze dressing group. No statistically significant difference was observed.

120

No data were reported for the secondary outcomes time to complete healing (days), proportion of
participants with ulcers recurring, and cost of treatment.

Analysis Table 11.1 Foam dressing compared with saline
gauze dressing
Outcome or
Subgroup
11.1 Number of
ulcers completely
healed

Studies
1

Participants
30

Statistical
Method
Risk Ratio (M-H,
Random, 95% CI)

Effect Estimate
1.71 [0.60, 4.86]

Comparison 12 Iodine impregnated fiber dressing compared with gauze dressing
(1 trial, 214 participants)
This comparison included 1 trial Jeffcoate 2009 with 214 participants. The follow up period was
24 weeks. The study comparison period was June 2003 to March 2007. There was some risk of
bias however many of the risk of bias considerations were low. Figure 3; Figure 4.

Types of Interventions

The interventions in these studies included Iodine impregnated fiber dressing as compared with
gauze dressing. All patient received ulcer management including regular use of debridement, and
"recommended" fiberglass or polyester boot for offloading. It was not clear whether another
alternate form of debridement was used or whether the study relied on the debridement effect of
the dressing itself Table 5; Table 13.

Initial Wound Stage
The wound surface area included in the study ranged between 0.25 - 2.25 cm2. It was further
subdivided into 3 additional ranges that included 0.25 - 1 cm2, 1.01 - 0.25 cm2, and 2.5 - 25cm2.
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The number of participants in each subgroup was 48, 36, and 24 for the Inadine group; and 50,
34, and 22 for the gauze group, respectively. The initial depth of wound, wound stage, and
wound duration were not reported in the study for either of the treatment arms Table 10.

Participant Characteristics

The study comprised a total of 214 participants. The mean age for the study participants was
reported was 59.6 (SD = 12.6) years. There were 159 males and 54 females Table 9. The study
setting included multidisciplinary outpatient centers, and the study was conducted in the UK
Table 3.

Primary Outcomes

Proportion of participants with amputations

The proportion of participants with amputations was lower in the Inadine dressing group 1/108
(1%) as compared with the gauze dressing group 2/106 (2%). There was a 51% reduction in
amputations observed in the Inadine group as compared to control. (RR 0.49, 95% CI 0.05 to
5.33; participants = 214; studies = 1); No statistically significant difference was observed.

Proportion of participants with complicating infections

The proportion of participants with complicating infections was higher in the Inadine dressing
group 71/108 (66%) as compared with the gauze dressing group 48/106 (45%). There was a 45%
increase in complicating infection observed in the Inadine group as compared to control. (RR
1.45, 95% CI 1.13 to 1.86; participants = 214; studies = 1); a statistically significant difference
was observed.
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Quality of Life

The Quality of life Index was higher in the Inadine dressing group 0.3838 +/- 0.1085 as
compared with the gauze dressing group 0.3939 +/- 0.1093. There was a - 0.01 Quality of life
mean difference reduction in the Inadine group as compared to control. (MD -0.01, 95% CI -0.04
to 0.02; participants = 214; studies = 1); No statistically significant difference was observed.

Secondary Outcomes

Proportion of participants with ulcers completely healed

The proportion of participants with ulcers completely healed was higher in the Inadine dressing
group 48/108 (44%) as compared with the gauze dressing group 41/106 (39%). There was a 15%
increase in the proportion of participants with ulcers completely healed in the Inadine dressing
group as compared with the gauze-dressing group. (RR 1.15, 95% CI 0.84 to 1.58; participants =
214; studies = 1); No statistically significant difference was observed.

Time to complete healing (days)

The time to complete healing was lower in the Inadine dressing group as compared with the
gauze dressing group. There was reduction of 2.9 days in time to complete healing in the Inadine
dressing group 127.8 (SD = 54.2) days as compared with the gauze dressing group 130.7 (SD =
52.4) days; (MD -2.90, 95% CI -17.18 to 11.38; participants = 214; studies = 1); No statistically
significant difference was observed.
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The proportion of participants with ulcers recurring after healing

The proportion of participants with ulcers recurring after healing was higher in the Inadine
dressing group 7/108 (6.5%) as compared with the gauze dressing group 3/106 (3%). There was
a 129% increase in the proportion of participants with ulcers completely healed in the Inadine
dressing group as compared with the gauze dressing group; (RR 2.29, 95% CI 0.61 to 8.62;
participants = 214; studies = 1); No statistically significant difference was observed.

Cost of treatment

The cost of treatment was higher in the Inadine dressing group 183.60 (SD = 286.47) British
Pounds as compared with the gauze dressing group 141.18 (SD = 171.31) British Pounds. The
mean difference in cost of treatment was 42.42 British Pounds greater in the Inadine dressing
group as compared with the gauze dressing group; (MD 42.42, 95% CI -20.69 to 105.53;
participants = 214; studies = 1).
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Analysis Table 12.1 – 12.7 Iodine impregnated fiber
dressing compared with gauze dressing
Outcome or
Subgroup
12.1 Number of
amputations reported

Studies

Participants

1

214

12.2 Number of
Infections reported

1

214

12.3 Quality of life

1

214

12.4 Number of
ulcers completely
healed
12.5 Time to
complete healing
(days)
12.6 Recurrence rates

1

214

1

214

1

214

12.7 Treatment cost

1

214

Statistical
Method
Risk Ratio (M-H,
Random, 95%
CI)
Risk Ratio (M-H,
Random, 95%
CI)
Std. Mean
Difference (IV,
Random, 95%
CI)
Risk Ratio (M-H,
Random, 95%
CI)
Mean Difference
(IV, Random,
95% CI)
Risk Ratio (M-H,
Random, 95%
CI)
Mean Difference
(IV, Random,
95% CI)

Effect Estimate
0.49 [0.05, 5.33]

1.45 [1.13, 1.86]

-0.09 [-0.36,
0.18]

1.15 [0.84, 1.58]

-2.90 [-17.18,
11.38]
2.29 [0.61, 8.62]

42.42 [-20.69,
105.53]

Comparison 13 Hydrofiber compared with gauze dressing (2 trials, 229
participants)
Jeffcoate 2009; Piaggesi 2001

Trial 1: Hydrofiber dressing as compared with gauze dressing (209 participants)

This comparison included 1 study Jeffcoate 2009 and a total of 209 participants. The follow up
period was 24 weeks. The study comparison period was June 2003 to March 2007.
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There was some risk of bias however many of the risk of bias considerations were low risk for
bias Figure 3; Figure 4.

Types of Interventions

The interventions in these studies included hydrofiber dressing as compared with gauze dressing.
All patient received ulcer management including regular use of debridement, and
"recommended" fiberglass or polyester boot for offloading. It was not clear whether another
alternate form of debridement was used or whether the study relied on the debridement effect of
the dressing itself Table 5; Table 13.

Initial Wound Stage
The wound surface area included in the study ranged between 0.25 - 2.25 cm2. It was further
subdivided into 3 additional ranges that included 0.25 - 1 cm2, 1.01 - 0.25 cm2, and 2.5 - 25cm2.
The number of participants in each subgroup was 53, 34, and 16 for the hydrofiber group; and
50, 34, and 22 for the gauze group, respectively. The initial depth of wound, wound stage, and
wound duration were not reported in the study for either of the treatment arms Table 10.

Participant Characteristics

The study comprised a total of 209 participants. The mean age for the study participants was
reported was 59.6 +/- 12.6 years. There were 159 males and 49 females Table 9. The study
setting included multidisciplinary outpatient centers, and the study was conducted in the UK
Table 3.
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Types of Outcomes

Primary Outcomes

Proportion of participants with amputations

The proportion of participants with amputations was higher in the Hydrofiber dressing group
4/103 (4%) as compared with the gauze dressing group 2/106 (2%). There was a 106% increase
in the proportion of participants with amputations observed in the Hydrofiber group as compared
to control. (RR 2.06, 95% CI 0.39 to 10.99; participants = 209; studies = 1); No statistically
significant difference was observed.

Proportion of participants with complicating infections

The proportion of participants with complicating infections was higher in the Hydrofiber
dressing group 54/103 (52%) as compared with the gauze dressing group 48/106 (45%). There
was a 16% increase in proportion of participants with complicating infections observed in the
Hydrofiber group as compared to the control group. (RR 1.16, 95% CI 0.88 to 1.53; participants
= 209; studies = 1); No statistically significant difference was observed.

Quality of Life

The Quality of life Index was higher in the Hydrofiber dressing group 0.3822 (SD = 0.1085) as
compared with the gauze dressing group 0.3939 (SD = 0.1093). There was a - 0.10 Quality of
life mean difference reduction in the Hydrofiber group as compared to control. (MD -0.10, 95%
CI -0.38 to 0.17; participants = 209; studies = 1); No statistically significant difference was
observed.
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Secondary Outcomes

Proportion of participants with ulcers completely healed

The proportion of participants with ulcers completely healed was higher in the Hydrofiber
dressing group 46/103 (45%) as compared with the gauze dressing group 41/106 (39%). There
was a 15% increase in the proportion of participants with ulcers completely healed in the
Hydrofiber dressing group as compared with the gauze-dressing group. (RR 1.15, 95% CI 0.84 to
1.59; participants = 209; studies = 1); No statistically significant difference was observed.

Time to complete healing (days)

The time to complete healing was lower in the Hydrofiber dressing group 125.8 (SD = 55.9) days
as compared with the gauze dressing group 130.7 (SD = 52.4) days. There was a mean reduction
of 4.9 days in time to complete healing in the Hydrofiber dressing group as compared with the
gauze dressing group; (MD -4.90, 95% CI -19.60 to 9.80; (participants = 209; studies = 1); No
statistically significant difference was observed.

The proportion of participants with ulcers recurring after healing

The proportion of participants with ulcers recurring after healing was higher in the Hydrofiber
dressing group 3/103 (3%) as compared with the gauze dressing group 3/106 (3%). There was a
small 3% increase in the proportion of participants with ulcers completely healed in the
Hydrofiber dressing group as compared with the gauze dressing group; (RR 1.03, 95% CI 0.21 to
4.98; participants = 209; studies = 1); No statistically significant difference was observed.
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Cost of treatment

The cost of treatment was higher in the Hydrofiber dressing group 191.33 (SD = 219.63 British
Pounds as compared with the gauze dressing group 141.18 (SD = 171.31). The mean difference
in cost of treatment was 50.15 British pounds greater in the Hydrofiber dressing group as
compared with the gauze dressing group; (MD 50.15, 95% CI -3.35 to 103.65; participants =
209; studies = 1), no statistically significant difference was observed.

Trial 2: Hydrofiber dressing as compared with gauze dressing (20 participants)

Piaggesi 2001

This comparison included 1 study Piaggesi 2001 and a total of 20 participants. The follow up
period was 8 weeks. The study period was 1998. There was significant risk of bias as many of
the risk of bias considerations were unclear or high risk for bias Figure 3; Figure 4.

Types of Interventions

The interventions in these studies included hydrofiber dressing as compared with gauze dressing.
All patient received for post-operative shoes for pressure relief and were trained to walk on
crutches until there was satisfactory healing Table 5; Table 13.
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Initial Wound Stage
The initial mean wound volume included in the study was 19.2 (SD = 6.4) cm3 in the Hydrofiber
dressing group and 22.6 (SD = 8.4) cm3 in the gauze-dressing group. The initial mean wound
depth was 2.9 (SD = 1.1) cm in the Hydrofiber dressing group and 2.3 (SD = 1.4) cm in the
Saline moistened dressing group. The wound stage, and wound duration were not reported in the
study for either of the treatment arms. Table 10

Participant Characteristics

The study comprised a total of 20 participants. The median age for the study participants was
reported was 59.5. Gender composition was not reported. Table 9 The study setting included
outpatients, and the study was conducted in the Italy. Table 3

Types of Outcomes

Primary Outcomes

Proportion of participants with amputations

The proportion of participants with amputations was lower in the hydrofiber dressing group 0/10
(0%) as compared with the gauze dressing group 1/10 (10%). There was a decrease in the
proportion of participants with amputations observed in the hydrofiber group as compared to
control. (RR 0.33, 95% CI 0.02 to 7.32; participants = 20; studies = 1); No statistically
significant difference was observed.

130

Proportion of participants with complicating infections

The proportion of participants with complicating infections was higher in the Hydrofiber
dressing group 1/10 (10%) as compared with the Saline moistened gauze dressing group 3/10
(30%). There was a 67% decrease in the proportion of participants with complicating infections
observed in the hydrofiber group as compared to the gauze group. (RR 0.33, 95% CI 0.04 to
2.69; participants = 20; studies = 1); No statistically significant difference was observed.

No data were reported for the primary outcome quality of life.

Secondary Outcomes

Proportion of participants with ulcers completely healed

The proportion of participants with ulcers completely healed was higher in the hydrofiber
dressing group 10/10 (100%) as compared with the saline nonadherent gauze dressing group
9/10 (90%). There was an 11% increase in the proportion of participants with ulcers completely
healed in the Hydrofiber dressing group as compared with the gauze dressing group. (RR 1.11,
95% CI 0.85 to 1.44; participants = 20; studies = 1); No statistically significant difference was
observed.
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Time to complete healing (days)

The time to complete healing was less in the Hydrofiber dressing group 127 (SD = 46) days as
compared with the gauze dressing group 234 (SD = 61) days. There was a mean reduction of 107
days in time to complete healing in the Hydrofiber dressing group as compared with the gauze
dressing group; (MD -107.00, 95% CI -154.35 to -59.65; (participants = 20; studies = 1);
Statistically significant difference was observed.

No data were reported for the secondary outcomes proportion of participants with ulcers
recurring after healing, or cost of treatment.

Summary: Hydrofiber compared with saline moistened gauze

The two trials (Jeffcoate 2009; Piaggesi 2001) comparing hydrofiber with saline moistened
gauze dressing were considered sufficiently similar to pool, using a random effects model. They
included a combined total of 229 participants. The follow up ranged from 12 - 24 weeks. The
study comparison period was 1998, and June 2003 - March 2007. There was significant risk of
bias as many of the risk of bias characteristics were either unclear (unreported) or high risk of
bias Figure 3; Figure 4.
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Proportion of participants with amputations

The two studies on the number of amputations and were pooled. Pooling these two studies
yielded a relative risk for amputation of (RR 1.34, 95% CI 0.29 to 6.10; participants = 229;
studies = 2); in the absence of significant heterogeneity, p = 0.31, I2 = 3%) Analysis 13.1. No
statistically significant difference. This translates to 34% increase in the proportion of
participants with amputations for the hydrofiber dressing group as compared to saline moistened
gauze dressing group; and a number needed to treat [NNTB] of 100 (95% CI 25 [NNTB], 15
[NNTH]): that is to prevent one additional patient with diabetic foot ulcer from having an
amputation, 100 patients must be treated with hydrofiber instead of saline moistened gauze. No
statistically significant difference was observed Figure 27.

Proportion of participants with complicating infections

Both studies reported on proportion participants with complicating infections.

Pooling the two trials yielded a relative risk for infections with hydrofiber of 0.96, (95% CI 0.40
to 2.31; participants = 229; studies = 2); in the absence of significant heterogeneity, p = 0.24, I2 =
27%); Analysis 13.2. This translates to 4% reduction in the proportion participants with
complicating infections for the hydrofiber dressing group as compared to saline moistened gauze
dressing group, and a number needed to treat [NNTB] of 50 (95% CI 4 [NNTB] to 5 [NNTH]):
that is to prevent one additional patient with diabetic foot ulcer from developing an infection,
fifty patients must be treated with hydrofiber instead of gauze (treatment time varied from 8 to
24 weeks). Though no statistically significant difference was observed Figure 28.
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Proportion of participants with ulcers healed

The proportion participants with ulcers healed yielded a relative risk of (RR 1.13, 95% CI 0.92 to
1.38; participants = 229; studies = 2); in the absence of significant heterogeneity, p = 0.79, I2 =
0%). This translates to a 13% increase in the proportion of ulcers healed in the hydrofiber
dressing group as compared to saline moistened gauze group, and a number needed to treat of 15
(95% CI 6 [NNTB], 20 [NNTH): (Analysis 13.4) that is to heal one additional patient with
diabetic foot ulcer, fifteen patients must be treated with hydrofiber instead of saline moistened
gauze (treatment time varied from 8 to 24 weeks). No statistically significant difference was
observed Figure 29.

Time to complete healing

The Time to complete healing yielded a mean difference of 53.37 days less in the hydrofiber
dressing group as compared to the saline moistened dressing group (MD -53.37, 95% CI -153.29
to 46.56; participants = 229; studies = 2); (Analysis 13.5) in the presence of significant
heterogeneity, p < 0.0001, I2 = 94%) (treatment time varied from 8 to 24 weeks). No statistically
significant difference was observed Figure 30.

The primary outcome quality of life index, and the secondary outcomes proportion of
participants with recurrent ulcers, and cost of treatment were not reported in one or both studies.
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Analysis Table 13.1 – 13.7 Hydrofiber compared with
gauze dressing
Outcome or
Subgroup

Studies

Participants

Statistical
Method

Effect Estimate

13.1 Number of
amputations
reported
13.2 Number of
Infections reported
13.3 Quality of life

2

229

Risk Ratio (M-H,
Random, 95% CI)

1.34 [0.29, 6.10]

2

229

0.96 [0.40, 2.31]

1

209

13.4 Number of
ulcers completely
healed
13.5 Time to
complete healing
(days)
13.6 Recurrence
rates
13.7 Treatment
cost

2

229

2

229

1

209

1

209

Risk Ratio (M-H,
Random, 95% CI)
Std. Mean
Difference (IV,
Random, 95% CI)
Risk Difference
(M-H, Random,
95% CI)
Mean Difference
(IV, Random,
95% CI)
Risk Ratio (M-H,
Random, 95% CI)
Std. Mean
Difference (IV,
Random, 95% CI)

-0.10 [-0.38, 0.17]

0.07 [-0.05, 0.19]

-53.37 [-153.29,
46.56]
1.03 [0.21, 4.98]
0.25 [-0.02, 0.53]

Comparison 14: Hydrocellular polyurethane foam compared with Calcium
Alginate (1 trial, 30 participants)
This comparison included 1 trial (Foster 1994) with 30 participants. The follow up period was 8
weeks or the ulcer healing whichever came first. The study comparison period was not reported.
There was significant risk of bias since many of the risk of bias considerations were either
unclear or high Figure 3; Figure 4.

Types of Interventions

The interventions in these studies included Hydrocellular foam dressing group as compared with
Calcium alginate dressing group. Patients were prescribed "appropriate antibiotic cover" for
prevention and control of infection Table 5; Table 13.
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Initial Wound Stage
The initial median wound surface area in the study was reported to be 0.88 cm2 in the
Hydrocellular foam dressing group and 0.79 cm2 in the Calcium alginate dressing group. The
initial depth of wound was not specified other than 12, and 13 without units for either respective
groups respectively. The wound stage was not reported in the study for either treatment arm. The
mean duration of ulcers for the sample was 15.3 weeks in the Foam dressing group and 24.3
weeks in the Calcium alginate group. Table 10

Participant Characteristics

The study comprised a total of 30 participants. The median age for the study was 65.5 years.
There were 20 males and 10 females. Table 9 The study setting included outpatients, and the
study was conducted in UK. Table 3

Primary Outcomes

No data were reported for any the primary outcomes.
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Secondary Outcomes

Proportion of participants with ulcers completely healed

The proportion of participants with ulcers completely healed was greater in the Hydrocellular
polyurethane foam group 9/15 (60%) as compared with the calcium alginate group 8/15 (53%).
(RR 1.13, 95% CI 0.60 to 2.11; participants = 30; studies = 1) Analysis 14.1. There was a 13%
increase in the proportion of participants with ulcers completely healed in the Foam dressing
group as compared with the Calcium alginate dressing group. No statistically significant
difference was observed.

No data were reported for the secondary outcomes time to complete healing (days), proportion of
participants with ulcers recurring after healing, cost of treatment.

Analysis Table 14.1 Hydrocellular polyurethane foam
compared with calcium alginate
Outcome or
Subgroup
14.1 Number of ulcers
completely healed

Studies
1

Participants
30

Statistical
Method

Effect
Estimate

Risk Ratio (M1.13 [0.60, 2.11]
H, Random, 95%
CI)

Comparison 15 Honey soaked dressing compared with povidone iodine saline
dressing (1 trial, 60 participants)
This comparison included 1 trial EhsanUrRehman 2013 with 60 participants. The follow up
period was 2 weeks. The study comparison period was from July to December 2012. There was
significant risk of bias since many of the risk of bias considerations were either unclear or high.
Figure 3; Figure 4.
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Types of Interventions

The interventions in these studies included Honey soaked dressing group as compared with
povidone iodine saline dressing group. Patient's in both groups had their wounds washed with
copious normal saline Table 5; Table 13.

Initial Wound Stage

The initial wound surface area, and initial wound depth in the study was not reported. The wound
stage was reported as Wagner grade 1 - 2. The mean duration of ulcers was not reported. Table
10

Participant Characteristics

The study comprised a total of 30 participants. The median age for the study was 55.3 (SD =
3.89) years. There were 35 males and 25 females. Table 9 The study setting included
hospitalized patients, and the study was conducted in Pakistan. Table 3

Primary Outcomes

No data were reported for any of the primary outcomes.
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Secondary Outcomes

Proportion of participants with ulcers completely healed

The proportion of participants with ulcers completely healed was greater in the honey soaked
dressing group 24/30 (80%) as compared with the povidone iodine saline dressing group 22/30
(73%). There was a 9% increase in proportion of participants with ulcers completely healed in
the honey soaked dressing group as compared with the povidone iodine saline dressing group
(RR 1.09, 95% CI 0.82 to 1.44; participants = 60; studies = 1) Analysis 15.1. No statistically
significant difference was observed.

No data were reported for the secondary outcomes time to complete healing (days), proportion of
participants with ulcers recurring after healing, and cost of treatment.

Analysis Table 15.1 Honey soaked dressing compared with
povidone iodine saline dressing
Outcome or
Subgroup
15.1 Number of
ulcers completely
healed

Studies
1

Participants
60

Statistical
Method
Risk Ratio (M-H,
Random, 95% CI)

Effect Estimate
1.09 [0.82, 1.44]

Comparison 16 Honey/Normal saline dressing compared with povidone iodine
saline dressing (1 trial, 200 participants)
This comparison included 1 trial Hammouri 2004 with 200 participants. The follow up period
was not pre-specified. The study comparison period was from 1996 to 2001. There was
significant risk of bias since many of the risk of bias considerations were either unclear or high.
Figure 3; Figure 4.
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Types of Interventions

The interventions in these studies included Honey/saline dressing group as compared with
povidone iodine/saline dressing group. All patients were debrided in advance in both treatment
arms and washed with normal saline Table 5; Table 13.

Initial Wound Stage

The initial wound surface area, initial wound depth, wound stage, and mean duration of ulcers
was not reported. Table 10

Participant Characteristics

The study comprised a total of 200 participants. The mean age for the study was 58 years. There
were 112 males and 88 females. Table 9 The study setting included hospitalized patients, and the
study was conducted in 4 district hospitals in Jordan. Table 3

Primary Outcomes

Proportion of participants with amputations

The proportion of participants with amputations were less in the honey/normal saline dressing
group 10/100 (10%) as compared with the povidone iodine saline dressing group 20/100 (20%).
There was a 50% decrease in the proportion of participants with amputations in the
honey/normal saline dressing group as compared with the povidone iodine saline dressing group
(RR 0.50, 95% CI 0.25 to 1.01; participants = 200; studies = 1); Analysis 16.1. No statistically
significant difference was observed.
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No data were reported for the primary outcomes proportion of participants with complicating
infections, and quality of life.

Secondary Outcomes

Cost of treatment

The cost of treatment was on average 334.00 Jordanian Dinar's less in the honey/normal saline
dressing group as compared with the povidone peroxide/saline dressing group (MD -334.00,
95% CI -373.99 to -294.01; participants = 200; studies = 1) Analysis 16.2. Whether this was total
cost or cost per treatment was not specified.

No data were reported for the secondary outcomes proportion of participants with ulcers
completely healed, time to complete healing (days), and proportion of participants with ulcers
recurring after healing.

Analysis Table 16.1 – 16.2 Honey/normal saline dressing
compared with povidone peroxide saline dressing
Outcome or
Subgroup

Studies

Participants

16.1 Number of
amputations reported

1

200

16.2 Treatment cost

1

200
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Statistical
Method

Effect
Estimate

Risk Ratio (MH, Random,
95% CI)
Mean Difference
(IV, Random,
95% CI)

0.50 [0.25, 1.01]

-334.00 [373.99, -294.01]

Comparison 17 Sugar jam (with hydrogen peroxide and topical antibiotic)
compared with (hydrogen peroxide and topical antibiotic) (1 trial, 80
participants)
This comparison included 1 trial Rhaiem 1998 with 80 participants. The follow up period was
not pre-specified. The study comparison period was from 1992 to 1995. There was significant
risk of bias since many of the risk of bias considerations were either unclear or high. Figure 3;
Figure 4.

Types of Interventions

The interventions in these studies included Honey/saline dressing group as compared with
povidone iodine/saline dressing group Table 5; Table 13.

Initial Wound Stage

The initial wound surface area, initial wound depth, wound stage, and mean duration of ulcers
was not reported Table 10.

Participant Characteristics

The study comprised a total of 80 participants. The mean age for the study was 56 (SD = 32)
years. There were 59 males and 21 females Table 9. The study setting included hospitalized
patients, and the study was conducted in Tunisia Table 3.

Primary Outcomes

No data were reported for any of the primary outcomes.
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Secondary Outcomes

Proportion of participants with ulcers completely healed

The proportion of participants with ulcers completely healed was higher in the Sugar jam (with
hydrogen peroxide and topical antibiotic) 19/40 (47.5%) as compared with the (hydrogen
peroxide and topical antibiotic) 16/40 (40%). There was a 19% increase in the proportion of
participants with ulcers completely healed in the Sugar jam (with hydrogen peroxide and topical
antibiotic) as compared with the (hydrogen peroxide and topical antibiotic) (RR 1.19, 95% CI
0.72 to 1.96; participants = 80; studies = 1); Analysis 17.1. No statistically significant difference
was observed.

No data were reported for the secondary outcomes, time to complete healing (days), proportion
of participants with ulcers recurring after healing, and cost of treatment.

Analysis Table 17.1 Sugar jam (hydrogen peroxide and
topical antibiotic) dressing compared with (hydrogen
peroxide and topical antibiotic)
Outcome or
Subgroup
17.1 Number of
ulcers completely
healed

Studies
1

Participants
80

Statistical
Method
Risk Ratio (M-H,
Random, 95% CI)
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Effect Estimate
1.19 [0.72, 1.96]

Comparison 18 Silver (standard cleaning and compression management
methods) dressing group as compared with control group (standard cleaning and
compression management methods without silver ointment) (1 trial, 66
participants)
Belcaro 2010

This comparison included 1 trial with 66 participants. The follow up period was 4 weeks. The
study comparison period was not reported. There was significant risk of bias since many of the
risk of bias considerations were either unclear or high. Figure 3; Figure 4.

Types of Interventions

The interventions in these studies included Silver (standard cleaning and compression
management methods) dressing group as compared with control group (standard cleaning and
compression management methods without silver ointment) Table 5; Table 13.

Initial Wound Stage
The initial mean wound surface area was 2.22 (SD = 0.24) cm2 in the Silver (standard cleaning
and compression management methods) dressing group, and 2.18 (SD = 1.66) cm2 in the control
group. The initial wound depth, wound stage, and mean duration of ulcers was not reported.
Table 10
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Participant Characteristics

The study comprised a total of 80 participants. The mean age for the study was 55.9 (SD = 3.8)
years. There were 29 males and 37 females Table 9. The study setting included hospitalized
patients, and the study was conducted in Tunisia Table 3.

Primary Outcomes

No data were reported for any of the primary outcomes.

Secondary Outcomes

Proportion of participants with ulcers completely healed

The proportion of participants with ulcers completely healed was higher in the Silver dressing
group 13/34 (38%) as compared with the control group 5/32 (16%). There was a 145% increase
in the proportion of participants with ulcers completely healed in the Silver dressing group as
compared with the control group (RR 2.45, 95% CI 0.98 to 6.09; participants = 66; studies = 1);
Analysis 18.1. No statistically significant difference was observed.

No data were reported for the secondary outcomes time to complete healing (days), proportion of
participants with ulcers recurring after healing, and cost of treatment.
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Analysis 18.1 Silver dressing compared with control group
(standard cleaning and compression management methods
without silver ointment)
Outcome or
Subgroup
18.1 Number of
ulcers completely
healed

Studies
1

Participants
66

Statistical
Method

Effect
Estimate

Risk Ratio (M-H,
Random, 95%
CI)

2.45 [0.98, 6.09]

Comparison 19 Debridement (Any form of debridement against gauze or saline
gauze) (10 trials, 807 participants)
Jeffcoate 2009; Jensen 1998; Piaggesi 2001; Piaggesi 1998; Vandeputte 1997; Lalau 2002;
D'Hemecourt 1998; Donaghue 1998; Goretti 2008; Roberts 2001

Summary: Any form of debridement as compared with gauze

The 10 trials (D'Hemecourt 1998; Donaghue 1998; Goretti 2008; Jeffcoate 2009; Jensen 1998;
Lalau 2002; Piaggesi 1998; Piaggesi 2001; Roberts 2001; Vandeputte 1997) comparing any form
of debridement with gauze dressing were considered sufficiently similar to pool, using a random
effects model. They included a combined total of 807 subjects. The follow up period ranged
from 4 - 24 weeks. The study comparison period ranged from 1995 to March 2007, however the
study period was not reported for 8/10 studies. There was significant risk of bias as many of the
risk of bias characteristics were either unclear (unreported) or at high risk of bias. Figure 3;
Figure 4.
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Types of Interventions

The interventions in these studies included: Any (All) forms of debridement as compared with
gauze or saline gauze. Gauze was the most frequently used method of control or "alternative"
treatment arm. This was often paired with some form of standard treatment to both arms that
when specified ranged from pressure relief/offloading, antiseptic or saline skin cleansing,
secondary dressings, or infection control with antibiotics. Some of the studies used an alternate
separate form of debridement that was not uniformly clearly defined in all studies. There were no
details in the studies as to the extent this was done other than references to "as needed", "as
required", or "regularly". If a study specified that a separate identical form of debridement was
used on both intervention arms throughout the study it was excluded, as this would confound any
debridement effect from the intervention and control groups Table 5; Table 13.

Initial Wound Stage
The initial wound size in the studies ranged from 0.21 cm2 to 25 cm2. The only study that did not
report wound size was Vandeputte 1997. The wound depth ranged from 0.4 cm to 2.9 cm. Four
studies in this comparison reported wound depth Table 10. The wound staging included in the
studies were classified as Wagner grade 1 - 4. Four studies reported Wound stage in this
comparison. The duration of ulcers in this comparison ranged from 5.9 weeks to 42 (SD = 42)
weeks. There were 7 studies that reported duration of ulcers Table 10.
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Participant Characteristics

The studies comprised a total of 807 participants Table 3. The mean ages for the studies ranged
from to 58.3 (SD = 12.13) years to 64.39 (SD = 11.67) years Table 9. There were a total of at
least 502 males in the studies that actually reported gender in this total sample Table 9. The
studies were conducted in a variety of settings including outpatient and inpatient (hospitalized)
patients Table 3. The studies were conducted in the following countries: Belgium, France, Italy,
UK, and the US Table 3. The risk of bias in the included studies was significant as most of the
risk of bias characteristics used in this review were unclear or high for the studies used in this
comparison Figure 3, Figure 4.

Types of Outcomes

Primary Outcomes

Proportion of participants with amputations

Five studies reporting on the number of amputations were pooled. There were fewer amputations
using ANY form of debridement 6/272 as compared with gauze 10/171. Pooling these studies
yielded a relative risk for amputation of (RR 0.48, 95% CI 0.17 to 1.37; participants = 443;
studies = 5; I2 = 0%); in the absence of significant heterogeneity, p = 0.75, I2 = 0%) Analysis
19.1. This translates to 52 % reduction in the proportion of participants with amputations in the
Any debridement group as compared to gauze dressing group; and a number needed to treat for
benefit [NNTB] of 50 (95% CI 15 [NNTB], 34 [NNTH]): that is to prevent one additional patient
with diabetic foot ulcer from having an amputation, 50 patients must be treated with Any form of
debridement instead of gauze. No statistically significant difference was determined Figure 31.
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Proportion of participants with complicating infections

The seven studies reporting on the number of infections were pooled. There were more
infections using ANY form of debridement 152/381 as compared with gauze 84/278. Pooling
these studies yielded a relative risk for amputation of (RR 1.07, 95% CI 0.76 to 1.52; participants
= 659; studies = 7); in the absence of significant heterogeneity, p = 0.15, I2 = 35%) Analysis
19.2; Figure 32.

This translates to 7% increase in the proportion of participants with infections in the Any
debridement group as compared to the gauze dressing group; and a number needed to treat
[NNTH] of 50 (95% CI 9 [NNTB], 12 [NNTH]): that is to prevent one additional patient with
diabetic foot ulcer from having an infection, 50 patients must be treated with Any form of
debridement instead of gauze. No statistically significant difference was determined Figure 32.

Secondary Outcomes

Proportion of participants with ulcers healed

The ten studies reporting on the number of patients with ulcers completely healed were pooled.
There were more ulcers healed using ANY form of debridement 213/462 as compared with
gauze 134/336. Pooling these studies yielded a relative risk for amputation of (RR 1.22, 95% CI
1.04 to 1.44; participants = 798; studies = 10); in the absence of significant heterogeneity, p =
0.18, I2 = 28%) Analysis 19.3.
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This translates to 22% increase in the proportion of participants with infections in the Any
debridement group as compared to the gauze dressing group; and a number needed to treat
[NNTB] of 10 (95% CI 5 to 100 [NNTB]): that is to heal one additional patient with diabetic foot
ulcer, 10 patients must be treated with Any form of debridement instead of gauze. Statistically
significant difference was determined Figure 33.

Proportion of participants with ulcers healed - Subgroup analysis excluding the two abstracts

A subgroup analysis was performed excluding two studies that were only available as abstracts
including: Goretti 2008; Roberts 2001.

The eight studies reporting on the number of patients with ulcers completely healed were pooled.
There were more ulcers healed using ANY form of debridement 190/428 as compared with
gauze 119/300. Pooling these studies yielded a relative risk for amputation of (RR 1.18, 95% CI
0.99 to 1.41; participants = 728; studies = 8); in the absence of significant heterogeneity, p =
0.14, I2 = 35%) Analysis 19.3.

This translates to an 18% increase in the proportion of participants with infections in the Any
debridement group as compared to the gauze dressing group; and a number needed to treat to
benefit [NNTB] of 12 (95% CI 6 [NNTB], 50 [NNTH]): that is to heal one additional patient
with diabetic foot ulcer, 12 patients must be treated with Any form of debridement instead of
gauze. No statistically significant difference was determined when excluding the two studies
available as abstracts only.
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Quality of Life Index

One study with 3 arms reported on this outcome. The mean difference was 0.01 points lower in
the Any debridement group (using either Hydrofiber or Iodine impregnated fiber dressing) as
compared with the gauze dressing group (MD -0.01, 95% CI -0.04 to 0.01; participants = 317;
studies = 1); in the absence of significant heterogeneity, p < 0.95, I2 = 0%; Analysis 19.4. No
statistically significant difference was demonstrated Figure 34.

Time to complete healing

Four studies reported on this outcome. Time to complete healing yielded a mean difference of 27.88 days less time to achieve healing in the Any debridement dressing group as compared to
the gauze dressing group (MD -27.88, 95% CI -52.53 to -3.23; participants = 458; studies = 4);
in the presence of significant heterogeneity, p < 0.0001, I2 = 90%); Analysis 19.5. No
statistically significant difference was observed Figure 35.

Proportion of participants with recurrent ulcers

Two studies reporting on the proportion of patients with recurrent ulcers were pooled. There
were less recurrent ulcers using ANY form of debridement group 13/232 as compared with
gauze dressing group 11/125. Pooling these studies yielded a relative risk for recurrent ulcers of
(RR 0.81, 95% CI 0.25 to 2.58; participants = 357; studies = 3); in the absence of significant
heterogeneity, p = 0.18, I2 = 39%); Analysis 19.6 .
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This translates to 19% reduction in the proportion of participants with recurrent ulcers in the Any
debridement group as compared to the gauze dressing group; and a number needed to treat
[NNTB] of 100 (95% CI 10 [NNTB], 13 [NNTH]): that is to prevent one additional patient with
diabetic foot ulcer from developing a recurrent ulcer, 100 patients must be treated with Any form
of debridement instead of gauze. No statistically significant difference was demonstrated Figure
36.

Cost of treatment was either not reported at all or not reported in at least 2 out of the 10 studies
used in this comparison.
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Analysis Table 19.1 – 19.6 Any debridement compared
with saline gauze control
Outcome or
Subgroup

Studies

Participants

Statistical
Method

Effect
Estimate

Risk Ratio (M-H,
Random, 95%
CI)
Risk Ratio (M-H,
Random, 95%
CI)

0.48 [0.17, 1.37]

Risk Ratio (M-H,
Random, 95%
CI)
Risk Ratio (M-H,
Random, 95%
CI)

1.07 [0.76, 1.52]

19.1 Number of
amputations reported

5

443

19.1.1 Any
debridement
compared with saline
gauze
19.2 Number of
Infections reported

5

443

7

659

19.2.1 Any
debridement
compared with saline
gauze
19.3 Number of
ulcers completely
healed
19.3.1 Any
Debridement vs
Saline Gauze
19.3.2 SA w/o
Abstracts
19.4 Quality of life

7

659

10

798

Risk Ratio (M-H,
Fixed, 95% CI)

1.17 [1.00, 1.36]

8

728

Risk Ratio (M-H,
Fixed, 95% CI)

1.12 [0.95, 1.32]

2

70

1.59 [1.04, 2.42]

1

317

19.5 Time to
complete healing
(days)
19.6 Recurrence rates

4

458

2

357

Risk Ratio (M-H,
Fixed, 95% CI)
Mean Difference
(IV, Random,
95% CI)
Mean Difference
(IV, Random,
95% CI)
Risk Ratio (M-H,
Random, 95%
CI)

153

0.48 [0.17, 1.37]

1.07 [0.76, 1.52]

-0.01 [-0.04,
0.01]
-27.88 [-52.53, 3.23]
0.81 [0.25, 2.58]

Summary of Results, Overall Effect sizes, and Heterogeneity
Table 14 below summarizes the overall results, effect sizes discussed in this section, along with
heterogeneity that were reported for all meta-analyses done in this review.

Table 14 Summary of Results, Overall Effect Sizes, and Heterogeneity
RR (95% CI) **MD (95% CI)
Intervention
comparison
Hydrogel vs.
Gauze

Foam vs. Wet to
Dry
Hydrofiber vs.
Gauze

Any debridement
vs. Gauze

Outcome

k

Fixed-Effects

Random-Effects

Heterogeneity of Outcome Effects Summary
Statisticsb
τ2
χ2
I2 (%)
p-value

Proportion of
Amputations
Proportion of
Infections
Proportion of
Ulcers Healing
Proportion of
Ulcers Healing
2 studies
Proportion of
Amputations 2
studies
Proportion of
Infections
2
studies
Proportion of
Ulcers Healing
2 studies
Mean Time to
Complete Healing
2 studies
Proportion of
Amputations 5
studies (n=6)
Proportion of
Infections
7
studies (n=8)
Quality of Life
1 study (n=2)
Proportion of
Ulcers Healing
10 studies (n=11)

2

0.26 (0.05, 1.37)

0.26 (0.05, 1.40)

0.00

0.11

0

0.74

3

0.87 (0.54, 1.40)

0.74 (0.18, 2.99)

0.91

4.89

59

0.09

3

1.68 (1.14, 2.49)

1.71 (1.16, 2.52)

0.00

0.95

0

0.62

2

4.35 (1.33, 14.29)

3.56 (0.93, 13.66)

0.18

1.15

13

0.28

2

1.31 (0.33, 5.16)

1.34 (0.29, 6.10)

0.05

1.03

3

0.31

2

1.11 (0.84, 1.46)

0.96 (0.40, 2.31)

0.21

1.37

27

0.24

2

0.06 (0.06, 0.19)

0.07 (0.05, 0.19)

0.00

0.09

0

0.76

2

**-13.87 (-27.91, 0.16)

**-53.37 (-153.29,
46.56)

4892.23

16.29

94

< 0.0001

5

0.49 (0.19, 1.27)

0.48 (0.17, 1.37)

0.00

2.67

0

0.75

7

1.10 (0.89, 1.36)

1.07 (0.76, 1.52)

0.07

10.82

35

0.15

1

-0.01 (-0.04, 0.01)

-0.01 (-0.04, 0.01)

0.00

0.00

0

0.95

3

1.17 (1.00, 1.36)

1.22 (1.04, 1.44)

0.02

13.89

28

0.18

Proportion of
Ulcers Healing
(two studies
available only as
abstracts)
Proportion of Ulcer
Recurrence 2
studies (n=3)
Mean Time to
Complete Healing
4 studies (n=5)

10

1.12 (0.95, 1.32)]

1.18 (0.99, 1.41)

0.02

12.26

35

0.14

2

0.77 (0.34, 1.71)

0.81 (0.25, 2.58)

0.42

3.29

39

0.19

4

2.54 (1.20, 3.87)

-27.88 (-52.53, -3.23)

614.40

39.33

90

< 0.00001

Note:
** indicates a significant effect; k represents the number of studies for each outcome included in the analysis; Q represents Cochran’s Q indicating
significance of heterogeneity; I2 represents the magnitude of heterogeneity; p-value represents the significance of heterogeneity.
b) Relative risk (RR) was the effect estimate for proportion of amputations, proportion of infections, and proportion of ulcers healed, and proportion of
recurrence. Mean difference (MD) was the effect estimate for the outcomes Quality of life, and Time to complete healing.
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Sensitivity Analysis

A sensitivity analysis was conducted by removing the two studies that were only available as
abstracts (Goretti 2008; Roberts 2001). This was performed in order to determine if the results
were robust despite their exclusion from the analysis. Prior to removing the studies there was a
statistically significant increase in proportion of ulcers healed using a random effects model.
When the studies were removed there was no statistically significant difference in the proportion
of ulcers healed. The fixed effects model demonstrated no statistically significant benefit
irrespective of whether the abstracts were included or not.

Table 14 contrasts the fixed effects versus random effects model estimates. The findings were
generally robust despite model used. The exception was in the comparisons Wet to Dry
debridement versus Foam dressing for the outcome proportion of ulcers healed where the fixed
effects model demonstrated a statistically significant increase in proportion of ulcers healed
whereas the random effects model did not demonstrate a statistically significant difference. The
Any debridement as compared with the control condition demonstrated the mean Time to
complete healing to be longer in the intervention group using the fixed effects model but shorter
in duration using the random effects model.
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Publication bias investigation

The studies used in this comparison of any debridement against gauze for the outcome
proportion of ulcers healed. These 10 studies were plotted in a funnel plot to investigate
publication bias. The funnel plot suggested slight asymmetry favoring disproportionately
positive studies to the right side of the graph including the smaller studies which suggests
publication bias Figure 37.

This analysis included the Beggs and Eggers tests which did not detect any significant
asymmetries using these statistical tests Table 15. 13/30 (43%) studies retrieved in this review
received funding through private sources though despite this fact few significant associations
were found further suggesting a lack of publication bias Figure 22.
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Chapter 6 Meta-regression Analysis
Introduction
Moderator analysis is an important part of any comprehensive SR and meta-analysis. It is
utilized in a manner similar to the way regression analysis is conducted in an individual study.
Moderators or covariates may result in effect modification, or interact with the intervention of
interest. This may include confounding, magnifying or diminishing the interventions effect.
Efforts were made to understand any unexplained heterogeneity. This systematic review and
meta-analysis demonstrated relatively low heterogeneity as evidenced by the statistical tests
reported in Table 14.
The tests for homogeneity including τ2, χ2, and I2 demonstrated large and significant
heterogeneity in one outcome (mean time to complete healing) for the interventions Hydrofiber
and “Any debridement”, both as compared with gauze. Moderate heterogeneity though not
statistically significant was suggested in the outcome proportion of infections for the intervention
Hydrogel as compared with gauze. The outcomes proportion of infections, proportion of ulcers
healed, and proportion of ulcer recurrence, demonstrated moderate heterogeneity for the
intervention “Any debridement” as compared with gauze, though these were not found to be
statistically significant. If the degree of heterogeneity reached significance based on our
statistical test results; then efforts were made to explain it. Therefore, this meta-regression
analysis was conducted on prognostic variables or moderators with the goal of explaining any
significant heterogeneity between the studies.

157

This portion of the analysis was limited. The optimal number of covariates is 10 studies per
moderator/covariate for each of the outcomes of interest. This is a similar threshold used in
multivariate regression analysis. Therefore, this analysis was limited to Comparison 19 where the
number of studies per covariate included 10 studies.
The moderators that were used for analysis included the sample and risk specific characteristics
age, peripheral arterial disease, duration of diabetes, proportion of females. These prognostic
factors are suspected of having an association with wound healing. The study specific
characteristics data collection year, and study duration follow up were also investigated.
There were two outcomes that satisfied the minimal studies per covariate requirement these
included proportion of infections and proportion of ulcers healed. The outcome included 10
studies though not all studies reported on every moderator of interest. See Tables 7, 9, 10, and 11
for the 30 respective studies which include information on which of the studies reported on the
moderators of interest for this review.

Methods
Assessment of heterogeneity
Design heterogeneity was discussed and summarized in the Characteristics of Included studies
tables. Methods for identifying statistical heterogeneity included visual graphical analysis of
Forest plots, the use of the Q-statistic, tau-squared, χ2 test, and the I2 test statistic).
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Assessment of heterogeneity included using visual assessment of the Forest Plots generated
whenever 2 or more studies were available for analysis to meet the study objectives. Evaluation
for heterogeneity included the use of the Q-test, τ2, and the I2 test statistics.

These statistical techniques were utilized to both detect the presence and magnitude of
heterogeneity, respectively (Higgins 2002; Higgins 2003; Higgins 2008). The homogeneity
statistic, Q, determines whether each set of the weighted mean effect sizes (d+s) shared a
common effect size, a significant Q indicates a lack of homogeneity and an inference of
heterogeneity of the effect sizes between studies (Higgins 2002; Higgins 2003; Higgins 2008).
To assess the extent or magnitude to which studies’ outcomes were consistent, the I2 index and
its corresponding 95% confidence intervals (CIs) were calculated; I2 varies between 0
(homogeneous) and 100% (non-homogeneous/heterogeneous). If the CI around I2 includes zero,
the set of effect sizes (ES’s) is considered homogeneous. The I2 has been demonstrated as a
statistic used to complement the Q-test statistic, but is not used in lieu of it (Huedo-Medina
2006).

In order to address residual unexplained heterogeneity that is not a function of a single outlier
effect or exaggerated idiosyncratic effects among outlying responders, the study reports were
reviewed. This was done to determine whether the authors of the studies described how they
addressed these outliers, and their explanations for any outlier effects. The effects of outliers
were either not reported or the threshold for defining outliers were not standardized across
studies. This information would be helpful at the individual study level since the respective
authors have access to these raw data.
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This systematic review relied on the summary statistics which poses greater challenges in
determining the reasons for within study variance. The unit of analysis or observation in this
systematic review is the study not the individual which compounds this challenge.

This systematic review used clinical, methodological, and statistical heterogeneity to help decide
whether to conduct a meta-regression analysis. We relied on visual graphical methods by
analyzing the Forest plots, the Q statistic, tau-squared (τ2), χ2 statistic, and the I2 statistic. Tausquared (τ2) is defined as the between-studies variance or the variance of the effect size
parameter across the population of studies. The risk of bias tables and the characteristic of
included studies tables served as the basis for methodological considerations (Borenstein 2009,
Higgins 2008, Cooper 2009).

Meta-regression was performed on moderators/covariates in order to explain any remaining
variability between studies for the 7 outcomes of interest. The approach to variability present in
the primary and secondary outcomes and for the comparison interventions was standardized for
all moderators. This was conditional on a sufficient number of studies to permit this type of
analysis.

Meta-regression and moderator analysis was limited since there were too few comparisons with
sufficient studies for the recommended 10 studies per moderator ratio. This restricted the
analysis to 2 of the 19 pairwise comparisons that were made. The 19 comparisons grouped
studies accordingly based on the same intervention against an alternate control/comparison
intervention. Comparison 19 grouped “any’ form of debridement intervention against the same
control group (see effects of interventions section).
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Besides varying in the type of debridement comparisons the studies varied in some
characteristics including design-specific, and sample-specific characteristics.
There were sample-specific factors that were considered to influence wound healing. These are
considered higher risk and include severity of diabetes, age, peripheral arterial disease and
offloading, among others that were previously discussed. These moderators are considered high
priority and clinically significant based on content expert opinion. There were also study-specific
factors including the duration of the intervention that might influence these clinical and public
health outcomes that warrant further study. However, many of the covariates of interest that were
originally sought in this systematic review were not reported adequately to allow for a
comprehensive meta-regression analysis.
This segment of the analysis includes modeling each of the moderators specified above in order
to determine if there is any effect on the between study variance irrespective of the lack of
significant heterogeneity. This will facilitate hypothesis generation and provide insight into
future areas for research.
The analysis included a series of models that utilize one covariate per model. The use of more
than one moderator in a model is precluded by the limitation in the information reported in the
studies and the finite number of studies available for more detailed meta-regression analysis. The
moderators are analyzed for purposes of hypothesis generation as well as to determine whether
they help explain heterogeneity. This approach was scrutinized to avoid over-reliance on
allowing the availability of data to drive the meta-regression analysis. Therefore, the Metaregression analysis proceeds with an effort to limit any broad conclusions on moderator effect
under these circumstances as a result of the limited information reported.
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The multivariate approach was not possible for all the reasons discussed. Weighted mean effect
size by the inverse of the variance of each study was calculated across all studies under the
random effects assumptions for the Meta-regression analysis. The random effects model assumes
that these data are coming from different populations and accounts for both within and betweenstudy variance. The random effects assumption is arguably more consistent with biological and
clinical variability in complex health systems. The fixed effects model assumes that all effect
sizes are from the same population and accounts strictly for within study variance. To test for
heterogeneity, Cochran’s Q and I2 were calculated. The Q test evaluates for the significance of
heterogeneity. I2 calculates the magnitude of heterogeneity with a range from 0%-100%.
In order to assess whether the moderators explain the heterogeneity of the effect sizes, moderator
analysis using weighted mixed-effects models with maximum likelihood estimation of the
random effects weights was performed.
This systematic review tested each variable for study where sufficiently reported information
was available and if clinically warranted based on known risk factors. Moderator analysis was
conducted by using CMA (CMA 2005).

Results
The Meta analyses portion of the systematic review reported previously was conducted on
comparisons 6, 10, 13, and 19. Of these 4 comparisons conducted, comparison 19 was the sole
comparison out of the four where an adequate number of studies were available for metaregression analysis on moderators (Analysis 19). The moderator analysis for Comparison 19
included 9 – 10 studies per covariate for two outcomes.
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The two outcomes included the proportion of complicating Infections (Analysis 19.2), and the
proportion of ulcers healed (Analysis 19.3). The meta analyses for these two respective outcomes
involved the comparison “any debridement” against the pre-specified control condition. Please
refer to Tables 16 – 31 concurrently.

Age
A model was generated in order to determine what effect if any does the moderating variable age
have on the outcome variables of interest including number of Infection, number of ulcers
healed.
There was no significant association or effect using age as a moderator for either outcomes of
interest including number of infections and number of ulcers healed. (Binfection = - 0.2131, p <
0.0651; Bulcerhealed = -0.0130, p < 0.6873 for number of infections, and ulcers healed
respectively). Therefore, the coefficient or slope of the effect of the moderator age on the
outcomes interest is no different from 0.
The comparison of the new model with the null model for Tau2, I2, Q, and R2 suggest no
significant effect on heterogeneity by including the moderator age. These results are presented in
Table 16 and Table 17 respectively with associated scatterplots (See also summary tables 28, 39,
and 30 below). Each circle on the scatterplot represents the point estimate of the effect for that
study. The size or area of that circle represents the weighting for that respective study in the
scatterplot.
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Peripheral Arterial Disease (PAD)
A model was generated in order to determine what effect if any does the moderating variable
PAD have on the outcome variables of interest including number of Infection, number of ulcers
healed, and the effect of heterogeneity. There was no significant association or effect using PAD
as a moderator for either outcomes of interest including number of infections and number of
ulcers healed. (Binfection = 3.3706, p = 0.3023; Bulcerhealed = -0.4095, p = 0.6191 for number of
infections, and ulcers healed respectively). Therefore, the coefficient or slope of the effect of the
moderator PAD on the outcomes interest is no different from 0. The comparison of the new
model with the null model for Tau2, I2, Q, and R2 suggest no significant effect on heterogeneity
by including the moderator PAD. These results are presented in Table 18 and Table 19
respectively with associated scatterplots (See also summary tables 28, 29, and 30 below).
Duration of Diabetes
A model was generated in order to determine what effect if any does the moderating variable
Duration of Diabetes have on the outcome variables of interest including number of Infection,
number of ulcers healed, and the effect of heterogeneity. There was no significant association or
effect using duration of diabetes as a moderator for either outcomes of interest including number
of infections and number of ulcers healed. (Binfection = - 0.1528, p = 0.5460; Bulcerhealed = 0.0419, p
= 0.5625 for number of infections, and ulcers healed respectively). Therefore, the coefficient or
slope of the effect of the moderator diabetes duration on the outcomes interest is no different
from 0. The comparison of the new model with the null model for Tau2, I2, Q, and R2 suggest no
significant effect on heterogeneity by including the moderator duration of diabetes.
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These results are presented in Table 20 and Table 21 respectively with associated scatterplots.
The moderator analysis displayed in Table 28 demonstrates no statistically significant effect on
the outcomes proportion of infections or proportion of ulcers healed for all but one of the
moderators. This analysis was conducted for the intervention any debridement as compared with
saline gauze and the proportion of females demonstrates a statistically significant reduction in
the proportion of infections (See also summary tables 28, 29, and 30 below).
Proportion of Females
A model was generated in order to determine what effect if any does the moderating variable
Proportion of females have on the outcome variables of interest including number of Infection,
number of ulcers healed, and the effect of heterogeneity. There was a statistically significant
effect on the proportion of infections. No significant association or effect using proportion of
females as a moderator for number of ulcers healed was found. (Binfection = - 6.1651, p = 0.0264;
Bulcerhealed = 0.2486, p = 0.8683 for number of infections, and ulcers healed respectively).
Therefore, the coefficient or slope of the effect of the moderator proportion of females on the
outcomes interest is different from 0. The comparison of the new model with the null model for
Tau2, I2, Q, and R2 suggest a significant effect on heterogeneity by including the moderator
proportion of females. These results are presented in Table 22 and Table 23 respectively with the
associated scatterplots (See also summary tables 28, 29, and 30 below).
Data collection year
A model was generated in order to determine what effect if any does the moderating variable
Data Collection Year have on the outcome variables of interest including number of Infection,
number of ulcers healed, and the effect of heterogeneity.
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There was no significant association or effect using data collection year as a moderator for either
outcomes of interest including number of infections and number of ulcers healed. (Binfection =
0.0246, p = 0.3890; Bulcerhealed = 0.0013, p = 0.9274 for number of infections, and ulcers healed
respectively). Therefore, the coefficient or slope of the effect of the moderator data collection
year on the outcomes of interest is no different from 0. The comparison of the new model with
the null model for Tau2, I2, Q, and R2 suggest no significant effect on heterogeneity by including
the moderator data collection year. These results are presented in Table 24 and Table 25
respectively with associated scatterplots (See also summary tables 28, 29, and 30 below).
Study duration follow up
A model was generated in order to determine what effect if any does the moderating variable
Study duration follow up have on the outcome variables of interest including number of
Infection, number of ulcers healed, and the effect of heterogeneity. There was no significant
association or effect using study duration of follow up as a moderator for either outcomes of
interest including number of infections and number of ulcers healed. (Binfection = 0.0482, p =
0.1857; Bulcerhealed = 0.0048, p = 0.6043 for number of infections, and ulcers healed respectively).
Therefore, the coefficient or slope of the effect of the moderator follow up period on the
outcomes interest is no different from 0. The comparison of the new model with the null model
for Tau2, I2, Q, and R2 suggest no significant effect on heterogeneity by including the moderator
follow up period. These results are presented in Table 26 and Table 27 respectively with
associated scatterplots (See also summary Tables 28, 29, and 30 below).
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Table 28 Moderators of effect size magnitude for the “Any debridement vs. gauzea”
comparison.
Outcome(s)

Proportion of
infections
Proportion of
infections
Proportion of
infections
Proportion of
infections
Proportion of
infections
Proportion of
infections
Proportion of
Ulcers healed
Proportion of
Ulcers healed
Proportion of
Ulcers healed
Proportion of
Ulcers healed

Moderator(s)Characteristic(s)/Level(s)
Participant-specific demographic
characteristics
Age
Risk-specific characteristics
PADc
Duration of diabetes (yrs.)
Proportion of females
Study-specific characteristics
Data collection year
Duration of follow up
Age
PAD(c)
Duration of diabetes (yrs.)
Proportion of females

RR (95%
CI)

Kb

Coefficient

p-value

1.07 (0.76,
1.52)

7

-0.2132

0.0651

1.07 (0.76,
1.52)
1.07 (0.76,
1.52)
1.07 (0.76,
1.52)

7

3.3706

0.3023

7

-0.1528

0.5460

7

-6.1651

0.0264

1.07 (0.76,
1.52)
1.07 (0.76,
1.52)
1.17 (1.00,
1.36)
1.17 (1.00,
1.36)
1.17 (1.00,
1.36)
1.17 (1.00,
1.36)

7

0.0246

0.3890

7

0.0482

0.1857

10

-0.0130

0.6873

10

-0.4095

0.6191

10

0.0419

0.5626

10

0.2486

0.8683

Study-specific characteristics
Proportion of
Data collection year
1.17 (1.00,
10 0.0013
0.9247
Ulcers healed
1.36)
Proportion of
Duration of follow up
1.17 (1.00,
10 0.0048
0.6043
Ulcers healed
1.36)
a. Each moderator listed is evaluated individually without controlling for the other listed moderators. Effect sizes
are based on random effects assumptions for the comparison and respective outcome listed in two columns. In this
analysis there was 1 comparison (“any debridement” as compared with gauze) and 2 outcomes (proportion of
infections, and Proportion of ulcers healed) that approximated a sufficient (number of studies): moderator ratio in
order to facilitate moderator analysis.
b. k = number of studies
c. PAD = proportion with initial baseline peripheral arterial disease.
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Table 29 Non-Significant Moderators
Non-Significant Moderators
All the following moderators assessed were non-significant.
Age
PAD (Peripheral arterial disease)
Duration of diabetes
Data collection year
Duration of follow up

Table 30 Moderators that were Unable to be analyzed due to lack of Reported Information
Out of the 235 coded variables on our data extraction form, 138 of these were non-effect size related
variables. These were reviewed as candidate variables for regression analysis and most were unable to
be analyzed due to the lack of reported information on the outcomes of interest for this systematic
review. See Data extraction form Appendix 2.
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Chapter 7
Discussion
Summary of main results
This systematic review included a comprehensive, exhaustive, and transparent search of the
literature accordingly using established standards. This systematic review retrieved, identified,
extracted, synthesized, and appraised all available evidence from randomized controlled studies
on the debridement of diabetic foot ulcers. The evidence included direct and indirect
fundamental clinical and public health outcomes on established and widely used forms of
debridement in the treatment of diabetic foot ulcers. A total of 19 comparisons were made in the
30 studies included in this review. This included variable reporting on all 7 pre-specified
outcomes of interest that have both clinical and public health implications. The comparisons
were based on data from the individual studies that were extracted in order to conduct both a
qualitative and quantitative systematic review (meta-analysis). There were a total of four
comparisons where evidence was pooled into meta-analyses for the pre-specified outcomes to
help answer our research question.

There was no statistically significant beneficial difference in amputation frequency, or infection
frequency in any of the comparisons that were analyzed with meta-analyses Table 14, for the
studies that reported on these outcomes.
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Quality of life was reported in 3 studies (Piaggesi 1998; D'Hemecourt 1998; Jeffcoate 2009) and
there was no significant difference found between the debridement and the control/comparison
condition (Jeffcoate 2009) utilized the (SF-36) questionnaire.

In the studies that reported on ulcers healed, no evidence of any difference in ulcer healing was
found between the specific forms of debridement when compared to each other except between
hydrogel as compared with gauze/good wound care. There was evidence of an increase in ulcers
healed in the comparison any form of debridement as compared with gauze dressing though this
was not statistically significant. However when the two studies (Goretti 2008; Roberts 2001) that
were available only as abstracts were excluded in a sensitivity analysis there was less significant
difference in complete healing found, see Table14.

There was no evidence of any difference in time to complete healing for diabetic foot ulcers
healed except in 3 analyses, the superoxide solution as compared with standard local treatment
with povidone iodine which was 6 days shorter (Goretti 2008). The time to complete healing was
2.8 days longer in the alginate dressing group as compared with the gauze (Donaghue 1998). The
Any debridement versus saline gauze group demonstrated a significant reduction of
approximately 28 days in healing time using the random effects model whereas there was a 2.5day increase in healing time using the fixed effects model, see Table 14.

The random effects model was pre-specified for this systematic review. However, the fixed
effects model was used for purposes of sensitivity analysis. The findings were relatively robust
irrespective of model used with one exception where the fixed effect model demonstrated a
significant beneficial effect on the proportion of ulcers healed in the Foam as compared to the
Wet to dry intervention; whose benefit was not significant under the random effects model.
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The other exception was in the Any debridement group as compared with gauze that found a
significant beneficial effect in proportion of ulcers healed using the random effects model but not
the fixed effects model. When the two studies available exclusively as abstracts were removed
both models failed to demonstrate a beneficial difference for the outcome proportion of ulcers
healed. See Table 14, Analysis Tables 1.1 through 19.6, Results section.

The meta-analysis using foam as compared with wet to dry debridement demonstrated no
beneficial effect in the random effects model though a significant beneficial difference was
found in fixed effects model for the outcome proportion of ulcers healed.

In the studies that reported recurrence rates there was no significant beneficial difference
between the competing forms of debridement or between any debridement and gauze dressing.

Cost of treatment was reported in 3 studies (Jensen 1998; Jeffcoate 2009; Hammouri 2004) the
Iodine impregnated fiber dressing group, the Hydrofiber group, and the honey normal saline
dressing group as compared with the gauze dressing group. No statistically significant difference
was found. The hydrogel group as compared with the gauze dressing group suggested a reduced
daily cost for hydrogel however this was not found to be statistically significant (Jensen 1998).

The studies retrieved in this review included trials that used relatively smaller sample sizes
which may have been statistically underpowered. This would create difficulty in detecting small
treatment effects.

A Meta-regression analysis found that none of the candidate moderators demonstrated a
beneficial effect on the respective outcomes of interest. The coefficients were not significantly
different from the null value with one exception, the proportion of females.
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This correlates with the coherent understanding that an observed gender predilection favors
males in the development of wounds and amputations. There was no significant study
heterogeneity that was explained with any of univariate models that were performed. (See Tables
16 – 30).

This finding may be a function of the variability in reporting that limited the moderator analysis
through meta-regression to a small sub sample of studies retrieved in this systematic review. The
effects of these moderators on the outcomes of interest may be better delineated as the
standardization of reporting across studies improves. This would increase sample size for metaregression analysis and improve detection of significant effect interactions.

Overall completeness and applicability of evidence
The clinical and public health indicators included seven pre-specified outcomes of interest that
were defined in the methods section of this review. Quality of life and cost of treatment were not
well defined. For example, an acceptable robust standardized quality of life measure such as SF36 or a similarly acceptable measurement tool was universally under-utilized in the included
studies.

Quality of life and treatment cost are fundamental considerations in comparing the various
debridement methods. Standardized reporting should include quality of life and economic data.
The other five outcomes of interest were variably reported between studies including outcomes
with very serious public health and clinical implications such as amputation and infection.
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Applicability of the evidence is dependent on the four primary outcomes (amputations,
complicating infections, quality of life, and cost) being universally reported as they have direct
public health and clinical implications.

Indirect evidence that is applicable to the primary outcomes of interest are provided by the 3 prespecified secondary outcomes (recurrence rates, complete healing, and time to complete healing)
as they have clinical and public health bearing (SVD 1990).

The pre-specified outcomes were variably reported throughout the 30 included studies making
meaningful and comprehensive synthesis and analysis challenging.

Quality of the evidence
All 30 studies included in this review were classifiable as unclear or high risk of bias for many of
the risk of bias characteristics utilized in this systematic review Characteristics of included
studies; Figure 3, Figure 4. Though randomization was reported throughout most of the included
studies did not report the method of randomization utilized. Allocation concealment was unclear
in greater than 75% of studies. Due to the nature of the interventions blinding may not have been
possible in the participants and the personnel delivering the intervention. Blinding of outcome
assessors was unclear or high risk in approximately 70% of studies. Incomplete outcome data
reporting was unclear or high risk in over 75% of the included studies. Selective reporting of
outcomes was unclear or high risk in 50% of the included studies. Other bias was either unclear
or high risk in the included studies.
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The studies did not follow established reporting practice conduct such as the CONSORT
guidelines (CONSORT). Major considerations consistent with these guidelines include
appropriate random sequence generation and allocation concealment. The 30 studies reported
randomization, though most studies did not report the specific method of randomization that was
used i.e. computer generated, coin toss, except in 5/30 studies (Amini 2013; Bowling 2011;
Jeffcoate 2009; Munter 2006; Tallis 2013) . Allocation concealment was universally unreported
except in 5/30 studies (Bowling 2011, Jeffcoate 2009, Jude 2007a, Munter 2006, and Tallis
2013).

Blinding was often either absent or incomplete. This could have been a function of the nature of
applying the specific debridement intervention. For example, in some cases it would be
challenging for the investigator delivering the intervention to be blinded from the intervention
they were using e.g. sharp/surgical debridement. It is difficult to blind the patient from the
debridement method used e.g. sharp debridement or maggot debridement therapy. The studies
that did report blinding/masking did not clearly define what was meant by "double-blinding"
(Devereaux 2002). It was unclear whether the principal investigator, and/or the participants,
and/or the outcome assessor were blinded.

The studies that did report blinding of the outcome assessor included the following 8 studies (Ali
2013; Apelqvist1990; D'Hemecourt 1998; Jeffcoate 2009; Lalau 2002; Piaggesi 2001; Shukrimi
2008; Singh 2006).

All study authors should report on these quality considerations. Study authors should anticipate
that their respective study might be considered for inclusion in systematic reviews.
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The Consort guidelines were meant to standardize reporting guidelines for study authors in order
to help better define and reduce the variability in what is reported in the medical and public
health literature. Universal standardized reporting guidelines would make it less difficult for
authors synthesizing the evidence in systematic reviews and meta-analyses.

Methods of addressing incomplete outcome data were not clearly reported in most of the studies.
Intention to treat analysis (ITT) was not reported in the majority of studies. The 4 studies that
reported an ITT analysis used last observation carried forward (D'Hemecourt 1998; Jeffcoate
2009; Munter 2006; Tallis 2013).

Other methods of Intention to Treat Analysis (ITT)such as Bayesian methods and imputation
(imputing values for missing data) were not utilized. Fundamentally better efforts should be
made before and during the conduct of the study to prevent or limit the amount of missing data to
the maximum degree possible. This is the most ideal approach and lessens the reliance of
researchers on the use of ITT methods to make up for missing data. ITT methods are not
universally standardized and the specific methods used are variable. However irrespective of ITT
method utilized, the reporting of method used should still be mandatory.

Selective reporting of outcomes was difficult to determine as all studies did not provide a prestudy protocol. Efforts were made to determine whether all of the outcomes defined and reported
in the methods sections were subsequently reported in the results sections of the included studies.
This was conducted as an alternative surrogate method of detecting selective reporting by the
authors. Many of the studies were characterized as unclear or high risk of bias with respect to
selective reporting of outcomes.
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Authors should specify every outcome of interest in the methods section and these should be
summarily reported in the results. Any deviation from this approach should be clearly explained.

All studies were characterized as high risk or unclear risk of bias (See Characteristics of Included
Studies Table Section and Risk of Bias Table section for individual studies), Figure 1 – 2. This
was in part due to the variability of inclusion/exclusion criteria, and patient/study specific
characteristics which were under-reported by the investigators of the included studies e.g. disease
severity, variable methods of measurement e.g. variable methods of determining the presence of
arterial insufficiency Table 7 - 11. The majority of studies were industry supported 13/30 Table
12. Publication bias was suggested graphically in the funnel plot. However other statistical tests
for publication bias including Beggs, and Eggers test did not demonstrate significant evidence of
publication bias. Publication bias assessment was limited to the Any debridement as compared
with the control condition for the outcome number of ulcers healed. This was the only condition
that met the recommended 10 studies threshold for publication bias testing.

Potential biases in the review process
This systematic review made efforts to include studies that were not published in English
language journals. These studies were translated using Google Translate, and the reviewers relied
on outside translators only when needed information was not translated by Google translate.
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Efforts were made to contact authors of the studies that were only available as abstracts but were
unsuccessful. We conducted a sensitivity analysis with and without the studies that were only
available as abstracts in order to determine what the impact that would have on the effect
estimates if they were excluded. This resulted in a smaller effect size and nonsignificance when
the two abstracts were not included as reported above.

The potential for bias in translating the studies that were screened and included is possible.
Though this risk is likely to be limited in this review given the negative findings in the translated
studies are concordant with other similar findings that have been published.

Many of the studies paired both intervention treatment arms with sharp debridement on an as
needed basis, even if sharp debridement was not one of the primary treatment arms. These
studies were included unless they specified regular use sharp debridement in both intervention
treatment arms, as this would have made it impossible to determine the inherent efficacy of the
primary alternate forms of debridement used in the respective study. This could have introduced
bias in that “as needed periodic” use of an alternative form of debridement conducted in both
treatment arms could still have confounded the effect of the primary debridement methods of
interest or debridement against control.

Studies with short-term follow-up periods were compared alongside studies that included longer
follow up periods e.g. 10 days to 24 weeks. Length of study was not used as inclusion/exclusion
criteria to prevent missing pertinent studies as a result of relying on narrower and more
restrictive search criteria.
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An additional study on Ultrasound debridement is currently underway and based on its
description would meet eligibility criteria for inclusion in future updates of this review.
Three studies are presently designated as “studies awaiting classification”. Three studies in a
previous review that were awaiting classification were assessed for inclusion during the course
of this review and have been designated to the excluded studies section.
The designation “studies awaiting classification” indicates that a study is unclassifiable until
further information is made available that can clarify whether or not it meets the
inclusion/exclusion criteria. It cannot be classified as included, or excluded until there is
sufficient additional information.

Agreements and disagreements with other studies or
reviews
The objectives in this review included the search and retrieval of all other systematic reviews
focusing on the same research question utilizing similar eligibility criteria. These other
systematic reviews could then be compared and contrasted with this review. The search retrieved
10 related systematic reviews that were compared with our findings, see Table 31 below. The
first row represents collective ranges and summary data of the 10 systematic reviews that were
retrieved. The first row is a condensed summary form of Table 6, see Table 6 for further details
on each of the other 10 respective systematic reviews. The systematic reviews that included
nonrandomized studies in addition to RCT’s made comparable conclusions to reviews restricted
to randomized studies.
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This summary table of the 10 systematic reviews retrieved that shared similar eligibility criteria
(i.e. Type 1 or 2 Diabetic participants with foot ulcers, randomized studies, and any debridement
method) are contrasted with the findings in this systematic review below:
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#

[Review]

[# Studies
included]

[Study
Type(s)]

10

SR’s

4 – 10

4–8
RCT’s
2–4
Pooled

1

SR

30

30 RCT’s
(10 pooled)

Table 31 Comparison of systematic reviews preceding this current systematic review
[Total
Follow
Study
Type of
[Participant
[Intervention
Outcomes
sample
up period period
wound
Type]
Type]
size]

149 - 575

2539

10 days
to 24
weeks

10 days
to 24
weeks

1989 2007

1992 2012

DFU
Ischemic
Venous

DFU

Diabetic
Nondiabetic

Diabetic
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1.Alginates
2.Foam
3.Film
4.Hydrogel
5.Hydrocolloid
6.Hydrotherapy
7.Larva
8.Sharp
9.LFU

Alginates
Foam
Film
Hydrogel
Hydrocolloid
Hydrotherapy
Larva
Silver dressing
Sharp
LFU
19 comparisons

SR/MA
methodology
Evidence
Grading

[Conclusions]

1.Amputation
2.Infection
3.HRQoL
4.Ulcer
healing
5.Time to
complete
healing
6.Recurrence
7.Adverse
events

5
CR/GRADE

“No evidence
Insufficient
evidence

1.Amputations
2.Infection
3.HRQoL
4.Ulcer
healing
5.Time to
complete
healing
6. Recurrence
7.Cost

SR/MA

AND
Low evidence
5 Other SR
No MetaRegression

AND
Metaregression
AND
GRADE
approach

Moderate Evidence
for Hydrogel
uncertain
Moderate for
Hydrocolloid but
not strong
evidence”
Very low to low
evidence.

The 10 systematic reviews retrieved in the search phase of this systematic review included Type
1 and Type two diabetics with one review restricted to Type 2 diabetics (Mason 1999). The
studies all included participants with diabetic foot ulcers with 2/10 systematic reviews including
venous and ischemic wound types (Game 2012, Voight 2011). These reviews reported their
results under the different wound types separately. The reviews included a range of 4 - 10
studies. The studies all included randomized studies with 3/10 systematic including
nonrandomized studies (Mason 1999; Game 2012; Hinchliffe 2008). If the systematic reviews
included nonrandomized studies the comparison with this systematic review was restricted to the
summary findings of the included randomized studies. The number of participants ranged from
149 - 575 participants. The follow up period in the retrieved systematic reviews ranged from 10
days to 24 weeks. The study period for the studies included in the systematic reviews ranged
from 1989 – 2007. The number of comparisons ranged from 1 - 9 methods of debridement
including: Alginates, Foam, Film, Hydrogel, Hydrocolloid, Hydrotherapy, Larva, Sharp, and
Low frequency ultrasound.

The outcomes reported in the retrieved systematic reviews included amputations, infections,
quality of life, ulcer healing, time to complete healing, recurrence. Frequently amputation, and
infection were reported as an adverse effect. It was unclear whether this was attributed to the
debridement intervention in these reviews or in the studies themselves as amputation and
infection are an inherent risk in the non-healing wound irrespective of method of debridement
used. This systematic review did not attribute these outcomes to either the intervention or to the
wound as this would be difficult to discern. This systematic review treated infection and
amputation not necessarily as adverse outcomes to the intervention as outcomes inherent in
chronic wounds that could also be averted through debridement interventions.
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Five out of the 10 systematic reviews utilized a standardized approach to summarizing their
findings. These were all Cochrane reviews and the method used was the Grade approach (Grade
Working Group 2010). The 10 systematic reviews pooled a range of 2 – 6 of their included
studies in their respective analyses. The systematic reviews findings were collectively consistent
in concluding no, low, to weak evidence that one form of debridement was superior to another
alternate form of debridement or superior to the control or standard condition. One systematic
review reported moderate evidence of efficacy for hydrogel as compared with basic wound
contact dressing, although this was uncertain due to risk of bias considerations (Dumville 2013).
None of the 10 systematic reviews utilized Meta-regression or conducted any type of moderator
analysis.

In contrast this review retrieved a total of 30 studies. 10 of these studies were pooled. This
review included a total of 2539 participants, a follow up period of 10 days to 24 weeks, and a
study period from 1992 – 2012. The studies included were exclusively RCT’s. The wound type
focus was exclusively diabetic foot ulcers in type 1 and type 2 diabetics. The methods of
debridement included: Alginates, Foam, Film, Hydrogel, Hydrocolloid, Hydrotherapy, Larva,
Silver dressing, Sharp, low frequency ultrasound. There were a total of 19 debridement
comparison types reported. The outcomes of interest in this review included: amputations,
infections, quality of life, ulcer healing, time to complete healing, recurrence, and cost. This
review included a qualitative systematic review, meta-analyses, and meta regression.
Summarizing of this reviews findings were based on the Grade approach (Grade Working Group
2010).
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Many of the conclusions reached in our review regarding the direction of future trials were
similar to these preceding reviews with respect to the need for larger sample sizes, and
standardized reporting.

The findings in this review are consistent with other similar systematic reviews that found low
evidence that any dressing type was more effective than others in healing diabetic foot ulcers.
There was low evidence for Hydrogel, and for Any debridement as compared with gauze but this
was unclear due to risk of bias. The geographic scope of the 30 studies in this review includes:
70% Europe/North America, 27% from Asia, with 1 study 3% not reporting international setting
see pie chart below.

International Study Settings (%)
3

27

70

Europe/US

Asia
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Unclear

Chapter 8 Conclusion
Implications for practice
Based on a comprehensive systematic review of all the currently available evidence, any
debridement method (i.e. any and all forms of the debridement types described) used as an
intervention in the treatment of diabetic foot ulcers do not appear to increase the healing rates of
diabetic foot ulcers compared with any other form of debridement or standard practice. Most of
the included studies evaluated debridement interventions on participants who appeared to have a
wide variation in foot ulcers including size and duration. However, disease severity and comorbidities may not have been balanced between both intervention groups. This may have been
more apparent in smaller studies despite the use of randomization to balance for confounding.

Grade assessments were made on the 4 Meta-analyses comparisons and the utilized in this data
synthesis. These included the Hydrogel compared with gauze/good wound care Summary of
findings Table 32, Foam dressing compared with wet to dry saline dressings Summary of
findings Table 33 Hydrofiber compared with gauze dressing Summary of findings Table 34, and
Any debridement compared with gauze dressing Summary of findings Table 35.
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The grading of the evidence is either High quality: Further research is very unlikely to change
our confidence in the estimate of effect, Moderate quality: Further research is likely to have an
important impact on our confidence in the estimate of effect and may change the estimate, Low
quality: Further research is very likely to have an important impact on our confidence in the
estimate of effect and is likely to change the estimate, and Very low quality: We are very
uncertain about the estimate. The use of the GRADE approach (Grade Working Group 2010) to
evaluate the evidence includes the following considerations: the quality of evidence includes all
of the following:

1) Risk of bias/study limitations, 2) Directness, 3) Consistency of results, 4) Precision, 5)
Publication bias, 6) Magnitude of the effect, 7) Dose-response gradient, and 8)
Influence of residual plausible confounding.

The quality of the evidence is low to very low for these comparisons using the Grade approach.
There was one outcome that was given a moderate evidence rating regarding the quality of life
indicator for any debridement compared with gauze. This comparison included two arms of the
same study (Jeffcoate 2009). The control condition was divided in half to avoid double counting
the participants. The reduction in quality of life index was modestly lower in the intervention
group for Any debridement compared with gauze Summary of findings Table 35.
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The evidence was found to be weak based on several considerations that are utilized in the
GRADE approach (Grade Working Group 2010):

1) Downgraded as substantial risk of bias characteristics were either unclear or high.
2) Downgraded due to the 95% confidence interval (or alternative estimate of precision)
around the pooled or best estimate of effect includes both 1) no effect and 2) appreciable
benefit or appreciable harm. (GRADE suggests that the threshold for "appreciable
benefit" or "appreciable harm" that should be considered for downgrading is a relative
risk reduction (RRR) or relative risk increase (RRI) greater than 25%.)
3) Downgraded due to total (cumulative) sample size being lower than the calculated
optimal information size (OIS) and/or total population size is less than 400 (a threshold
rule-of-thumb value; using the usual α and β, and an effect size of less than 0.2 SD,
representing a small effect).
4) 95% confidence interval includes no effect and the upper or lower confidence limit
crosses the minimal important difference (MID), either for benefit of harm.
5) Downgraded due to widely differing estimates of the treatment effect (i.e. heterogeneity
or variability in results) across studies suggest true differences in underlying treatment
effect.

These findings collectively do not support the endorsement of any single form of debridement
over any other form of debridement. Nor do the findings support the use of ANY form of
debridement over the frequently used control comparison gauze. This systematic review may be
considered a non-inferiority study.
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The confidence intervals for the point estimates have been large, frequently including thresholds
that would include equivalence and the threshold of inferiority making this a reasonable
conclusion.

Practitioners may therefore elect to consider other characteristics such as individualization of
therapy, tolerability, indications/contraindications, cost, when choosing between the alternative
methods of debridement. Alterations in practice habits with respect to the wide choices of
debridement types available to clinicians may be based on clinical experience, biological
plausibility, mechanistic and animal data, individual patient characteristics, tolerability. Relying
on information from individual nonrandomized human studies which are available may have
more biased effect estimates as a function of their design. These challenges should be
appreciated along with the consideration that uncertainty exists around this treatment decision
due to the quality of data used to inform clinical decision making.

Implications for research
Currently inadequate evidence exists to conclude that there is any difference, advantage or
benefit between the various competing forms of debridement or against standard care.

It is of critical importance that future studies include better standardized reporting of outcomes
including quality of life and cost-effectiveness analyses. There needs to be less variability and
more uniform reporting of specific outcomes that clearly have direct implications on clinical
decision making and critical public health implications including amputation frequency,
infection frequency, and quality of life.

187

Future research clearly needs to be optimized to be of greater value to all stakeholders including
patients, physicians, allied health providers, public health professionals, and policy makers.
There exist numerous choices of debridement available and the design of future studies should be
guided by findings reached in this systematic review to help meet the needs of all stakeholders.
The comprehensive set of outcomes utilized in this systematic review include important direct
and indirect clinical and public health indicators e.g. diabetics account for most of the
amputations and this can be directly extrapolated to mortality risk.

It is important to view the ulcer or wound as a determinant or risk factor for these adverse
outcomes, rather than viewing the ulcer or wound strictly as a disease state. Future research
studies should qualify what constitutes standard care, and address patient lifestyle issues. The
standard of care in diabetic foot ulcers includes offloading, nutritional services, infection
eradication, smoking status and cessation, and addressing arterial insufficiency. The status of
these other interventions should be universally reported in future studies.

Studies should be conducted in accordance with standardized uniform good practice guidelines
in the design, conduct, and reporting of randomized controlled trials. This would afford
researchers the opportunity to design and conduct better quality systematic reviews of the
evidence. The synthesis could potentially be more comprehensive and include both qualitative
and quantitative components in the systematic review for all comparisons. This will undoubtedly
aid in the decision making about the competing forms of debridement.
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The costs associated with complicating amputations, infections, premature mortality, quality of
life and mortality transcends monetary costs. These complications are rising and
disproportionately burden the individual, healthcare resources, society, the family unit, the
workplace, the employer, along with government and private services for the disabled. The
obesity epidemic, diabetes incidence rates, and non-healing wounds qualify as an imminent and
growing pandemic with serious public health and clinical implications. Methods of prevention
and intervention including debridement require further investigation to determine efficacy.
Systematic reviews that are undertaken area useful tool in Evidence based Medicine. They
require summarizing and pooling studies of high quality in order to make broader inference and
can identify knowledge gaps. This will not only summarize and make broader inference on the
state of current evidence but help direct future research efforts as this systematic review has
highlighted.
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Differences between protocol and review
This systematic review was a significant expansion and revision on the subject of Debridement
of Diabetic Foot Ulcers. The creation of a new protocol was necessary in order to make the
expansion and revision transparent and reduce the risk of bias in this review. The review
expanded the outcomes from 4 to 7 including amputation risk, infection frequency risk, and cost.
These were added in addition to the 4 other variables. One of the 3 searches conducted included
a comprehensive search without any date restrictions. The other two searches relied on finite
search dates from the dates of the last review on this research question.
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Characteristics of included studies/Risk of
bias summaries
Characteristics of included studies

1.

Ali 2013

Randomized Clinical Trial

Methods

Texas classification used.

A) 35 (25M10F, age <50 yrs. = 10,
age > 50 yrs. = 25, 7 smoking, 10
Hgba1c </= 7)

Participants

B) 35 (23M/12F, age < 50yrs = 12,
age > 50 yrs. = 23, 8 smoking, 9
Hgba1c </= 7)
No statistical difference in
demographics between both groups
nor in initial glycemic or
cholesterol control.
A) Cutimed Sorbact

Interventions

B) Standard Dressing (Saline
cleansed povidone soaked gauze
dressing)
No outcomes were reported that
were targeted in this review.
Outcomes reported in this study
include comparison of foot
inspection pre and post intervention
(i.e. edema, pulse, temperature, skin
color). Other outcomes included
comparison of wound granulation
and grade pre and post intervention,
and wound changes and pain pre
and post intervention (i.e. wound
size, wound depth, and exudates).

Outcomes
Notes

Reported that edema, impaired
pulse, cold extremities, and
abnormal skin color demonstrated
better improvements in the study
group.
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Improvements in granulation tissue
and wound grade were reported in
the study group.
Reported that the study group
patients had higher wound grades
than control at study onset.
These findings were found to be
statistically significant differences.
Wound size but not depth improved
in the study group and was found to
be statistically significant.
Risk of bias table
Bias
Random sequence generation
(selection bias)

Allocation concealment (selection
bias)
Blinding (performance bias and
detection bias)
Blinding participants
Blinding personnel delivering
intervention
Blinding outcome assessors

Unclear risk

Support for judgment
Study Reports randomization of
subjects but does not specifically
identify the method of sequence
generation.
Not reported

Unclear risk

Not reported

Unclear risk
Unclear risk

Not Reported
Not reported

Low risk

Incomplete outcome data (attrition
bias)
Selective outcome reporting
(reporting bias)

Unclear risk

The study reports blind assessment
of the outcomes was done by
trained nurses not involved in the
study.
Not reported

Other Bias

Authors' judgment
Low risk

Low risk

Unclear if a protocol was prepared
for this study. The outcomes
discussed in the methods section
were reported in the results. The
point estimates reported in this
study included dichotomous
nominal cutoff values in lieu of
mean point estimates it is unclear if
the cutoffs assigned were arbitrary.
The study text reports that 60
patients were enrolled in the study
however the tables suggest that 70
were enrolled in the study.

Unclear risk

224

2. Amini 2013

Methods

Randomized Clinical Trial
6 months’ duration or until
complete wound healing
Weekly wound evaluations
(photo documentation)
Plain x-rays and bone scan to
exclude osteomyelitis
40 patients from a diabetic foot
ulcer clinic

Participants

Hgba1c = 8.9 +/- 2.3
#patients, gender, mean age +/-SD,
diabetes duration, smoker, BMI,
PVD
A) 20, 14M/6F, 55.3 +/- 9.5 yrs.,
14.4 +/- 8.2 yrs., 0.05, 27.9, 0.60
B) 20, 10M/10F, 55 +/- 9.6 yrs.,
15.2 +/- 6.2 yrs., 0.10, 28.7, 0.40
Reported that the only statistically
significant difference was more
heart disease in the ultrasound
group.
A) Low frequency (20-60kHz)
ultrasound assisted wound therapy
+ standard wound care

Interventions

B) Standard wound care alone (
All wounds reported to be initially
surgically debrided and thereafter
as needed.
Daily dressing changes
All patients received offloading and
antibiotics.
1) Proportion Healed

Outcomes

A) 0.60
B) 0.55
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Not statistically significant
difference
2) Complete healing Time
A) 61.6 +/- 84 days
B) 81.2 +/- 78.4 days
Other outcomes reported included:

Notes

Mean wound size reduction at 6
months
A) 0.879 +/- 0.338
B) 0.824 +/- 0.33
No statistically significant
difference
Risk of bias table
Bias
Random sequence generation
(selection bias)
Allocation concealment (selection
bias)
Blinding (performance bias and
detection bias)
Blinding participants
Blinding personnel delivering
intervention
Blinding outcome assessors
Incomplete outcome data (attrition
bias)
Selective outcome reporting
(reporting bias)

Other Bias

Authors' judgment
Low risk

Unclear risk

Support for judgment
RCT reported. Specific method of
sequence generation reported as
simple randomization.
Not reported

Unclear risk

Not reported

Unclear risk
Unclear risk

Not Reported
Not reported

Unclear risk
Unclear risk

Not reported
Not reported

Low risk

Preselected outcomes in the
methods section were reported in
the results section. No pre-specified
protocol was reported.
Sharp debridement reportedly
performed initially and as needed.

Unclear risk
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3.

Apelqvist 1990

Methods

-Open randomized controlled
study
5-week study
Blinded evaluation
Weekly evaluation included
color photos and evaluation
by combined foot care team
(diabetologist, orthopedist,
orthotist, podiatrist, and a
nurse)
Study reports foot wear
corrected when necessary.
Intervention stopped for
surgical debridement,
hospitalization,
noncompliance, increase in
size or necrosis of the ulcer
by 50%, and reaction to
dressing.
44 outpatients 26M/18F, mean age
63 yrs. (23-86), Hgba1c = 8.2 mean
duration of diabetes = 20 yrs. (2 54),

Participants

A) 22, 8.4 +/- 1.4, 22 +/- 15,
B) 22, 8.0 +/- 2.1, 19 +/- 12,
A) Hydrocolloid

Interventions

B) Adhesive Zinc Oxide tape
Ulcers cleaned with sterile saline.
Dressing changes daily for 1st week
then every 3 days afterwards where
wound and surrounding area
inspected and assessed.
Outcomes

1) Proportion healed
A) 5/22 = 0.227
B) 9/22 = 0.409
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2) Proportion of Infections
A) 1/22 = 0.045
B) 0/22 = 0
Not statistically significant
difference
2) Complete healing Time
A) 61.6 +/- 84 days
B) 81.2 +/- 78.4 days

Risk of bias table
Bias
Random sequence generation
(selection bias)
Allocation concealment (selection
bias)
Blinding (performance bias and
detection bias)
Blinding participants
Blinding personnel delivering
intervention
Blinding outcome assessors
Incomplete outcome data (attrition
bias)
Selective outcome reporting
(reporting bias)

Other Bias

Notes

Changes in necrotic ulcer
area were also reported.

Authors' judgment
Low risk

Unclear risk

Support for judgment
Randomized study reported.
Method of sequence generation not
specified.
Not reported

Unclear risk

Not reported

Unclear risk
Unclear risk

Not Reported
Not reported

Low risk
Unclear risk

Blinded evaluation was reported.
Not reported

Low risk

Prespecified protocol not reported.
Prespecified outcomes in the
methods section reported in the
results.
Study financially supported by
industry.

Unclear risk
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4.

Baker 1993

Methods

RCT - Pilot Study
Duration - 12 weeks
Limited - Abstract available
only
19 with neuropathic foot ulcers,
number of participants in each
intervention group not reported.

Participants

Age, sex, grade or duration of
wounds, severity of peripheral
arterial disease, presence of
infection and diabetes disease
severity not reported.
A) Allevyn Hydrocellular dressing

Interventions

B) Sorbsan Calcium-Alginate
dressings
Outcomes

1) Proportion of ulcers healed
90% vs 44% at 12 weeks
2) Median time to healing 28
days vs. 84 days
Allevyn Hydrocellular
reported as significantly more
absorbent (p= 0.001) and less
adherent or easier to remove
(p=0.011) than the alginate
dressing.

Notes

Risk of bias table
Bias
Random sequence generation
(selection bias)
Allocation concealment (selection
bias)
Blinding (performance bias and
detection bias)
Blinding participants
Blinding personnel delivering
intervention
Blinding outcome assessors
Incomplete outcome data (attrition
bias)
Selective outcome reporting
(reporting bias)
Other Bias

Authors' judgment
Low risk

Unclear risk

Support for judgment
Randomization was reported.
Specific method of sequence
generation was unspecified.
Not reported

Unclear risk

Not reported

Unclear risk
Unclear risk

Not Reported
Not reported

Unclear risk
Unclear risk

Not reported.
Not reported

Unclear risk

No protocol reported or clearly prespecified outcomes in methodology.
Only abstract available.
Other significant covariates and
differences between intervention
groups not reported.

High risk
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5.

Belcaro 2010

Methods

Open-label registry
randomized pilot study. 4
weeks
Categorized: venous ulcers
and diabetic ulcers
148 patients

Participants

A) 34 patients, 16M/18F, Mean
Age 56.5 +/- 4.4 years
B) 32 patients, 13M/19F Mean Age
55.3 +/- 3.2 years
A) Multivalent silver oxide Ag4O4
ointment + elastic compression

Interventions

B) Control group (standard cleaning
and elastic compression
management methods without
silver ointment)
Outcomes

Complete closure of the
ulceration
A) 39%
b) 16%
(p </=0.05).
Notes The study also
reported the following
outcomes of noninvasive
vascular investigations to
exclude major vascular
problems that could result in
decreased perfusion. These
include Skin PO2 and Skin
flux.

Notes

perimalleolar Skin (P02)
(Oxygenation in the skin of
the affected limb)
Baseline at 4 weeks
A) 43 mmHg 53 mmHg
(increase of 23.3%)
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B) 44 mmHg 48mmHg
(increase of 9.1 %)
(p </= 0.05)
Laser Doppler flowmetry
perimalleolar Skin flux (RF)
Baseline at 4 weeks
A) 3.22 flux units 2.36 flux
units (decrease of -26.7%)
B) 3.21 flux units 3.01 flux
units (decrease of -6.2%)
(p </= 0.05)
Total surface area reduction
of the ulcer
A) -89.0%
B) -23.9%
(p </= 0.05)
Risk of bias table
Bias
Random sequence generation
(selection bias)

Allocation concealment (selection
bias)
Blinding (performance bias and
detection bias)
Blinding participants
Blinding personnel delivering
intervention
Blinding outcome assessors
Incomplete outcome data (attrition
bias)
Selective outcome reporting
(reporting bias)

Other Bias

Authors' judgment
Low risk

Unclear risk

Support for judgment
The study reports that the patients
were randomly assigned however
method of sequence generation was
not specified.
Not reported

Unclear risk

Not reported

Unclear risk
Unclear risk

Not Reported
Not reported

Unclear risk
Low risk

Not reported.
The study reported no dropouts.

High risk

No protocol was available for this
study and the outcomes were not all
clearly pre-specified in the methods
section of the study.
The study does not compare the
intervention groups on other risk
factors that could influence
outcomes. No further detail was

Unclear risk
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provided on how balanced both
intervention groups were.
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6.

Blackman 1994

Methods

RCT
Surface area tracings of
wound margins.
Foot ulcer measurements
every 3 weeks for a follow up
period of 24 weeks.
Cross-over design after two
months to group A
Subjects encouraged to obtain
orthotic footwear
Subjects followed until ulcer
healed, or until 6 months had
elapsed.
18 subjects Type 1 and 2 DM

Participants

#, gender, mean age, Hgba1c,
A) 11, 11M/0F, 59 +/- 5yrs, 8.4 +/0.9
B) 7, 6M/1F, 51 +/- 4yrs, 9.5 +/1.1
No statistical significant difference
A) Polymeric dressing

Interventions

B) Wet to dry saline dressing
Dressing changes at minimum once
daily or when saturated.
4 wounds surgically debrided in
group A and 3 in group B prior to
start.
Outcomes

1) Proportion healed
A) 0.73 OR 0.27
B) 0
(p </=0.05).
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Notes

Other outcomes reported
included:
Ulcer size reduction
A) 35 +/- 16%
B) 105 +/- 28% -> 35 +/11% (post-crossover, p <
0.02, 5 subjects were crossed
over from conventional
treatment to polymeric
membrane after two months
of treatment)
Statistically significant
difference (p < 0.03)

Risk of bias table
Bias
Random sequence generation
(selection bias)

Authors' judgment
Low risk

Allocation concealment (selection
bias)
Blinding (performance bias and
detection bias)
Blinding participants
Blinding personnel delivering
intervention
Blinding outcome assessors
Incomplete outcome data (attrition
bias)

Unclear risk

Support for judgment
Reported that subjects were
randomly assigned. Method of
sequence generation not specified.
Not reported

Unclear risk

Not reported

Unclear risk
Unclear risk

Not Reported
Not reported

Unclear risk
High risk

Selective outcome reporting
(reporting bias)

Low risk

Other Bias

High risk

Not reported.
2 patients from each group
progressed to Wagner grade 3 and
were not included in the study.
Prespecified protocol not reported.
Prespecified outcomes in the
methods section were reported in
the results.
2 patients in underwent
debridement in their referring
physician’s office during the study.
No patient obtained new orthotic
footwear. The study was industry
supported.
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7.

Bowling 2011

Methods

Prospective randomized,
controlled, double blind, pilot
study.
Weekly treatments for 4
weeks.
Semi-quantitative wound
tissue cultures postdebridement at baseline and
week 4.
Maximum wound size Length
X Width
20 patients

Participants

#, Gender M/F, Type 1/2, Duration
of diabetes, Hgba1c %
A) 10, 6/4, 3/7, 21.2 +/- 9.0 yrs.,
9.3 +/- 1.7,
B) 10, 6/4, 2/8, 17.5 +/- 7.2 yrs., 8.1
+/- 1.9,
A) Jet lavage debridement with
superoxide aqueous solution +
hydrogel

Interventions

B) Jet lavage debridement with
saline solution + hydrogel
All dressing changes every 3-4
days, specified treating physician
Superoxide solution or saline
applied at every dressing change.
Outcomes

The study qualitatively
reports no adverse effects
were recorded. The study did
not report that 15% of the
study ulcers were healed. The
study reported no statistically
significant results between
the two treatments (p>0.05).
No further information was
specified on the outcomes of
interest for this review.
Wound bio-burden (bacterial
load) was reported on an

Notes
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ordinal scale as scatted (0/+),
light (+), medium (++), heavy
(+++)
Reduction in bacterial load at
week 4
A) 1.6 +/- 1.3 -> 1.1 +/- 1.2
B) 1.7 +/- 1.4 -> 1.2 +/- 1.2
No statistically significant
difference (p = 0.9)
The study reports trend
toward a 75% reduction in
necrotic tissue in the study
group (p>0.05)
Risk of bias table
Bias
Random sequence generation
(selection bias)

Authors' judgment
Low risk

Allocation concealment (selection
bias)

Low risk

Blinding participants

Unclear risk

Blinding personnel delivering
intervention

Unclear risk

Blinding outcome assessors
Incomplete outcome data (attrition
bias)
Selective outcome reporting
(reporting bias)

Unclear risk
Unclear risk

Other Bias
Notes

Unclear risk

High risk

Support for judgment
Randomized controlled pilot study.
Method of sequence generation
reported as computer-generated
block randomization scheme.
Reported that medical centers were
provided with sealed randomization
envelopes for conducting the
treatment assignment.
The authors report that this was a
double blind study, however it is
not specified which combination of
participants, personnel delivering
the intervention, or outcome
assessors was blinded.
The authors report that this was a
double blind study, however it is
not specified which combination of
participants, personnel delivering
the intervention, or outcome
assessors was blinded.
Not reported.
Not reported
No pre-specified protocol was
reported. The outcomes prespecified in the methods section
were reported in the outcomes.
However full numeration for both
groups was not reported in the
results.
Offloading status was not reported.
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8.

Clever 1995

Methods

Open, randomized, controlled
study
comparing two polyurethane
dressings
40 patients
Objective clinical evaluation:
ulcer tracings, photographs
and date of healing.
At end of treatment, both the
investigator and patient
evaluated the wound care
product subjectively.
A) 20 patients, 15M/5F, age 58.85
+/- 11.64 years

Participants

B) 20 patients, 17M/3F, age 53.15
+/- 14.62 years No statistically
significant difference was reported
in gender or age.
Sample age range 18 - 80
Pure neuropathic superficial
diabetic ulcer of 1-5 cm in
diameter.
No clinical or radiological signs of
osteomyelitis or tendon
involvement.
Study reports no statistically
significant differences between
intervention groups in terms of
ankle-brachial pressure index,
threshold of vibration, average
duration of ulcer before entering
study, and number of recent
recurrences.
Number of Smokers (9 vs 4, p <
0.01) was statistically significant.
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A) Hydroactive polyurethane gel
dressing Cutinova Hydro +
standard therapy*

Interventions

B) Hydrophilic polyurethane foam
dressing Allevyn + standard
therapy*
"Dressing changes reportedly
performed as often as required, but
at least once a week."
*Standard therapy included:
(i) pressure relief comprising a halfshoe or so-called "heel sandal"
therapeutic footwear with
cushioned insoles and crutches as
required to meet individual needs.
(ii) infection control with systemic
antibiotics if required,
(iii) wound cleansing with Ringer's
solution, and
(iv) debridement with removal of
callus if needed
Outcomes

Time to Healing
A) 25.19 ± 23.52 days
B) 20.43 ± 14.74 days (p >
0.2)
Proportion healed
A) 14/20 = 0.70
B) 16/20 = 0.80
Excluding dropouts, 88% of
the patients were healed in an
average of 23 days, 50%
within 16 days.
Dressing changes by patient’s
in-between the weekly
assessments:

Notes
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A) 2.23 ± 2.19 times
B) 2.37 ± 2.18 times, No
statistically significant
difference (p > 0.2)
The study reported
"subjective product
evaluation" including ease of
showering with dressing (p >
0.1), absorption capacity (p >
0.1), handling and suitability
(lack of side-effects or skin
problems) (p > 0.2), and all
were found to not be
statistically significant. No
details on the subjective
evaluation was specified.
Risk of bias table
Bias
Random sequence generation
(selection bias)

Authors' judgment
Low risk

Allocation concealment (selection
bias)
Blinding participants
Blinding personnel delivering
intervention
Blinding outcome assessors
Incomplete outcome data (attrition
bias)

Unclear risk

Support for judgment
Randomization reported but method
of sequence generation not
specified.
Not reported.

Unclear risk
Unclear risk

Not reported
Not reported

Unclear risk
High risk

Selective outcome reporting
(reporting bias)

High risk

Other Bias

High risk

Not reported.
2 patients in group A and 4 patients
in group B were reported to not
have completed the study. It is
unclear how the missing data were
addressed.
The study broadly reported
outcomes in the methods section
but did not specify all outcomes
that were reported in the results. No
protocol specified.
Unclear if both groups were
adequately balanced for
confounders or other risk factors
including disease severity.
Prospective wound healing study
was possible due to financial
support from manufacturer.

Notes
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9.

D'Hemecourt 1998

Methods

RCT Multi-centered (10
sites); Evaluator-blind
Study period was not
reported. Follow up period
was 140 days.
172 patients

Participants

A) 68
B) 70
C) 34
45 women/127 men; 19 years or
older; Type 1 / Type 2 diabetes. At
least one full thickness Stage 3 or
Stage 4 chronic diabetic ulcer of the
lower extremity.
Wound size (area and depth)
measured at baseline.
A) Good wound care*

Interventions

B) Good wound care & NaCMC
hydrogel
C) Good wound care &
Becaplermin
Off-loading of pressure and
systemic control of infection for all
wounds.
*'Good wound care' was defined by
the study authors as follows: "this
regimen consisted of daily dressing
changes, sharp debridement of the
ulcer when deemed necessary by
the investigator, systemic control of
infection if present, and off-loading
of pressure".
Outcomes

1. Proportion with complete
wound healing at 20 weeks
A) 15 / 68 (22%)
B) 25 / 70 (36%)
2. Time to complete healing
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A) 141 days *
B) 98 days *
3. Proportion with Infection
A) 0.28
B) 0.30
Largest trial with regard to
patient numbers

Notes

* It is unclear if these are
mean or median times to
healing.
Two other indicators reported
in the study included:
Pain reported as adverse
event
A) 10 / 68 (15%)
B) 11 / 70 (16%)
Wound related adverse events
A) 25 / 68 (37%)
B) 19 / 70 (27%)
Risk of bias table
Bias
Random sequence generation
(selection bias)

Authors' judgment
Low risk

Allocation concealment (selection
bias)
Blinding participants

Unclear risk

Blinding personnel delivering
intervention

Unclear risk

Unclear risk

Support for judgment
The method of sequence generation
procedure was not specified:
"patients were randomly assigned
in a 2:2:1 ratio to one of three
treatment groups".
Not reported.
Statement by authors from
published study: "both the NaCMC
gel and Becaplermin gel treatment
groups were conducted in doubleblind fashion; the group receiving
good wound care alone was blinded
to the investigator by a third party".
Blinding of personnel delivering the
intervention: yes - control group;

241

Blinding outcome assessors

Low risk

Incomplete outcome data (attrition
bias)

Low risk

Selective outcome reporting
(reporting bias)

Low risk

Other Bias

High risk

unclear - intervention groups (see
statement from authors above).
Blinding of outcomes assessor: yes.
Study described as "evaluatorblind".
Intention-to-treat analysis was
conducted. However, the specific
Intention to treat analytic method
was not reported.
Four parameters pre-specified as
outcomes, all of which were
reported
Baseline differences in group size
and ulcer characteristics (mean
area, depth, and duration):
Good wound care (n=68): n=65 at
stage III; 3.5 cm2; 67cm; 24 weeks.
NaCMC gel (n=70): n=70 at stage
III; 3.2 cm2; 69 cm; 24 weeks.
Becaplermin gel (n=34): n=32 at
stage III; 2.4 cm2; 33cm; 11 weeks.
The group receiving Becaplermin
gel were not comparable with the
two other groups.
'Good wound care' included "sharp
debridement of the ulcer when
deemed necessary by the
investigator". No other data
reported on diabetes disease
severity or other risk factors.

Notes
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10. Donaghue 1998

Methods

75 patients enrolled in an
open-label design with
random assignment to two
groups in 2:1 ratio.
Wagner classification used.
Offloading prescribed to all
patients with self-adhesive
felted foam and window at
wound site, and use of
healing sandals.
Seen weekly until target ulcer
healed or maximum of 8
weeks.
Exit interview to determine
satisfaction level.
# Gender Age (range) Duration of
DM(range) Weight Creatinine
Albumin Proportion

Participants

M/F yrs. (yrs.) (lbs.) (mg/dl)
(gms/dl) Retinopathy
A) 50, 33/17, 59 (30-81), 19 (4-47),
195 +/- 45, 1.2 +/- 0.6, 3.72 +/0.07 0.56
B) 25, 21/4, 60 (33-79), 17 (2-25),
214 +/- 49, 1.14 +/- 0.06, 3.79 +/0.11 0.76
No statistically significant
difference in any of these baseline
participant characteristics was
reported in the study.
A) Collagen Alginate

Interventions

B) Saline gauze
Patients or caregivers given
instructions to change as often as
required.
Outcomes

1) Proportion healed
A) 24/50 = 0.48
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B) 9/25 = 0.36
No statistically significant
difference (p=0.3933)
2) Mean time to complete
healing
A) 43.4 +/- 2.8 days
B) 40.6 +/- 2.8 days
The study authors reported
that there were no differences
in the number or severity of
adverse effects (p=0.453) No
other information was
provided.
The study also reported:

Notes

Baseline values:
Additional outcome included:
Mean percent reduction of the
wound area at the end of the
study was reported as:
A) 80.6 +/- 6%
B) 61.1 +/- 26%
No statistically significant
difference (p=0.4692)
The study reported wound
size reduction rate in a
multivariate analysis to be
statistically significant in
favor of Collagen alginate
over saline gauze (p=0.049).
No other information was
provided.
Subgroup analysis was
reported for wounds of less
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than 6 month’s duration and
the authors report a faster
healing rate for Collagen
alginate over saline gauze but
the result was not statistically
significant.
Risk of bias table
Bias
Random sequence generation
(selection bias)

Authors' judgment
Low risk

Allocation concealment (selection
bias)
Blinding participants
Blinding personnel delivering
intervention
Blinding outcome assessors
Incomplete outcome data (attrition
bias)

Unclear risk

Support for judgment
Random assignment to treatment
groups was reported but method of
sequence generation was not
specified.
Not reported.

Unclear risk
Unclear risk

Not reported
Not reported.

Unclear risk
Unclear risk

Selective outcome reporting
(reporting bias)

High risk

Other Bias

Unclear risk

Not reported.
75 patients enrolled, 61 completed
study, 14 withdrawals (6 patients in
group A and 8 in group B did not
complete the study, 5 withdrew no
reason reported, 3 patients missed >
2 visits, and 6 patients experienced
adverse events). The authors report
that all 75 patients enrolled were
included in the intention to treat
analysis. The method used in the
intention to treat analysis to address
the 14 withdrawals was
unspecified.
No protocol was specified in the
report. The outcomes reported in
the results section were not
explicitly prespecified outcomes in
the methods section.
The study reported adverse effects
were not statistically significant
between both groups. Specific
information on adverse effects was
not reported.

Notes
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11. EhsanUrRehman 2013

Methods

60 subjects randomly
assigned to two groups.
non-probability purposive
sampling
Wound measurements were
done on day 15.
Wagner grade I & II ulcers.
Length, width and maximum
perpendicular depth of ulcer
were measured and multiplied
post-surgical debridement
Not reported.
A) Honey soaked dressing

Participants
Interventions

B) Povidone-iodine/normal saline
dressing
Daily dressing changes
All wounds washed with saline
prior to
Surgical debridement at the time of
presentation.
Outcomes

1) Proportion healed
A) 24/50 = 0.48
B) 9/25 = 0.36
No statistically significant
difference (p=0.3933)
2) Mean time to complete
healing
A) 43.4 +/- 2.8 days
B) 40.6 +/- 2.8 days
The study authors reported
that there were no differences
in the number or severity of
adverse effects (p=0.453) No
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other information was
provided, Proportion healed
A) 0.867
B) 0.733
Other outcomes reported
include:

Notes

% decrease in wound size
A) 80.81 +/- 17.27%
B) 54.63 +/- 3.42%
Risk of bias table
Bias
Random sequence generation
(selection bias)

Authors' judgment
Low risk

Allocation concealment (selection
bias)
Blinding participants
Blinding personnel delivering
intervention
Blinding outcome assessors
Incomplete outcome data (attrition
bias)
Selective outcome reporting
(reporting bias)

Unclear risk

Support for judgment
Subjects reported randomly
assorted into two groups. Method of
sequence generation not specified.
Not reported.

Unclear risk
Unclear risk

Not reported
Not reported.

Unclear risk
Unclear risk

Not reported.
Not reported

High risk

Other Bias

High risk

The study reports swab and culture
would be carried out in the methods
section but infection not reported in
the results. Other outcomes
reported in the results section were
not pre-specified in the methods
section.
Prespecified outcomes not reported
in methods section. Comorbidities
used as exclusion criteria reported
in methods section but not
specified. No patient baseline
characteristics reported unclear
whether both groups balanced for
confounding. Non-probability
purposive sampling which could
produce sampling bias.

Notes
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12. Foster 1994

Methods

RCT, Stratified according to
neuropathic or ischemic
diabetic foot ulcers
Study length 8 weeks or until
the ulcer.
Weekly clinic assessments of
wounds and dressings, and
where ulcers were debrided.
30 Patients

Participants

A) 15 patients, 12M/3F, mean age
61, DMT1 = 6
B) 15 patients 8M/7F, mean age 70,
DMT1 = 4
A) Hydrocellular polyurethane
foam dressing Allevyn

Interventions

B) Calcium sodium alginate
dressing changes
All wounds washed with saline
prior to
Surgical debridement at the time of
presentation.
Outcomes

Proportion Healed
A) 9/15 = 0.60
B) 8/15 = 0.533
No statistically significant
difference in time to healing
between both intervention
groups.
Study reported that some
evidence ulcer more likely to
heal if IDDM as opposed to
NIDDM (p=0.07).

Notes

Also smaller ulcers or ulcers
of neuropathic origin more
likely to heal.
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A statistically significant
difference was reported
favoring Polyurethane foam
dressings over Calcium
alginate dressings in 1) time
taken for application (2.1 +/0.6 minutes vs 3.2 +/- 1.0
minutes), and in subjective
ordinal scales including ease
of application (p<0.001),
absorbency (p<0.01), patient
comfort (p<0.01), nonadherence (p<0.01), and ease
of removal (0.001). %
decrease in wound size
A) 80.81 +/- 17.27%
B) 54.63 +/- 3.42%
Risk of bias table
Bias
Random sequence generation
(selection bias)
Allocation concealment (selection
bias)
Blinding participants
Blinding personnel delivering
intervention
Blinding outcome assessors
Incomplete outcome data (attrition
bias)

Authors' judgment
Low risk

Unclear risk

Support for judgment
Study reports randomization but
method of sequence generation is
unspecified.
Not reported.

Unclear risk
Unclear risk

Not reported
Not reported.

Unclear risk
High risk

Not reported.
4 patients from the alginate group
withdrew due to:

Selective outcome reporting
(reporting bias)

High risk

Other Bias

High risk

severe pain (1); plugged lesion
prevented free drainage of exudate
(3) with one becoming infected.
Unclear how incomplete outcome
data were addressed.
Study pre-specified a number of
"ideal" parameters in the
introduction including infection
however these were not all were
reported in the results section. No
parameters were pre-specified in
the methods section.
The study reported stratification
was conducted in order to ensure
that a more equitable number of
individuals with neuropathic,
ischemic ulcers, traumatic wounds
in each intervention group.
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However, no mention was made on
whether other risk factors such as
diabetes disease severity was
balanced in both intervention
groups. Duration of ulcer was
longer in the calcium alginate group
(170 days vs 107 days).
Notes
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13. Goretti 2008

Methods

RCT; Randomized into two
groups.

Participants

A) 20
B) 20
Wounds > 5 cm2, ABI >/= 0.9 and
two arteries in the ankle palpable by
pulse or Doppler.
Age, gender, diabetes type, duration
of diabetes, proportion of wounds
infected, or other data not provided.
A) Super-oxidized solution (SOS)
treatment

Interventions

B) Standard local treatment with
povidone iodine
Frequency or number of times
intervention used was not reported.
The study abstract mentions that the
patients received metabolic control,
systemic antibiotics, and offloading
as necessary, but no further detail
was provided.
Outcomes

1. Proportion Healed
A) 0.85
B) 0.53
(p<0.01, statistically
significant difference)
2. Healing Time
A) 10.5 +/- 1.3 weeks
B) 16.5 +/- 1.7 weeks
(p<0.01, statistically
significant difference)
The study reports weekly
visits to record lesions
clinical signs of infection,
microbiological sampling,
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eventual new debridement
procedures, and adverse
events. No further detail is
available.
Other outcomes that were
reported include:

Notes

Sterilization of lesions (ST)
A) 5.5 +/- 2.1 weeks
B) 16.2 +/- 6.6 weeks
(p<0.01, statistically
significant difference)
Number of Debridement
procedures (ND)
A) 3/20
B) 9/20
(p<0.01, statistically
significant difference)
Adverse Events (NA)
A) 4
B) 9
No other information
provided other than a
statement that no differences
were observed in (NA)
Risk of bias table
Bias
Random sequence generation
(selection bias)

Authors' judgment
Low risk

Allocation concealment (selection
bias)
Blinding participants

Unclear risk

Blinding personnel delivering
intervention

Unclear risk

Unclear risk
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Support for judgment
Published abstract only.
Randomization reported but the
method of sequence generation
used was not specified
Published abstract only. Not
reported.
Published abstract only. Not
reported.
Published abstract only. Not
reported.

Blinding outcome assessors

Unclear risk

Incomplete outcome data (attrition
bias)
Selective outcome reporting
(reporting bias)

Unclear risk

Other Bias

Unclear risk

Published abstract only. The study
reports weekly visits to "blindly"
record lesions clinical signs of
infection, microbiological
sampling, eventual new
debridement procedures, and
adverse events. Unclear if other
outcomes were blinded.
Published abstract only. Not
reported.
Published abstract only. Results
were available for all outcomes
reported in the methods section
however unclear if protocol was
written ahead of the study.
Published abstract only. Other
sources of bias not discernible.

Low risk

Notes
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14. Hammouri 2004

Methods

203 patients allocated
randomly to two groups, 3
excluded.

Participants

200 patients, 112M/88F, Mean age
= 58
A) 100 58M/42F, (24-100),
B) 100 54M/46F, (22-100)
A) Honey/Normal Saline, washed
with normal saline postdebridement

Interventions

B) Povidone Iodine/H2O2 (3:1)
washed with same solution postdebridement
All dressings applied 3 times daily
then declined as treatment
progresses in both groups.
Outcomes

1) Time to healing
A) Median 21 days, (7-70
days), SD = 15.97
B) Median 32 days, (7-90
days), SD = 20.89
Statistically significant
difference (p<0.001)
2) Treatment Cost
A) 282 +/- 66.33 Jordan
Dinar,
B) 616 +/- 192.97 Jordan
Dinar,
Statistically significant
difference (p<0.001)
3) Proportion amputations
A) 0.10
B) 0.20
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Statistically significant
difference (p<0.05)
Other outcomes reported:

Notes

Hospital stay
A) Median 23 days (7-42
days), SD = 8.26
B) Median 13 days (7-56
days), SD = 14.54
Statistically significant
difference (p<0.001)
Risk of bias table
Bias
Random sequence generation
(selection bias)

Authors' judgment
Low risk

Allocation concealment (selection
bias)
Blinding participants
Blinding personnel delivering
intervention
Blinding outcome assessors
Incomplete outcome data (attrition
bias)

Unclear risk

Support for judgment
The authors report random
allocation. Method of sequence
generation is not specified in the
report.
Not reported

Unclear risk
Unclear risk

Not reported
Not reported

Unclear risk
Unclear risk

Selective outcome reporting
(reporting bias)

High risk

Other Bias

High risk

Not reported
The authors report that 3 patients
were excluded from the analysis
that died from other medical illness.
No protocol is reported. The study
authors report healing, hospital
stay, and cost as the respective
outcomes of interest in the methods
section. These were reported in the
results section. The study reported
amputation proportion, bioburden
reduction which were not explicitly
pre-specified in the methods
section.
The study authors did not report
exclusion criteria and reported only
diabetic foot ulcers as inclusion
criteria. Baseline characteristics of
the ulcers in each group were not
reported. Disease severity
indicators including Hgba1c,
duration of diabetes were not
reported. Grade of diabetic foot
ulcers not reported. Debridement
under anesthesia is reported but
study authors do not specify
whether this was an initial
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debridement only or if
debridements were conducted
throughout the course of the study.
Notes
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15. Jeffcoate 2009

Methods

A multicenter, prospective,
observer-blinded, parallel
group, randomized controlled
trial.
Research nurse monitored
every two weeks.
Primary endpoint number of
ulcers healing in each group
within 24 weeks.
Ulcers monitored by nurses
every two weeks. Blinded
wound assessments made at
baseline, 12 weeks, 24 weeks,
4 weeks after healing, and 12
weeks after the 24-week
assessment.
Healing defined as complete
epithelialization with no
drainage for 4 weeks and
confirmed by a blinded
assessor. If an ulcer was
assessed as healed at any
point the authors stated that
ulcer was reassessed at 2 and
4 weeks after healing. If the
ulcer recurred within 4 weeks
or at any point up to 24
weeks, the patient was reentered into the study using
the allocated dressing.
The study reported on ulcerrelated endpoints, patientrelated endpoints, and process
related endpoints.
A health economics
evaluation which included the
direct costs associated with
dressings used and patient
travel costs was reported. The
quality of life assessment
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included SF-36 questionnaire,
a visual analogue scale for
pain, and the CWIS (Cardiff
wound impact schedule).
# Gender M/F Age (yrs.) DM Type
1/2 DM duration (yrs.)

Participants

Total 317, 240/76, 59.6 +/- 12.6,
240/76, 15.7 +/- 10.8
A) 103, 81/22, 59.5 +/- 11.5, 22/81,
16.0 +/- 11.4
B) 108, 81/27, 58.8 +/- 13.2, 25/83,
15.3 +/- 9.8
C) 106, 78/27, 61.9 +/- 12.8, 78/27,
15.8 +/- 11.4
A) Hydrofiber dressing Aquacel

Interventions

B) Iodine impregnated gauze
C) Non-adherent viscous filament
gauze
Other care reported to include:
regular use of debridement,
offloading,
The study reports dressings were
changed daily, on alternate days,
and 3X/week depending on the
need by the patient or caregiver
who received training, or by the
nurse. If patient changed the
dressing, then nursing oversight
was conducted every two weeks.
The study reported that off-loading
was variable, and 42% of
participants were issued the
preferred casting device, two
centers issued no casting devices,
one center issued 1.
Outcomes

1) Proportion of ulcers healed
A) 46/103 = 0.447
B) 48/108 = 0.444
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C) 41/106 = 0.387
No statistically significant
difference (p=0.38)
2) Proportion of ulcers
recurring
A) 3/103 = 0.029
B) 7/108 = 0.065
C) 3/106 = 0.028
3) Time to healing
A) 125.8 +/- 55.9 days
B) 127.8 +/- 54.2 days
C) 130.7 +/- 52.4 days
No statistically significant
difference (p=0.80)
4) Proportion amputated
A) 4/103 = 0.039
B) 1/108 = 0.009
C) 2/106 = 0.019
Statistical significance not
reported.
5) Proportion infected
A) 54/103 = 0.524
B) 71/108 = 0.657
C) 48/106 = 0.453

259

Statistical significance not
reported
6) Treatment cost
A) 194.03
B) 184.17
C) 141.1
Statistical significance not
reported
7) Quality of life index
A) 0.382
B) 0.384
C) 0.394
No statistically significant
difference (p=NS)
Other outcomes reported:

Notes

Hospital stay
A) Median 23 days (7-42
days), SD = 8.26
B) Median 13 days (7-56
days), SD = 14.54
Statistically significant
difference (p<0.001)
Risk of bias table
Bias
Random sequence generation
(selection bias)

Authors' judgment
Low risk
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Support for judgment
Randomization was reported to be
stratified by center, size, using
block size of nine design.
Randomization was also stratified
across the whole population by
ulcer area in three groups. The
study reports that randomization
lists were created using statistical
software.

Allocation concealment (selection
bias)

Low risk

Blinding participants
Blinding personnel delivering
intervention
Blinding outcome assessors

Unclear risk
Unclear risk

Incomplete outcome data (attrition
bias)

Low risk

The randomization lists and records
of the allocation details were
reported to be held at a central
location and each recruiting center
telephoned.
Not reported
Not reported

Low risk

The study reports that the clinician
in charge of care and assessing for
healing was blinded to the
randomization group.
The authors reported that 88
participants (27.8%) out of the 317
enrolled were withdrawn. The
reasons for withdrawal were
reported as:
Adverse event = 35
Protocol violation = 24
Loss to follow up = 7
Consent withdrawal = 16
Death = 5
Other = 1

Selective outcome reporting
(reporting bias)

Low risk

Other Bias

High risk

Intention to treat analysis was
carried out using last observation
carried forward.
No protocol was available or
referred to in the study. The
outcomes reported in the results
were pre-specified in the methods
section.
The study reported 88 withdrawals
out of 317 participants, last
observation carried forward was
utilized as intention to treat. This
may have biased the results in
either direction.

Notes
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16. Jensen 1998

Methods

RCT; Randomized into 2
groups.
Study period was not
reported. Follow up period
was 20 weeks.
31 patients

Participants

A) 14
B) 17
No description of age, sex, type of
diabetes, or disease severity was
reported.
Wound area measured at baseline.
Average duration of ulceration
A) 8.9 months
B) 3 months
A) Carrasyn hydrogel wound
dressing (CHWD) cleansed with
ULTRAKLENZ wound cleanser.

Interventions

B) Wet-to-moist saline gauze
cleansed with ULTRAKLENZ
wound cleanser.
Adjunctive wound care included all
patients who initially received sharp
debridement to remove all nonviable (dead) tissue and all patients
received custom made healing
sandals for pressure redistribution.
Dressings changes were conducted
daily. Saline moist gauze
remoistened as needed. Patients
evaluated weekly using wound
tracings and computer planimetry.
Outcomes

1. Proportion with complete
wound healing at 16 weeks
(Defined as 100% wound reepithelialization)
A) 11/13 84.6%
B) 6/13 46.1% P=0.05
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2. Time to complete healing
A) 10.3 weeks *
B) 11.69 weeks *
3. Proportion with amputation
A) 0/14 = 0
B) 1/17 = 0.059
4. Proportion with Infection
A) 2/14 = 0.143
B) 1/17 = 0.059

5. Cost
A) 7.01 - ($/day)
B) 12.28 - ($/day)
* It is unclear if these are
mean or median times to
healing. 13/14 patients
completed the study in the
Hydrogel group whereas
13/17 completed the study in
the control group.

Notes

Other outcomes that were
reported in this study
included:
Complications
A) 2/14 (14%)
B) 4/17 (24%)
Risk of bias table
Bias
Random sequence generation
(selection bias)

Authors' judgment
Low risk
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Support for judgment
Randomization was reported but
method of sequence generation not
specified.

Allocation concealment (selection
bias)
Blinding participants
Blinding personnel delivering
intervention
Blinding outcome assessors
Incomplete outcome data (attrition
bias)

Unclear risk

Not reported

Unclear risk
Unclear risk

Not reported
Not reported

Unclear risk
High risk

Selective outcome reporting
(reporting bias)

Unclear risk

Other Bias

High risk

Not reported
5 patients dropped out (n=1 in
Group A; n=4 in Group B): no
intention-to-treat analysis or other
method of handling missing data
were specified.
No protocol available. No
parameters clearly pre-specified as
outcomes in the methods section.
No Group A and Group B data
reported on ulcer size, depth, on
entry to trial other than ulcer with
minimum of 1cm diameter; and
Wagner grade II thickness.
However, the trial report suggests
that Group A had average ulcer
duration of 8.9 months compared
with 3 months for group B.
Study supported by an educational
grant from Carrington Laboratories,
Inc. (the manufacturers of
Carrasyn).

Notes
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17. Lalau 2002

Methods

Open - label multicenter
randomized controlled trial.
Study reported 13 centers
throughout France
participated.
Number of wound dressings
and adverse events recorded
weekly. Follow up visits
scheduled at weeks 1, 2, 4, 6
to monitor healing efficacy
and safety.
Planimetric evaluation used
for surface area.
The study reported a 6-week
treatment period, though
efficacy analysis was reduced
to 4 weeks due to premature
cessation of treatment in 13
patients. Reported that there
was no revision to efficacy
criteria.
The study reported that
conservative management
was carried out using
pressure relieving methods.
77 patients enrolled, 13 withdrawn

Participants

#, Gender, Age, BMI, DM type,
Diabetes duration, Hgba1c, #
revascularizations, TcPO2,
A) 39, 22M/17F, 60.8 +/- 10.7 yrs.,
27.6 +/- 5.11, 15/24, 19.2 +/- 11.8
yrs., 7.6 +/- 2.0, 13, 44.6 +/- 12.3
B) 38, 23M/25F, 63.5 +/- 12.8 yrs.,
27.3 +/- 5.52, 16/22, 16.9 +/- 8.9
yrs., 7.9 +/- 1.5, 4, 42.6 +/- 10.3
No statistically significant
difference in participants except for
# revascularizations.
A) Calcium Alginate

Interventions
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B) Vaseline Gauze
The study reported daily dressing
changes initially until thoroughly
debrided, then once granulation
occurred, every 2 - 3 days
depending on exudate amount as
determined by nurses. The authors
reported no other local treatments
except unrestricted saline.
The study reported that mechanical
debridement was authorized as
necessary.
Outcomes

Proportion of infections
A) 1/39 = 0.026
B) 3/38 = 0.079
Proportion of patients with
granulation tissue > 75% of
wound area, and a 40%
decrease in wound surface
area. Secondary outcomes
included: pain on dressing
changes, cumulative number
of dressing changes, and
number of adverse events. All
were reported not to be
statistically significant except
for pain and cumulative
number of dressing changes
in favor of calcium alginate.

Notes

Risk of bias table
Bias
Random sequence generation
(selection bias)

Allocation concealment (selection
bias)
Blinding participants
Blinding personnel delivering
intervention
Blinding outcome assessors

Authors' judgment
Low risk

Unclear risk

Support for judgment
Randomization of participants was
reported. The method of random
sequence generation was not
specified.
Not reported

Unclear risk
Unclear risk

Not reported
Not reported

Low risk

The study reported that an
independent investigator, blind to
the allocated treatment, was
assigned to analyze wound surface
areas. Analysis reportedly
performed two times for each
patient, and a third as warranted.
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Incomplete outcome data (attrition
bias)

Unclear risk

Selective outcome reporting
(reporting bias)

Low risk

Other Bias

High risk

77 patients enrolled, and 64
completed the study for the full 6
weeks. 13 withdrawals - 1 consent
withdrawal, and 4 adverse events in
the Calcium Alginate group, 1
ineffective treatment, 1
aggravation, and 6 adverse events
in the Vaseline group. The study
reports that due to the loss of data
as a result of the 13 withdrawals the
study was shortened to efficacy
analysis at 4 weeks.
No protocol was reported in the
study. Outcomes pre-specified in
the methods section were reported
in the results section.
The revascularizations were
reportedly higher in the Calcium
Alginate group. Sub group analysis
on acute versus chronic lesions was
also reported but demonstrated no
statistically significant difference.
Most of the lesions were chronic
and reportedly may have been more
refractory to treatment.

Notes
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18. Markevich 2000

Methods

RCT; Multi-centered;
Double-blind
Study period not reported,
follow up period was 10 days
140 patients,

Participants

A) 70
B) 70
Average Age: 53.6 +/- 15.4 years.
Average duration of Diabetes: 15.8
+/- 10.7 years
No description of sex, type of
diabetes, disease severity, infection
status, offloading status, or wound
grade, other than qualitative
statement that depth and volume
were comparable at baseline
between both groups.
A) Larval therapy (green bottle fly Lucilia sericata 6-10 larva per 1
cm2 of wound surface area)
removed after 72 hours

Interventions

B) Hydrogel (no data on frequency
of dressing change)
Outcomes

Complete healing (no data as
to time this took)
A) 5/70 (7.1%)
B) 2/70 (2.8%)
(no report of whether this was
a statistically significant
difference was mentioned)
A) Average Surface area of
wound 14.9 cm2

Notes

B) Average Surface area of
wound 15.14 cm2
(no statistically significant
difference)

268

Qualitatively reported in
abstract that surface area,
depth and volume,
surrounding skin, tissue
quality, exudate, odor, and
glucose levels were
comparable at baseline but no
numerical data were
provided.
Assessments reported every 3
days during first 10 days.
At 10 days granulation tissue
covering 50% of wound was
higher in larval therapy (60%
vs 34.3%; p<0.001
statistically significant
difference)
Proportion of patients with
greater than 50% reduction in
wound area was higher in the
larval group than in the
hydrogel group (51.1% vs
27.1% p<0.05, statistically
significant difference)
Risk of bias table
Bias
Random sequence generation
(selection bias)

Allocation concealment (selection
bias)
Blinding participants

Blinding personnel delivering
intervention

Authors' judgment
Low risk

Unclear risk
Unclear risk

Support for judgment
Published abstract only Randomization reported but method
of sequence generation not
reported.
Published abstract only - allocation
concealment not reported.
N.B. RCT described as "doubleblind" by study authors but no
further detail given.
Blinding of participants - not
reported (published abstract only):
This may be difficult due to nature
of treatments - larval therapy vs.
hydrogel.
Blinding of personnel - not reported
(published abstract only): This may
be difficult due to nature of
treatments - larval therapy vs.
hydrogel.

Unclear risk
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Blinding outcome assessors

Unclear

Incomplete outcome data (attrition
bias)

Unclear risk

Selective outcome reporting
(reporting bias)
Other Bias

Unclear risk

Blinding of outcome assessors: not
reported (published abstract only).
Published abstract only incomplete outcome data were not
reported, if incomplete outcome
data were present then assessment
and how outcome data were
addressed is not discernible.
Published abstract only - selective
reporting not discernible.
Published abstract only - other bias
not discernible.

Unclear risk

Notes
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19. Mazzone 1993

RCT, Method of random
sequence generation was not
reported.
19

Methods

Participants

A) 11
B) 8
No data on age, sex, or other
patient specific demographics or
characteristics were reported.
A) Polymeric membrane foam
dressing

Interventions

B) Wet to Dry saline gauze
mesh dressing
Complete healing (no data on
the time to this endpoint
reported)

Outcomes

A) 5/70 (7.1%)
B) 2/70 (2.8%)
(no report of whether this was a
statistically significant
difference was mentioned)
Wound size reduction was
reported as well.

Notes

No other information on other
risk factors such as diabetes
type, duration, or disease
severity was reported. No data
reported on wound size or grade
between treatment groups.
Risk of bias table
Bias
Random sequence generation
(selection bias)

Allocation concealment
(selection bias)
Blinding participants
Blinding personnel delivering
intervention
Blinding outcome assessors

Authors' judgment
Low risk

Unclear risk

Support for judgment
The study reports randomization
however method of random
sequence generation was not
specified.
Not reported

Unclear risk
Unclear risk

Not reported
Not reported

Unclear risk

Not reported
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Incomplete outcome data
(attrition bias)
Selective outcome reporting
(reporting bias)
Other Bias

Unclear risk

Not reported

Unclear risk

Not discernible; abstract only
available.
No data were reported on study
participant characteristics
between treatment groups, nor
on other risk factors such as
diabetes type, duration, or
disease severity. No data
reported on wound size or grade
between treatment groups.

High risk

Notes
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20. Munter 2006

Methods

Randomized controlled trial
Duration = 4 weeks
Reported that patients were
assessed weekly at wound
clinic as judged necessary.
Study reports that
participating clinics used
same clinical guidelines and
data-collection forms.
619 patients, Multi-etiology ulcers

Participants

Mean age = 55.2 +/- 9.4 yrs.,
Duration of diabetes = 14.8 yrs.
# Age Gender M/F (%),
A) 326, 69.8 +/- 13.7 yrs., 38/62
B) 293, 68.8 +/- 14.1 yrs., 39/61
A) Silver releasing hydrophilic
polyurethane foam dressing

Interventions

Mean dressing changes = 3.1 days
B) Local Best Practice (Study
reports that this ranged from gauze,
moist wound healing, wound
healing products, to antimicrobial
treatments)
Mean dressing changes = 2.1 days
Wound management included
compression therapy.
DFU's comprised 8% of Silver and
8% Local best practice group
Outcomes

The study conducted a
subgroup analysis for diabetic
foot ulcers. The study
reported one of the outcomes
of interest for this review,
quality of life. The authors
did not specify the results of
this outcome for the subgroup
of diabetic foot ulcers instead
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it was reported that the results
were comparable for all
parameters between the two
treatment groups, except for
wound progress, exudate, and
odor.
The study reported other
outcomes such as ulcer area
reduction, slough, wound
progress, maceration,
exudate, leakage, ease of
dressing use and time spent,
malodor, pain, and cost
effectiveness.

Notes

Risk of bias table
Bias
Random sequence generation
(selection bias)

Authors' judgment
Low risk

Allocation concealment (selection
bias)

Unclear risk

Blinding participants
Blinding personnel delivering
intervention
Blinding outcome assessors
Incomplete outcome data (attrition
bias)

Unclear risk
Unclear risk

Selective outcome reporting
(reporting bias)

Low risk

Other Bias

High risk

Unclear risk
Low risk

Support for judgment
The study reports open prospective
parallel, block randomized
evaluation. Specific method of
sequence generation was a
computer generated list.
The study reports that the computer
generated sequence list was in
sealed envelopes.
Not reported
Not reported
Not reported
The study reports that in order to
include patients in the analysis all
missing data were addressed with
last observation carried forward and
obtained data were analyzed as
intention to treat.
There was no protocol available or
reported in the study. The outcomes
reported in the outcomes section
were pre-specified in the methods
section.
The study reports private financial
support.

Notes
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21. Ogce 2007

Methods

Randomly assigned
30 days’ study duration
Weekly follow up with 4
follow ups. Study reports that
participating clinics used
same clinical guidelines and
data-collection forms.
60 patients, Gender = 36M/24F,
mean age = 59.85, Hgba1c = 7.73,
BMI = 25.06 24.47

Participants

#, DM Type (1/2) Mean Age
Hgba1c
A) 30, 0.867/0.133 59.47 yrs.,
7.60%,
B) 30, 0.733/0.267 60.23 yrs.,
7.86%
A) Hydrocolloid dressing
(combined with paste for wound
cavities, and powder for infection)

Interventions

B) Classic wound dressing
Daily dressing changes
Outcomes

The study reported that
healing was much better and
faster in the experimental
group.
The article was only available
in Turkish and was translated
through the use of Google
translate as were all nonEnglish language publications
that were retrieved through
our search and accepted in
this review. The translation
was of higher quality for
some languages and difficult
in others. This study was
among those that was
difficult to translate. This
posed a limitation in data
extraction.

Notes

Risk of bias table
Bias

Authors' judgment
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Support for judgment

Random sequence generation
(selection bias)

Low risk

Allocation concealment (selection
bias)
Blinding participants
Blinding personnel delivering
intervention
Blinding outcome assessors
Incomplete outcome data (attrition
bias)
Selective outcome reporting
(reporting bias)

Unclear risk

Random assignment reported but
method of sequence generation was
not specified.
Not reported

Unclear risk
Unclear risk

Not reported
Not reported

Unclear risk
Unclear risk

Not reported
Not reported

High risk

Other Bias
Notes

Unclear risk

No protocol was available or
reported in the study. The outcomes
reported in the results were not
explicitly pre-specified in the
methods section.
Limited reporting.
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22. Piaggesi 2001

Methods

Study duration = 8 weeks
All subjects initial surgical
debridement + postoperative
pressure relieving shoes +
crutches
Weekly assessments:
Photographed lesions traced
on acetate film to measure
maximal dimensions.
Wound depth measured by
probe and volume by gel.
24 identified, 20 enrolled, 4
withdrawn

Participants

A) 10, 61.3 +/- 7.5 years
Duration of diabetes = 16.1 +/- 8.9
years
Hgba1c = 8.9 +/- 3.1%
ABPI = 1.0 +/- 0.2
B) 10, 63.1 +/- 4.6 years,
Duration of diabetes = 14.8 +/- 6.2
years
Hgba1c = 8.1 +/- 2.7%
ABPI = 1.1 +/- 0.3
A) Saline moistened gauze
(renewed twice daily with saline to
prevent drying)

Interventions

B) Sodium Carboxy-Methyl
Cellulose Hydrofiber (Aquacel)
changed every 2nd or 3rd day
depending on extent of exudate
produced by wound.
Dressing changes by trained
relative or visiting nurse.
Outcomes

1) Proportion healed
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A) 10/10 = 1
B) 9/10 = 0.90
2) Healing Time
A) 234 +/- 61 days
B) 127 +/- 46 days
Statistically significant
difference
3) Proportion with Infection
A) 1/10 = 0.30
B) 3/10 = 0.10
4) Proportion amputations
a) 1/10
b) 0/10
No statistically significant
difference
Notes
Risk of bias table
Bias
Random sequence generation
(selection bias)

Authors' judgment
Low risk

Allocation concealment (selection
bias)
Blinding participants
Blinding personnel delivering
intervention
Blinding outcome assessors

Unclear risk

Support for judgment
Study reports random assignment
but specific method of sequence
generation was not reported.
Not reported

Unclear risk
Unclear risk

Not reported
Not reported

Low risk

Incomplete outcome data (attrition
bias)

High risk

Selective outcome reporting
(reporting bias)

Low risk

Reported that blindly evaluated by
one of the authors.
24 eligible patients, 20 enrolled and
randomized. 2 refused consent, 1
due to missed visits, 1 due to neuroosteoarthropathy.
The study states a protocol was
written and submitted to an ethics
committee however this was
unavailable, however the methods
section reported the outcomes to be
studied including: 1) rate of
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Other Bias

reduction in lesion volume, 2) rate
of granulation tissue, 3) infective
complications, and 4) healing time.
These outcomes are reported in the
results section. Proportion requiring
amputation was also reported that
was not in methods section.
Reported that manufacturers not
involved in any part of experiment.
Amputations reported but difficult
to determine if in same individuals
or different individuals based on the
report. Unclear if groups were
balanced for other risk factors.

Unclear risk

Notes
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23. Piaggesi 1998

Methods

Randomized into 2 treatment
groups
Study period 1995. Follow up
period was 24 weeks. Patients
were followed twice a week.
42 patients with 46 ulcers

Participants

A) 22 patients, (17 NIDDM / 3
IDDM), 24 ulcers
Mean age = 63.24 +/- 13.46 years
Duration of diabetes = 18.2 +/- 8.41
years
Hgba1c = 9.5 +/- 3.8%
B) 24 patients, (19 NIDDM / 2
IDDM), 22 ulcers
Mean age = 65.53 +/- 9.87
Duration of diabetes = 16.84 +/10.61 years
Hgba1c = 8.9 +/- 2.2%
No description of sex
Baseline wound area measurement
not reported.
A) Control - Non-surgical
conventional treatment including
pressure relief and regular dressing
(type of dressing not reported.

Interventions

B) Treatment - Surgical
debridement, removal of bone
segments
Outcomes

1. Complete healing at 6
months: Group A = complete
re-epithelialization of lesions;
Group B = formation of
continuous scar
A) 19/24 (79%)
B) 21/22 (95%)

280

2. Healing time
A) 48.7 +/- 36.99 days
B) 130.38 +/- 90.49 days
4. Recurrence rate
A) 8/24 (33%)
B) 3/22 (14%)
5. Infective complications
A) 3/24 (13%)
B) 1/22 (5%)
6) Amputations
A) 1/24 = 0.04
B) 0/22 = 0
Notes
Risk of bias table
Bias
Random sequence generation
(selection bias)
Allocation concealment (selection
bias)
Blinding participants

Blinding personnel delivering
intervention

Authors' judgment
Low risk

Unclear risk
Unclear risk

Support for judgment
Exact sequence generation not
reported: "a table of
randomization".
Not reported
Non-surgical debridement and
pressure relief vs. surgical
debridement.
Blinding of participants difficult
due to nature of treatments –
nonsurgical control vs. surgical
intervention.
Blinding of personnel: difficult due
to nature of treatments - nonsurgical control vs. surgical
intervention.

Unclear risk

Yes - Group A. Physicians and
nurses treating Group A (control)
patients were unaware of their
patients' involvement in the trial:
"the whole treatment course of
group A patients from initial
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debridement to follow-up visit was
performed by physicians and nurses
unaware of the participation of
patients in the study, and did not
differ from the standard protocol of
treatment of non-complicated
neuropathic ulcerations in our foot
clinic".

Blinding outcome assessors

Unclear risk

Incomplete outcome data (attrition
bias)
Selective outcome reporting
(reporting bias)

Unclear risk

Other Bias

High risk

Unclear - Group B. It was not
reported if personnel for the Group
B (intervention) were aware of their
patients' participation in the trial.
Blinding of outcome assessors:
unclear who conducted outcome
assessment for both Groups (A and
B).
Patient numbers at follow-up were
not reported.
Four parameters were pre-specified
as outcomes, all of which were
reported.
Group B given antibiotics 5 days
after surgery: "general therapy for
group B patients differed from
group A in that systemic parenteral
therapy with wide-spectrum
antibiotics was given 5 days after
surgery, according to the protocols
of our hospital for the prophylaxis
of nosocomial infection".

Low risk

Notes
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24. Rhaiem 1998

Methods

Randomization of subjects
into 3 groups
Study period was 1992 1995, Follow-up period was
40 +/- 13 days
80 patients, Gender 59M/21F, DM
type 1/2 = 61/19, mean age = 56 +/32 yrs. (26 - 89), diabetes duration
= 13 +/-10.6 yrs. (1 - 26) yrs.,
peripheral neuropathy 74.6%,
smokers 55%, Alcohol users 21%,
infected wounds at baseline =
51.7%

Participants

G1: 16 patients
G2: 24 patients
G3: 40 patients
3 treatment groups:

Interventions

A) G2: cleaning ulcers with
hydrogen peroxide 3% + antibiotictherapy + local applied Jam sugar
B) G3: cleaning ulcers with
hydrogen peroxide 3% + antibiotictherapy (40 patients)
C) G1: cleaning ulcers with
hydrogen peroxide 3% + local
applied Jam sugar
Outcomes

ln groups 1 and 2 (using
sugar): 47.5% of ulcers
healed, compared with group
3 in which 40% of ulcers
healed with a mean delay
respectively of 6 and 9
weeks.
Proportion healed
A) G1 and G2 = 0.475
B) G1 = 0.40
Not a statistically significant
difference.
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Risk of bias table
Bias
Random sequence generation
(selection bias)

Notes

This study was translated
using Google translate from
French into English.

Authors' judgment
Low risk

Allocation concealment (selection
bias)
Blinding participants
Blinding personnel delivering
intervention

Unclear risk

Support for judgment
The study reports randomization,
but does not specify the method of
sequence generation.
Not reported

Unclear risk
Unclear risk

Not reported
Not reported

Blinding outcome assessors
Incomplete outcome data (attrition
bias)
Selective outcome reporting
(reporting bias)

Unclear risk
Unclear risk

Not reported
Not reported.

High risk

Other Bias

High risk

The study does not report whether a
protocol was pre-established. The
methods section of the study does
not pre-specify the outcomes
reported in the results section.
The study does not explicitly report
whether the subjects received offloading. It is not mentioned in the
study how the determination of
ischemic wounds was established.
The study does not clarify. The
study reports the combined healing
proportion for the G1 and G2
groups, it does not report the
proportion separately. The study
reports that 51.7% of wounds were
infected, no information was
provided on whether infected or
ischemic wounds were balanced
between the 3 treatment groups.

Notes
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25. Roberts 2001

Methods

RCT
Dressing changed and wound
assessment with tracings were
reported to occur weekly.
Study duration was 13 weeks
30 patients 23M/7F

Participants

Type 1 DM
Median Age = 59.5 years Range
(37-77)
Neuropathic ulcers of the plantar
surfaces.
Median wound size for sample was
123 mm2, range (21 - 350 mm2)
Median wound size for
Hydrocellular foam was 114.5 mm2
and 144.5 mm2 for saline soaked
low adherent dressing.
Median Wound duration 15.2
weeks, range (1 week - 6 years)
ABPI < 0.8
A) 14
B) 16
A) Allevyn hydrocellular foam
dressing

Interventions

B) Saline soaked (low adherent)
dressing and standard podiatric care
Outcomes

1) Proportion healed over 13
weeks
A) 6/14 = 43%
B) 4/16 = 25%
2) Time to healing - Not
significantly different
between both groups p =
0.325
285

Notes

The study also reported the
proportion of patients in each
group that demonstrated a
50% area reduction over 13
weeks:
A) 13/14 = 93%
B) 12/16 = 75%
The study reports that after
adjusting for covariate risk
factors: age, sex, ulcer size
and duration, the
hydrocellular dressing was
associated with a significantly
faster response (p=0.013),
than saline soaked (low
adherent) dressing.

Risk of bias table
Bias
Random sequence generation
(selection bias)

Authors' judgment
Low risk

Allocation concealment (selection
bias)
Blinding participants

Unclear risk

Blinding personnel delivering
intervention
Blinding outcome assessors

Unclear risk

Incomplete outcome data (attrition
bias)

Unclear risk

Selective outcome reporting
(reporting bias)

High risk

Other Bias

High risk

Unclear risk

Unclear risk

Support for judgment
Randomization was reported
however method of sequence
generation was not specified.
Published abstract only - allocation
concealment not reported.
Published abstract only - blinding
not reported.
Published abstract only - blinding
not reported.
Published abstract only - blinding
not reported.
Published abstract only incomplete outcome data not
reported.
Not clear that a protocol was
available and methods did not prespecify outcomes reported.
Published abstract only - other bias
not discernible.
Unclear if risk factors such as
diabetes disease severity or others
were balanced between the two
intervention groups. Depth of
wound between intervention groups
was not reported. Study supported
by an educational grant from
manufacturer Smith & Nephew Group Research Centre).
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Notes
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26. Shukrimi 2008

Wagner grade II diabetic foot ulcers

Methods

Wound assessments every other day
by a surgeon blinded to the material
of the dressing.
30 patients (31-51 yrs.), 15M/15F,
mean age = 52.1 yrs. (31-65 yrs.),
TcPO2 mean = 39 mmHg (36 - 42
mmHg)
A) Honey dressing

Participants

Interventions

B) Standard dressing (Povidone
Iodine/Normal saline, 1:10)
All patients received antibiotics and
ulcers debrided initially surgically
(debridement specimens were sent
for culture)
Wound dressing started on first
postoperative day by nurses and
reported as daily dressing changes.
The outcomes of interest for this
review were not reported in this
study.

Outcomes

The study reported the cost to buy a
bottle of commercial honey. The
study reported that a bottle of honey
could be used for the entire period
of study. No other information on
cost was provided on the standard
dressing.
Other outcomes reported include:

Notes

Time to healing for surgical closure
A) 14.4 days (7-26 days)
B) 15.4 days (9-36 days)
Statistically significant difference
(p<0.005)
The study reported all patients had
less pain in the honey group.
Risk of bias table
Bias
Random sequence generation
(selection bias)
Allocation concealment (selection
bias)

Authors' judgment
Low risk

Unclear risk
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Support for judgment
The authors report randomization.
Method of sequence generation not
specified.
Not reported.

Blinding participants
Blinding personnel delivering
intervention
Blinding outcome assessors

Unclear risk
Unclear risk

Not reported.
Not reported.

Low risk

Incomplete outcome data (attrition
bias)
Selective outcome reporting
(reporting bias)

Unclear risk

The study authors reported blinding
of outcome assessor.
Not reported.

Other Bias

Unclear risk

High risk

No protocol was reported in the
study. The outcomes reported in the
results section including wound
culture results and time to healing
for surgical wound closure was
reported in the methods section.
Cost was reported in the results
section but was not pre-specified in
the methods section.
No information on diabetes disease
severity such as Hgba1c or duration
of diabetes was reported.

Notes
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27. Singh 2006

Methods

Randomized clinical trial
Ulcers x-ray to exclude
Osteomyelitis
Duration: two weeks
First assessment at first day
of debridement and again at
day fourteen.
59 patients - 60 ulcers, 33M/27F,
DM type 1/2 = 5/55, mean age =
56.87 +/- 11.06 yrs.

Participants

A) 33, 5/28
B) 27 0/27
A) Non-contact Ultrasonic
debridement (24 KHz) performed
every other day

Interventions

B) Sharp/surgical debridement
conducted every other day
Outcomes

None of the outcomes of
interest for this systematic
review were reported in the
study.

Notes
Risk of bias table
Bias
Random sequence generation
(selection bias)

Authors' judgment
Low risk

Allocation concealment (selection
bias)
Blinding participants
Blinding personnel delivering
intervention

Unclear risk

Support for judgment
The study reports the subjects were
randomized into the two treatment
groups. The specific method of
sequence generation was not
specified.
Not reported

Unclear risk
Unclear risk

Not reported
Not reported

Blinding outcome assessors

Low risk

Incomplete outcome data (attrition
bias)
Selective outcome reporting
(reporting bias)

Unclear risk

The study reports that assessment
was done by two independent
observers who were blinded.
Not reported.

Low risk

No protocol was available or
reported in the study. The outcomes
reported in the results section were
pre-specified in the methods
section.
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Other Bias

Unclear risk

The authors did not report other
important risk factors for wound
healing including disease severity
and off-loading status.

Notes
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28. Tallis 2013

Methods

Randomized controlled
parallel group multicenter
open-label study
Duration 12 weeks, patients
seen weekly.
Wounds are measured with
length of long axis times
greatest width perpendicular
to long axis.
48 patients, 32M/16F, 61 +/- 11.8
yrs., 45 Caucasian 3 AA

Participants

A) 24, 16M/8F, 58.5 +/- 13.3 yrs.,
22 Caucasian 2 AA
B) 24 16M/8F, 63.5 +/- 9.8 yrs., 23
Caucasian 1 AA
No statistically significant
difference in demographics,
including race.
A) Clostridial Collagenase
Ointment (CCO)

Interventions

B) Saline Moistened Gauze (SMG)
+ Selective Sharp Debridement
Randomized to both groups after
baseline surgical debridement and
6.9 mean debridement in total for
the SMG group.
Outcomes

1) Direct mean costs per
responder
Physician office Wound
clinic facility
A) $832 $1607
B) $1042 $1980

Risk of bias table
Bias

Notes

Cost effectiveness analysis
was used.
.

Authors' judgment

Support for judgment
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Random sequence generation
(selection bias)
Allocation concealment (selection
bias)

Low risk

Blinding participants
Blinding personnel delivering
intervention

Unclear risk
Unclear risk

Blinding outcome assessors
Incomplete outcome data (attrition
bias)

Unclear risk
Low risk

Selective outcome reporting
(reporting bias)

Low risk

Other Bias

High risk

The study reports a computergenerated randomization sequence.
The study reports randomization
was centralized and for or each
qualified patient investigative sites
contacted the central call center for
the next sequential pre-determined
treatment assignment.
Not reported
Not reported

Low risk

Not reported
The study reports that 8 patients
discontinued the study. The authors
reported that an Intention to treat
analysis was used. Specifically, last
observation carried forward was
utilized for missing wound area
measurements at any of the weeks
resulting from wound healing, early
discontinuations, or for any other
reasons.
No protocol was available for
review or was reported in the study.
The outcomes reported in the
results section were pre-specified in
the methods section.
The study reports that a total of 23
patients (28 in the CCO group, and
33 in the SMG group) in the study
experienced 61 treatment-emergent
adverse events. The specific nature
of the events was not specified
other than the adverse events were
reported to be similar in the
treatment groups and unrelated to
the treatment.

Notes
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29. Vandeputte 1997

Methods

Pre-prepared randomization
listing
Study period was not
reported. Follow up period
was 12 weeks. Patients were
followed up every 4 weeks.
29 patients with 30 wounds
A) 15 patients (15 wounds)
B) 14 patients (15 wounds)
No description of age, sex or type
of diabetes.
Baseline wound area measurement
not reported.
A) Hydrogel
B) Dry gauze (control) includes
moistened gauze with antiseptic.

Participants

Interventions

Other ancillary wound care
measures not reported.
Outcomes

Complete Healing at 3
months
A) 14/15 (93%)
B) 7/14 (50%)
Infective complications
A) 1/15 (7%)
B) 7/14 (50%)
Amputations
A) 1/15
B) 5/14

Notes

Other outcomes reported
included:
Peri-ulcer maceration
A) 11.6%
B 22.1%
Low grade skin
reactions/allergies reported
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qualitatively in both groups,
no numerical data provided.

Risk of bias table
Bias
Random sequence generation
(selection bias)

Authors' judgment
Low risk

Allocation concealment (selection
bias)
Blinding participants

Unclear risk

Blinding personnel delivering
intervention
Blinding outcome assessors

Unclear risk

Incomplete outcome (attrition bias)

Unclear risk

Unclear risk

Support for judgment
Specific sequence generation
procedure was not reported:
"patients were allocated to
treatment groups according to a
pre-prepared randomization
listing".
Not reported.
Blinding of participants was unclear
in the report.
Blinding of personnel delivering
intervention was unclear.
Blinding of outcome assessors: no same nurses as personnel and
outcome assessors.

High risk

Lack of clarity concerning
patient deaths in control
group.
Methods and Results sections
report control group as n=14.
Results section states: "one
patient of the control group
died. One patient had a
wound on both legs. The
number of legs treated was 30
(15 in each group)".
Two deaths in the control
group are reported in the
'Overall healing time’ Table 5
in the Results section: '2 died during trial' in the
control group, although the
total participants remains
stated as n=14.

Selective outcome reporting
(reporting bias)

Low risk

Other Bias

High risk

Nine parameters were pre-specified
as outcomes, all of which were
reported.
Author had an affiliation with
wound product manufacturer.

Notes
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30. Whalley 2001

Methods

RCT Randomized into 2
comparison groups
Study period not reported,
follow up period was 10
weeks.
74 patients; (66 patients evaluated)
no further data were available
including how many patients
allocated to each group. Age 55.2
+/- 9.4
A) Purilon Hydrogel

Participants

Interventions

B) Intrasite Hydrogel using Biatain
Non-adhesive dressing (Coloplast
A/S) as a secondary dressing
Dressings changed at least every
second day
Outcomes

1. Complete healing at 10
weeks
A) 35% healed
B) 19% healed
No report of whether this was
a statistically significant
difference.
2. Change in mean wound
area
A) 2.5 cm2 (SD 3.2) to 0.6
cm2 (SD 1.1)
B) 2.4 cm2 (SD 2.9) to 1.0
cm2 (SD 1.8)
Offloading reported in both
groups.

Notes

Abstract only; limited data
Other outcomes reported
included:
Peri-ulcer maceration

296

A) 11.6%
B 22.1%
Low grade skin
reactions/allergies reported
qualitatively in both groups,
no numerical data provided.

Risk of bias table
Bias
Random sequence generation
(selection bias)

Authors' judgment
Low risk

Allocation concealment (selection
bias)
Blinding participants

Unclear risk

Blinding personnel delivering
intervention
Blinding outcome assessors

Unclear risk

Incomplete outcome data (attrition
bias)

Unclear risk

Selective outcome reporting
(reporting bias)
Other Bias

Unclear risk

Unclear risk

Unclear risk

Unclear risk

Notes
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Support for judgment
Published abstract only Randomization reported but method
of sequence generation not
reported.
Published abstract only - allocation
concealment not reported.
Published abstract only - allocation
concealment not reported.
Published abstract only - allocation
concealment not reported.
Published abstract only - allocation
concealment not reported.
Published abstract only incomplete outcome data were
reported but assessment and how
outcome data were addressed is not
discernible. "66 patients were
evaluable" from the 74 patients
recruited.
Published abstract only - selective
reporting not discernible.
Published abstract only - other bias
not discernible.

Characteristics of excluded studies
Abbruzzese 2009
Reason for exclusion

Both groups received debridement.

Abdelatif 2008
Reason for exclusion

Nonrandomized study

Aceechurovai 2003
Reason for exclusion

Nonrandomized study

Aftab 2010
Reason for exclusion

Soft tissue laser intervention in this study was not used
as a form of debridement.

Ahroni 1993
Reason for exclusion

Surgical debridement was reported as being carried out
routinely throughout study on both treatment arms.

Apelqvist 1994
Reason for exclusion

Varidase is used as a debriding agent but no separate
data were available for this group of patients. If such
data had been available, the size of the study (n=17) is
unlikely to be sufficiently powered.

Apelqvist 1996

Reason for exclusion

Authors report that both treatment groups received
surgical debridement performed during the course of the
study indicating that debridement was not the primary
focus of this study.
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Armstrong 2000
Reason for exclusion

Although all wounds were debrided the primary
intervention measured was a foot compression system,
there was no comparison or conclusions drawn regarding
the debridement methods used.

Ashry 1998
Reason for exclusion

Not an RCT on debrdement but a cost related archival
analysis on amputations among in diabetic minority
groups.

Bahrami 2008
Reason for exclusion

Intervention was not a form of debridement but an oral
herbal preparation.

Berry 1996
Reason for exclusion

Randomized study on the debridement of cavity wounds
not diabetic foot ulcers.

Biliaieva 2009
Reason for exclusion

This was a non-randomized study investigating
absorptive dressings.

Bowling 2007
Reason for exclusion

This was a non-randomized study - case series
investigating larval therapy.

Brenes 2011
Reason for exclusion

This was a non-randomized study - case series on
hyaluronate iodine.

Caputo 2009
Reason for exclusion

The study does not report outcomes separately for
diabetic and other wound types.
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Cardinal 2009
Reason for exclusion

Non-randomized retrospective study of healing rates as
predictors of complete wound closure.

Chan 2007
Reason for exclusion

Systematic review of Maggot debridement therapy not
RCT.

Chiglashvili 2004
Reason for exclusion

Non-randomized study - case series not on debridement
but IV infusion of complex medical regimen.

Clavel 2008
Reason for exclusion

Narrative review article on preventing amputations in
diabetics.

Davydov 20111
Reason for exclusion

Narrative review article on Larval therapy.

Dekhtiar 1995
Reason for exclusion

Non-randomized case series.

Dereure 2012
Reason for exclusion

RCT on Venous leg ulcers and Mixed etiology ulcers
using Hyaluronic acid.

Ennis 2005
Reason for exclusion

Study utilized another form of debridement in both
treatment arms.

Freeman 2010
Reason for exclusion

Non-randomized study of bee honey.
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Gelunenko 2000
Reason for exclusion

The intervention under study is an oral immune
modulating agent not a form of debridement.

Gottrup 2001
Reason for exclusion

This is a cost evaluation paper. Not an RCT.

Gough 1997
Reason for exclusion

RCT which compares granulocyte stimulating factor,
with a placebo. There is no debriding agent included in
the trial.

Graham 2014
Reason for exclusion

The study involved wounds of varying etiologies and
was a non-randomized case series study on Oakin
dressing.

Grayson 1994
Reason for exclusion

RCT assessing the effectiveness of Imipenem / Cilastatin
against ampicillin / Sulbactam in the treatment of pedal
infections in diabetic. No debriding agent was
considered.

Holtzer 1998
Reason for exclusion

This study was not an RCT but an archival data analysis.

Jan 2012
Reason for exclusion

This study was not an RCT but was reported as a quasiexperimental study.

Jude 2007
Reason for exclusion

Standardized surgical debridement was used regularly in
both treatment arms concurrently as part of standard
care.
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Jude 2004
Reason for exclusion

RCT of 120 people that compares silver based fiber
dressing with an alginate, alternate form of debridement
confounded both arms.

Kaviani 2011
Reason for exclusion

The laser therapy was not used here for debridement but
to stimulate growth. Debridement was carried out
separately.

Khramilin 2011
Reason for exclusion

Narrative review article not an RCT.

Krupski 1991
Reason for exclusion

RCT which compared platelet derived wound healing
with a placebo. Although all wounds were extensively
debrided initially, there were no debriding agents
included in the trial. The trial sample was 'mixed ulcers'
- with leg ulcers mainly identified.

Krymets 2013
Reason for exclusion

Non-randomized study not an RCT.

Kuo 2012
Reason for exclusion

Randomized study on the use of herbal botanical antiinflammatory creams. These herbal botanicals were not
used as a form of debridement.

Li 2006
Reason for exclusion

Growth factors as focus of RCT. (Debridement to aid
growth factor only).

Logachev 2001
Reason for exclusion

Nonrandomized study - Case series.
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Macleod 1991
Reason for exclusion

Not an RCT.

Martinez-de-Jesus 1997
Reason for exclusion

RCT where all foot ulcers underwent surgical
debridement and were then treated with either topical
Ketanserin or normal saline (placebo). Excluded as the
topical treatment, although gel based was compounded
by the fact that it contained Ketanserin gel.

Metha 1999
Reason for exclusion

Review article on cost using claims data.

Mohajeri 2014
Reason for exclusion

Though topical Kiwifruit possesses debridement
properties both treatment arms of the study were
subjected regularly to surgical debridement concurrently
throughout the study.

Moore 2011
Reason for exclusion

Systematic review on Silver dressings but in mixed
etiology wounds, not restricted to diabetic foot ulcers.

Moretti 2009
Reason for exclusion

Study on shock wave therapy which was not used for
debridement but for angiogenesis. Debridement was
conducted similarly in both groups.

Motley 2014
Reason for exclusion

Serial sharp debridement was carried out on both
treatment arms with and without enzymatic debridement.
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Mulder 1994a
Reason for exclusion

RCT comparing lamin gel with standard care and
vehicle gel. The lamin gel contains a peptide copper
complex, which has been shown to be a chemoattractant
for capillary endothelial cells and stimulates
angiogenesis. It is therefore not a debriding agent.

Mulder 2005
Reason for exclusion

RCT comparing lamin gel with standard care and
vehicle gel. The lamin gel contains a peptide copper
complex, which has been shown to be a chemoattractant
for capillary endothelial cells and stimulates
angiogenesis. It is therefore not a debriding agent.

Naidu 2005
Reason for exclusion

Study did not pertain to debridement but on off-loading
of callus.

Nielsen 2012
Reason for exclusion

Nonrandomized study on surgical wounds and not
specific to diabetic patients.

Oluwatosin 2000
Reason for exclusion

Intervention was not a comparison between forms of
debridement but included a comparison Phenytoin.

Pettican 2012
Reason for exclusion

This study was not an RCT but a Non-randomized study
on larval therapy, specifically a case series.
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Pollak 1997
Reason for exclusion

RCT which assesses the effectiveness of human dermis
replacement against conventional treatment. There is
initially sharp debridement, but there is no debriding
agent assessed in the trial.

Ramsey 1999
Reason for exclusion

Nonrandomized study on healthcare costs of foot ulcers
in diabetes.

Razzak 1997
Reason for exclusion

RCT including 24 patients, dividing patients into
treatment with either antibiotics or local insulin
application. No debriding agent was assessed in this
trial.

Ricci 2010
Reason for exclusion

Nonrandomized study on unspecified leg wounds.

Richard 2012
Reason for exclusion

Nonrandomized study on Immunomodulating NOSF
dressing.

Saap 2002
Reason for exclusion

Fulfills the inclusion criteria for RCT and diabetic foot
ulcers. The paper, however, is concerned with measuring
the standard of debridement and the effectiveness of a
debridement scale rather than the effectiveness of
debridement as a treatment.

Saied 2011
Reason for exclusion

RCT of low intensity laser therapy as biostimulation not
as a form of debridement.
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Sanchez 2006
Reason for exclusion

This was a retrospective non-randomized study on
collagen matrix.

Santra 2012
Reason for exclusion

The comparison in the study was not form of
debridement.

Schindl 1998
Reason for exclusion

RCT of Low intensity laser therapy for use as
biostimulation not a form of debridement.

Schindl 2002
Reason for exclusion

An RCT of Low intensity laser therapy for use as
biostimulation not a form of debridement.

Sedlarik 1969
Reason for exclusion

This is a Non-randomized study - case series.

Seidel 1994
Reason for exclusion

RCT which assess the use of short term retrograde
transvenous leg perfusion. The trial is concerned with
infection of foot ulcers; wound healing was not an
outcome.

Siavash 2015
Reason for exclusion

Though Royal Jelly could be considered a form of
autolytic debridement both treatment arms received a
regular form of debridement that was unspecified.

Singh 2004
Reason for exclusion

Systematic review on using hydrocolloids in chronic
wounds not strictly diabetic foot ulcers.

306

Solway 2011
Reason for exclusion

Non-randomized study. Sharp debridement was done on
both groups.

Soos 2003
Reason for exclusion

Narrative review article on diabetic foot ulcer
management.

Steed 1996
Reason for exclusion

RCT of 118 patients which compares treatment of
human-derived growth factor against a placebo. The
influence of debridement was evaluated by reviewing
the records of the trial. This paper was used in the
discussion section of this review.

Steenvoorde 2007
Reason for exclusion

Non-randomized study - prospective case series on
larval therapy.

Tennvall 2000
Reason for exclusion

Non-randomized study on cost of care in diabetics with
deep foot infections.

Van Acker 2000
Reason for exclusion

Costs for prevention and treatment of foot lesions in
diabetics in Belgium not on debridement.

Van Houtum 1995
Reason for exclusion

The study investigates cost of amputations in the
Netherlands not cost of debridement.

Varma 2006
Reason for exclusion

RCT undertaken on people whose wounds had already
been debrided, and the effectiveness of the post
debridement dressing was the focus of the trial.
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Wieman 1998
Reason for exclusion

RCT of 382 patients which assessed the efficacy and
safety of topically applied recombinant human platelet
derived growth factor at two strengths, either
Becaplermin 30 mg or Becaplermin 100 mg.

Wolff 2003
Reason for exclusion

Nonrandomized study - case series of larval therapy.

Reason for exclusion

Expert opinion narrative review not RCT.

Zgonis

Zimny 2008
Reason for exclusion

RCT of competing methods of off-loading including
felted foam dressing versus pressure
relief half-shoe. The debridement method was the same
in both groups.

Characteristics of studies awaiting classification
Callaghan 1993
Callaghan DP. Assessment of the effectiveness of Debrisan in healing ulceration on pressure
areas of diabetic patients' feet. In: 2nd European Conference on Advances in Wound
Management; 1992, 20-23 October; Harrogate, UK. 1993:82.

Dolynchuk 2001
Dolynchuk K. The use of collagenase in the debridement of diabetic foot ulcers: a double-blind
prospective randomized study. In: 7th Annual Conference of the Canadian Association of
Wound Care 1-3 November 2001 London, Ontario, Canada. 2001:56.

Mulder 1994b
Mulder GD, Jensen JL, Seeley JE, Peak Andrews K. A controlled randomized study of an
amorphous hydrogel to expedite closure of diabetic ulcers. In: 4th European Tissue Repair
Society Meeting; 1994, 25-28 August; Oxford, England. 1994:130 (Abstract 90).
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Characteristics of ongoing studies
Michaeldis 2014
Michailidis L, Williams CM, Bergin SM, Haines TP. Comparison of healing rate in diabetesrelated foot ulcers with low frequency ultrasonic debridement versus non-surgical sharps
debridement: a randomized trial protocol. Journal of foot and ankle research. 2014;7(11):1 - 10.
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Additional tables
Table 1 of Descriptive Statistics
Total number of
30
studies
Total number of
2564
participants
Sample size range
18 to 619
Average sample size
152
per study
Total Range of follow
10 days to 24 weeks
up
Total Study period or
1992 - 2012
duration
Studies reporting age
24/30 (70%)
Mean age (range)
52.1 – 69.3 years
Total number of
21/30 (70%)
studies reporting
gender
Range of number of
12 to 240
males
Range of number of
1 to 88
females
Number of studies
5/30 (16.7%)
reporting ethnicity
Number of studies
1/30 (3.3%)
reporting
socioeconomic status
Geographic setting
Europe and US (70%)
Publication Language
English 93%
Hospital 8/30 (26.7%)
Healthcare setting
Outpatient 17/30
(56.7%)

Studies reporting
wound size (area)
Studies reporting
wound duration
Studies reporting
Hemoglobin a1c
(Hgba1c)
Hgba1c (range)
Studies reporting on
duration of diabetes
Duration of diabetes
(range)
Studies reporting
baseline peripheral
arterial insufficiency
Studies reporting BMI

Both 2/30 (6.7%)
20/30 (67%)
14/30 (70%)
8/30 (26.7%)

7.25% - 9.25%
14/30 (70%)
13 to 21 years
9/30 (30%)

5/30 (16.7%)
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Table 2 IWGDF 2012 (Reproduced here with permission from the IWGDF)
Costs of Treating Foot Ulcers and Amputations
Reference
Country
Number
Costs
USD 2005 Comments
of
(year of
equivalent
Patients
costing)
Ulcers not requiring amputation
Apelqvist et al, Sweden
197
Sweden
8,654
All ulcer types; total
1994
197 SEK
51,000

Harrington, et
al, 2000

Holzer et al,
1998

Metha et al,
1999

USA

USA

USA

400,000

1846 c

5149

(1990)
USA
400,000
USD
3,999-6
(1996)
USD
1,929
(1992)
USA
5149
USD

4,9827,821

Inpatient and
outpatient costs

2,695

1,1503,322

Inpatient and
outpatient costs, those
>64 yr. excluded
Private insurance
charges; mean age 51
yr.

900-2,600

Ragnarson
Tennvall et al,
2000

Ramsey et al,
1999

Van Acker et al
2000

Sweden

USA

Belgium

88

514 d

120

(1995)
Sweden
88 SEK
136,600
(1997)
USD
27,987
(1995)
Belgium
120 USD
5,227
(1993)

Costs of lower extremity amputations
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18,719

Deep foot infection;
total direct costs

35,758

Including 2 yr. after
diagnosis

7,039

Inpatient and
outpatient costs

Apelqvist et al
1994

Apelqvist et al
1994

Sweden

Sweden

27

50

Sweden
27 SEK
258,000
(1990)
Sweden
50 SEK
390,000

43,778

All ulcer types; minor
LEA; total direct
costs

66,176

All ulcer types; major
LEA; total direct
Costs

Ashry et al 1998 USA

Holzer et al,
1998

van Houtum et
al, 1995

USA

Netherlands

Panayiotopoulos UK
et al, 1997

5062

(1990)
USA
5062
USD
27,930

39,891

Hospital charges
Only

504 c

(1991)
USD
15,792

22,062

Gangrene/amputation,
those >64 yr.
excluded

1575 e

(1992)
NLG
28,433

19,052

Hospital costs only

33,587

Inpatient and
prostheses costs

20

(1992)
UK 20
GBP
15,500

(46% diabetics)
Ragnarson
Tennvall

Sweden

77

(1994-95)
Sweden
77 SEK
261,000

35,767

Deep infection;
minor LEA; total

et al, 2000
Ragnarson
Tennvall

Sweden

19

Belgium

7

(1997)
Sweden
19 SEK
234,500

32,136

direct costs
Deep infection; major
LEA; total direct
costs

et al, 2000
Van Acker et al,
2000

(1997)
Belgium
7 USD
18,515
(1993)
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24,933

Inpatient and
outpatient costs;
minor LEA

Van Acker et al,

Belgium

9

2000

Belgium
9 USD
41,984

56,538

Inpatient and
outpatient costs;
major LEA

(1993)
Footnotes
For comparison of the results, costs were first adjusted for inflation to 2005 prices with the
consumer price index f and then converted to USD with the appropriate currency exchange
rate for 2005.
NA = not applicable.
LEA = Lower Extremity Amputation.
Minor = amputation below the ankle;
Major = amputation above the ankle.
a Based on data from observational studies
b Based on data from databases and other secondary sources
c Number of episodes
d Includes 80 amputations
e Number of hospitalizations
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Table 3 Wagner Wound Grade Classification System
Grade
0
1
2
3

No ulcer in a
high risk foot

Wound
involving full
skin thickness

Wound
extending to
ligament and
muscle

4

Wound with
cellulitis or
abscess

Localized Extensive
gangrene gangrene
involving
the whole
foot

Table 4 University of Texas Wound Classification System
Grade
Stage
0
1
2
Pre or Post
ulcerative lesion
completely
epithelialized

5

3

A

0A

Superficial
wound not
involving
tendon, muscle,
or bone
1A

No Infection, or
Ischemia
B

0B

1B

2B

3B

Infection but no
ischemia
C

0C

1C

2C

3C

Ischemia but no
infection
D

0D

1D

2D

3D

Infection and
ischemia are
present
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Wound
penetrating to
tendon or
capsule

Wound
penetrating to
bone or joint

2A

3A

Table 5 Methods of debridement
Debridement
Method
Mechanical
Surgical
(scalpel)

Wet-to dry

Aqueous High
Pressure
Lavage or
Irrigation

Low frequency
Ultrasound

Bio-Surgery
Maggot
Debridement
therapy
(larva, maggots)

Explanation

Advantages

Disadvantages

The technique is considered a rapid means of
debriding a wound, requiring the use of sterile
scissors, a scalpel, or curette, it does require a
certain amount of skill and may slightly
enlarge the wound.

Allows rapid
removal of
devitalized
tissue.

Can be complicated by infection,
and bleeding.

The wound is soaked in saline to moisten the
hardened wound material before the
application of a moist gauze pad is placed over
the affected area. As both the gauze and
wound tissue dry, the wound tissue and gauze
adhere to each other. When the dressing is
removed it non-selectively pulls off the
tissues.

Allows rapid
removal of
hardened
devitalized tissue

It is not discriminating/nonselective and may remove healing
granulation tissue. It also may be
painful for the patient.

This involves a pressurized stream of aqueous
solution such as saline to mechanically
dislodge devitalized tissue from a wound.
Whirlpool is also a form of lavage irrigation
that is carried out with the affected wound
immersed in the solution.

Allows for rapid
removal of
devitalized
tissue.

This process uses sound waves through a
contact or noncontact form of transducer to
dislodge devitalized tissue.

Permits a rapid
removal of
devitalized
tissue.

Sterile maggots of the green bottle fly Lucilia
sericata are placed directly on to the wound
(loose) and covered by a dressing, or held
within a closed net dressing against the wound
(bagged). The larvae have a ferocious appetite
for necrotic material while actively avoiding
newly formed healthy tissue. They also use
enzymes to digest devitalized tissue and are
believed to secrete antimicrobial and tissuegrowth promoting substances. Therefore, they
are considered a complete system of wound
care.
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Expensive

Inexpensive

They
discriminate
between the
nonviable and
the viable
granulating
tissue.

It is non-selective and can dislodge
healing granulation tissue.
This procedure may be painful.
Cross contamination and infection is
possible.
Nonselective and can remove
healthy granulation tissue.
Cost implication
Aerosolizing pathogens
There is at present no conclusive
evidence of effectiveness in foot
ulcers, there may also be a
reluctance to use this treatment by
patients and clinicians. There is a
cost implication but other treatments
discussed above may be costlier.

Debridement
Method
Non-Mechanical
These treatments
are easy to apply
and have
additional
properties that may
be beneficial for
wound healing
Enzyme
Preparations

Non-Mechanical
Primarily
facilitating
Autolytic
Debridement
Hydrogels

Alginates

Hydrocolloids

Explanation

Advantages

The only formulation available in the
UK contains Streptokinase and
Streptodornase. This enzyme digests the
proteins fibrin, collagen & elastin, which
are commonly found in the necrotic
exudate of a wound. This includes the
enzymes Matrix Metalloproteinases
contained within the wound and
promoting auto-digestion or selfdigestion of the wound. Other enzymatic
preparations include trypsin and
collagenase, are licensed in other
countries including the U.S.

They can be applied
directly onto the
necrotic area.

These gels are biologically inert and
have significant water content. They
complement the body's natural debriding
process by providing a moist
environment, which promotes autolytic
debridement, while still acting to
preserve living healthy tissue. (Bradley
1999)

Can be applied to a
wound at any stage,
promotes moist wound
healing and autolytic
debridement. Minimal
level of skill required.

These are absorbent, biodegradable
dressings derived from seaweed. The
high absorptivity is due to the
hydrophilic gel formation that is formed
when in contact with wounds. Alginate
dressings are used for moderate to
heavily exudating wounds

Widely available in a
wide variety of
healthcare settings and
can be applied to a
wound at any stage,
promotes moist wound
healing and autolytic
debridement. Minimal
level of skill required.
Not associated with pain
as mechanical forms of
debridement may be.
Can be applied to a
wound at any stage,
promotes moist wound
healing and autolytic
debridement. Minimal
level of skill required.
Not associated with pain
as mechanical forms of
debridement may be.

Hydrocolloids contain gel-forming
substances, such as sodium
carboxymethylcellulose (NaCMC) and
gelatin. They can be combined with
elastomers and adhesives and associated
with a carrier such as polyurethane foam
or film dressing. The result is an
absorbent, self-adhesive, waterproof
adherent dressing. When they contact
wound exudate, hydrocolloids are
hydrophilic and form a gel.
Hydrocolloids are impermeable to water
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Nonpainful

Disadvantages

Streptokinase can be
systemically
absorbed and is
therefore
contraindicated in
patients at risk of an
MI. There is a cost
implication.

Promotes a slow
process of
debridement.
If the surrounding
skin is not masked
properly they may
macerate the
surrounding tissue.
Promotes a slow
process of
debridement.
If the surrounding
skin is not masked
properly they may
macerate the
surrounding tissue.
Cost factor.
Promotes a slow
process of
debridement.
If the surrounding
skin is not masked
properly they may
macerate the
surrounding tissue.
Cost Factor

Foam

Film

Honey

Saline gauze

vapor initially but subsequently become
more permeable.
These are absorbent dressings made
from a hydrophilic polyurethane foam.
Foams can absorb exudate absorbing it
from the wound and can decrease
maceration to the surrounding tissue.
The direct contact between the foam and
the wound will maintain a moist wound
environment. Used for exudative
wounds.

Film dressings are made of thin
polyurethane membrane coated with a
layer of acrylic adhesive. They are
flexible and allow direct visualization of
the wound without always needing to
remove the dressing. They do not absorb
wound exudate.

Honey provides an osmotic hydrophilic
environment that allows the rehydration
of devitalized tissue, among other
benefits.

Moist saline gauze is often widely
utilized and can potentially serve as a
control or standard form of debridement.

Can be applied to a
wound at any stage,
promotes moist wound
healing and autolytic
debridement. Minimal
level of skill required.
Not associated with pain
as mechanical forms of
debridement may be.

They are believed to
limit friction and
shearing forces that may
be more common with
other dressings. Film
dressings should not be
used for infected, deep,
or significantly
exudative wounds.
Can be applied to a
wound at any stage,
promotes moist wound
healing and autolytic
debridement. Minimal
level of skill required.
Not associated with pain
as mechanical forms of
debridement may be.
Can be applied to a
wound at any stage,
promotes moist wound
healing and autolytic
debridement. Minimal
level of skill required.
Not associated with pain
as mechanical forms of
debridement may be.

Can be applied to a
wound at any stage,
promotes moist wound
healing and autolytic
debridement as long as
it is kept from drying
Minimal level of skill
required.
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Promotes a slow
process of
debridement.
If the surrounding
skin is not masked
properly they may
macerate the
surrounding tissue.
Cost factor
Promotes a slow
process of
debridement.
If the surrounding
skin is not masked
properly they may
macerate the
surrounding tissue.
Cost factor

Promotes a slow
process of
debridement.
If the surrounding
skin is not masked
properly they may
macerate the
surrounding tissue.
Cost factor
Promotes a slow
process of
debridement.
If the surrounding
skin is not masked
properly they may
macerate the
surrounding tissue.

Table 7 Study year, sample sizes and study settings of included studies
#

1

[Study ID]

Ali 2013

Year

2013

[Total
Sample
Size]

[Primary Intervention]
(# patients preceding)

[Comparator/Control] (#
patients preceding)

A) Cutimed Sorbact

B) Standard Dressing
(Saline cleansed
povidone soaked gauze
dressing)

70

Study Setting

Country

Hospital

Saudi
Arabia

Clinic

Iran

Outpatient

Sweden

Clinic

Unclear

Unclear

Italy

Unclear

US

35 patients
35 patients

2

Amini 2013

2013

40

A) Low frequency (2060kHz) ultrasound
assisted wound therapy
+ standard wound care

B) Standard wound care
alone
20 patients

20 patients
A) Hydrococolloid
3

Apelqvist 1990

1990

44
22 patients

4

Baker 1993

1993

19

A) Allevyn
Hydrocellular dressing
? patients

5

Belcaro 2010

2010

66

A) Multivalent silver
oxide Ag4O4 ointment
+ elastic compression

B) Adhesive Zinc Oxide
tape
22 Patients
B) Sorbsan CalciumAlginate dressings
? patients
B) Control group
(standard cleaning and
elastic compression
management methods
without silver ointment)

34 patients
A) Polymeric dressing
6

Blackman 1994

1994

18
11 patients

7

Bowling 2011

2011

20

A) Jet lavage
debridement with
superoxide aqueous
solution + hydrogel

32 patients
B) Wet to dry saline
dressing
7 Patients
B) Jet lavage
debridement with saline
solution + hydrogel

Hospital,
US, UK
Outpatient

8

Clever 1995

1995

40

10 patients
A) Hydroactive
polyurethane gel
dressing Cutinova
Hydro + standard
therapy*
20 patients
A) Good wound care +

9

10

D'Hemeourt 1998

Donaghue 1998

1998

1998

138

75

Sodium
Carboxymethylcelluose
Hydrogel
70 patients
A) Collagen Alginate
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10 patients
B) Hydrophilic
polyurethane foam
dressing Allevyn +
standard therapy*

Outpatient

Germany

Unclear

USA

Outpatients

USA

20 patients

B) Good wound care*
alone
68 patients
B) Saline gauze

50 patients

11

EhsanUrRehman
2013

2013

60

A) Honey soaked
dressing
? patients

12

13

Foster 1994

Goretti 2008

1994

2008

Hammouri 2004

2004

30

40

15 patients
A) Super-oxidized
solution (SOS)
treatment

203

Hospital, ED

Pakistan

Outpatient

UK

Hospital

Italy

Hospital

Jordan

? patients

A) Hydrocellular
polyurethane foam
dressing Allevyn

20 patients

14

25 patients
B) Povidoneiodine/normal saline
dressing

A) Honey/Normal
Saline, washed with
normal saline postdebridement
100 patients

B) Calcium sodium
alginate dressing
15 patients
B) Standard local
treatment with povidone
iodine
20 patients
B) Povidone
Iodine/H2O2 (3:1)
washed with same
solution postdebridement
100 patients

A) Hydrofiber
Multidisciplinary
15

Jeffcoate 2009

2009

103 patients

C) Gauze

B) Iodine Gauze

106 patients

Outpatient
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UK

9 centers

16

Jensen 1998

1998

31

108 patients
A) Carrasyn hydrogel
wound dressing
(CHWD) cleansed with
ULTRAKLENZ
wound cleanser.
14 patients
A) Calcium Alginate

17

18

Lalau 2002

Markevich 2000

2002

1998

B) Wet-to-moist saline
gauze cleansed with
ULTRAKLENZ wound
cleanser

140

USA

Outpatients

France

Unclear

Europe

Outpatient

USA

17 patients
B) Vaseline Gauze

77
39 patients
A) Larval therapy
(green bottle fly Lucilia sericata 6-10
larva per 1 cm2 of
wound surface area)
removed after 72 hours

Outpatient

38 patients
B) Hydrogel (no data on
frequency of dressing
change)
70 patients

19

Mazzone 1993

1993

19

70 patients
A) Polymeric
membrane foam
dressing
11 patients

20

Munter 2006

2006

619

A) Silver releasing
hydrophilic
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B) Wet to Dry saline
gauze mesh dressing
8 patients
B) Local Best Practice
(study reports that this
ranged from gauze,
moist wound healing,
wound healing products,

Germany
Outpatient

UK

polyurethane foam
dressing

to antimicrobial
treatments)

326 patients

293 patients

Denmark
Italy
Switzerland
Belgium
Slovenia
Brazil
Canada

21

Ogce 2007

2007

60

A) Hydrocolloid
dressing (combined
with paste for wound
cavities, and powder
for infection)

B) Classic wound
dressing

Hospital

Turkey

Outpatient

Italy

Outpatient

Italy

Hospital

Tunisia

40 patients
B) Saline soaked (low
adherent) dressing and
standard podiatric care

Hospital

UK

16 patients
B) Standard dressing
(Povidone
Iodine/Normal saline,
1:10)

Hospital

Malaysia

30 patients

22

Piaggesi 2001

2001

24

30 patients
A) Sodium CarboxyMethyl Cellulose
Hydrofiber (Aquacel)
changed every 2nd or
3rd day depending on
extent of exudate
produced by wound.

B) Saline moistened
gauze (renewed twice
daily with saline to
prevent drying)
10 patients

10 patients

23

Piaggesi 1998

1998

46

A) Treatment Surgical debridement

B) Control - Nonsurgical conservative
treatment and pressure
relief

22 patients
24 patients
B) G2: cleaning ulcers
with hydrogen peroxide
3% + antibiotic-therapy

24

Rhaiem 1998

1998

80

A) G1: cleaning ulcers
with hydrogen
peroxide 3% + local
applied Jam sugar
16 patients

25

Roberts 2001

2001

30

A) Allevyn
hydrocellular foam
dressing
14 patients
A) Honey dressing

26

Shukrimi 2008

2008

30

24 patients
C) G3: cleaning ulcers
with hydrogen peroxide
3% + antibiotic-therapy

? patients
? patients
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27

Singh 2006

2006

60

A) Non-contact
Ultrasonic debridement
(24 KHz) performed
every other day
33 patients

28

Tallis 2013

2013

48

A) Clostridial
Collagenase Ointment
(CCO)
24 patients
A) Hydrogel

29

Vandeputte 1997

1997

A) Purilon Hydrogel
Whalley 2001

2001

66
? patients

B) Saline Moistened
Gauze (SMG) +
Selective Sharp
Debridement
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Malaysia

Outpatient

USA

Outpatient

Belgium

Unclear

Europe

24 patients
B) Dry gauze (control)
14 patients
B) Intrasite Hydrogel
using Biatain Nonadhesive dressing
(Coloplast A/S) as a
secondary dressing
Dressings changed at
least every second day
? patients

Footnotes: G1 = Group 1, G2 = Group 2

Hospital

27 patients

29
15 patients

30

B) Sharp/surgical
debridement conducted
every other day

Table 8 Inclusion & exclusion criteria for included studies
Trial Author
1) Ali 2013
2) Amini 2013

3) Apelqvist 1990

Inclusion Criteria
1) Texas 2nd grade diabetic foot ulcer
1) Diabetes (type 1 and type 2)

Exclusion Criteria
Not reported.
1) 0.6 </= ABI* </= 1.2

2) Diabetic foot ulcer

(*Ankle Brachial Index)

3) Wagner Grade 3 chronic (>1 month)
1) Previous diabetes mellitus

1) Patch test positive individuals.

2) Superficial skin ulcer below the ankle

2) Clinical signs of cellulitis.

3) Systolic toe pressure > 45 mmHg or an
absence of cutaneous erythema.

3) Ulcers where application of intervention
dressings would be inappropriate.

4) Ulcers between 1 - 25 cm2 and > 50%
covered by dry or wet necrotic tissue.

4) Baker 1993

5) Belcaro 2010
6) Blackman 1994

5) Only one ulcer the largest was chosen for
study in each patient.
1) Patients with neuropathic foot ulcer in a
diabetic foot center
Type of DM unspecified
1) Patients who had ulcers resulting from
chronic venous insufficiency or diabetes
1) Diabetes Type 1 or Type 2
2) Partial or full thickness open wound or foot
ulcer free; free of hard eschar

Not reported

Not reported.
1) Ulcers with Wagner stage 3 or higher
2) Ulcers progressing to Wagner stage 3 or higher
3) Subjects needing vascular surgery
4) Ulcers from Charcot joints

7) Bowling 2011

1) Type 1 or Type 2 DM

5) Ulcers of non-diabetic origin
1) Ulcers larger than 25 cm2

2) Foot ulcer, full thickness, distal to malleoli

2) Texas Classification grade 3

2) Chronic > 4 weeks

3) Osteomyelitis

3) Non-clinically infected foot ulcers

4) Peripheral arterial disease (ABI < 0.8/absent
pulses.

4) Necrotic tissue present and mechanical
debridement indicated.

5) Prescription use of anticoagulants,
immunosuppressive drug treatment

5) One ulcer per patient included
6) Allergies to chlorine
7) Clinically infected wounds excluded on
grounds of antibiotic use.
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8) Clever 1995

1) Age 18 - 80 years

Diabetics with an ankle-brachial pressure
index < 0.8 (measured using Doppler ultrasound)

2) Pure neuropathic superficial ulcer 1-5 cm in
diameter

Clinical or radiological signs of osteomyelitis or
tendon
involvement.
Large vessel disease
Ulcers requiring additional topical treatment

9) D'Hemecourt
(1998): written
consent needed

Known allergies to any product used
1) Osteomyelitis affecting area of ulcer

1) 19 years or older

2) Target area < 1cm2 OR > 10 cm2 postdebridement

2) Type 1 or type 2 diabetes
3) At least 1 full thickness ulcer (stage 3 or 4)
chronic diabetic foot ulcer present for at least
8 weeks.
4) Target area (Length x Width) 1cm2-10cm2
post debridement 5) Transcutaneous oximetry
in the affected limb (TcpO2) >/= 30 mmHg

3) More than 3 ulcers present at baseline
4) A cause of ulcer other than diabetes e.g.
electrical, chemical or radiation
5) Patients with cancer at time of enrollment
6) Concomitant medication known to affect
wound healing e.g. corticosteroids, chemotherapy,
immunosuppressant’s

10) Donaghue 1998

1) At least 21 years of age

7) Pregnant, nursing or of child bearing potential
not using acceptable contraception.
1) Severe renal impairment (creatinine >)

2) Adequate nutritional intake (albumin > 2.5
gms/dl)

2) Severe liver impairment (liver function tests
>/= 2 times normal levels.

3) Adequate blood flow to lower extremity
(palpable pulses, normal noninvasive tests)

3) Serious medical disorder that can interfere with
wound healing.

4) Foot ulceration at least 1 cm2 postdebridement.

4) Osteomyelitis (deep ulcer probing to bone, or
radiographic evidence)
5) Clinical signs of infection

11) EhsanUrRehman
2013

12) Foster 1994

1) Diabetic patients of either gender

6) History of alcohol or drug abuse.
1) Nonconsenting patients

2) All age groups

2) Systemic infection and other comorbidities

3) Diabetic foot ulcers Wagner grade I & II
1) At least 18 years’ old

1) Slough, necrotic, or infected ulcer

2) A clean diabetic foot ulcer
3) Willing and able to comply with study
protocol
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13) Goretti (2008)

1) Infected foot lesions post-surgical
debridement

Not reported

2) surgical outcomes > 5 cm2
3) ankle-brachial index > 0.9,

14) Hammouri 2004
15) Jeffcoate 2009

4) presence of at least two arteries in the ankle
documented by palpable pulses or Doppler
CW
1) Diabetic foot ulcers
1) Type 1 and type 2 Diabetes

Not reported
1) Known allergy to treatment preparations

2) Age > 18 yrs.

2) Ulcer extending to tendon, periosteum, or bone

3) Chronic (>/= 6 weeks) full thickness foot
ulcer on or below malleoli

3) Osteomyelitis

4) Cross sectional area 25 mm2 - 2500 mm2
5) Able and willing to give informed consent

4) Soft tissue infection requiring systemic
antibiotics
5) Ulcer on a limb being considered for
revascularization

6) Reasonably accessible by car to the hospital
6) Management with a non-removable cast
without a dressing window.
7) Gangrene on affected foot
8) Eschar not removable by clinical debridement
9) Sinus or deep track
10) Hallux amputation preventing toe pressure
measurement
11) ABI < 0.7 or toe systolic pressure < 30 mmHg
12) Ulceration by disease other than diabetes
13) Any other serious disease likely to
compromise outcome
14) Cr > 300 µMol/L
15) Immunosuppressant’s, systemic steroids other
than inhalation, or any other preparation that could
interfere with healing.
16) Living > 10 miles from clinic

16) Jensen (1997):
written consent needed

1) Diabetic foot ulcer of at least 1cm diameter
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17) Those withholding consent
No exclusion criteria specified

2) No evidence of infection in ulcer or periwound tissue
3) Wagner grade 2 ulcer, full thickness into
subcutaneous tissue, not involving tendon,
joint capsule, or bone
4) Documented blood supply consistent with
the ability to heal (palpable pulses, noninvasive vascular study)

17) Lalau 2002

5) Willingness to comply with protocol.
1) Age < 75 yrs.
2) Diabetes either Type 1 or Type 2
3) Foot lesion in the phase of cleansing
(granulation tissue < 50% for wound area)

1) Hgba1c > 10%
2) Presence of clinical infection (redness,
swelling, warmth, periwound erythema)
3) Osteomyelitis (on plain radiography, or probing
of bone)

4) Surface area between 1 - 50 cm2.
4) Tunneled wound
Acute (< 2 months) and Chronic lesions
cm2

18) Markevich (2000)
19) Mazzone 1993

2) Surface area of 1 - 50
Diabetic Neuropathic Foot wounds
1) Diabetic subjects with chronic foot ulcers

5) Severe hypo-vascularization (TcPO2 <
30mmHg)
No exclusion criteria specified
No exclusion criteria specified.

Type of DM unspecified.

20) Munter

No other inclusion criteria pre-specified.
1) 18 years or older

Not reported

2) Not pregnant or lactating
3) Chronic wounds
4) Mixed etiology wounds including: burns,
donor sites, post-operative wounds, but most
reported as leg ulcers, pressure ulcers, and
Diabetic foot ulcers (Wagner grade 1 - 3)

21) Ogce 2007

22) Piagessi 2001

5) Ulcer depth < 0.5 cm
1) Type 1 or Type 2 Diabetes

Not reported

2) Wagner grade 2 or grade 3 diabetic foot
ulcers
1) All patients presenting to foot clinic in
1998
2) Age 18 - 75

1) Active infection: Local signs (purulent
discharge, redness, swelling, tenderness or odor)
OR systemic signs (fever, malaise, leukocytosis) +
confirmed culture exams

3) Type 1 or Type 2 diabetes > 5 years

2) Plasma creatinine > 2 mg/dl

4) Ulcer deeper than 1 cm for 3 weeks

3) Recent episode of ketoacidosis
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23) Piaggesi (1998)

5) Palpable peripheral pulses or ABPI > 0.9

4) Malignancies

6) Ulcers due to diabetic neuropathy or
surgical drainage of previous infection or
both.

5) Any therapy of pathology that might interfere
with healing process

1) All patients newly presenting to the
diabetic foot clinic between January December 1995

6) Candidates for a major amputation
1) Presence of symptomatic claudication OR
absence of foot pulses
2) Recent ketoacidosis

2) One or more diabetic neuropathic ulcer
3) Renal Failure Cr > 177 micromole/L
3) Diabetes type 1, type 2, at least 5 years
duration uncomplicated.

4) Presence of Infection
5) Congenital foot deformities or diabetic
neuroarthropathy
6) BMI > 30
7) Clinical history of stroke, cardiac failure,
cancer, HIV, Mental Illness
8) ABPI < 0.9

24) Rhaiem 1998
25) Roberts 2001

26) Shukrimi 2008

1) Diabetic hospitalized patients from 1992 1995
1) Type 1 diabetics with neuropathic foot
ulcers of the plantar surface.
No other inclusion criteria pre-specified.
1) All NIDDM patients with Wagner grade II
ulcers admitted for surgery.

9) Osteomyelitis
Not reported
ABPI < 0.8 No exclusion criteria specified.

1) Multiple medical comorbidity
2) Steroid therapy

2) Age 35 - 65
3) Neutrophil count < 2000/mm3
3) TcPO2 > 30 mmHg

27) Singh 2006

4) Albumin > 35 g/dl
1) Diabetic foot ulcers admitted to orthopedic
wards.

1) Wagner grade 3 or grade 4 diabetic foot ulcers
2) Ulcers covered with hard scab

2) Wagner type 1 and type 2
3) Peripheral neuropathy based on modified NDS
3) Known cases of DM Type 1 or Type 2
treated medically
4) Glycemic control during hospitalization
with insulin.
5) Sensate feet based on Modified
Neuropathic Disability Score (NDS)
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4) Patients without at least one of the foot pulses
palpable (dorsalis pedis or posterior tibial)

28) Tallis 2013

6) At least one of the foot pulses palpable
(dorsalis pedis or posterior tibial arteries)
1) 18 yrs. or older, any race, either sex

Not reported

2) Type 1 or Type 2 DM requiring diabetic
medications.
3) Full thickness neuropathic ulcers between
0.5 cm2 - 10 cm2
4) Ulcer duration 1 month
5) Willing and able to perform daily dressing
changes at home.
6) Willing and able to use off-loading
7) Adequate perfusion to target foot ulcer
(TcPO2 > 40 mmHg, or toe pressure > 40
mmHg or Doppler waveform consistent with
adequate flow)
8) Adequate nutrition (albumin >/= 2.0 g/dL
and pre-albumin > 15 mg/dL)
9) No active infection
10) No target wound tunneling

29) Vandeputte
(1997): written
consent needed
30) Whalley (2001)

11) Target could not be on heel or over a
Charcot deformity
Diabetic wound on foot

Patient receiving systemic antibiotics

1) Diabetic neuropathic foot ulcer

No exclusion criteria specified

2) Type 1 and Type 2 Diabetics

Foot notes
TcPo2 – Transcutaneous oximetry in mmHg
ABI – Ankle Brachial Index
Hga1c = Hemoglobin a1c
BMI – Body Mass Index
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Table 9 Patient demographics for Included studies
# [Study ID]
[Mean Age yrs. +/- SD]
1 Ali 2013
Not reported
2 Amini 2013
55.2 +/- 9.4
3 Apelqvist 1990
63 +/- 36
4 Baker 1993
Not reported
5 Belcaro 2010
55.9 +/- 3.8
6 Blackman 1994
55.9 +/- 13.6
7 Bowling 2011
53.1 +/- 12.6
8 Clever 1995
56 +/- 13.13
9 D'Hemeourt 1998
58.3 +/- 12.13
10 Donaghue 1998
59.5
11 EhsanUrRehman 2013 55.3 +/- 3.89
12 Foster 1994
65.5
13 Goretti 2008
Not reported
14 HammouriJRMS2004 58
15 Jeffcoate 2009
59.6 +/- 12.6
16 Jensen 1998
Not reported
17 Lalau 2002
62.2 +/- 11.75
18 Markevich 2000
53.6 +/- 15.4
19 Mazzone 1993
Not reported
20 Munter 2006
69.3 +/- 13.90
21 Ogce 2007
59.85
22 Piaggesi 2001
62.2 +/- 6.05
23 Piaggesi 1998
64.39 +/- 11.67
24 Rhaiem 1998
56 +/- 32
25 Roberts 2001
59.5 Median
26 Shukrimi 2008
52.1
27 Singh 2006
56.87 +/- 11/06
28 Tallis 2013
61 +/- 11.8
29 Vandeputte 1997
63.95 +/- 14.5
30 Whalley 2001
Not reported
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[Gender M/F]
48/22
24/16
26/20
Not reported
29/37
17/1
12/8
32/8
127/45
54/21
35/25
20/10
Not reported
112/88
240/76
Not reported
45/32
Not reported
Not reported
Not reported
36/24
Not reported
Not reported
59/21
23/7
15/15
33/27
32/16
13/16
Not reported

Table 10 Baseline wound size and duration characteristics of included studies
Surface Area of
Depth of wound
Wound Staging
Duration of ulcer
wound **
**
**
(Wagner Wound
** Expressed as
Grade 0 - 5 OR Texas
means +/- SD unless
classification 1 - 3, A,
otherwise noted
B, C, or D)

1) Ali 2013

Reported only as:

(Staging indicates
maximum stage or
grade accepted for
study.)
Texas 1A -> 2D

Reported as:

< 3 cm 3+ cm

(Texas 2D)

< 4 cm2 4+ cm2

A) 0 35

Mean duration of
foot ulcers = 9
weeks (1 - 105)

A) 0 35

B) 19 16

B) 8 27
2) Amini 2013

Not reported

Wagner Grade 3

A) 3.4 +/- 3.5
months

Total Sample

A) 6.8 +/- 6 cm2
(15.6 +/- 16.8
weeks)

B) 9.9 +/- 7.6 cm2

B) 4.4 +/- 4.7
months

Not reported

Not reported

(17.6 +/- 18.8
weeks)
Not reported

B) median 2.2 cm2 (0.9
- 20.4)
4) Baker 1993

Not reported

Not reported

Not reported

No baseline data
reported.
5) Belcaro 2010

Not reported

Not reported

Not reported

3) Apelqvist 1990
A) median 2.2 cm2 (1 10.5)
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Baseline at 4 weeks
A) 2.22 cm2 0.24 cm2
B) 2.18 cm2 1.66 cm2
p<0.05 statistically
significant difference
6) Blackman 1994

Not reported.

A) 2.67 +/- 1.20 cm2

Wagner Grade 1-2

A) 25 +/- 7 weeks

(Wagner 3)

B) 28 +/- 6 weeks

Texas Grade 1-2

A) 13.7 +/- 12.0
weeks

B) 1.81 +/- 0.75 cm2
No statistically
significant difference
7) Bowling 2011

Not reported

A) 3.0 +/- 3.7 cm2

(Texas 2)
B) 9.7 +/- 8.1 weeks

B) 1.8 +/- 1.6 cm
8) Clever 1995

2

Not reported

Not reported

A) 162.37 +/325.55 days

Initial After 4 weeks
(23.2 ± 46.5 weeks)
A) 2.05 +/- 3.14 cm2
A) 0.32 ± 0.54 cm2

B) 165.00 +/318.68 days

B) 2.08 +/- 2.72 cm2
B) 0.34 ± 0.75 cm2

(23.6 ± 42.5 weeks)

(p > 0.2) Not
statistically significant
9) D'Hemecourt (1998) A) 0.4 +/- 0.52 cm
A) (Good Wound Care
alone)
3.5 +/- 3.53 cm

2

B) 0.4 +/- 0.20 cm

Wagner Grade 3 - 4

A) 42 +/- 42 weeks

(Wagner 4)

B) 52.8 +/- 60.92
weeks

Full thickness
Stage 3 or 4

B) (Good Wound Care
+ NaCMC)
3.2 +/- 2.75 cm2
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Target area 1 cm2 to 10
cm2 post-debridement
10) Donaghue 1998
Not reported

Wagner Grade 1 - 3

A) 146 +/- 73 days

A) 2.6 +/- 0.50 cm2

(Wagner 3)

(20.86 +/- 10.43
weeks)

B) 2.99 +/- 0.62 cm2
B) 225 +/- 104 days
No statistically
significant difference
(p=0.6237)

(32.14 +/- 14.86
weeks)
No statistically
significant
difference

11) EhsanUrRehman
2013

Not reported

Wagner Grade 1 - 2

(p=0.5369)
Not reported

(Wagner 2)
Not reported
12) Foster 1994

Superficial Deep

A) 0.88 cm2

A) 12 3

(15.3 weeks)

B) 0.79 cm2

B) 13 2

B) 170 days

Not reported

Not reported

(24.3 weeks)
Not reported

No other baseline data
specified
14) Hammouri 2004

Not reported

Not reported

Not reported

Not reported
15) Jeffcoate 2009

Not reported

Not reported

Not reported

13) Goretti (2008)

Not reported

A) 107 days

Surgical outcomes > 5
cm2

0.25-1 cm2 1.01- 0.25
cm2 2.5-25 cm2
A) 53 34 16
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B) 48 36 24
C) 50 34 22
16) Jensen (1997)

No other baseline
data specified

Wagner Grade 2

All ulcers at least 1
cm2

A) 8 months
(32 weeks)
B) 3 months

No other baseline data
specified
17) Lalau 2002

Not reported

Not reported

(12 weeks)
A) 4.9 +/- 7.8
months

A) 8.0 +/- 10.5 cm2
(19.6 +/- 31.2
weeks)

B) 8.8 +/- 16.0 cm2

B) 9.1 +/- 13.1
months

18) Markevich (2000)
A) 14.90 cm2

Reported as
comparable at
baseline, but not
otherwise specified

Not reported

(36.4 +/- 52.4
weeks)
Average duration
reported for total
sample as 15.8 +/10.7 years.

B) 15.14 cm2
(821.6 +/- 556.4
weeks)

19) Mazzone 1993

Not reported

Not reported

Not reported
separately for each
intervention group.
Not reported

Not reported
20) Munter 2006

Not reported

Wagner Grade 1 - 3

Not reported

A) 52.9 +/- 90 cm2

(Wagner grade 3)

B) 36.6 +/- 64.4 cm2
21) Ogce

Not reported

Not reported

Not reported

Not reported
22) Piagessi 2001

A) 2.9 +/- 1.1 cm

Not reported

A) 5.9 +/- 1.3 weeks
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A) 19.2 +/- 6.4 cm3

B) 2.3 +/- 1.4 cm

B) 6.8 +/- 2.6 weeks

B) 22.6 +/- 8.4 cm3

No statistically
significant
difference

No statistically
significant
difference

No statistically
significant difference
23) Piagessi 1998
Not reported

A) 1.58 +/- 2.20 cm

Wagner Grade 1 - 2

B) 1.98 +/- 1.07 cm

(Wagner Grade 2)

A) 32.74 +/- 19.25
days
(4.7 +/- 2.75 weeks)
B) 39.43 +/- 18.92

24) Rhaiem 1998

Not reported

Not reported

(5.6 +/- 2.7 weeks)
Not reported

Not reported
25) Roberts 2001

Not reported

Not reported

Sample 15.2 weeks

Sample median 1.23
cm2

Range (1 week - 6
years)

Sample median range
(0.21 - 3.50 cm2)
A) Median 1.1 cm2
B) Median 1.45 cm2
26) Shukrimi 2008

Not reported

Wagner Grade 2

Not reported

Not reported
27) Singh 2006

Not reported

Wagner Grade 1 - 2

Not reported

Not reported

(Wagner Grade 2)
Not reported

Not reported

B) 2.4 +/- 2.1 cm2
29) Vandeputte 1997

Not reported

Not reported

Not reported

Not reported
30) Whalley 2001

Not Reported

Wagner Grade 1 - 2

Not reported

Not reported
28) Tallis 2013
A) 3.0 +/- 2.1 cm2

A) 2.5 +/- 3.2 cm2

(Wagner grade 2)
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B) 2.4 +/- 2.9 cm2
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Table 11 Baseline participant complicating risk factors for delayed healing in the included studies
[#]

[Study ID]

[Mean Hgba1c
(%)]

[Mean Duration of
DM (yrs.)]

[Proportion of sample
with baseline
PAD/PVD]

[Proportion of
sample with baseline
Infection]

1

Ali 2013

Not reported

Not

Not reported

Not reported

2

Amini 2013

8.9 +/- 2.3

reported
14.8 +/- 7.3

0.50

3

Apelqvist 1990

8.2 +/- 1.75

20.5 +/- 13.5

4

Baker 1993

Not

5

Belcaro 2010

6

[Offloading]

[Proportion with
Baseline Immunesuppression]

[Nutritional status]

Proportion of sample
Smoking

Reported Y/N
Not reported

Proportion of
sample with
Venous
Insufficiency

Not

Not

0.214

Not

Not reported

Yes

reported
Not

reported
Not

0.075

reported
Not

Not reported

Not reported

Yes

reported
Not

reported
Not

Not reported

reported
Not

Not

Not

Not

Not Reported

reported
Not

reported
Not

Not Reported

reported
Not Reported

Reported
Not

Reported
Not

Reported
Not reported

Reported
Not reported

Not reported

Reported
Not

Reported
Not

Not reported

Not

Blackman 1994

Reported
8.95 +/- 1

reported
Not

Not reported

Not reported

Yes

reported
Not

reported
Not

Not reported

reported
Not

7

Bowling 2011

8.7 +/- 1.8

reported
19.35 +/- 8.1

0

0

Not reported

reported
Not

reported
Albumin

Not reported

reported
Not

reported
8

Clever 1995

Not reported

Not

Not reported

0.725

Yes

Not

40.1 +/- 4.5
grams/Liter
Not reported

0.325

Not

9

D'Hemeourt 1998

Not reported

reported
Not

Not reported

Not reported

Yes

reported
Not

Not reported

Not reported

reported
Not

10

Donaghue 1998

Not reported

reported
18

Not reported

0

Yes

reported
Not

Alb

Not reported

reported
Not

11

EhsanUrRehman 2013

Not reported

Range (30 - 81)
Not reported

Not reported

Not reported

Not reported

reported
Not

3.76 +/- 0.09
Not reported

Not reported

reported
Not reported

12

Foster 1994

Not reported

Not reported

Not reported

Not reported

Not reported

reported
Not

Not reported

Not reported

Not reported

13

Goretti 2008

Not reported

Not reported

0

1

Not reported

reported
Not

Not reported

Not reported

Not reported

14

Hammouri 2004

Not reported

Not reported

Not reported

Not reported

Not reported

reported
Not

Not reported

Not reported

Not reported

15
16

Jeffcoate 2009
Jensen 1998

Not reported
Not reported

15.7 +/- 10.8
Not reported

0.196
0

0
0

Yes
Yes

reported
0
Not

Not reported
Not reported

0.170
Not reported

Not reported
Not reported

17

Lalau 2002

7.75 +/- 1.75

18.05 +/- 10.35

0.22

Not reported

Yes

reported
Not

Not reported

Not reported

Not reported

18

Markevich 2000

Not reported

15.8 +/- 10.7

Not reported

Not reported

Not reported

reported
Not

Not reported

Not reported

Not reported

19

Mazzone 1993

Not reported

Not reported

Not reported

Not reported

Not reported

reported
Not

Not reported

Not reported

Not reported

20

Munter 2006

Not reported

Not reported

Not reported

Not reported

Not reported

reported
Not

Not reported

Not reported

Not reported

21

Ogce 2007

7.73

Not reported

Not reported

Not reported

Not reported

reported
Not

Not reported

Not reported

Not reported

22

Piaggesi 2001

8.5 +/- 2.9

15.45 +/- 7.55

0

0

Yes

reported
Not

Not reported

Not reported

Not reported

23
24

Piaggesi 1998
Rhaiem 1998

9.2 +/- 3.0
Not reported

17.52 +/- 9.51
13 +/- 10.6

0
Not reported

0
0.517

Yes
Not reported

reported
0
Not

Not reported
Not reported

Not reported
0.55

Not reported
Not reported

reported
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reported

25

Roberts 2001

Not reported

Not reported

Not reported

Not reported

Not reported

Not

Not reported

Not reported

Not reported

26

Shukrimi 2008

Not reported

Not reported

Not reported

Not reported

Not reported

reported
Not

Not reported

Not reported

Not reported

27

Singh 2006

Not reported

Not reported

Not reported

Not reported

Not reported

reported
Not

Not reported

Not reported

Not reported

28

Tallis 2013

Not reported

Not reported

0

0

Yes

reported
Not

Not reported

Not reported

Not reported

29
30

Vandeputte 1997
Whalley 2001

Not reported
Not reported

Not reported
Not reported

Not reported
Not reported

0.069
Not reported

Not reported
Yes

reported
Not reported
Not

Not reported
Not reported

Not reported
Not reported

Not reported
Not reported

reported
Footnotes

Study ID = Study Identification

Hgba1c % = Hemoglobin A1c in percent

Duration of DM = Duration of Diabetes in years

PAD/PVD = Peripheral arterial disease/Peripheral vascular disease
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Table 12 Table of industry supported included
studies
[#]
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

[Study ID]
Ali 2013
Amini 2013
Apelqvist 1990
Baker 1993
Belcaro 2010
Blackman 1994
Bowling 2011
Clever 1995
D'Hemeourt
1998
Donaghue 1998
EhsanUrRehman
2013
Foster 1994
Goretti 2008
Hammouri 2004
Jeffcoate 2009
Jensen 1998
Lalau 2002
Markevich 2000
Mazzone 1993
Munter 2006
Ogce 2007
Piaggesi 2001
Piaggesi 1998
Rhaiem 1998
Roberts 2001
Shukrimi 2008
Singh 2006
Tallis 2013
Vandeputte
1997
Whalley 2001

[Industry support] 0 = No, 1 = Yes, 2 = Unclear
2
0
1
1
2
1
1
1
2
1
2
2
1
2
2
1
1
2
1
1
2
0
2
2
1
2
2
1
2
2
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Table 13 Table of study debridement types
Study
[Sur
gical
]

2
3
2
2
8
2
0
5
1
1
1
4
2
6
2
5
1
5
2
1
2
2
1
0
1
7
9

1
6
1
7
1
8
1
9
2
0
2
1
2
2
2
3
2
4
2
5
2
6
2
7
2
8
2
9
3
0

Piaggesi
1998
Amini
2013
Tallis
2013
Munter
2006
Belcaro
2010
EhsanUr
Rehman
2013
Hammou
ri 2004
Shukrimi
2008
Roberts
2001
Jeffcoate
2009
Ogce
2007
Piaggesi
2001
Donaghu
e 1998
Lalau
2002
D'Heme
ourt
1998
Jensen
1998
Lalau
2002
Markevi
ch 2000
Mazzone
1993
Munter
2006
Ogce
2007
Piaggesi
2001
Piaggesi
1998
Rhaiem
1998
Roberts
2001
Shukrimi
2008
Singh
2006
Tallis
2013
Vandepu
tte 1997
Whalley
2001

[W
et
to
Dr
y]

[Aqu
eous
Lava
ge]

[Ultras
ound]

[Biosurge
ry/MDT]

[Enzy
matic]

Exp

[Saline
Gauze]

[Hydr
ogels]

[Algi
nates]

[Hydroc
olloids]

[Fo
am]

[Fi
lm]

[Ho
ney
]

[Zi
nc]

[Topica
l
Antimi
crobial]

Comp
Exp

Comp
Exp

Comp
Comp

Exp

Comp

Exp(Sil
ver)

Comp

Exp

Comp

Exp

Comp

Exp

Comp

Exp

Comp

Exp

Comp

Exp

Comp

Exp

Comp

Exp

Comp

Exp

Comp

Exp

Comp

Exp

Comp
Exp

Exp
Comp

Co
mp

Exp
Comp

Exp

Exp

Comp

Exp

Comp

Exp

Comp
Exp
Comp

Exp

Comp
Com
p

Exp

Exp
Exp
Co
mp

Comp
Exp
ExpComp
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Table 14 Summary of Results, Overall Effect Sizes, and Heterogeneity
RR (95% CI) **MD (95% CI)
Intervention
comparison
Hydrogel vs.
Gauze

Foam vs. Wet to
Dry
Hydrofiber vs.
Gauze

Any debridement
vs. Gauze

Outcome

k

Fixed-Effects

Random-Effects

Heterogeneity of Outcome Effects Summary
Statisticsb
τ2
χ2
I2 (%)
p-value

Proportion of
Amputations
Proportion of
Infections
Proportion of
Ulcers Healing
Proportion of
Ulcers Healing
2 studies
Proportion of
Amputations 2
studies
Proportion of
Infections
2
studies
Proportion of
Ulcers Healing
2 studies
Mean Time to
Complete Healing
2 studies
Proportion of
Amputations 5
studies (n=6)
Proportion of
Infections
7
studies (n=8)
Quality of Life
1 study (n=2)
Proportion of
Ulcers Healing
10 studies (n=11)

2

0.26 (0.05, 1.37)

0.26 (0.05, 1.40)

0.00

0.11

0

0.74

3

0.87 (0.54, 1.40)

0.74 (0.18, 2.99)

0.91

4.89

59

0.09

3

1.68 (1.14, 2.49)

1.71 (1.16, 2.52)

0.00

0.95

0

0.62

2

4.35 (1.33, 14.29)

3.56 (0.93, 13.66)

0.18

1.15

13

0.28

2

1.31 (0.33, 5.16)

1.34 (0.29, 6.10)

0.05

1.03

3

0.31

2

1.11 (0.84, 1.46)

0.96 (0.40, 2.31)

0.21

1.37

27

0.24

2

0.06 (0.06, 0.19)

0.07 (0.05, 0.19)

0.00

0.09

0

0.76

2

**-13.87 (-27.91, 0.16)

**-53.37 (-153.29,
46.56)

4892.23

16.29

94

< 0.0001

5

0.49 (0.19, 1.27)

0.48 (0.17, 1.37)

0.00

2.67

0

0.75

7

1.10 (0.89, 1.36)

1.07 (0.76, 1.52)

0.07

10.82

35

0.15

1

-0.01 (-0.04, 0.01)

-0.01 (-0.04, 0.01)

0.00

0.00

0

0.95

3

1.17 (1.00, 1.36)

1.22 (1.04, 1.44)

0.02

13.89

28

0.18

Proportion of
Ulcers Healing
(two studies
available only as
abstracts)
Proportion of Ulcer
Recurrence 2
studies (n=3)
Mean Time to
Complete Healing
4 studies (n=5)

10

1.12 (0.95, 1.32)]

1.18 (0.99, 1.41)

0.02

12.26

35

0.14

2

0.77 (0.34, 1.71)

0.81 (0.25, 2.58)

0.42

3.29

39

0.19

4

2.54 (1.20, 3.87)

-27.88 (-52.53, -3.23)

614.40

39.33

90

< 0.00001

Note:
** indicates a significant effect; k represents the number of interventions for each outcome included in the analysis; Q represents Cochran’s Q indicating
significance of heterogeneity; I2 represents the magnitude of heterogeneity; p-value represents the significance of heterogeneity.

b) Relative risk (RR) was the effect estimate for proportion of amputations, proportion of infections, and proportion of ulcers healed, and proportion of
recurrence. Mean difference (MD) was the effect estimate for the outcomes Quality of life, and Time to complete healing.
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Table 15 Tests for Publication Bias
Intervention
Outcome
Egger’s
Begg’s
Any debridement as
Proportion of Ulcers
*p = 0.8958
**p = 0.5858
compared with gauze
Healing
Footnote
*2 tailed p-value
* Beggs performed without continuity correction, 2 tailed p-value.
Beggs and Eggers test for publication bias performed on outcomes and interventions that
included 10 or more studies.
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Table 16 with scatterplot. Model for outcome
Proportion of complicating infections using
Age as a moderator. Any debridement vs
Moistened gauze.

Outcome

Moderator

Coeff

Proportion of
Complicating
Infections

Age(yrs.)

-0.2132

Standard
error
0.1156

Model
Q
p-value

R2

Goodness of fit
Tau2
Q

I2(%)

p-value

3.40

0.00

0.0014

13.57

0.3263

0.0651

341

6.94

Regression of Log risk ratio on age
2.00
1.50

0.50
0.00
-0.50

Log risk ratio

1.00

-1.00
-1.50
-2.00
-2.50
-3.00
-3.50
56.0

57.0

58.0

59.0

60.0

61.0

62.0

63.0

64.0

age

Age (years)
Coeff = -0.2132, CI = (-0.4397, 0.0133), R2 = 0.00

342

65.0

66.0

Table 17 with scatterplot. Model for outcome
proportion of ulcers healed using age as a
moderator. Any debridement vs Moistened
gauze.

Outcome

Moderator

Coeff

Proportion of
ulcers healed

Age (yrs.)

0.0130

Standard
error
0.0322

Model
Q
pvalue
0.16 0.6873

343

R2

Goodness of fit
Tau2 Q
I2(%)

0.00

0.00

1.68

0.00

pvalue
0.8917

Regression of Log risk ratio on age
0.80

0.70

0.60

0.50

Log risk ratio

0.40

0.30

0.20

0.10

0.00

-0.10

-0.20

-0.30
56.0

57.0

58.0

59.0

60.0

61.0

62.0

63.0

64.0

age

Age (years)
Coeff = -0.0130, CI = (-0.0760, 0.0501), R2 = 0.00

344

65.0

66.0

Table 18 with scatterplot. Model for outcome
Proportion of complicating infections using
Peripheral Arterial Disease (PAD) as a
moderator. Any debridement vs Moistened
gauze.

Outcome

Moderator

Coeff

Proportion of
Complicating
Infections

Proportion
with
peripheral
arterial
disease

3.3706

Standard
error
3.2676

Model
Q
p-value

R2

Goodness of fit
Tau2
Q
I2(%)

p-value

1.06

0.00

0.00

0.3502

0.3023

345

4.44

9.82

Regression of Log risk ratio on proportion of baseline PAD
2.00

1.00

0.50

0.00

Log risk ratio

1.50

-0.50

-1.00

-1.50

-2.00

-2.50

-3.00
-0.1

0.0

0.0

0.1

0.1

0.2

0.2

0.3

Proportion of baseline PAD

Proportion of sample with Peripheral arterial disease
Coeff = 3.3706, CI = (-3.0338, 9.7750), R2 = 0.00

346

0.3

Table 19 with scatterplot. Model for outcome
ulcers healed using Peripheral Arterial
Disease (PAD) as a moderator. Any
debridement vs Moistened gauze.

Outcome

Moderator

Proportion Proportion
of ulcers
of baseline
healed
with
peripheral
arterial
disease

Coeff
0.4095

Standard
error
0.8237

Model
Q
pvalue
0.25 0.6191

347

R2

Goodness of fit
Tau2 Q
I2(%)

0.00

0.00

3.89

0.00

pvalue
0.4206

Regression of Log risk ratio on Proportion with baseline PAD
0.80
0.70

0.50
0.40
0.30

Log risk ratio

0.60

0.20
0.10
0.00
-0.10
-0.20
-0.30
-0.40
-0.1

0.0

0.0

0.0

0.0

0.1

0.1

0.1

0.1

0.2

0.2

0.2

Proportion with baseline PAD

Proportion of sample with peripheral arterial disease
Coeff = -0.4095, CI = (-2.0240, 1.2050), R2 = 0.00

348

0.3

Table 20 with scatterplot. Model for outcome
proportion of complicating infections using
diabetes duration as a moderator. Any
debridement vs Moistened gauze.

Outcome

Moderator

Coeff

Standard

Q

p-value

R2

Tau2

Q

I2(%)

p-value

Proportion of
Complicating

Duration of diabetes
(years)

-0.1528

error
0.2530

0.36

0.5460

0.00

0.00

5.11

21.68

0.2764

Infections

349

Regression of Log risk ratio on Duration of Diabetes
5.00
4.00

2.00
1.00
0.00

Log risk ratio

3.00

-1.00
-2.00
-3.00
-4.00
-5.00
-6.00
13.0

14.0

15.0

16.0

17.0

18.0

19.0

20.0

21.0

Duration of Diabetes (yrs)

Duration of Diabetes (years)
Coeff = -0.1528, CI = (-0.6487, 0.3432), R2 = 0.00

350

22.0

23.0

Table 21 with scatterplot. Model for outcome
number of ulcers healed using duration of
diabetes as a moderator. Any debridement vs
Moistened gauze.

Outcome

Moderator

Proportion Diabetes
of ulcers
duration
healed
(years)

Coeff
0.0419

Standard
error
0.0723

Model
Q
pvalue
0.34 0.5625

351

R2

Goodness of fit
Tau2 Q
I2(%)

0.00

0.00

0.09

0.00

pvalue
0.9930

Regression of Log risk ratio on Duration of Diabetes
0.80
0.70

0.50
0.40
0.30

Log risk ratio

0.60

0.20
0.10
0.00
-0.10
-0.20
-0.30
-0.40
15.0

15.5

16.0

16.5

17.0

17.5

18.0

Duration of Diabetes

Diabetes Duration (years)
Coeff = 0.0419, CI = (-0.0999, 0.11836), R2 = 0.00

352

18.5

19.0

Table 22 with scatterplot. Model for outcome
proportion of complicating infections using
proportion of females as a moderator. Any
debridement vs Moistened gauze.

Outcome

Moderator

Coeff

Proportion
of
Complicating
Infections

Proportion
of females

6.1651

Standard
error
2.7765

Model
Q
pvalue
4.93 0.0264

353

R2

Goodness of fit
Tau2 Q
I2(%)

0.00

0.00

2.76

0.00

pvalue
0.5995

Regression of Log risk ratio on Proportion of Females
3.00

1.00

0.00

-1.00

Log risk ratio

2.00

-2.00

-3.00

-4.00

-5.00

-6.00
0.2

0.2

0.3

0.3

0.3

0.4

0.4

0.5

0.5

0.6

Proportion of Females

Proportion of sample with females
Coeff = -6.1651, CI = (-11.6070, -07232), R2 = 0.00

354

0.6

Table 23 with scatterplot. Model for outcome
number of ulcers healed using proportion of
females as a moderator. Any debridement vs
Moistened gauze.

Outcome

Moderator

Coefficient

Proportion of
ulcers healed

Proportion of
females

0.2486

Standard
error
1.4998

355

Q
0.03

pvalue
0.8683

R2

Tau2

Q

I2(%)

p-value

0.00

0.00

1.62

0.00

0.8053

Regression of Log risk ratio on Proportion of Females
2.50

1.50

1.00

Log risk ratio

2.00

0.50

0.00

-0.50

-1.00

-1.50
0.1

0.1

0.2

0.2

0.3

0.3

0.4

0.4

0.5

0.5

0.6

Proportion of Females

Proportion of sample with females
Coeff = 0.2486, CI = (-2.6909, 3.1882), R2 = 0.00

356

0.6

Table 24 with scatterplot. Model for outcome
proportion of complicating infections using
data collection year as moderator. Any
debridement vs Moistened gauze.

Outcome

Moderator

Coeff

Proportion
of
Complicating
Infections

Data
collection
year

0.0246

Standard
error
0.0286

Model
Q
pvalue
0.74 0.3890

357

R2

Goodness of fit
Tau2 Q
I2(%)

0.00

0.00

3.98

0.00

pvalue
0.5526

Regression of Log risk ratio on Data Collection Year
2.00

1.00

0.50

0.00

Log risk ratio

1.50

-0.50

-1.00

-1.50

-2.00

-2.50
1982.5

1985.0

1987.5

1990.0

1992.5

1995.0

1997.5

2000.0

2002.5

2005.0

2007.5

2010.0

Data Collection Year

Data Collection year
Coeff = 0.0246, CI = (-0.0314, 0.0806), R2 = 0.00

358

2012.5

Table 25 with scatterplot. Model for outcome
number of ulcers healed using data collection
year as a moderator. Any debridement vs
Moistened gauze.

Outcome

Moderator

Coefficient

Proportion of
ulcers healed

Data collection
year

0.0013

Standard
error
0.0137

Q
0.01

359

pvalue
0.9274

R2

Tau2

Q

I2(%)

p-value

0.00

0.00

5.55

0.00

0.6972

Regression of Log risk ratio on Data Collection Year
0.80
0.70

0.50
0.40
0.30

Log risk ratio

0.60

0.20
0.10
0.00
-0.10
-0.20
-0.30
1992.0

1994.0

1996.0

1998.0

2000.0

2002.0

2004.0

2006.0

2008.0

Data Collection Year

Data collection Year
Coeff = 0.0013, CI = (-0.0256, 0.0281), R2 = 0.00

360

2010.0

Table 26 with scatterplot. Model for outcome
proportion of complicating infections using
duration of follow up as moderator. Any
debridement vs Moistened gauze.

Outcome

Moderator

Coeff

Proportion
of
Complicating
Infections

Duration
of follow
up

0.0482

Standard
error
0.0365

Model
Q
pvalue
1.75 0.1857

361

R2

Goodness of fit
Tau2 Q
I2(%)

0.00

0.00

4.35

0.00

pvalue
0.6294

Regression of Log risk ratio on Duration of Follow up
2.00
1.50

0.50
0.00
-0.50

Log risk ratio

1.00

-1.00
-1.50
-2.00
-2.50
-3.00
-3.50
0.0

2.5

5.0

7.5

10.0

12.5

15.0

17.5

20.0

22.5

25.0

Duration of Follow up

Follow up period (days)
Coeff = 0.0482, CI = (-0.0232, 0.1197), R2 = 0.00

362

27.5

30.0

Table 27 with scatterplot. Model for outcome
number of ulcers healed using duration of
follow up as a moderator. Any debridement
vs Moistened gauze.

Outcome

Moderator

Coefficient

Proportion of
ulcers healed

Duration of
follow up

0.0048

Standard
error
0.0093

Q
0.27

363

pvalue
0.6043

R2

Tau2

Q

I2(%)

p-value

0.00

0.00

5.29

0.00

0.6252

Regression of Log risk ratio on Duration of Follow up
0.80
0.70

0.50
0.40
0.30

Log risk ratio

0.60

0.20
0.10
0.00
-0.10
-0.20
-0.30
6.0

8.0

10.0

12.0

14.0

16.0

18.0

20.0

22.0

24.0

Duration of Follow up (days)

Follow up period (days)

Coeff = 3.3706, CI = (-3.0338, 9.7750), R2 = 0.00
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Table 28 Moderators of effect size magnitude for the “Any debridement vs. gauzea”
comparison.
Outcome(s)

Proportion of
infections
Proportion of
infections
Proportion of
infections
Proportion of
infections
Proportion of
infections
Proportion of
infections
Proportion of
Ulcers healed
Proportion of
Ulcers healed
Proportion of
Ulcers healed
Proportion of
Ulcers healed

Moderator(s)Characteristic(s)/Level(s)
Participant-specific demographic
characteristics
Age
Risk-specific characteristics
PADc
Duration of diabetes (yrs.)
Proportion of females
Study-specific characteristics
Data collection year
Duration of follow up
Age
PAD(c)
Duration of diabetes (yrs.)
Proportion of females

RR (95%
CI)

Kb

Coefficient

p-value

1.07 (0.76,
1.52)

7

-0.2132

0.0651

1.07 (0.76,
1.52)
1.07 (0.76,
1.52)
1.07 (0.76,
1.52)

7

3.3706

0.3023

7

-0.1528

0.5460

7

-6.1651

0.0264

1.07 (0.76,
1.52)
1.07 (0.76,
1.52)
1.17 (1.00,
1.36)
1.17 (1.00,
1.36)
1.17 (1.00,
1.36)
1.17 (1.00,
1.36)

7

0.0246

0.3890

7

0.0482

0.1857

10

-0.0130

0.6873

10

-0.4095

0.6191

10

0.0419

0.5626

10

0.2486

0.8683

Study-specific characteristics
Proportion of
Data collection year
1.17 (1.00,
10 0.0013
0.9247
Ulcers healed
1.36)
Proportion of
Duration of follow up
1.17 (1.00,
10 0.0048
0.6043
Ulcers healed
1.36)
a. Each moderator listed is evaluated individually without controlling for the other listed moderators. Effect sizes
are based on random effects assumptions for the comparison and respective outcome listed in two columns. In this
analysis there was 1 comparison (“any debridement” as compared with gauze) and 2 outcomes (proportion of
infections, and Proportion of ulcers healed) that approximated a sufficient (number of studies): moderator ratio in
order to facilitate moderator analysis.
b. k = number of studies
c. PAD = proportion with initial baseline peripheral arterial disease.
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Table 29 Non-Significant Moderators
Non-Significant Moderators
All the following moderators assessed were non-significant.
Age
PAD (Peripheral arterial disease)
Duration of diabetes
Data collection year
Duration of follow up

Table 30 Moderators that were Unable to be analyzed due to lack of Reported Information
235 coded variables on our data extraction form
138 of these were non-effect size related variables.
These were thoroughly reviewed as candidate variables for regression analysis and most were unable to
be analyzed due to lack of reported information as either none of the studies reported certain outcomes
or only very few did. Many had as few as 1 or no study reporting information. See Data extraction form
Appendix 2.
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32 Summary of Finding Tables (SoF)
Hydrogel compared to Gauze/Good wound care (gwc) for
Diabetic foot ulcers (DFU)
Hydrogel compared to Gauze/Good wound care (gwc) alone for Diabetic foot ulcer
Patient or population: patients with Diabetic foot ulcer
Settings: Outpatient
Intervention: Hydrogel
Comparison: Gauze/Good wound care (gwc) alone

Outcomes

Illustrative comparative risks* (95% CI)
Assumed risk

Corresponding risk

Relative effect No of Participants Quality of the
(95% CI)
(studies)
evidence
(GRADE)

Comments

Gauze/Good wound care (gwc) Hydrogel
alone
Number of amputations
reported
Follow-up: 20 weeks

Study population
19 per 100

RR 0.26
(0.05 to 1.4)

5 per 100
(1 to 26)

60
(2 studies)

⊕⊕⊝⊝
low1,2,3

Moderate
20 per 100
Number of Infections reported Study population
Follow-up: 12 - 20 weeks
27 per 100

5 per 100
(1 to 27)

20 per 100
(5 to 82)

198
RR 0.74
(0.18 to 2.99) (3 studies)

⊕⊝⊝⊝
very low1,2,4,5,6

198
RR 1.71
(1.16 to 2.52) (3 studies)

⊕⊕⊝⊝
low1,7

Moderate
28 per 100
Number of ulcers completely
healed
Follow-up: 12 - 20 weeks

21 per 100
(5 to 83)

Study population
26 per 100

45 per 100
(30 to 66)

Moderate
35 per 100

60 per 100
(41 to 89)

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1

Many of the risk of bias characteristics were either unclear or high.
The 95% confidence interval (or alternative estimate of precision) around the pooled or best estimate of effect includes both 1) no effect and 2) appreciable benefit.
3
2/3 did not mention whether industry support was sought and the studies yet all had negative findings.
4
No explanation was provided
5
Point estimates are far apart and confidence intervals do not overlap.
6
The 95% confidence interval (or alternative estimate of precision) around the pooled or best estimate of effect includes both 1) no effect and 2) appreciable harm.
7
The total (cumulative) sample size is lower than the calculated OIS.
2
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Table 33 Summary of Findings Table
Foam dressing compared with Wet to Dry Saline for DFU
Foam dressing compared to Wet to Dry Saline for Diabetic foot ulcer
Patient or population: patients with Diabetic foot ulcer
Settings:
Intervention: Foam dressing
Comparison: Wet to Dry Saline
Outcomes

Number of ulcers
completely healed
Follow-up: 8 to 24 weeks

Illustrative comparative risks* (95%
CI)
Assumed risk

Corresponding risk

Wet to Dry
Saline

Foam dressing

Study population
13 per 100

47 per 100
(12 to 100)

Relative
effect
(95% CI)

No of Participants Quality of the
(studies)
evidence
(GRADE)

RR 3.56
(0.93 to
13.66)

37
(2 studies)

Comments

⊕⊕⊝⊝
low1,2,3

Moderate
12 per 100

44 per 100
(12 to 100)

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its
95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the
estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the
estimate.
Very low quality: We are very uncertain about the estimate.
1

Many of the risk of bias characteristics were either unclear or high.
The 95% confidence interval (or alternative estimate of precision) around the pooled or best estimate of effect includes both 1) no effect and 2)
appreciable benefit.
3
The total (cumulative) sample size is lower than the calculated Optimal Information Size OIS and/or total number of events is less than 300 (a
threshold rule-of-thumb value) (based on: Mueller et al. Ann Intern Med. 2007;146:878
2
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Table 34 Summary of Findings Table
Hydrofiber compared to Gauze dressing for DFU
Hydrofiber compared to Gauze dressing for Diabetic foot ulcers
Patient or population: patients with Diabetic foot ulcers
Settings: Outpatient
Intervention: Hydrofiber
Comparison: Gauze dressing

Outcomes

Number of amputations
reported

Illustrative comparative risks* (95% CI)
Assumed risk

Corresponding risk

Gauze dressing

Hydrofiber

Study population
3 per 100

3 per 100
(1 to 16)

Relative
effect
(95% CI)

No of
Participants
(studies)

Quality of the
evidence
(GRADE)

229
RR 1.34
(0.29 to 6.1) (2 studies)

⊕⊕⊝⊝
low1,2,3

229
RR 0.96
(0.4 to 2.31) (2 studies)

⊕⊕⊝⊝
low1,2,3

229
RR 1.13
(0.92 to 1.38) (2 studies)

⊕⊕⊝⊝
low1,2,4

Comments

Moderate
6 per 100
Number of Infections
reported
Follow-up: 8 - 24 weeks

8 per 100
(2 to 36)

Study population
44 per 100

42 per 100
(18 to 100)

Moderate
38 per 100
Number of ulcers
completely healed
Follow-up: 8 - 24 weeks

36 per 100
(15 to 87)

Study population
43 per 100

49 per 100
(40 to 59)

Moderate

Time to complete healing
(days)
Scale from: 0 to 295.
Follow-up: 8 to 24 weeks

64 per 100

73 per 100
(59 to 89)

The mean time to complete healing (days)
ranged across control groups from
78.3 to 295 days

The mean time to complete healing (days) in
the intervention groups was
53.37 lower
(153.29 lower to 46.56 higher)

229
(2 studies)

⊕⊝⊝⊝
very low1,5,6,7

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1

Many of the risk of bias characteristics were either unclear or high.
The total (cumulative) sample size is lower than the calculated optimal information size OIS) and total number of events is less than 300 (a threshold rule-of-thumb value) (based on: Mueller et
al. Ann Intern Med. 2007;146:878-881.
3
The 95% confidence interval (or alternative estimate of precision) around the pooled or best estimate of effect includes both 1) no effect and 2) appreciable benefit and appreciable harm.
GRADE suggests that the threshold for "appreciable benefit" or "appreciable harm" that should be considered for downgrading is a relative risk reduction (RRR) or relative risk increase (RRI)
greater than 25%.
4
The 95% confidence interval (or alternative estimate of precision) around the pooled or best estimate of effect includes both 1) no effect and 2) appreciable benefit. GRADE suggests that the
threshold for "appreciable benefit" or "appreciable harm" that should be considered for downgrading is a relative risk reduction (RRR) or relative risk increase (RRI) greater than 25%.
5
There exists widely differing estimates of the treatment effect (i.e. heterogeneity or variability in results) across studies suggesting true differences in underlying treatment effect.
6
The total (cumulative) sample size is lower than the calculated Optimal Information Size (OIS) and/or total population size is less than 400 (a threshold rule-of-thumb value; using the usual α
and β, and an effect size of 0.2 SD, representing a small effect.
7
The 95% confidence interval includes no effect and the upper or lower confidence limit crosses the minimal important difference (MID), either for benefit of harm (Note: if the MID is not
known or the use of different outcomes measures required calculation of an (ES), we suggest downgrading if the upper or lower confidence limit crosses an effect size of 0.5 in either direction).
2
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35 Any debridement compared to Gauze control for Diabetic
Foot Ulcers
Any debridement compared to Saline gauze for Diabetic Foot Ulcers
Patient or population: patients with Diabetic Foot Ulcers
Settings:
Intervention: Any debridement
Comparison: Saline gauze

Outcomes

Number of amputations reported
Follow-up: 8 to 24 weeks

Illustrative comparative risks* (95% CI)
Assumed risk

Corresponding risk

Saline gauze

Any debridement

Relative effect No of Participants
(95% CI)
(studies)

Study population
6 per 100

3 per 100
(1 to 8)

Quality of the evidence Comments
(GRADE)

RR 0.48
(0.17 to 1.37)

443
(5 studies)

⊕⊕⊝⊝
low1,2

RR 1.07
(0.76 to 1.52)

659
(7 studies)

⊕⊕⊝⊝
low1,2

RR 1.22
(1.04 to 1.44)

798
(10 studies)

⊕⊝⊝⊝
very low1,2,3

RR 1.18
(0.99 to 1.41)

728
(8 studies)

⊕⊕⊝⊝
low2

RR 1.57
(1.05 to 2.35)

70
(2 studies)

⊕⊕⊝⊝
low1,2

Moderate
5 per 100
Number of Infections reported
Follow-up: 4 to 24 weeks

2 per 100
(1 to 7)

Study population
30 per 100

32 per 100
(23 to 46)

Moderate
29 per 100
Number of ulcers completely healed
Follow-up: 4 to 24 weeks

31 per 100
(22 to 44)

Study population
40 per 100

49 per 100
(41 to 57)

Moderate
40 per 100
Number of ulcers completely healed - Any Debridement vs
Saline Gauze
Follow-up: 4 to 24 weeks

48 per 100
(41 to 57)

Study population
40 per 100

47 per 100
(39 to 56)

Moderate
40 per 100
Number of ulcers completely healed - SA w/o Abstracts
Follow-up: 13 to 24 weeks

47 per 100
(39 to 56)

Study population
42 per 100

65 per 100
(44 to 98)

Moderate
40 per 100

63 per 100
(42 to 94)

Quality of life
Scale from: 0 to 100.
Follow-up: 13 to 24 weeks

The mean quality of life in the intervention groups was
0.01 lower
(0.04 lower to 0.01 higher)

317
(1 study)

⊕⊕⊝⊝
low1,4

Time to complete healing (days)
Follow-up: 8 to 24 weeks

The mean time to complete healing (days) in the intervention
groups was
27.88 lower
(52.53 to 3.23 lower)

458
(4 studies)

⊕⊕⊝⊝
low1,5

357
(2 studies)

⊕⊕⊝⊝
low1,2

Recurrence rates

Study population
88 per 1000

RR 0.81
(0.25 to 2.58)

71 per 1000
(22 to 227)

Moderate
38 per 1000

31 per 1000
(9 to 98)

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1

Downgraded as substantial risk of bias characteristics were either unclear or high.
Downgraded due to the 95% confidence interval (or alternative estimate of precision) around the pooled or best estimate of effect includes both 1) no effect and 2) appreciable benefit or appreciable harm. GRADE suggests that the
threshold for "appreciable benefit" or "appreciable harm" that should be considered for downgrading is a relative risk reduction (RRR) or relative risk increase (RRI) greater than 25%.
3
Downgraded for asymmetric funnel plot distribution around the null value is observed favoring a positive effect that includes studies with smaller sample sizes.
4
Downgraded due to total (cumulative) sample size is lower than the calculated optimal information size (OIS) and/or total population size is less than 400 (a threshold rule-of-thumb value; using the usual α and β, and an effect size
of less than 0.2 SD, representing a small effect). 95% confidence interval includes no effect and the upper or lower confidence limit crosses the minimal important difference (MID), either for benefit of harm.
5
Downgraded due to widely differing estimates of the treatment effect (i.e. heterogeneity or variability in results) across studies suggest true differences in underlying treatment effect.
2
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Figures
Figure 1 Serial images depicting measurements of wound progress
over the course of sequential combined forms of debridement lasting
12 weeks including sharp, enzymatic, and autolytic.
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Figure 2 Study selection Prisma flow diagram.
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Figure 3 Methodological quality graph across all studies

Methodological quality graph: review authors' judgements about each methodological quality
item presented as percentages across all included studies.
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Figure 4 Methodological quality summary review of risk of
bias tables across all studies.
Methodological quality summary:
review authors' judgements about
each methodological risk of bias
quality item for each included
study.
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Figure 23 (Analysis 6.1)

Forest plot of comparison: 6 Hydrogel compared with gauze or good wound care (gwc),
outcome: 6.1 Number of amputations reported.

Figure 24 (Analysis 6.2)

Forest plot of comparison: 6 Hydrogel compared with gauze or good wound care (gwc),
outcome: 6.2 Number of Infections reported.
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Figure 25 (Analysis 6.3)

Forest plot of comparison: 6 Hydrogel compared with gauze or good wound care (gwc),
outcome: 6.3 Number of ulcers completely healed.

Figure 26 (Analysis 10.1)

Forest plot of comparison: 10 Foam dressing compared with Wet to Dry Saline, outcome: 10.1
Number of ulcers completely healed.
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Figure 27 (Analysis 13.1)

Forest plot of comparison: 13 Hydrofiber compared with gauze dressing, outcome: 13.1 Number
of amputations reported.

Figure 28 (Analysis 13.2)

Forest plot of comparison: 13 Hydrofiber compared with gauze dressing, outcome: 13.2 Number
of Infections reported.
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Figure 29 (Analysis 13.4)

Forest plot of comparison: 13 Hydrofiber compared with gauze dressing, outcome: 13.4 Number
of ulcers completely healed.

Figure 30 (Analysis 13.5)

Forest plot of comparison: 13 Hydrofiber compared with gauze dressing, outcome: 13.5 Time to
complete healing (days).

396

Figure 31 (Analysis 19.1)

Forest plot of comparison: 19 Any debridement compared with saline gauze control, outcome:
19.1 Number of amputations reported.
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Figure 32 (Analysis 19.2)

Forest plot of comparison: 19 Any debridement compared with saline gauze control, outcome:
19.2 Number of Infections reported.
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Figure 33 (Analysis 19.3)

Forest plot of comparison: 19 Any debridement compared with saline gauze control, outcome:
19.3 Number of ulcers completely healed.
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Figure 34 (Analysis 19.4)

Forest plot of comparison: 19 Any debridement compared with saline gauze control, outcome:
19.4 Quality of life.

Figure 35 (Analysis 19.5)

Forest plot of comparison: 19 Any debridement compared with saline gauze control, outcome:
19.5 Time to complete healing (days).
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Figure 36 (Analysis 19.6)

Forest plot of comparison: 19 Any debridement compared with saline gauze control, outcome:
19.6 Recurrence rates.
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Figure 37 (Analysis 19.3)

Funnel plot of comparison: 19 Any debridement compared with Saline Gauze, outcome: 19.3
Number of ulcers completely healed. Note: Funnel plot to assess for publication bias was
performed on outcomes and interventions that included 10 or more studies. This included the
outcome Number of ulcers healed for the intervention Any debridement vs. Saline gauze.
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Sources of support
Internal sources


No sources of support provided

External sources


No sources of support provided
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Appendix – Search Strategies
1 Search strategy for the fourth update and expansion of the
existing review 2014
There were three separate and independent searches conducted. The first search was carried out
by the Cochrane Review Group - Wounds through the trials search coordinator. The second
search was conducted as an institutional search by the authors independent of Cochrane Review
Group - Wounds. The reason for this was that this systematic review was not strictly an update of
an existing review but a significant expansion on the outcomes of interest in order to include
additional public health related and clinical outcomes beyond the outcomes covered in the earlier
reviews. This entailed expanding on the existing search provided through the trials search
coordinator at CRG-wounds. It included new search terms with expanded dates and not restricted
to the dates used by CRG-wounds. The search involved the same databases previously searched
with the addition of the Web of Science database that is included. The third search was
conducted by CRG-wounds to include any recent literature that might have been published since
the last search provided by CRG-wounds through April 2015. All search strategies are described
in detail below.

2 Ovid MEDLINE, PubMed search strategy
The trials search coordinator with the Cochrane Review Group - Wound searched the database
Ovid Medline utilizing the following search strategy and dates:
Database: Ovid MEDLINE(R) without Revisions <1996 to March Week 4 2013>
Search Strategy:
-------------------------------------------------------------------------------1 exp Debridement/ (7831)
2 (debrid$ or slough$ or deslough$).ti,ab. (12051)
3 exp Larva/ (24406)
4 (larva$ or maggot$ or biosurgery or bio-surgery).ti,ab. (38005)
5 (wound$ adj (irrigat$ or cleanse$)).ti,ab. (161)
6 whirlpool.ti,ab. (149)
7 (collagenase$ or fibrinolytic$ or proteolytic$ or trypsin or streptokinase or streptodornase or
varidase).ti,ab. (58063)
8 exp Papain/ (1033)
9 papain.ti,ab. (2276)
10 (hypochlorite or hydrogen peroxide).ti,ab. (25102)
11 (malic acid or benzoid acid or salicylic acid or propylene glycol).ti,ab. (6877)
12 dakin solution.ti,ab. (1)
13 (dextranomer$ or cadexomer or xerogel or eusol or debrisan).ti,ab. (451)
14 (polysaccharide adj (bead$ or paste$)).ti,ab. (7)
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15 (iodoflex or iodosorb).ti,ab. (8)
16 (((gauze or adherent or absorbent or tulle or polysaccaride or alginate or foam or hydrofibre
or hydrofiber) adj dressing$) or saline gauze or hydrocolloid$ or granuflex or tegasorb or aquacel
or hydrocoll or combiderm or duoderm).ti,ab. (1122)
17 "wet-to-dry dressings".ti,ab. (18)
18 exp Honey/ (1503)
19 honey$.ti,ab. (7264)
20 exp Hydrogel/ (2336)
21 (hydrogel$ or intrasite gel or intrasitgel or sterigel or granugel or nugel or purilon or
vigilon).ti,ab. (9889)
22 exp Zinc Oxide/ (2378)
23 zinc oxide.ti,ab. (1273)
24 or/1-23 (170471)
25 exp Foot Ulcer/ (5689)
26 exp Diabetic Foot/ (4929)
27 (diabet$ adj3 ulcer$).ti,ab. (1975)
28 (diabet$ adj3 (foot or feet)).ti,ab. (3663)
29 (diabet$ adj3 wound$).ti,ab. (1091)
30 or/25-29 (7198)
31 24 and 30 (800)
32 randomized controlled trial.pt. (245491)
33 controlled clinical trial.pt. (39951)
34 randomized.ab. (200013)
35 placebo.ab. (93002)
36 clinical trials as topic.sh. (80489)
37 randomly.ab. (137654)
38 trial.ti. (74410)
39 or/32-38 (554321)
40 (animals not (humans and animals)).sh. (1639102)
41 39 not 40 (504319)
42 31 and 41 (111)
43 (2009* or 2010* or 2011* or 2012* or 2013*).ed. (3070501)
44 42 and 43 (50)
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The authors conducted a search in conjunction with our library search coordinator at the
University of Connecticut. The database Medline was searched utilizing the following search
strategy and search dates:
PubMed
Dates Searched: 1940’s to present
Results: 811
(diabetes OR diabetic* OR "Diabetes Mellitus"[Mesh]) AND (wound* OR ulcer* OR callus*
OR "Diabetic Foot"[Mesh] OR "diabetic foot" OR "diabetic feet") AND ("Toes"[Mesh] OR toe
OR toes OR phalange* OR "Lower Extremity"[Mesh] OR "Leg"[Mesh] OR leg OR legs OR
extremity OR "Foot"[Mesh] OR foot OR feet) AND ("Debridement"[Mesh] OR debrid* OR
slough* OR deslough* OR larva* OR maggot* OR MDT OR biosurgery OR "bio-surgery" OR
surgery OR surgical OR scalpel* OR hydrogel* OR "moist wound healing" OR enzyme* OR
mechanical OR autolytic OR ultrasound OR laser OR lasers OR sharp OR irrigate* OR irrigation
OR cleanse* OR whirlpool* OR collagenase* OR fibrinolytic* OR proteolytic* OR trypsin OR
streptokinase OR streptodornase OR varidase OR papain OR hypochlorite OR "hydrogen
peroxide" OR acid OR acids OR "propylene glycol" OR "dakin solution" OR dextranomer* OR
cadexomer* OR xerogel* OR eusol* OR debrisan* OR paste* OR iodoflex OR iodosorb OR
gauze* OR tulle OR polysaccharide* OR bead OR alginate*OR foam* OR hydrofibre* OR
hydrofiber* OR dressing* OR saline OR honey* OR gel OR gels OR hydrocolloid* OR
granuflex OR tegasorb OR aquacel OR hydrocoll* OR combiderm OR duoderm OR sterigel*
OR granugel* OR nugel OR purilon OR vigilon OR "zinc oxide" OR phenytoin) AND
(("clinical"[tiab] AND "trial"[tiab]) OR "clinical trials as topic"[mesh] OR "clinical trial"[pt] OR
random*[tiab] OR "random allocation"[mesh] OR "therapeutic use"[sh]) AND "humans"[mesh]
NOT ("Cross-Sectional Studies"[MeSH Terms] OR "Case Reports"[pt] OR Comment[pt] OR
Editorial[pt] OR Letter[pt] OR Review[pt] OR "case control"[ti] OR "case report"[ti] OR "case
study"[ti] OR "case series"[ti] OR "Case-Control Studies"[Mesh] OR "Follow-Up
Studies"[Mesh] OR "observational study"[ti] OR "prospective cohort"[ti] OR "cohort studies"
[Mesh:NoExp] OR "cohort study"[ti] OR "Longitudinal Studies" [Mesh:NoExp] OR "Follow-Up
Studies"[mesh] OR "Retrospective Studies"[mesh] OR "non-randomized"[ti] OR "follow up
study"[ti] OR rat[ti] OR rats[ti] OR mice[ti] OR mouse[ti] OR dog[ti] OR dogs[ti] OR cats[ti])
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PubMed Supplemental Search 1: systematic reviews & meta-analysis
Dates Searched: 1940’s to present
Results: 237
(diabetes OR diabetic* OR "Diabetes Mellitus"[Mesh]) AND (wound* OR ulcer* OR callus*
OR “Diabetic Foot”[Mesh] OR “diabetic foot” OR “diabetic feet”) AND ("Toes"[Mesh] OR toe
OR toes OR phalange* OR "Lower Extremity"[Mesh] OR "Leg"[Mesh] OR leg OR legs OR
extremity OR "Foot"[Mesh] OR foot OR feet) AND ("Debridement"[Mesh] OR debrid* OR
slough* OR deslough* OR larva* OR maggot* OR MDT OR biosurgery OR bio-surgery OR
surgery OR surgical OR scalpel* OR hydrogel* OR "moist wound healing" OR enzyme* OR
mechanical OR autolytic OR ultrasound OR laser OR lasers OR sharp OR irrigate* OR irrigation
OR cleanse* OR whirlpool* OR collagenase* OR fibrinolytic* OR proteolytic* OR trypsin OR
streptokinase OR streptodornase OR varidase OR papain OR hypochlorite OR “hydrogen
peroxide” OR acid OR acids OR “propylene glycol” OR “dakin solution” OR dextranomer* OR
cadexomer* OR xerogel* OR eusol* OR debrisan* OR paste* OR iodoflex OR iodosorb OR
gauze* OR tulle OR polysaccharide* OR bead OR alginate*OR foam* OR hydrofibre* OR
hydrofiber* OR dressing* OR saline OR honey* OR gel OR gels OR hydrocolloid* OR
granuflex OR tegasorb OR aquacel OR hydrocoll* OR combiderm OR duoderm OR sterigel*
OR granugel* OR nugel OR purilon OR vigilon OR “zinc oxide” OR phenytoin) AND
systematic [sb] NOT (rat[ti] OR rats[ti] OR mice[ti] OR mouse[ti] OR dog[ti] OR dogs[ti] OR
cats[ti])
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PubMed Supplemental Search 2: pre-indexed citations
Dates Searched: 2014 to present
Results: 89
(diabetes OR diabetic* OR "Diabetes Mellitus"[Mesh]) AND (wound* OR ulcer* OR callus*
OR “Diabetic Foot”[Mesh] OR “diabetic foot” OR “diabetic feet”) AND ("Toes"[Mesh] OR toe
OR toes OR phalange* OR "Lower Extremity"[Mesh] OR "Leg"[Mesh] OR leg OR legs OR
extremity OR "Foot"[Mesh] OR foot OR feet) AND ("Debridement"[Mesh] OR debrid* OR
slough* OR deslough* OR larva* OR maggot* OR MDT OR biosurgery OR bio-surgery OR
surgery OR surgical OR scalpel* OR hydrogel* OR "moist wound healing" OR enzyme* OR
mechanical OR autolytic OR ultrasound OR laser OR lasers OR sharp OR irrigate* OR irrigation
OR cleanse* OR whirlpool* OR collagenase* OR fibrinolytic* OR proteolytic* OR trypsin OR
streptokinase OR streptodornase OR varidase OR papain OR hypochlorite OR “hydrogen
peroxide” OR acid OR acids OR “propylene glycol” OR “dakin solution” OR dextranomer* OR
cadexomer* OR xerogel* OR eusol* OR debrisan* OR paste* OR iodoflex OR iodosorb OR
gauze* OR tulle OR polysaccharide* OR bead OR alginate*OR foam* OR hydrofibre* OR
hydrofiber* OR dressing* OR saline OR honey* OR gel OR gels OR hydrocolloid* OR
granuflex OR tegasorb OR aquacel OR hydrocoll* OR combiderm OR duoderm OR sterigel*
OR granugel* OR nugel OR purilon OR vigilon OR “zinc oxide” OR phenytoin) NOT ("CrossSectional Studies"[MeSH Terms] OR “Case Reports”[pt] OR Comment[pt] OR Editorial[pt] OR
Letter[pt] OR Review[pt] OR "case control"[ti] OR "case report"[ti] OR "case study"[ti] OR
“case series”[ti] OR "Case-Control Studies"[Mesh] OR "Follow-Up Studies"[Mesh] OR
“observational study”[ti] OR “prospective cohort”[ti] OR “cohort studies” [Mesh:NoExp] OR
“cohort study”[ti] OR “Longitudinal Studies” [Mesh:NoExp] OR “Follow-Up Studies”[mesh]
OR “Retrospective Studies”[mesh] OR “non-randomized”[ti] OR “follow up study”[ti] OR rat[ti]
OR rats[ti] OR mice[ti] OR mouse[ti] OR dog[ti] OR dogs[ti] OR cats[ti])
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3 Ovid EMBASE, Embase via Scopus search strategy
The trials search coordinator with the Cochrane Review Group - Wound searched the database
Embase utilizing the following search strategy and dates:
Database: Embase <1996 to 2013 Week 13>
Search Strategy:
-------------------------------------------------------------------------------1 exp Decubitus/ (9327)
2 (pressure adj (ulcer$ or sore$)).ti,ab. (5772)
3 (decubitus adj (ulcer$ or sore$)).ti,ab. (801)
4 (bedsore$ or (bed adj sore$)).ti,ab. (417)
5 or/1-4 (10522)
6 exp Nutrition/ (910056)
7 nutrition$.ti,ab. (142489)
8 diet$.ti,ab. (282256)
9 (tube adj (fed or feed or feeding)).ti,ab. (2344)
10 or/6-9 (1017934)
11 5 and 10 (1232)
12 exp Clinical trial/ (798274)
13 Randomized controlled trial/ (288746)
14 Randomization/ (50983)
15 Single blind procedure/ (15731)
16 Double blind procedure/ (86635)
17 Crossover procedure/ (32192)
18 Placebo/ (167856)
19 Randomi?ed controlled trial$.tw. (81720)
20 RCT.tw. (10802)
21 Random allocation.tw. (919)
22 Randomly allocated.tw. (14440)
23 Allocated randomly.tw. (1221)
24 (allocated adj2 random).tw. (265)
25 Single blind$.tw. (9774)
26 Double blind$.tw. (91413)
27 ((treble or triple) adj blind$).tw. (244)
28 Placebo$.tw. (139064)
29 Prospective study/ (203909)
30 or/12-29 (1099022)
31 Case study/ (16391)
32 Case report.tw. (169255)
33 Abstract report/ or letter/ (515715)
34 or/31-33 (697032)
35 30 not 34 (1070653)
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36 animal/ (727929)
37 human/ (8737685)
38 36 not 37 (486914)
39 35 not 38 (1048222)
40 11 and 39 (227)
41 (2011* or 2012* or 2013*).em. (2630697)
42 40 and 41 (47)
The authors conducted an independent search in conjunction with our library search coordinator
at the University of Connecticut. The database EMBASE via Scopus was searched utilizing the
following search strategy and search dates:
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EMBASE via Scopus
Dates Searched: 1960 to present
Limiters: Exclude Publication Types: Review, Editorial, Letter
Results: 893
1 diabet*
2 (wound* OR ulcer* OR callus* OR “diabetic foot” OR “diabetic feet”)
3 (toe OR toes OR phalange* OR "lower extremity" OR leg OR legs OR extremity OR foot OR
feet)
4 (debrid* OR slough* OR deslough* OR larva* OR maggot* OR MDT OR biosurgery OR biosurgery OR surgery OR surgical OR scalpel* OR hydrogel* OR "moist wound healing" OR
enzyme* OR mechanical OR autolytic OR ultrasound OR laser OR lasers OR sharp OR irrigate*
OR irrigation OR cleanse* OR whirlpool* OR collagenase* OR fibrinolytic* OR proteolytic*
OR trypsin OR streptokinase OR streptodornase OR varidase OR papain OR hypochlorite OR
“hydrogen peroxide” OR acid OR acids OR “propylene glycol” OR “dakin solution” OR
dextranomer* OR cadexomer* OR xerogel* OR eusol* OR debrisan* OR paste* OR iodoflex
OR iodosorb OR gauze* OR tulle OR polysaccharide* OR bead OR alginate*OR foam* OR
hydrofibre* OR hydrofiber* OR dressing* OR saline OR honey* OR gel OR gels OR
hydrocolloid* OR granuflex OR tegasorb OR aquacel OR hydrocoll* OR combiderm OR
duoderm OR sterigel* OR granugel* OR nugel OR purilon OR vigilon OR “zinc oxide” OR
phenytoin)
5 (in article title) clinical OR trial
6 (in abstract) clinical OR trial
7 (in article title) random*
8 (in abstract) random*
9 “clinical trial”
10 #5 AND #6
11 #10 OR #7 OR #8 OR #9
12 #1 AND #2 AND #3 AND #4 AND #11
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13 (in article title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "crosssectional study" OR “case report” OR comment OR editorial OR letter OR "case control" OR
"case study" OR “case series” OR "follow-up study” OR “observational study” OR “prospective
cohort” OR “cohort study” OR “longitudinal study” OR “retrospective study” OR “nonrandomized” OR review
14 #12 AND NOT #13

412

EMBASE Supplemental Search: systematic reviews & meta-analysis
Dates Searched: 1960 to present
Limiters: Exclude Publication Types: Editorial, Letter
Results: 189
1 diabet*
2 (wound* OR ulcer* OR callus* OR “diabetic foot” OR “diabetic feet”)
3 (toe OR toes OR phalange* OR "lower extremity" OR leg OR legs OR extremity OR foot OR
feet)
4 (debrid* OR slough* OR deslough* OR larva* OR maggot* OR MDT OR biosurgery OR biosurgery OR surgery OR surgical OR scalpel* OR hydrogel* OR "moist wound healing" OR
enzyme* OR mechanical OR autolytic OR ultrasound OR laser OR lasers OR sharp OR irrigate*
OR irrigation OR cleanse* OR whirlpool* OR collagenase* OR fibrinolytic* OR proteolytic*
OR trypsin OR streptokinase OR streptodornase OR varidase OR papain OR hypochlorite OR
“hydrogen peroxide” OR acid OR acids OR “propylene glycol” OR “dakin solution” OR
dextranomer* OR cadexomer* OR xerogel* OR eusol* OR debrisan* OR paste* OR iodoflex
OR iodosorb OR gauze* OR tulle OR polysaccharide* OR bead OR alginate*OR foam* OR
hydrofibre* OR hydrofiber* OR dressing* OR saline OR honey* OR gel OR gels OR
hydrocolloid* OR granuflex OR tegasorb OR aquacel OR hydrocoll* OR combiderm OR
duoderm OR sterigel* OR granugel* OR nugel OR purilon OR vigilon OR “zinc oxide” OR
phenytoin)
5 “systematic review” OR “systematic literature review” OR “meta-analysis” OR “metasynthesis”
6 #1 AND #2 AND #3 AND #4 AND #5
7 (in article title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats
8 #6 AND NOT #7
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4 EBSCO CINAHL search strategy
The trials search coordinator with the Cochrane Review Group - Wound searched the database
EBSCO CINAHL utilizing the following search strategy and dates:
S30S23 and S29
S29S24 or S25 or S26 or S27 or S28
S28TI diabet* N3 wound* or AB diabet* N3 wound*
S27TI (diabet* N3 foot or diabet* N3 feet) or AB (diabet* N3 foot or diabet* N3 feet)
S26TI diabet* N3 ulcer* or AB diabet* N3 ulcer*
S25(MH "Foot Ulcer+")
S24(MH "Diabetic Foot")
S23S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or
S15 or S16 or S17 or S18 or S19 or S20 or S21 or S22
S22TI zinc oxide or AB zinc oxide
S21(MH "Zinc Oxide")
S20TI (hydrogel* or intrasite gel or intrasitgel or sterigel or granugel or nugel or purilon or
vigilon) or AB (hydrogel* or intrasite gel or intrasitgel or sterigel or granugel or nugel or purilon
or vigilon)
S19(MH "Hydrogel Dressings")
S18TI honey or AB honey
S17(MH "Honey")
S16TI wet-to-dry dressings or AB wet-to-dry dressings
S15TI (dressing* or gauze or adherent or absorbent or tulle or polysaccaride or alginate or foam
or hydrofibre or hydrofiber or hydrocolloid* or granuflex or tegasorb or aquacel or hydrocoll* or
combiderm or duoderm)or AB (dressing* or gauze or adherent or absorbent or tulle or
polysaccaride or alginate or foam or hydrofibre or hydrofiber or hydrocolloid* or granuflex or
tegasorb or aquacel or hydrocoll* or combiderm or duoderm)
S14TI ( iodoflex or iodosorb ) or AB ( iodoflex or iodosorb )
S13TI (polysaccharide bead* or polysaccharide paste) or AB (polysaccharide bead* or
polysaccharide paste)
S12TI (dextranomer* or cadexomer or xerogel or eusol or debrisan) or AB (dextranomer* or
cadexomer or xerogel or eusol or debrisan)
S11TI dakin solution or AB dakin solution
S10TI (malic acid or benzoid acid or salicylic acid or propylene glycol) or AB (malic acid or
benzoid acid or salicylic acid or propylene glycol)
S9TI (hypochlorite or hydrogen peroxide) or AB (hypochlorite or hydrogen peroxide)
S8TI whirlpool or AB whirlpool
S7TI (wound irrigat* or wound cleans*) or AB (wound irrigat* or wound cleans*)
S6TI papain or AB papain
S5TI (collagenase* or fibrinolytic* or proteolytic* or trypsin or streptokinase or streptodornase
or varidase) or AB (collagenase* or fibrinolytic* or proteolytic* or trypsin or streptokinase or
streptodornase or varidase)
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S4TI (larva* or maggot* or biosurgery or bio-surgery) or AB (larva* or maggot* or biosurgery
or bio-surgery)
S3(MH "Larval Therapy")
S2TI (debrid* or slough* or deslough*) or AB (debrid* or slough* or deslough*)
S1(MH "Debridement")
The authors conducted an independent search in conjunction with our library search coordinator
at the University of Connecticut. The database EBSCO CINAHL was searched utilizing the
following search strategy and search dates:
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CINAHL
Dates Searched: 1981 to present
Limiters: Exclude MEDLINE records; Human
Results: 57
S1 (MH "Diabetes Mellitus+")
S2 diabet*
S3 (MH "Diabetic Foot")
S4 wound* OR ulcer* OR callus* OR “diabetic feet” OR “diabetic foot”
S5 (MH "Toes")
S6 (MH "Lower Extremity+")
S7 (MH "Leg")
S8 (MH "Foot+")
S9 toe OR toes OR phalange* OR leg OR legs OR extremity OR foot OR feet
S10 (MH "Debridement+")
S11 debrid* or slough* OR deslough* OR larva* OR maggot* OR MDT OR biosurgery OR biosurgery OR surgery OR surgical OR scalpel* OR hydrogel* OR "moist wound healing" OR
enzyme* OR mechanical OR autolytic OR ultrasound OR laser OR lasers OR sharp OR irrigate*
OR irrigation OR cleanse* OR whirlpool* OR collagenase* OR fibrinolytic* OR proteolytic*
OR trypsin OR streptokinase OR streptodornase OR varidase OR papain OR hypochlorite OR
"hydrogen peroxide" OR acid OR acids OR "propylene glycol" OR "dakin solution" OR
dextranomer* OR cadexomer* OR xerogel* OR eusol* OR debrisan* OR paste* OR iodoflex
OR iodosorb OR gauze* OR tulle OR polysaccharide* OR bead OR alginate* OR foam* OR
hydrofibre* OR hydrofiber* OR dressing* OR saline OR honey* OR gel OR gels OR
hydrocolloid* OR granuflex OR tegasorb OR aquacel OR hydrocoll* OR combiderm OR
duoderm OR sterigel* OR granugel* OR nugel OR purilon OR vigilon OR "zinc oxide" OR
phenytoin
S12 TI (clinical OR trial) AND AB (clinical OR trial)
S13 (MH "Clinical Trials+")
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S14 TI random* OR AB random*
S15 S1 OR S2
S16 S3 OR S4
S17 S5 OR S6 OR S7 OR S8 OR S9
S18 S10 OR S11
S19 S12 OR S13 OR S14
S20 S15 AND S16 AND S17 AND S18 AND S19
S21 (in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "cross-sectional
study" OR “case report” OR comment OR editorial OR letter OR "case control" OR "case study"
OR “case series” OR "follow-up study” OR “observational study” OR “prospective cohort” OR
“cohort study” OR “longitudinal study” OR “retrospective study” OR “non-randomized” OR
review
S22 S20 NOT S21
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CINAHL Supplemental Search: systematic reviews & meta-analysis
Dates Searched: 1981 to present
Limiters: Exclude MEDLINE records; Human; Publication Type: Meta Analysis, Meta
Synthesis, Systematic Review
Results: 18
S1 (MH "Diabetes Mellitus+")
S2 diabet*
S3 (MH "Diabetic Foot")
S4 wound* OR ulcer* OR callus* OR “diabetic feet” OR “diabetic foot”
S5 (MH "Toes")
S6 (MH "Lower Extremity+")
S7 (MH "Leg")
S8 (MH "Foot+")
S9 toe OR toes OR phalange* OR leg OR legs OR extremity OR foot OR feet
S10 (MH "Debridement+")
S11 debrid* or slough* OR deslough* OR larva* OR maggot* OR MDT OR biosurgery OR biosurgery OR surgery OR surgical OR scalpel* OR hydrogel* OR "moist wound healing" OR
enzyme* OR mechanical OR autolytic OR ultrasound OR laser OR lasers OR sharp OR irrigate*
OR irrigation OR cleanse* OR whirlpool* OR collagenase* OR fibrinolytic* OR proteolytic*
OR trypsin OR streptokinase OR streptodornase OR varidase OR papain OR hypochlorite OR
"hydrogen peroxide" OR acid OR acids OR "propylene glycol" OR "dakin solution" OR
dextranomer* OR cadexomer* OR xerogel* OR eusol* OR debrisan* OR paste* OR iodoflex
OR iodosorb OR gauze* OR tulle OR polysaccharide* OR bead OR alginate* OR foam* OR
hydrofibre* OR hydrofiber* OR dressing* OR saline OR honey* OR gel OR gels OR
hydrocolloid* OR granuflex OR tegasorb OR aquacel OR hydrocoll* OR combiderm OR
duoderm OR sterigel* OR granugel* OR nugel OR purilon OR vigilon OR "zinc oxide" OR
phenytoin
S12 S1 OR S2

418

S13 S3 OR S4
S14 S5 OR S6 OR S7 OR S8 OR S9
S15 S10 OR S11
S16 S12 AND S13 AND S14 AND S15
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5 Web of Science search strategy
The authors conducted an independent search in conjunction with our library search coordinator
at the University of Connecticut. The database Web of Science was searched utilizing the
following search strategy and search dates:
Web of Science
Dates Searched: 1974 to present
Results: 522
1 diabet*
2 (wound* OR ulcer* OR callus* OR “diabetic foot” OR “diabetic feet”)
3 (toe OR toes OR phalange* OR "lower extremity" OR leg OR legs OR extremity OR foot OR
feet)
4 (debrid* OR slough* OR deslough* OR larva* OR maggot* OR MDT OR biosurgery OR biosurgery OR surgery OR surgical OR scalpel* OR hydrogel* OR "moist wound healing" OR
enzyme* OR mechanical OR autolytic OR ultrasound OR laser OR lasers OR sharp OR irrigate*
OR irrigation OR cleanse* OR whirlpool* OR collagenase* OR fibrinolytic* OR proteolytic*
OR trypsin OR streptokinase OR streptodornase OR varidase OR papain OR hypochlorite OR
“hydrogen peroxide” OR acid OR acids OR “propylene glycol” OR “dakin solution” OR
dextranomer* OR cadexomer* OR xerogel* OR eusol* OR debrisan* OR paste* OR iodoflex
OR iodosorb OR gauze* OR tulle OR polysaccharide* OR bead OR alginate*OR foam* OR
hydrofibre* OR hydrofiber* OR dressing* OR saline OR honey* OR gel OR gels OR
hydrocolloid* OR granuflex OR tegasorb OR aquacel OR hydrocoll* OR combiderm OR
duoderm OR sterigel* OR granugel* OR nugel OR purilon OR vigilon OR “zinc oxide” OR
phenytoin)
5 clinical AND trial
6 random*
8 #5 OR #6
11 #1 AND #2 AND #3 AND #4 AND #8
12 Title=(rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "cross-sectional study"
OR “case report” OR comment OR editorial OR letter OR "case control" OR "case study" OR
“case series” OR "follow-up study” OR “observational study” OR “prospective cohort” OR
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“cohort study” OR “longitudinal study” OR “retrospective study” OR “non-randomized” OR
review)
13 #11 NOT #12
Web of Science Supplemental Search: systematic reviews & meta-analysis
Dates Searched: 1974 to present
Results: 70
1 diabet*
2 (wound* OR ulcer* OR callus* OR “diabetic foot” OR “diabetic feet”)
3 (toe OR toes OR phalange* OR "lower extremity" OR leg OR legs OR extremity OR foot OR
feet)
4 (debrid* OR slough* OR deslough* OR larva* OR maggot* OR MDT OR biosurgery OR biosurgery OR surgery OR surgical OR scalpel* OR hydrogel* OR "moist wound healing" OR
enzyme* OR mechanical OR autolytic OR ultrasound OR laser OR lasers OR sharp OR irrigate*
OR irrigation OR cleanse* OR whirlpool* OR collagenase* OR fibrinolytic* OR proteolytic*
OR trypsin OR streptokinase OR streptodornase OR varidase OR papain OR hypochlorite OR
“hydrogen peroxide” OR acid OR acids OR “propylene glycol” OR “dakin solution” OR
dextranomer* OR cadexomer* OR xerogel* OR eusol* OR debrisan* OR paste* OR iodoflex
OR iodosorb OR gauze* OR tulle OR polysaccharide* OR bead OR alginate*OR foam* OR
hydrofibre* OR hydrofiber* OR dressing* OR saline OR honey* OR gel OR gels OR
hydrocolloid* OR granuflex OR tegasorb OR aquacel OR hydrocoll* OR combiderm OR
duoderm OR sterigel* OR granugel* OR nugel OR purilon OR vigilon OR “zinc oxide” OR
phenytoin)
5 ("systematic review" OR "systematic literature review" OR "meta-analysis" OR "metasynthesis")
6 #1 AND #2 AND #3 AND #4 AND #5
7 Title=(rat OR rats OR mice OR mouse OR dog OR dogs OR cats )
8 #6 NOT #7
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6 The Cochrane Library search strategy
The authors conducted an independent search in conjunction with our library search coordinator
at the University of Connecticut. The database Web of Science was searched utilizing the
following search strategy and search dates:
The Cochrane Library
Dates searched: 1898 to present
Results: 103 Central Register of Controlled Trials (CENTRAL)
3 Database of Abstracts of Reviews of Effect (DARE)
Title, Abstract, Keywords= debrid*
AND
Title, Abstract, Keywords= diabet*
NOT
Record Title=(rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "cross-sectional
study" OR “case report” OR comment OR editorial OR letter OR "case control" OR "case study"
OR “case series” OR "follow-up study” OR “observational study” OR “prospective cohort” OR
“cohort study” OR “longitudinal study” OR “retrospective study” OR “non-randomized”)
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7 Cochrane Wounds Group Specialized Register (Searched
15/04/15)
Cochrane Wounds Group Specialized Register (Searched 15/04/15)
The Cochrane Central Register of Controlled Trials (CENTRAL) - The Cochrane Library 2015,
Issue 3
Ovid MEDLINE & Ovid MEDLINE - In-Process & Other Non-Indexed Citations 2013 to April
14 2015
Ovid EMBASE - 2013 to April 14 2015
EBSCO CINAHL - 2013 to April 15 2015
Cinahl Search Strategy
S43 S30 and S42
S42 S31 or S32 or S33 or S34 or S35 or S36 or S37 or S38 or S39 or S40 or S41
S41 MH "Quantitative Studies"
S40 TI placebo* or AB placebo*
S39 MH "Placebos"
S38 TI random* allocat* or AB random* allocat*
S37 MH "Random Assignment"
S36 TI randomi?ed control* trial* or AB randomi?ed control* trial*
S35 AB ( singl* or doubl* or trebl* or tripl* ) and AB ( blind* or mask* )
S34 TI ( singl* or doubl* or trebl* or tripl* ) and TI ( blind* or mask* )
S33 TI clinic* N1 trial* or AB clinic* N1 trial*
S32 PT Clinical trial
S31 MH "Clinical Trials+"
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S30 S23 and S29
S29 S24 or S25 or S26 or S27 or S28
S28 TI diabet* N3 wound* or AB diabet* N3 wound*
S27 TI (diabet* N3 foot or diabet* N3 feet) or AB (diabet* N3 foot or diabet* N3 feet)
S26 TI diabet* N3 ulcer* or AB diabet* N3 ulcer*
S25 (MH "Foot Ulcer+")
S24 (MH "Diabetic Foot")
S23 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or
S15 or S16 or S17 or S18 or S19 or S20 or S21 or S22
S22 TI zinc oxide or AB zinc oxide
S21 (MH "Zinc Oxide")
S20 TI ( hydrogel* or intrasite gel or intrasitgel or sterigel or granugel or nugel or purilon or
vigilon ) or AB ( hydrogel* or intrasite gel or intrasitgel or sterigel or granugel or nugel or
purilon or vigilon )
S19 (MH "Hydrogel Dressings")
S18 TI honey or AB honey
S17 (MH "Honey")
S16 TI wet-to-dry dressings or AB wet-to-dry dressings
S15 TI ( dressing* or gauze or adherent or absorbent or tulle or polysaccaride or alginate or foam
or hydrofibre or hydrofiber or hydrocolloid* or granuflex or tegasorb or aquacel or hydrocoll* or
combiderm or duoderm ) or AB ( dressing* or gauze or adherent or absorbent or tulle or
polysaccaride or alginate or foam or hydrofibre or hydrofiber or hydrocolloid* or granuflex or
tegasorb or aquacel or hydrocoll* or combiderm or duoderm )
S14 TI ( iodoflex or iodosorb ) or AB ( iodoflex or iodosorb )
S13 TI ( polysaccharide bead* or polysaccharide paste ) or AB ( polysaccharide bead* or
polysaccharide paste )
S12 TI ( dextranomer* or cadexomer or xerogel or eusol or debrisan ) or AB ( dextranomer* or
cadexomer or xerogel or eusol or debrisan )
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S11 TI dakin solution or AB dakin solution
S10 TI ( malic acid or benzoid acid or salicylic acid or propylene glycol ) or AB ( malic acid or
benzoid acid or salicylic acid or propylene glycol )
S9 TI ( hypochlorite or hydrogen peroxide ) or AB ( hypochlorite or hydrogen peroxide )
S8 TI whirlpool or AB whirlpool
S7 TI ( wound irrigat* or wound cleans* ) or AB ( wound irrigat* or wound cleans* )
S6 TI papain or AB papain
S5 TI ( collagenase* or fibrinolytic* or proteolytic* or trypsin or streptokinase or streptodornase
or varidase ) or AB ( collagenase* or fibrinolytic* or proteolytic* or trypsin or streptokinase or
streptodornase or varidase )
S4 TI ( larva* or maggot* or biosurgery or bio-surgery ) or AB ( larva* or maggot* or
biosurgery or bio-surgery )
S3 (MH "Larval Therapy")
S2 TI ( debrid* or slough* or deslough* ) or AB ( debrid* or slough* or deslough* )
S1 (MH "Debridement")
Search Name: 42 Smith Debridement for DFU_Issue 3 2015
Date Run: 17/06/15 08:33:47.466
Description: Re-ran searches over all issues (Issue 3 2015) [Revised SS Issue 2 2009]
ID Search Hits
#1 MeSH descriptor: [Debridement] explode all trees
#2 (debrid* or slough* or deslough*):ti,ab,kw
#3 MeSH descriptor: [Larva] explode all trees
#4 (larva* or maggot* or biosurgery or bio-surgery):ti,ab,kw
#5 (wound* next (irrigat* or cleanse*)):ti,ab,kw
#6 whirlpool:ti,ab,kw
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#7 (collagenase* or fibrinolytic* or proteolytic* or trypsin or streptokinase or streptodornase or
varidase):ti,ab,kw
#8 MeSH descriptor: [Papain] explode all trees
#9 papain:ti,ab,kw
#10 (hypochlorite or hydrogen peroxide):ti,ab,kw
#11 (malic acid or benzoid acid or salicylic acid or propylene glycol):ti,ab,kw
#12 "dakin solution":ti,ab,kw
#13 (dextranomer* or cadexomer or xerogel or eusol or debrisan):ti,ab,kw
#14 (polysaccharide next (bead* or paste*)):ti,ab,kw
#15 (iodoflex or iodosorb):ti,ab,kw
#16 (((gauze or adherent or absorbent or tulle or polysaccaride or alginate or foam or hydrofibre
or hydrofiber) next dressing*) or saline gauze or hydrocolloid* or granuflex or tegasorb or
aquacel or hydrocoll* or combiderm or duoderm):ti,ab,kw
#17 "wet-to-dry dressings":ti,ab,kw
#18 MeSH descriptor: [Honey] explode all trees
#19 honey:ti,ab,kw 302
#20 MeSH descriptor: [Hydrogel] explode all trees
#21 (hydrogel* or intrasite gel or intrasitgel or sterigel or granugel or nugel or purilon or
vigilon):ti,ab,kw
#22 MeSH descriptor: [Zinc Oxide] explode all trees
#23 "zinc oxide":ti,ab,kw
#24 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15
or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23
#25 MeSH descriptor: [Foot Ulcer] explode all trees
#26 MeSH descriptor: [Diabetic Foot] explode all trees
#27 diabet* near/3 ulcer*:ti,ab,kw
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#28 diabet* near/3 (foot or feet):ti,ab,kw
#29 diabet* near/3 wound*:ti,ab,kw
#30 #25 or #26 or #27 or #28 or #29
#31 #24 and #30
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Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid
MEDLINE(R) <1946 to Present>
Search Strategy:
-------------------------------------------------------------------------------1 exp Debridement/
2 (debrid$ or slough$ or deslough$).ti,ab.
3 exp Larva/
4 (larva$ or maggot$ or biosurgery or bio-surgery).ti,ab.
5 (wound$ adj (irrigat$ or cleanse$)).ti,ab.
6 whirlpool.ti,ab.
7 (collagenase$ or fibrinolytic$ or proteolytic$ or trypsin or streptokinase or streptodornase or
varidase).ti,ab.
8 exp Papain/
9 papain.ti,ab.
10 (hypochlorite or hydrogen peroxide).ti,ab.
11 (malic acid or benzoid acid or salicylic acid or propylene glycol).ti,ab.
12 dakin solution.ti,ab.
13 (dextranomer$ or cadexomer or xerogel or eusol or debrisan).ti,ab.
14 (polysaccharide adj (bead$ or paste$)).ti,ab.
15 (iodoflex or iodosorb).ti,ab.
16 (((gauze or adherent or absorbent or tulle or polysaccaride or alginate or foam or hydrofibre
or hydrofiber) adj dressing$) or saline gauze or hydrocolloid$ or granuflex or tegasorb or aquacel
or hydrocoll or combiderm or duoderm).ti,ab.
17 "wet-to-dry dressings".ti,ab.
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18 exp Honey/
19 honey$.ti,ab.
20 exp Hydrogel/
21 (hydrogel$ or intrasite gel or intrasitgel or sterigel or granugel or nugel or purilon or
vigilon).ti,ab.
22 exp Zinc Oxide/
23 zinc oxide.ti,ab.
24 or/1-23
25 exp Foot Ulcer/
26 exp Diabetic Foot/
27 (diabet$ adj3 ulcer$).ti,ab.
28 (diabet$ adj3 (foot or feet)).ti,ab.
29 (diabet$ adj3 wound$).ti,ab.
30 or/25-29
31 24 and 30
32 randomized controlled trial.pt.
33 controlled clinical trial.pt.
34 randomized.ab.
35 placebo.ab.
36 clinical trials as topic.sh.
37 randomly.ab.
38 trial.ti.
39 or/32-38
40 (animals not (humans and animals)).sh.
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41 39 not 40
42 31 and 41
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Database: Embase <1974 to 2015 June 16>
Search Strategy:
-------------------------------------------------------------------------------1 exp Decubitus/
2 (pressure adj (ulcer$ or sore$)).ti,ab.
3 (decubitus adj (ulcer$ or sore$)).ti,ab.
4 (bedsore$ or (bed adj sore$)).ti,ab.
5 or/1-4
6 exp Nutrition/
7 nutrition$.ti,ab.
8 diet$.ti,ab.
9 (tube adj (fed or feed or feeding)).ti,ab.
10 or/6-9
11 5 and 10
12 exp Clinical trial/
13 Randomized controlled trial/
14 Randomization/
15 Single blind procedure/
16 Double blind procedure/
17 Crossover procedure/
18 Placebo/
19 Randomi?ed controlled trial$.tw.
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20 RCT.tw.
21 Random allocation.tw.
22 Randomly allocated.tw.
23 Allocated randomly.tw.
24 (allocated adj2 random).tw.
25 Single blind$.tw.
26 Double blind$.tw.
27 ((treble or triple) adj blind$).tw.
28 Placebo$.tw.
29 Prospective study/
30 or/12-29
31 Case study/
32 Case report.tw.
33 Abstract report/ or letter/
34 or/31-33
35 30 not 34
36 animal/
37 human/
38 36 not 37
39 35 not 38
40 11 and 39
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Appendix 2
DATA EXTRACTION CODING FORM
DEBRIDEMENT OF DIABETIC FOOT ULCERS
SYSTEMATIC REVIEW, META-ANALYSIS, AND META_REGRESSION
Developed July 2013
For any missing or unreported data, indicate with “blank”
Study Information
(V1)

coder

________ Coder (Dayya = 1, Huedo-Medina = 2, O’Neill = 3, Habib = 4, Other = 5)

(V2) study_id

________ Study ID # Study Citation (e.g. 1stAuthorJournalYear, i.e. SmithJAMA2014 ):

(V3)

________ Publication Year (e.g. 2014) (consider this missing if unpublished)

pub_yr

(V4) data_yr

________ Estimated year of data collection (e.g. 2014) (earliest date for data collection or
manuscript submission/publication; if unpublished and date unknown, use year
manuscript was acquired; for
dissertation or thesis, use year)

(V5) lang

________ Language of publication
0=English
1=Spanish
2=French
3=German
4=Other, specify: __________________________

(V6) source

________:
0= journal
1= book
2= thesis/dissertation
3= conference proceedings
4= unpublished document/abstract
5= other, specify:______________________

(V7)

finance

__________Financial Support
0= None
1= Public; agency:____________________
2= Private; company:_______________________
3= Unclear

(V8)

score

________ Impact Score of the Journal (use ISI Web of Knowledge journal citation reports)

(V9)

debride

________Method of Debridement Intervention
0= Autolytic
1= Sharp/Surgical Debridement
2= Biosurgery or Maggot debridement Therapy
3= Mechanical Debridement
4= Enzymatic Debridement
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Sample

5= Ultrasound
6= Laser
Characteristics (proportion: 0.0- 1.0)

(V7)
(V8)
(V9)
(V10)
(V11)
(V12)

eth
prop_wh
prop_blk
prop_hisp
prop_asian
prop_min

________
________
________
________
________
________

Ethnicity reported? 0 = no; 1 = yes
Proportion Caucasian (e.g. 0.50 for 50%); if whole number available:______
Proportion African American; if whole number: ______
Proportion Latino/Hispanic; if whole number: ______
Proportion Asian; if whole number: ______
Proportion Minority/other; if whole number: ______

(V13)
(V14)
(V15)
(V16)

educ
prop_hs
prop_coll
prop_grad

________
________
________
________

Education reported? 0 = no; 1 = yes
Proportion high school; if whole number available: ______
Proportion college; if whole number available: ______
Proportion graduate school; if whole number available:______

(V17)
(V18)
(V19)
(V20)

ses
prop_low
prop_mid
prop_high

________
________
________
________

SES reported? 0 = no; 1 = yes
Proportion of low SES Low (< 25k)
Proportion of Middle SES (25k-100k)
Proportion of high SES (>100k)

(V21) #female
(V22) prop_fem

________ Number of Females in Sample as a whole number?
________ Proportion of females in sample (e.g. 0.50 for 50%)

(V23) region

________ of sample
1=American city: __________________
2=Other U.S. general region (city not specified): __________________
3=Canada (city: _______________________)
4=Europe (city: _______________________)
5=South or Central America, Mexico, Caribbean (city: _______________________)
6=Africa (city: _______________________)
7=Asia (city: _______________________)
8=Australia (city: _______________________)

(V24) us_zip

________ Zip Code (US Only) _____________

(V25) pop_type

________ Population
0= Not reported
1= Outpatient Office
2= Specialized Center source (e.g., wound clinic/center, hyperbaric center)
________________________________________________________
3=Hospitalized; specify source (e.g. inpatient, hospital):
________________________________________________________

________ Notes on sample characteristics relevant to coding
_______________________________________________________________________________
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Risk Characteristics (if SEM, change to SD; SD= SEM *√𝑛; use DSTAT to pool variances if applicable)
(V26) age
(V27) age_sd

________ Mean age of total sample (years)
________ SD for age (years)

(V28) ht
(V29) ht_sd

________ Mean height of total sample (cm)
________ SD of height (cm)

(V30) wt
(V31) wt_sd

________ Mean weight of total sample (kg)
________ SD of weight (kg)

(V32) waist
(V33) waist_sd

________ Mean waist circumference of total sample (cm)
________ SD of waist circumference (cm)

(V34) w-h
(V35) w-h_sd

________ Mean Waist-to-Hip Ratio of total sample
________ SD of Waist-to-Hip Ratio

(V36) bmi

________ Mean Body Mass Index of total sample (BMI, kg•m-2) (if calculating, use
NHLBI equation)
________ SD of mean BMI for total sample.
________ Proportion normal weight (18.5-24.9)
________ Proportion overweight (25.0-29.9)
________ Proportion obese, Class I (30.0-34.9)
________ Proportion obese, Class II (35.0-39.9)
________ Proportion obese, Class III (≥ 40.0)

(V37)
(V38)
(V39)
(V40)
(V41)
(V42)

bmi_sd
bmi_norm
bmi_over
bmi_obese1
bmi_obese2
bmi_obese3

(V43) bf%
(V44) bf%_sd
(V45) bf%_assess

________ Mean value of body fat composition of total sample (Body Fat %)
________ SD of Body Fat %
________ Method of Body Fat % Assessment
1= Skinfold thickness
2= Hydrostatic weighing
3= Bioelectrical impedance, specify:_________________
4= Air displacement plethysmography, specify:_________________
5= Dual energy x-ray absorptiometry (DEXA),
specify:_________________
6= Other, specify:__________________

(V46)

prop_pad

________ Proportion of total sample with peripheral arterial vascular disease; if
whole number available__

(V47)

tcpo2

________ Mean peri-wound tissue oxygenation levels (mmHg) for total sample.

(V48)

hgba1c

________ Mean Hgba1c (% glycosylated Hgb) for total sample.

(V49)

prop_immune

________ Proportion of total sample with immunosuppression including: HIV
status, chemotherapy, steroids, immunosuppressants; If whole number
available__

(V50)

prop_hd

________ Proportion of total sample with history of coronary heart disease; if
whole number available ______

(V51)

prop_ htn

________ Proportion of total sample with hypertension;
if whole number available ______
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(V52) prop_thyroid

________ Proportion of total sample with Thyroid disease; if whole number
available _____
(If mean TSH level available for total sample enter this value instead and
Notate accordingly in coding form)

(V53) prop_neurop

_________ Proportion of total sample with peripheral Neuropathy; if whole
number available _____

(V54) prop_venous

_________ Proportion of total sample with Venous Insufficiency; if whole number
available ______

(V55) prop_rf

_________ Proportion of total sample w/ Renal Failure/Dialysis; if whole number
available ______
(If mean creatinine level for total sample is available enter this value
instead and notate accordingly in coding form)

(V56) prop_anemia

_________ Proportion of total sample with Anemia; if whole number available
______(If mean hemoglobin level for total sample is available enter this
value instead and notate accordingly in coding form)

(V57) prop_copd

_________ Proportion of total sample with Chronic Obstructive Pulmonary
Disease; if whole number available________ OR if available report
mean oxygen hemoglobin saturation for sample in mmHg. Notate
accordingly here in coding form which is to be used.

(V58) chf

________ Enter proportion of total sample with congestive heart failure

(V59) heartfunc

(V60) prop_sed

________ If available enter the functional classification of CHF/Heart Disease for
the sample according to New York Heart Association NYHA criteria.
0= Not Reported
1= Class I, 2= Class II, 3= Class III, 4= Class IV
________ Proportion of sample that is sedentary (≤ 2d/ wk of regular physical
activity); if whole number available ______

(V61) antithromb_med ________ Proportion of the patients on antithrombotic medications (includes
anticoagulants, antiplatelet agents aspirin/Nsaids, etc.)
(V62) prop_ocp_use

_________Proportion of total sample using oral contraceptives.

(V63) caffeine_use

________ Mean number of days per week of caffeine consumption for total sample

(V64) caffeine_day

________ Mean number of caffeinated beverages per day for total sample

(V65) caffeine_wk

________ Mean number of caffeinated beverages per week for total sample

(V66) prop_caffeine

________ Proportion of sample with regular caffeine consumption; if whole
number available ______

(V67) etoh_use

________ Mean number of days per week of alcohol consumption for total sample

(V68) etoh_day

________ Mean number of alcoholic drinks per day for total sample

(V69) etoh_wk

________ Mean number of alcoholic drinks per week for total sample
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(V70) prop_etoh

________ Proportion of sample reporting regular alcohol consumptions. Those
drinking at home and more often than restricting to social occasions; if
whole number available ______

(V71) smoking

________ Proportion of total sample currently smoking, or smoked within last 6
months.

(V72) smoking_yrs

________ Mean number of years smoking for total sample

(V73) smoke_pack

________ Mean number of packs per day for total sample

(V74) smoke_pack_yrs

________ (Pack years calculated in pack/day*yrs for total sample)

(V75) diabetes_duration ________ Enter the mean duration of diabetes in years for total sample.

Notes on risk characteristics relevant to coding
_____________________________________________________________________________________

Co-Interventions (Associated Standard of Care Measures in Diabetic Foot Ulcers)
(V76) offload

_________0= No, 1= Yes (includes orthotics, Inserts, crutches, wheelchairs, Partial weight-bearing,
Non weight bearing etc.), 2= Unclear

(V77) pt

_________0= No, 1= Yes, 2= Unclear If so number of sessions__________

(V78) nutcons

_________0= No, 1= Yes, 2= Unclear If so number of sessions__________

(V79) vascsurg

_________0= No, 1= Yes (Includes percutaneous interventions such as angioplasty, stenting, or
thrombectomy, bypass procedures), 2= Unclear If so number of procedures__________

(V80) hbot

_________0= No, 1= Yes, 2= Unclear If so number of sessions__________

(V81) antibiotic

_________0= No, 1= Yes (Includes topical or systemic treatment), 2= Unclear If so number of
sessions__________
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Methods & Design
DESIGN & MEASUREMENT
(V82)

design_typ ______Type of Design
1= Quasi-experimental
2= Matched with Randomization
3= Randomized controlled trial
4= Other:_______________________

(V83)

unit_assign ______Unit of Assignment
1= Community (e.g., city)
2= Group (hospital, clinic, etc.)
3= Individual
4= Other: _______________________

(V84)

recruit_meth _____Recruitment Method
1= Self-selected from community (e.g. via flyers, community centers, etc.)
2= Recruited on the internet
3= Recruited though chart review
4= Recruited through clinical contact (hospital, primary care, clinic, hyperbaric center,
wound center,
other consultant etc)
5= Experimental credit or equivalent in class (i.e. subject pool)
6= Other, specify: ___________________________________________
7= Unclear
(V85) accept_rate _____Acceptance rate (if reported: percent successfully recruited = # who agreed to
participate / #
targeted)
(V86)

incent

______Specific incentives offered/facilitators:
1. Free Medical Care 5. Transportation provided
2. Monetary
6. No apparent
3. Food
7. Other, specify:_______________________________
4. Childcare
8. Multiple, specify:____________________________

(V87)

#f/u

______Number of follow-ups: ______________________________
(e.g 1= acute/post intervention only, 2= pre and postintervention, 3, 4, 5 follow ups)

(V88)

f/u_int

______Interval of follow-ups: ______________________________
(0= acute, 1= every 3 days, 1= weekly, 2= biweekly, 3= monthly)

(V89)

short_f/u

______Short-term follow-up period for the entire study in weeks (if less than 1 year, specify
time(s):_____________________________)

(V90) long_f/u
more, specify

______Long-term follow-up period for the entire study in years (if greater than 1 year or
time(s):______________________________)

438

CONTROL/COMPARISON CONDITION:
**Label given by author and description of control condition (if more than one, use the control condition with
the least
contact such as an assessment only condition):
________________________________________________
(V91)

cont

_________Control condition:
0= No control/comparison group used.
1= Yes control/comparison group used.
2= Unclear

(V92)

cont_grp

_________Type of control group used
0= non-random assignment of individuals to conditions (i.e. intervention or control group)
1= random assignment of individuals to conditions (i.e. intervention or control group)
2= other, specify: _____________________________________________________

(V93)

cont_comp

(V94)

cont_meth

(V95)

#cont

(V96)

#part_beg_cont _________Number of participants at study beginning in the control/comparison group.

(V97)

#part_end_cont _________Number of participants at study completion in the control/comparison group.

(V98)

#part_lost_cont _________Number of participants lost during study in the control/comparison group

(V99)

%adhere_cont _________Percent Participant adherence in the control group (V97/V96) x 100 or

_________Composition of comparison condition
0= Targeted to group, other specify:
________________________________________________
1= Individual (e.g. targeted to one person)
2= Unclear
_________Method of control/comparison delivery was followed according to generally
accepted standards.
0= No
1= Yes
2= Unclear
_________Total number of participants in control/comparison group (Men: ______;
Women: ______)

𝑐𝑜𝑚𝑝𝑙𝑒𝑡𝑒𝑑 𝑠𝑒𝑠𝑠𝑖𝑜𝑛𝑠
)x100
𝑡𝑜𝑡𝑎𝑙 𝑠𝑒𝑠𝑠𝑖𝑜𝑛𝑠

(
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EXPERIMENTAL/INTERVENTION CONDITION:
(V100) #exp_cond

_________Number of experimental conditions for which effect sizes will be calculated
(complete pages separately if needed, using variables for each experimental

condition)
(V101) exp_cond

_________Specify intervention/experimental condition
0= Autolytic
1= Sharp/Surgical Debridement
2= Biosurgery or Maggot debridement Therapy
3= Mechanical Debridement
4= Enzymatic Debridement
5= Ultrasound
6= Laser

(V102) del_meth

_________Method of delivery:
0= Delivered by a primary care provider
1= Delivered by non-surgeon wound care physician
2= Delivered by a surgeon
3= Multiple/Other, specify:
______________________________________________________
4= Unclear

(V103) exp_meth

________Method of intervention delivery according to generally accepted standards.
0= No
1= Yes
2= Unclear

(V104) #part_beg_exp ______Number of participants at beginning of intervention in the experimental group
(V105) #part_end_exp ______Number of participants at study completion in the experimental group
(V106) #part_lost_exp ______Number of participants lost during study in the experimental group (V104-V105)
(V107) %adhere_exp ______ Percent participant adherence in the experimental group (V105/V104) x 100
𝑐𝑜𝑚𝑝𝑙𝑒𝑡𝑒𝑑 𝑠𝑒𝑠𝑠𝑖𝑜𝑛𝑠
)x100
𝑡𝑜𝑡𝑎𝑙 𝑠𝑒𝑠𝑠𝑖𝑜𝑛𝑠

or (
(V108) #sess_exp

_______Number of sessions in experimental group

(V109) #fac/exp

_______Number of facilitators/experimenters in the study. (blank if no contact/wait
list)_____

(V110) rand_assign

_______Random assignment
0= Violated randomization and/or nonequivalence of comparison group was not

addressed
1= Quasi-experimental design; group assignment, arbitrary assignment;
sequential; how:
_____________________
2= Matching individuals on some variable or strata (e.g., SES, age), then random
assignment
3= Random assignment of individuals
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(V111) qual_cont

_______Quality control
0 = No standardization of treatment is specified
1 = Treatment standardized by manual, specific training, content coding, sessions
monitored for fidelity.
2= Unclear

(V112) pretest_eval _______Pretest evaluation of intervention conducted. (0 = No, 1 = Yes, 2= Unclear)
(V113) f/u_rate

_______Follow-up rate (i.e., largest follow-up rate at any delayed post-test)
2 = 85-100% completed, 1 = 70 – 84% completed, 0 = <70% completed

(V114) f/u_length

_______Follow-up length of the study. (i.e. final assessment interval) ____________
2 = 6 months or longer, 1 = 3 to 5 months, 0 = less than 3 months
(V115) obj_meas __________Used objective measures to define the intervention..
0 = No objective measure used or unspecified
1 = Objective measures (e.g., laboratory testing) used in more than 50% of the cases
2= Unclear
(V116) with_drop __________Withdrawal/Drop-outs and/or attrition
0 = Not reported or all non-completers were excluded from analyses
1 = Enumerated
2 = Compared with completed cases (e.g., intent-to-treat; baseline differences, imputing
missing values)
(V117) %loss_f/u __________Loss to follow up?
(e.g 10%, 20%, 50%) % Dropouts______;If whole number available_______

_____Notes on methods & study design relevant to coding
______________________________________________________________________________________

(V118) exper _________Experimental condition(s)
Independent (unrelated/unpaired) groups
1= autolytic debridement control/comparison + one experimental group
2= autolytic debridement control/ comparison + two experimental groups
3= autolytic debridement control/ comparison + three experimental groups
4= autolytic debridement control/ comparison + three experimental groups
5= autolytic debridement control/ comparison + four experimental groups
6= autolytic debridement control/ comparison + five experimental groups
7= autolytic debridement control/comparison + six experimental groups
Non-Independent (related/paired) groups
6= autolytic debridement control/comparison + one experimental group
7= autolytic debridement control/ comparison + two experimental groups
8= autolytic debridement control/ comparison + three experimental groups
9= autolytic debridement control/ comparison + three experimental groups
10= autolytic debridement control/ comparison + four experimental groups
11= autolytic debridement control/ comparison + five experimental groups
12= autolytic debridement control/comparison + six experimental groups

441

(V119) exp_setting _______Setting of Experiment/ Intervention
1= private office
2= wound clinic/center
3= hospital setting
4= Other, specify:_____________________________
5= multiple, specify:___________________________
(V120) inter_lvl

________ Dose of level of intervention used in the study
1= 1-3
debridement sessions required
2= 4-6
debridement sessions required
3= 7-9
debridement sessions required
4= 10-12 debridement sessions required
5= multiply, specify number of debridement sessions required:______________________

(V121) sub_group (i.e. female, male, hypertensive, normotensive, white, black, etc.), specify:________________
(0= No, 1= Yes, 2=Unclear)

STUDY QUALITY
Cochrane Risk of Bias Table
(V122) asg

___________Adequate sequence generation
(0= No, 1=Yes, 2= Unclear)

(V123) asc

___________Allocation sequence concealment
(0= No, 1=Yes, 2= Unclear)

(V124) blind

___________Blinding (single, double, triple)
(0=No, 1= single, double, or triple blinding, 4= Unclear) Specify what level of
blinding:________

(V125) inc_out_data __________Incomplete outcome data addressed
(0= No, 1= Yes 2= Unclear)
(If so how ITT, Bayesian methods, impution, Last Observation Carried Forward
(LOCF), dropped
Missing data)______________
(V126) fsr

__________Free of selective reporting
(0= No, 1= Yes, 2= Unclear)

(V127) fob

__________Free of other bias
(0= No, 1= Yes, 2= Unclear)

(V128) fs

__________Financial support
(0= No, 1= Yes, 2= Unclear)
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Other Study Quality Considerations
(V129) #hypoth_test __________Number of hypothesis tests performed_________
(V130) alpha

__________Alpha cutoff value used

(V131) typ1_error __________Type 1 error probability reported if positive study________
(V132) power

__________Power Reported

(V133) typ2_error __________Type 2 error probability reported if negative study
(V134) stat_anal

__________ Hypothesis test used for statistical Analyses
0= No statistical analysis; inappropriate, or unspecified
1= Appropriate statistical analyses of group differences (e.g., comparing two

groups using at least
more than one t or F test but did not control for baseline and/or other
characteristics)
2= Controlled for baseline and/or other characteristics in appropriate statistical
analyses of group
differences (e.g. compared two groups using at least a t or F test)
(V135) sampl_bal
Control

__________Samples Balanced for Confounders/Effect Modifiers between Sample and
(0 = No, 1= Yes, 2= Unclear)

(V136) sampl_bias __________Sampling Bias Probable
(0 = No, 1= Yes, 2= Unclear)
(V137) sel_bias

__________Selection Bias Probable
(0 = No, 1 = Yes, 2 = Unclear)

(V138) info_bias

__________Information Bias Probable
(0 = No, 1 = Yes, 2 = Unclear)
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EFFECT SIZES
VARIABLE

Initial and Post Debridement
Wound Assessments

(V139) total#part_beg
# of participants at beginning of
intervention
(V140) total#part_end
# of participants at study completion
(V141) total#part_lost
# of participants lost during study
(V142) meanadherence
Mean participant adherence
(

𝑐𝑜𝑚𝑝𝑙𝑒𝑡𝑒𝑑 𝑠𝑒𝑠𝑠𝑖𝑜𝑛𝑠
)
𝑡𝑜𝑡𝑎𝑙 𝑠𝑒𝑠𝑠𝑖𝑜𝑛𝑠

x 100

(V143) wound_assess
Wound Measurement Type
1= Length, width, depth
2= Surface area
3= Volume
4= multiple, specify #s__________
(V144) wound_size_init_cont
Initial Mean Wound Measurement
control/comparison
[size (cm), surface area (cm2)]
(V145) wound_size_initial_cont_sd
SD of Initial Mean Wound Size
control/comparison
(V146) wound_size_post_cont
Post Intervention Mean Wound
Measurement
control/comparison.
[size (cm), surface area (cm2)]
(V147) wound_size_post_cont_sd
SD of Post Intervention Mean Wound
Size
control/comparison
(size, surface area)
(V148) wound_size_init_exp
Initial Mean Wound Measurement
experimental
group [size (cm), surface area (cm2)]
(V149) wound_size_initial_exp_sd
SD of Initial Mean Wound Size
experimental
group (size, surface area)
(V150) wound_size_post_exp
Post Intervention Mean Wound
Measurement
experimental group (size, surface area)
(V151) wound_size_post_exp_sd
SD of Post intervention Mean Wound
Size
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experimental group (size, surface area?)
(V152) wound_size_cont_absΔ
Absolute change in mean wound size in
control/comparison group.
if not calculated, leave blank (calculate
in
spreadsheet)
(V153) wound_size_cont_absΔ_sd
SD of Absolute change in mean wound
size in
control group.
(V154) wound_size_exp_absΔ
Absolute change in mean wound size
experimental group. if not calculated,
leave
blank (calculate in spreadsheet)
(V155) wound_size_exp_absΔ_sd
SD of mean absolute change in wound
size in
experimental group.
(V156) time_to_heal_cont
Time to complete healing for
control/comparison
group.
(V157) time_to_heal_cont_sd
SD for time to complete healing for
control/comparison group.
(V158) time_to_heal_exp
Time to complete healing for
experimental
group.
(V159) time_to_heal_exp_sd
SD for time to complete healing for
experimental group.
(V160) time_to_heal_cont_absΔ
Absolute change in time to complete
healing in
control/comparison group.
if not calculated, leave blank (calculate
in
spreadsheet)
(V161) time_to_heal_cont_absΔ_sd
SD of Absolute change time to
complete
healing in control/comparison group.
(V162) time_to_heal_exp_absΔ
Absolute change in time to complete
healing in
experimental group.
if not calculated, leave blank (calculate
in
spreadsheet)
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(V163) time_to_heal_exp_absΔ_sd
SD of Absolute change time to
complete
healing in experimental group.
(V164) prop_indiv_heal_cont
Proportion of individuals w/ complete
healing
control/comparison group.
(V165) prop_indiv_heal_cont_sd
SD for proportion of individuals w/
complete
healing control/comparison group.
(V166) prop_indiv_heal_exp
Proportion of individuals w/ complete
healing
experimental group.
(V167) prop_indiv_heal_exp_sd
SD for proportion of individuals w/
complete
healing in the experimental group.
(V168) prop_indiv_heal_cont_absΔ
Absolute change in proportion of
individuals w/
complete healing in control/comparison
group.
if not calculated, leave blank (calculate
in
spreadsheet)
(V169) prop_indiv_heal_cont_absΔ_sd
SD of absolute change in proportion of
individuals w/ complete healing in
control/comparison group.
(V170) prop_indiv_heal_exp_absΔ
Absolute change in proportion of
individuals w/
complete healing in experimental
group.
if not calculated, leave blank (calculate
in
spreadsheet)
(V171) prop_indiv_heal_exp_absΔ_sd
SD of absolute change in proportion of
individuals w/ complete healing in
experimental
group.
(V172) prop_ulcers_recur_cont
Proportion of individuals w/ ulcer
recurrence in
control/comparison group.
(V173) prop_ulcers_recur_cont_sd
SD for proportion of individuals w/
ulcer
recurrence in control/comparison
group.
(V174) prop_ulcers_recur_exp
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Proportion of individuals w/ ulcer
recurrence in
experimental group.
(V175) prop_ulcers_recur_exp_sd
SD for Proportion of individuals w/
ulcer
recurrence in experimental group.
(V176) prop_ulcers_recur_cont_absΔ
Absolute change in proportion of
individuals w/
ulcer recurrence in control/comparison
group.
if not calculated, leave blank (calculate
in
spreadsheet)
(V177) prop_ulcers_recur_cont_absΔ_sd
SD of Absolute change in proportion of
individuals w/ ulcer recurrence in
control/comparison group.
(V178) prop_ulcers_recur_exp_absΔ
Absolute change in proportion of
individuals w/
ulcer recurrence in experimental group.
if not calculated, leave blank (calculate
in
spreadsheet)
(V179) prop_ulcers_recur_exp_absΔ_sd
SD of Absolute change in proportion of
individuals w/ ulcer recurrence in
experimental group.
(V180) amp_freq_cont or
amp_prop_cont
# of amputations/proportion of
amputations in
control/comparison group.
(V181) amp_freq_cont_sd or
amp_prop_cont_sd
SD of # of amputations/proportion of
amputations in control/comparison
group
(V182) amp_freq_exp or amp_prop_exp
# of amputations/proportion of
amputations in
experimental group.
(V183) amp_freq_exp_sd or
amp_prop_exp_sd
SD of # of Amputations/proportion of
Amputations in experimental group.
(V184) amp_freq_cont_absΔ or
amp_prop_cont_absΔ
Absolute change in amputation
frequeny or
proportion of individuals requiring
amputation in
control/comparison condition
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if not calculated, leave blank (calculate
in
spreadsheet)
(V185) amp_freq_cont_absΔ_sd or
amp_prop_cont_absΔ_sd
SD of Absolute change AMP_FREQ
or
PROP_AMP in control/comparison
condition.
(V186) amp_freq_exp_absΔ or
amp_prop_exp_absΔ
Absolute change in amputation
frequeny or
proportion of individuals requiring
amputation in
experimental condition
if not calculated, leave blank (calculate
in
spreadsheet)
(V187) amp_freq_exp_ absΔ_sd or
amp_prop_exp_absΔ_sd
SD of Absolute change AMP_FREQ
or
PROP_AMP in experimental
condition.
(V188) inf_freq_cont or
inf_prop_cont
# of Infections/Proportion of Infections
of
control/comparison group
(V189) inf_freq_cont_sd or
inf_prop_cont_sd
SD of # of Infections/Proportion of
Infections of
control/comparison group
(V190) inf_freq_exp or inf_prop_exp
# of Infections/Proportion of Infections
in
experimental group.
(V191) inf_freq_exp_sd or
inf_prop_exp_sd
SD of # of Infections/proportion of
amputations
in experimental group.
(V192) inf_freq_cont_absΔ or
inf_prop_cont_absΔ
Absolute change INF_FREQ or
INF_PROP in
control/comparison group.
if not calculated, leave blank (calculate
in
spreadsheet)
(V193) inf_freq_cont absΔ_sd or
inf_prop_cont_absΔ_sd
SD of Absolute change INF_FREQ or
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INF_PROP in control/comparison
condition.
(V194) inf_freq_exp_absΔ or
inf_prop_exp_absΔ
Absolute change INF_FREQ or
INF_PROP in
experimental group.
If not calculated, leave blank (calculate
in
spreadsheet)
(V195) inf_freq_exp_ absΔ_sd or
inf_prop_exp_absΔ_sd
SD of Absolute change INF_FREQ or
INF_PROP in control/comparison
condition.
(V196) cost_cont
Mean treatment cost for the
control/comparison
group.
(V197) cost_cont_sd
Standard Deviation for mean treatment
cost for
the control/comparison group.
(V198) cost_exp
Mean treatment cost for the
experimental group.
(V199) cost_exp_sd
Standard Deviation for mean treatment
cost for
the experimental group.
(V200) cost_cont_absΔ
Absolute change mean COST in the
control
/comparison group.
if not calculated, leave blank (calculate
in
spreadsheet)
(V201) cost_cont_absΔ_sd standard deviation
of
Absolute change in mean COST for the
control/comparison group.
(V202) cost_exp_absΔ
Absolute change mean COST in the
experimental group.
if not calculated, leave blank (calculate
in
spreadsheet)
(V203) cost_exp_absΔ_sd standard deviation
of
Absolute change in mean COST for the
experimental group.
(V204) qol_indices_cont
Mean quality of life indices for the
control/comparison group.

449

(V205) qol_indices_cont_sd
Standard Deviation for quality of life
indices for
the control/comparison group.
(V206) qol_indices_exp
Mean quality of life indices for the
experimental
group.
(V207) qol_indices_exp_sd
Standard Deviation for mean quality of
life
indices for the experimental group.
(V208) qol_indices_cont_absΔ
Absolute change QOL_INDICES for
the
control/comparison condition.
if not calculated, leave blank (calculate
in
spreadsheet)
(V209) qol_indices_cont_absΔ_sd
SD of Absolute change
QOL_INDICES for the
control/comparison condition.
(V210) qol_indices_exp_absΔ
Absolute change QOL_INDICES for
the
experimental condition.
if not calculated, leave blank (calculate
in
spreadsheet)
(V211) qol_indices_exp_absΔ_sd
SD of Absolute change
QOL_INDICES for the
experimental condition.
________ Notes relevant to coding
______________________________________________________________________________________
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Statistical Analyses

Cont
rol
Auto
lytic

Sharp
(specify
:___)

Operativ
e
(specify:
____)

Statistical Variable

Biosur
gery

(V212)
wound_size_pval
P-Value
(0= if not calculated)
(V213) time_to_heal_
pval
P-Value
(0= if not calculated)
(V214) prop_indiv_he
al_pval
P-Value
(0= if not calculated)
(V215) prop_ulcers_r
ecur_pval
P-Value
(0= if not calculated)
(V216) amp_freq_pva
l or amp_prop_pval
P-Value
(0= if not calculated)
(V217) inf_freq_pval
or inf_prop_pval
P-Value
(0= if not calculated)
(V218) cost_pval
P-Value
(0= if not calculated)
(V219) qol_indices_pv
al
P-Value
(0= if not calculated)
(V220)
wound_size_test_stat
Test Statistic
(0= if not calculated)
(V221) time_to_heal_t
est_stat
Test Statistic
(0= if not calculated)
(V222) prop_indiv_he
al_test_stat
Test Statistic
(0= if not calculated)
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Mecha
nical

Enzy
matic

Ultras
ound

La
ser

(V223) prop_ulcers_r
ecur_test_stat
Test Statistic
(0= if not calculated)
(V224) amp_freq_test
_stat or
amp_prop_test_stat
Test Statistic
(0= if not calculated)
(V225) inf_freq_pval
or inf_prop_test_stat
Test Statistic
(0= if not calculated)
(V226) cost_test_stat
Test Statistic
(0= if not calculated)
(V227) qol_indices_tes
t_stat
Test Statistic
(0= if not calculated)
(V228)
wound_size_ci
Confidence Interval
(0= if not calculated)
(V229) time_to_heal_c
i
Confidence Interval
(0= if not calculated)
(V230) prop_indiv_he
al_ci
Confidence Interval
(0= if not calculated)
(V231) prop_ulcers_r
ecur_ci
Confidence Interval
(0= if not calculated)
(V232) amp_freq_ci or
amp_prop_ci
Confidence Interval
(0= if not calculated)
(V233) inf_freq_pval
or inf_prop_ci
Confidence Interval
(0= if not calculated)
(V234) cost_ci
Confidence Interval
(0= if not calculated)
(V235) qol_indices_ci
Confidence Interval
(0= if not calculated)
________ Notes on statistical analyses relevant to coding
_____________________________________________________________________________________
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